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[i]  
Rationale: Converging evidence suggests that cannabis use can induce psychosis and is a 
distinct risk factor for schizophrenia.  Taken together with the effects of Tetrahydrocannabinol 
(THC) on neural systems, dopamine and endocannabinoids it is likely that cannabis use may 
also produce sub- clinical psychosis-linked changes in a much larger number of regular 
recreational users; observable in schizophrenia-sensitive assessments.  Use of the drug by 
individuals with genetic risk factors for schizophrenia appears to magnify the chances of 
pathology, and so changes in recreational users with one or more of these genetic markers may 
be more evident or pronounced. 
           Method: 50 cannabis users and 50 non cannabis users were assessed in each of two studies. Study 
one assessed selective attention in the Latent Inhibition (LI) and Kamin Blocking (KB) paradigms 
and examined schizophrenia-linked traits using the short form of the Schizotypal Personality 
Questionnaire (the SPQ-B; Raine and Benishay, 1995).  Study two assessed executive control 
(using an Anti-Saccade Test), decision-making (using the Iowa Gambling Task), and 
selective/sustained attention and inhibitory control (Continuous Performance Test).  Study two 
included additional personality measures to explore paranoia, emotional processing, ambivalence 
and impulsivity.  Across both studies, the relative contribution of seven genetic risk markers in 
five candidate genes for schizophrenia (DAOA, COMT, NRG1, FAAH and CNR1) were assessed. 
          Key Results: Cannabis use was associated with abolished latent inhibition and significantly 
riskier decision making, especially in those who used the drug more frequently.  Cannabis users 
reported significantly higher scores for psychosis-linked personality traits and there was a dose-
response effect with heavier users experiencing more of these schizotypal traits. Some key 
trends existed in the genotyping data for the cannabis group.  The psychosis-risk C allele in the 
NRG1 gene was linked to higher SPQ-B scores and more errors on the AST; and was also 
associated with longer use of cannabis.  Cannabis users without the protective three-way T-G-G 
haplotype COMT gene had higher scores for the SPQ-B disorganised thinking subscale than 
users with the protective haplotype. 
          Discussion: The data in this thesis suggests that cannabis users are showing differences in brain 
inhibitory function and decision-making akin to previous research with schizophrenic patients, 
their first degree relatives and high schizotypy scorers.  Exposure to THC may contribute to 
changes in individuals by pushing them further along a schizophrenia-spectrum resulting in the 
display of more psychotic-like traits and cognitive dysfunction at sub-clinical levels.  These 
preliminary findings need expansion and replication, particularly with regards to the COMT 
three-way haplotype.
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Chapter 1: Background Literature review  
  
1.1        Cannabis 
Seventy-five million Europeans have reportedly used cannabis at least once in their lifetime, 
with an estimated twenty-million Europeans having used cannabis in the past year (Seshadri 
et al., 2011).  Data taken from the 2008 national school survey reported that lifetime use 
among fifteen to sixteen year olds in the UK ranged from 26%-32% (European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), 2010).  A recent report from the Crime 
Survey in England and Wales (CSEW, 2015) found a 21% rise in the number of 16-24 years 
reporting cannabis use in 2014-2015 compared to 2013-2014 data.    
 
1.1.1 Basic psychopharmacology  
Cannabis is derived from the plant Cannabis sativa, and is made up of over 400 naturally 
occurring compounds, with delta-9-tetrahydrocannabinol (THC) involved in creating the 
main psychoactive effect of the drug (Gaoni & Mechoulam, 1964).  More recently another 
compound referred to as cannabidiol (CBD), also present in significant quantities, has been 
shown to have a role in moderating the impact of THC, in terms of reducing the 
psychoactive/psychological effects of the drug (Mechoulam et al, 2007; Morgan & Curran, 
2008).  The cannabis plant is either male or female, with THC more concentrated in the 
female version of the plant.  Cannabis cultivated indoors, through the use of soils, light and 
hydroponics for shorter time frames (e.g. around four months) produces high THC levels at 
the expense of CBD,  these are often referred to as the ‘skunk’ and stronger forms of cannabis 
(see Potter et al, 2008).  There is emerging research on recreational use of the legal high 
‘Spice’, which contains a mixture of highly potent synthetic cannabinoids (Vardakou et al, 
2010).   
 
The ‘pleasurable’ effect of cannabis use is named as one of the key reasons for using the drug 
(e.g. Chait & Perry, 1992).  The influence of the drug on the mind is very subjective and it 
has a varied euphoriant effect (e.g. a feeling of being ‘high’ or stoned) depending on the dose, 
route of administration, expectations and other individual factors such as personality (Aston 
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et al, 1981).  Users often report feeling relaxed, having a heightened sense of awareness, and 
that their senses are distorted; they experience profound thoughts and a distorted sense of 
time (Jaffe, 1985; Tart, 1970).  It is thought that this distortion of time, with participants 
tending to focus on the present rather than on the past or the future, could amplify the drug 
experience and is linked to the rush in thinking and sensations experienced through the high 
(Melges et al., 1971).  Negative effects of cannabis intoxication include making the user feel 
nauseous, dizzy, anxious, and the drug may induce panic attacks (Ashton, 2001) or psychotic-
like symptoms (Arendt et al, 2005).   
 
Smoking is the preferred method of administration, providing effective delivery to the brain.  
Thus the psychoactive effects start within seconds to a few minutes after smoking and the 
peak levels of THC are usually present after 30 minutes and can last up to several hours 
(Grotenhermen, 2003).  Experienced cannabis users (e.g. minimum of two years) can regulate 
the dose required for the subjective high.  Herning et al. (1986) found that when such users 
were given different quantities of THC via a cigarette without knowing the exact quantities, 
they adjusted their smoking behaviour to reach the same THC absorption, i.e., those with 
higher doses took smaller puffs from the cigarette and vice versa for the low doses.  Another 
form of administration is oral absorption (e.g. cannabis oil or cannabis baked into a cake or 
other food products), but this method is less predictable for its psychoactive effect, as it is 
slow and can deliver inconsistent doses of THC with peak levels occurring anytime between 
1-4 hours after consumption (Mason & Mc Bay, 1985).  
 
An average joint contains about 10-20 milligrams (mg) of THC, with around 10-20% (i.e. 1-
mg of THC) normally absorbed through the lungs, which then rapidly enters the blood stream 
and reaches the brain within minutes (for a review see Agurell et al, 1986 or Mayat, 1985).  
Elimination of cannabis compounds from the body is inconsistent; in some people it can be 
rapidly metabolised in days whereas in others it takes nearly one month (Huestis et al, 1996).  
It has been estimated that cannabis has a 3-5 day half-life but in some people it may persist 
for weeks (Agurell et al., 1986).  Objective tests using urine or blood to assess for one of the 
major metabolites, 11-nor-carboxy-THC, can give positive results for days or weeks after 
consumption (Huestis et al., 1996).    
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In animal models, tolerance to THC can be seen even after very modest doses, but is very 
apparent after large doses greater than 5mg/kg.  When animals are given 20 mg injections per 
day they become insensitive to any further treatment with THC (Hutchenson et al, 1998).  In 
humans, it has been predicted that around 10% of cannabis users will become dependent on 
the drug (Hall & Solowij, 1997).  A survey conducted in Australia of more than 10,000 
participants indicated that 20% of cannabis users met DSM-IV (APA, 1994) criteria for 
substance dependence (Swift et al., 2001).  However, there is a contentious issue as to 
whether people become dependent or addicted to cannabis.  Animal research has shown rats 
become physically dependent on THC, with withdrawal symptoms such as convulsive 
shaking, compulsive grooming, spasms, head shakes, arched back (De Fonseca et al, 1997).  
In humans, when cannabis is suddenly stopped withdrawal is not typically seen and this may 
be due to THC’s long half-life.  However, controlled studies using a CB₁ antagonist upon 
cessation of cannabis has shown withdrawal symptoms, such as weight loss, poor sleep, 
decreased appetite, anger, aggression and increased irritability (Budney et al., 2001). 
 
1.1.2 Neuropharmacology of cannabis  
THC is currently viewed as acting as a partial agonist at two endocannabinoid receptors; CB1 
(Devane et al, 1988) and CB2 (Munro et al, 1993).  CB1 receptors are distributed across 
numerous brain loci, including the cerebral cortex, limbic areas (including the hippocampus 
and amygdala), the basal ganglia, the cerebellum, the thalamus and to a lesser degree in the 
brainstem (Herkenham, 1990; 1995).  CB1 receptor regions are highly implicated in 
producing the psychological effects associated with smoking cannabis.  Huestis et al. (2001) 
looked at the effects of taking rimonabant (a CB1 antagonist) or placebo in those who smoked 
a THC cigarette or a placebo THC cigarette in 63 cannabis users.  Rimonabant blocked the 
acute psychological effects of THC in the cannabis cigarette.  However, research in this area 
of inhibition of neurotransmitter release is only emerging and has not been clearly established 
as to how action of cannabis on CB₁ receptors leads to the psychoactive effects of THC.  
What is clear is that cannabinoids have generally been implicated in the inhibition of 
neurotransmitter release, and have been involved in reducing the release of the amino acid y-
aminobutyric acid (GABA) and the amines noradrenaline and acetylcholine (Szabo & 
Schlicker, 2005).  Reducing the release of GABA inhibits other neurotransmitters and it 
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could be implicated in two important effects of cannabinoids: one would be that the 
administration of THC leads to a release of dopamine, and the second effect would be that 
they increase endorphin levels (Iverson, 2003; Pertwee, 2005).   
 
1.2 Cannabis and Cognitive research  
There is growing evidence for cognitive dysfunction associated with long term and heavy use 
of cannabis which runs parallel with the endophenotypes of schizophrenia.  These are seen to 
represent a risk for vulnerability to developing schizophrenia or psychotic disorders (Solowij 
& Michie, 2007); to which we turn in more detail in the next section.  Problems with 
learning, memory, decision-making and attention are common in people that misuse cannabis 
(Millsap et al., 1994; Tapert et al., 2002; Fried et al., 2002; Whitlow et al, 2003; 2004).  
These deficits may persist for weeks after abstinence from the drug (e.g. Schwartz et al., 
1989).  It is argued that regular use of cannabis is linked to cognitive brain dysfunction, 
specifically in areas of the brain which are rich in CB₁ receptors (Solowij & Michie, 2007), 
due to the links between CB₁ receptors areas and higher level cognitive processing (Miller et 
al, 2002). 
 
1.2.1 Effects on decision-making 
Decision making deficits have been observed amongst groups of cannabis users and are seen 
as one of the key reasons why people continue to consume the drug even when there is 
potential for negative physical, psychological, social and legal consequences (Whitlow et al, 
2003; 2004).  Decision making can be defined as the ability to select the most adaptable 
behaviour which has the best outcome when faced with a range of alternative outcomes (see 
Bechara et al., 2001).  Volkow & Fowler (2000) conducted a study scanning the brains of 
cannabis users whilst they also performed a decision making task.  The researchers reported 
that the right orbital frontal cortex (OFC) is less efficient in regular cannabis users; a brain 
area linked to decision-making.  Similarly, Bolla et al (2005) also reported that cannabis 
users had greater activation in the cerebellum, and less activation in the right lateral OFC, and 
that there is a dose-response effect, with heavy use of cannabis linked to less efficient OFC 
activation in decision-making.  Whitlow et al (2003) found that short term withdrawal from 
cannabis was associated with poorer outcomes on the Iowa Gambling decision making task 
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(IGT).  Bolla et al (1995) found deficits on the IGT in a group of cannabis users even after a 
28-day abstinence period.  Verdejo-Gracia et al (2007) found decision making deficits in 
cannabis users after a 25-day abstinence period and a dose response effect, with heavier use 
being linked to poorer outcomes on the IGT.  However, some researchers have not found 
these effects in cannabis users who abstained for seven days (Quednow et al, 2007).   
 
It is worth noting here that OFC regions are also associated with decision making dysfunction 
in schizophrenia (Convit et al., 2001; Goldstein et al., 1999; Pantelis et al., 2003)  and people 
diagnosed with schizophrenia perform badly on neurocognitive decision making tasks (see 
review: Moburg et al, 1999).  The OFC seems to be very important for complex decision 
making processes as well as emotional and social decision making in people with acquired 
damage to that brain region (Rolls, 1999).  Damasio (1996) postulated that damage to the 
OFC causes poorer decision making as a result of the inability to ‘somatically mark’ an 
internal representation of a given situation with either a positive or negative valance based on 
their previous experiences.  Poor decision-making in the cannabis group is seen as either 
being less responsive to bad outcomes on the decision-making task or alternatively are being 
driven by immediate higher rewards which leads to poorer decision making overall.  Chapter 
3 reviews the decision-making literature in cannabis users, particularly for outcomes on the 
IGT. 
 
1.2.2 Effects on Associative learning 
Human learning is underpinned by a fundamental need to form relationships between 
concepts, of which ‘associative learning’ is a term used to describe this process (Gallistel, 
1990).  The working memory system plays a key role along with the executive system in 
providing the ability to learn new skills to form associations (Tanji & Hoshi, 2001).  Some 
research has revealed associative learning deficits in cannabis users.  Jager et al (2006) tested 
20 frequent cannabis users versus 20 non-users, using an associative memory task and 
functional magnetic resonance imaging (fMRI) techniques.  It was found that cannabis users 
displayed lower activation in brain regions involved with associative learning, particularly the 
(para) hippocampal region implicated in memory functioning and the dorsolateral pre frontal 
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cortex (associated with higher level cognitive functions), despite no differences found 
between the groups on associative learning in overall task performance. 
 
Skosnik et al (2008) examined the effect of chronic cannabis use on classical eyeblink 
conditioning (EBC), which is an associative learning task.  They tested 14 cannabis users and 
10 non users, on EBC where there is a paired association between a conditioned stimulus 
(CS, e.g 400ms tone) and a corneal airpuff, the unconditioned stimulus (US), which is a puff 
of air to the eye at 50ms.  Both of these stimuli paired together results in a conditioned 
response of an eyeblink.  Cannabis users exhibited fewer and more poorly timed conditioned 
responses (CR) compared to the non-cannabis group.  Interestingly, no differences were 
found in the unconditioned response between the groups (i.e. learning the paired associated 
without any previous conditioning of the white noise).  Further to this, no differences were 
found in EEG responding to the conditioned stimulus.  The authors therefore argued that the 
findings in the cannabis group represented specific problems relating to conditioned response 
acquisition. 
 
In a later study, Skosnik et al (2012) assessed 10 cannabis users, 10 ex users, and 10 non-
cannabis users on EBC and found that cannabis users exhibited more errors in the acquisition 
and timing of the conditioned responses compared to non-users.  The ex-users had intact 
conditioned response acquisition but were impaired in having shorter conditioned response 
latencies (e.g. timing of the CR during each block of trials).  The authors argued that cannabis 
is seen to disrupt acquisition of conditioned responses and this may improve upon complete 
cessation of the drug, although ex-users still demonstrated difficulty in correctly timing their 
response on the EBC task.  CB₁ receptors have their highest density in the cerebellum and a 
previous animal study indicated that CB₁ knockout mice also highlight severe impairment 
using a version of the EBC task (Kishimoto & Kano, 2006).  Therefore it could be argued 
that cannabis use may be a risk factor for functional deficits in the cerebellum which controls 
for some aspects of associative learning (Skosnik et al, 2008; 2012). 
 
The above findings run parallel to research in people diagnosed with schizophrenia who 
cannot filter out irrelevant information, as demonstrated by the selective attention tasks, 
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namely Latent Inhibition (Lubow, Weiner & Feldon, 1982; Serra et al, 2001) and Kamin 
Blocking (Serra et al, 2001; Jones et al, 2002); these tasks will be further explored in Chapter 
2.  The inability to filter out what appears to be irrelevant information, is typically detected in 
the earlier stages of schizophrenia, and has been linked to explaining more of the positive 
symptomology e.g., delusions, hallucinations and so forth (Hemsley, 1993). 
 
1.2.3 Effects on executive control 
Response inhibition is an important executive function that allows for the suppression of 
actions and resistance to interference from irrelevant stimuli (Bjorklund & Harnishfeger, 
1995).  This key executive function is also seen as controlling complex cognition and 
behaviours, which is essential for effective interaction with our environment (Burke et al., 
1991).  Response inhibition has also been characterised as a level of control over a voluntary 
response, and has been demonstrated in a range of standardised tasks.  For example, the 
Stroop task has been used most often for assessing inhibitory function in cannabis users, with 
mixed results (Pope et al, 1996; 2001; Solowij et al, 2002).  However, most of these studies 
generally find that frequency and duration of cannabis use interact with IQ; with longer 
duration of use, increased joints per week and low IQ appearing all to contribute to greater 
impairments (Solowij & Michie, 2007).  Further to this, imaging studies have shown that 
altered activation in the dorsolateral pre-frontal cortex (DLPFC) and anterior cingulate are 
seen during the interference component of the Stroop task, despite lack of differences in 
performance between cannabis users and non-cannabis users (Gruber & Yurgelun-Todd, 
2005).  Neuroimaging studies have reported that increased activity of bilateral PFC and right 
premotor cortex and attenuation of left cerebellar activity can be found in response selection 
and inhibition, as demonstrated by the Go/No-go task in people prenatally exposed to 
cannabis (Smith et al, 2004).  Administration of THC to healthy controls increased 
impulsiveness on the Stop signal but not the Go/No-go task (Mc Donald et al, 2003); with 
THC intoxication related to premature responding and poorer control of inhibitory responses 
(Hart et al, 2001).  Ploner et al (1998; 1999) assessed the acute effects of THC on humans 
and found that this substance affected spatial accuracy, volitional saccades and inhibition of 
inappropriate saccades for eye movement control.  Executive control in cannabis users is 
further explored in Chapter 3. 
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1.2.4 Effects on attention 
Cannabis users have been shown to demonstrate impaired attention, on tasks assessing either 
sustained (maintaining a consistent level of attention) or selective (selecting what is relevant 
and irrelevant) attention (Hall & Solowij, 1998).  Similar effects were also found using EEG, 
as selective attention for selecting relevant from irrelevant information was disrupted in 
cannabis users and linked to duration of use.  For example, the speed of processing for the 
P300 response (an indicator of frontal brain activity), was slower in people using cannabis 
and worsened in those who used cannabis for longer durations (Solowij et al, 2002).  Age of 
onset of cannabis (e.g. before 16 years old) is also seen as one of the strongest predictors of 
attentional dysfunction in adults for visual searching (Ehrenreich et al., 1999).  Attentional 
problems are also seen in light users of cannabis (e.g. once a week) as demonstrated by a 
negative priming study, where cannabis users showed deficits in trying to select the relevant 
from irrelevant material when compared to non-cannabis users (Skosnik et al, 2001).  Other 
studies assessing levels of attention in cannabis users, reported a disruption in sustained 
attention as a result of acute cannabis (e.g. naturally smoked), particularly in regards to 
shifting and sustaining attention (Pope & Yurgelun-Todd, 1996).  Selective attention in 
cannabis users is further explored in Chapter 2 and selective/sustained attention is also 
covered in Chapter 3. 
 
The decision-making, attention, and executive control assessments described above are 
together linked by the component of behavioural and trait impulsivity (Giel et al, 2013; 
Swann et al, 2010, Upton et al, 2011).  Impulsivity is defined as actions which are poorly 
conceived, prematurely expressed, unduly risky, or inappropriate to the situation and may 
results in negative consequences (Wrege et al, 2014).  Impulsivity is linked to a broad 
spectrum of psychiatric disorders, including schizophrenia (Ouzir, 2013) and is a core deficit 
in addictive disorders and substance misuse problems (Crews & Boettinger, 2009).  
Impulsive behaviour is a pre-existing personality that may motivate the initiation of drug use, 
whereas the consumption of cannabis may result in other behavioural changes which include 
alterations of impulsivity (Wrege et al, 2014).   
 
 
9 
 
1.2.5 Effects on other brain areas linked to cognition 
Studies indicate that brain structure may change as a result of cannabis use.  For example, 
Arnone et al. (2008) assessed prolonged and heavy use in 11 participants versus 11 controls 
of non-cannabis users, using a method called diffusion tensor imaging (DTI) which looks at 
white matter tracts.  The researchers reported the axonal connectivity was impaired in regions 
in the hippocampus and corpus callosum in the heavy cannabis users relative to the control 
sample.  However, these findings were not replicated in people diagnosed with schizophrenia 
and in those who started using cannabis during adolescence (Dekker et al., 2010).  Yucel et 
al. (2008) assessed people who reported use of more than 5 joints daily for more than 10 
years, compared with a control group of non-users and found that heavy use was associated 
with bilateral reduced hippocampal and amygdala volumes.  Deficits were pronounced in left 
hemisphere hippocampal volume and exposure to cannabis was associated with greater 
positive psychotic symptoms.  This finding runs parallel to research conducted on people 
diagnosed with schizophrenia as having more left hemispheric hippocampal deficits (Petty, 
1999).  Further to this, Rais et al. (2008) followed up people, diagnosed with a first episode 
of a psychosis, for a period of over 5 years and found that those people who continued to use 
cannabis had more grey matter loss, compared to non-users and healthy controls.  Regular use 
of cannabis during adolescence was also associated with gyrification abnormalities in the 
cortex (e.g. a process of cortical folding), which suggests that pre-exposure to cannabis in 
early adolescence may affect normal brain development (Mati et al., 2008).  Neuroimaging 
studies looking at the acute effects of cannabis on brain function reported that resting global, 
prefrontal and anterior cingulate cortex blood flow seem to be lower in cannabis users 
relative to non-cannabis using controls (Martino-Santos et al., 2010).  This is supported by 
research on acute administration of THC or cannabis cigarettes which show increased 
prefrontal, insular and anterior cingulate activity during rest state and also during cognitive 
testing.  For example, Bhattacharyya et al. (2009) administered THC and placebo to healthy 
volunteers and assessed them on a verbal learning tasks performed under fMRI scanning.  
The researchers found that THC was associated with an increase in blood flow in the 
mediotemporal and anterior cingulate (key areas in the brain linked to decision-making) and 
in the medioprefrontal cortex (which plays a central role in memory relational binding) 
during the learning phase of the task, and THC also appeared to induce psychotic symptoms 
in the healthy volunteers.     
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The research presented here in section 1.2 indicates that cognitive disruption and changes in 
brain activity and structures linked to key cognitive processes appear to be commonplace in 
cannabis users, and that those that use the drug more frequently demonstrate more cognitive 
deficits.  Importantly, in the context of this thesis, these cognitive data in cannabis users 
reflect similar results to those found in persons diagnosed with schizophrenia.   
 
1.3 Schizophrenia and schizotypy 
1.3.1 Schizophrenia 
Schizophrenia belongs to a group of disorders that are called ‘psychosis’, usually 
representing a detachment from reality.  The term schizophrenia which literally means 
‘splitting of psychic functions’ was first described by Eugen Bleuler in 1908, to describe 
patients with the four As: symptoms of loosening of associations, ambivalence, autism, and 
affective problems.  The splitting of the mind referred to the loss of unity in the person’s 
personality (as cited in Kuhn, 2004).  Schizophrenia today is seen as a heterogeneous disorder 
which is linked to a range of symptoms, but each individual’s experience is unique.  
Clinicians have attempted to classify these clusters of symptoms into the DSM III (American 
Psychiatric Association (APA), 1987) and revised DSM-IV (APA, 2000); DSM-V (APA, 
2013) as a way of diagnosing this disorder.  Schizophrenia is classified into three main 
factors: positive symptoms (e.g. hallucinations), and negative symptoms (e.g. flat affect, 
blunted emotional responses) and disorganised thinking and behaviours in relation to odd 
speech, odd associations (Liddle, 1987) as well as cognitive disruption (Bilder et al, 1996; 
Heinrichs & Zakzanis, 1998). 
 
About 1 in a 100 people are at risk of developing schizophrenia during the course of their 
lifetime (DeLisi, 1992), increasing to around 10 in 100 if it runs in the family (Rosenthal et 
al., 1980).  The concordance rates of schizophrenia being diagnosed in identical twins is 45.5 
in 100 compared to 10 in 100 in non-identical twins at (Holzman & Matthyse, 1990).  That 
schizophrenia is not concordant to 100% in identical twins indicates that environmental 
causes play a major role in its aetiology, and include factors such as infections, toxins, 
traumatic injury, and psychosocial stress (Leask, 2004).  
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In the 1950s, there was the discovery of the first anti-schizophrenic drug called 
chlorpromazine, which alleviated symptoms in people diagnosed with schizophrenia (for a 
review see Ban et al, 2006).  Carlsson and Lindqvist (1963) found differential effects of two 
antipsychotic drugs by antagonising levels of dopamine, chlorpromazine and reserpine, with 
the former binding to dopamine receptors and the latter depleting the brain of dopamine.  
Traditionally the formulation of the dopamine theory of schizophrenia was linked to the 
excessive transmission at dopamine receptors (Matthysse, 1973; Snyder, 1976).  The 
dopamine theory was supported by research on the clinical effectiveness of anti-psychotic 
drugs linked to their affinity for dopamine receptors (Seeman & Lee, 1975; Creese et al, 
1976; Seeman et al, 1976).  The revised the dopamine theory of schizophrenia is that rather 
than high levels of dopamine, it was due to high levels of activity at the receptors (Davis et 
al, 1991), but modern research has moved also towards a genetic level and 
neurodevelopmental understanding (Howes & Kapur, 2009).    
 
1.3.2 Schizophrenia Genes 
Schizophrenia has multiple causes and on-going research is investigating the link between 
candidate genes and risk for developing the disorder (Plomin et al, 1994).  Genetic wide 
association studies (GWAS) have been conducted to look for a genetic link in Schizophrenia.  
GWAS look at the density of genetic markers and the extent of linkage disequilibrium (e.g. 
non-random association between the alleles at different sites in the genome) in a population, 
to make sure it is sufficient enough to capture variation amongst these groups. Manolio et al 
(2010) carried out some GWAS and documented at least 5 candidate genes that have been 
implicated as potential risk markers for developing schizophrenia: NRG1 (Neuregulin 1); 
DISC1 (Disrupted in Schizophrenia); DTNBP1 (Dysbindin); DAAO (D-aminoacid oxidase); 
COMT (Cathecol-O-methyltransferase).   
 
Chapter 4, section 4.3 reports a study conducted with the Dunedin cohort investigated 
whether specific genes increase the risks associated with early cannabis use (Caspi et al, 
2005).   The researchers examined the role of the catechol-O-methyltransferase (COMT) 
gene, which is responsible for the breakdown of dopamine. A functional polymorphism of 
this gene, Val158Met, has been shown to slow the metabolism of dopamine, which 
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potentially increases the risk of psychosis (Lachman et al., 1996; Bilder et 2004).  It was 
found that those with Val/Val or Val/Met genotypes and adolescent cannabis use were at 
increased risk for schizophreniform disorder, whereas individuals with Met/Met genotypes 
were not.  This finding therefore implicates genetic factors as important distinct risk factor to 
the cannabis-psychosis link.  Chapter 4 provides a more detailed account of risk genes for 
schizophrenia, but it is clear that there are several distinct genes and gene markers which may 
link to schizophrenia, symptoms and/or underlying risk.   
 
1.3.3 Schizotypy       
Schizotypy is characterised by symptoms similar to schizophrenia but are seen as less severe.  
Some people could represent an at-risk group and do not have a diagnosis of schizophrenia, 
but may score highly on one or more aspects of schizotypy measures and such traits are often 
referred to as schizotypal traits.  There is some debate over whether such ‘schizotypy’ as a 
personality trait, differs in nature from aspects of schizophrenia and so may be a distinct 
characteristic, which are distinct from schizotypal personality disorder (Claridge, 1997).  On 
one hand, there is the quasi-dimensional approach that views schizotypy on a dimension but 
its presence is indicative of risk for future psychopathology (Eckblad & Chapman, 1983).  
Others view schizotypy as a personality dimension and rather than being associated with 
psychosis itself (e.g. meeting a diagnosis for schizotypal personality disorder or 
schizophrenia) it exists on a continuum across which we are all dispersed (McCreery & 
Claridge, 1995).  The latter assumption uses a model of risk for psychosis of interacting 
variables such as schizotypy, stressors and social support (e.g. Claridge & Beech, 1995).   
Schizotypy has been conceptualised in many ways, with Rado (1953) and Meehl (1962) first 
describing it as a genetic predisposition to schizophrenia.  The traditional view (e.g. quasi 
dimensional) by (Meehl, 1962; 1990) posits a categorical view that these traits (or symptoms) 
are dichotomous, either people have these or do not, and measures have been created to 
assess for these traits using  Yes/No response measures (e.g. the Schizotypal Personality 
Questionnaire (Benishay & Raine, 1995).  Whereas, other researchers (e.g. Claridge, 1994; 
Eysenck & Eysenck, 1976; Claridge, 1994; Chapman, Chapman and Miller, 1982) posit the 
continuum view, where these traits are represented along a continuum and these have been 
measured using a likert-scale responding for personality traits associated with schizophrenia 
(e.g. Schizotypal Personality Scale, Jackson & Claridge, 1991).  As a result of this, there has 
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been varying theoretical and empirical origins of schizotypy (Lenzenweger, 1994), however, 
most researchers are now in agreement for a factor structure of schizotypy and the two 
approaches are converging to look at psychosis-proneness within each of these measures 
(Claridge et al, 1996).  What is clear is that people scoring high on schizotypy traits 
demonstrate some of the clinical features of schizophrenia, in that they share similar 
performance deficits on certain cognitive, neuropsychological and psychophysiological 
assessments (Lenzenweger, 1998; Claridge, 1994; Raine, Sheard, Reynolds & Lencz, 1992; 
Rawlings & Claridge, 1984).  Further to this, relatives of those diagnosed with schizophrenia 
are more likely to show higher scores on schizotypy measures and performance decrements 
on schizophrenia sensitive tests/traits relative to those in the general population (Kendler et 
al., 1995; Vollema & Postma, 2002).    
 
Meehl (1990) postulated a model for schizotypy to a gene defect which causes a generalised 
dysfunction throughout the brain, which he coined as ‘hypokrisia’, a Greek word to describe 
insufficiency of separation, differentiation or discrimination.  The integrative failure is at the 
sub-cellular level which produces a neurochemical deficiency leading to Schizotaxia.  
Schizotaxia causes a person to be socially avoidant and misinterpret social relationships and 
predisposes an individual to schizophrenia, and this is acted upon by epigenetics (social or 
physiological) and leads to degrees or levels of schizotypy.  However, Meehl argues that only 
a small minority with the CNS defect are diagnosable by DSM criteria.  Manifestations of the 
gene defect are linked to personality traits, social learning history and unpredictable life 
events.  Schizotypy and such traits may be produced as changes happen to structures which 
are involved in schizophrenia.   
 
Schizophrenic-like tendencies have been explained in terms of existing on a continuum, at 
one end those being classified with very low (or no) psychotic traits or behaviours within the 
general population compared to those at the other end being classified as having 
schizophrenia.  Those ‘at risk’ or with higher schizotypal traits would be seen somewhere 
higher up the scale or in the middle (i.e., relatives of those with schizophrenia and have a 
high number of psychotic-like traits and behaviours but do not have a full blown disorder 
(Claridges & Broks, 1984; Eysenck & Eysenck, 1975; Claridges & Beech, 1995).  There is 
some debate over ‘schizotypy’ being seen as a personality trait, which is distinct from 
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schizotypal personality disorder (Claridge, 1997).  One view is that presence is indicative of 
risk for future psychopathology (Eckblad & Chapman, 1983).  Others view schizotypy as a 
personality dimension and rather than being associated with psychosis itself (e.g. meeting a 
diagnosis for schizotypal personality disorder or schizophrenia), it exists on a continuum in 
which all people vary (McCreery & Claridge, 1995).  What is clear is that people scoring 
high on schizotypy traits demonstrate some of the clinical features of schizophrenia for 
performance deficits on certain cognitive, neuropsychological and psychophysiological 
assessments (e.g. Lenzenweger, 1998; Claridge, 1994; Raine, Sheard, Reynolds & Lencz, 
1992; Rawlings & Claridge, 1984).  Further to this, relatives of those diagnosed with 
schizophrenia are more likely to show higher scores on schizotypy measures, and 
performance decrements on schizophrenia sensitive tests relative to those in the general 
population (Kendler et al., 1995; Vollema & Postma, 2002).    
 
In essence, there are two ways to assess schizotypy and cannabis effects: 
1.  There is variation between individuals on this schizotypy factor (with each individual 
somewhere on the continuum), which might also indicate who is more or less at risk 
of any issues with cannabis. 
2.  Cannabis use causes changes centrally over time, which push the brain to function in 
a more schizophrenia-like fashion – with changes in cognitive functioning and 
increased schizotypy, as a marker of this change. 
 
1.4  Drugs and Psychosis 
Drug induced psychosis is a term that has been used since the 1930s to describe the 
symptoms/behaviours linked to a psychotic disorder, which can be induced through heavy 
drug use.  Young and Scovell (1938) first reported a case of psychosis following use of 
amphetamine; with these symptoms reduced following 2 weeks of abstinence.  Amphetamine 
is a highly addictive drug which act directly on the mesolimbic dopaminergic reward system 
by inducing release of dopamine, and to some extent norepinephrine (Robinson & Berridge, 
2000) and it is also commonly used amongst psychiatric patients (Gonzales et al., 2008; Katz 
et al., 2008).  Use of amphetamine can cause acute psychotic symptoms and may also 
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contribute to persistent psychotic conditions such as schizophrenia (see Bramness et al, 
2012).  There is overwhelming evidence that patients with psychotic disorders have an 
increased vulnerability to compulsively use drugs (Cantor-Graae et al., 2001; Regier et al., 
1990).  There may be several causal explanations for this increased co morbidity, but the 
most convincing evidence comes from animal studies arguing that this is due to shared 
vulnerabilities for both psychosis and drug use disorders due to reduced inhibitory control 
over dopamine mediated behaviour which regulates drug reward and reinforcement.  More 
specifically, abnormalities in hippocampal formation and the frontal cortex facilitates the 
positive reinforcement from drug use and reduces inhibitory control over drug-seeking 
behaviours (see: Chambers et al., 2001).  Since then many published studies have explored 
the link between certain other drugs and psychosis, such as alcohol (Ringen et al, 2008); 
methamphetamine (Medhus et al, 2012) cocaine (Brady et al, 1996) and cannabis (Degenhart, 
1993).  Interestingly, in the drug induced psychosis research most (if not all) of the people 
using stimulant drugs such as amphetamine and cocaine also use cannabis, whereas not all 
cannabis users are poly drug users.   
 
1.4.1 Cannabis and schizophrenia 
It is estimated that rates of co-occurring cannabis use in people diagnosed with schizophrenia 
ranges between 12%-42% (Chambers et al., 2001).  One of the first studies to document a 
link between cannabis and schizophrenia was Chopra and Smith (1974) who reported that 
200 people who were admitted to a psychiatric unit in Calcutta over a period of five years, 
had psychotic symptoms (which included sudden onset of confusion, hallucinations, 
depersonalisation, and paranoia) following heavy cannabis use.  A third of these cases had no 
previous history of psychopathology, and there was an association between heavier use of 
cannabis and developing psychotic symptoms in the shortest period of use.  These findings on 
heavier cannabis use and risk for developing psychotic symptoms have been supported 
globally in the Caribbean (Spencer, 1971), New Zealand (Eva, 1992), Scotland (Wylie et al., 
1995), the USA (Talbott & Teague, 1969) and here in the UK (Carney et al., 1984; 
Drummon, 1986).  Both the International Classification of Diseases (ICD-10; WHO, 1992) 
and the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV; APA, 1994), 
include a specific diagnosis for cannabis-induced psychosis.  However, some researchers are 
critical of this evidence based on the lack of information about cannabis use, lack of 
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accounting for genetic vulnerability and heterogeneity in terms of defining a specific 
cannabis psychosis (Gruber & Pope, 1994).  However, the strongest evidence seems to come 
from the research on heavy consumption of the drug leading onto the person developing a 
specific cannabis-psychosis (Hall & Degenhardt, 2009) and heavy use is linked to higher risk 
of developing a first episode in psychosis (De Forti et al, 2015).  Further to this, cannabis 
intoxication can induce brief episodes of psychotic symptoms, and it can exacerbate or bring 
about the reoccurrence of pre-existing psychotic symptoms (Negrete et al., 1986; Thornicroft, 
1990; Mathers and Ghodse, 1992).   
 
Thacore and Skukla (1976) published a case control study of people diagnosed with cannabis 
psychosis and 25 people with a diagnosis of schizophrenia (paranoid subtype) but no history 
of cannabis use.  There was a direct correlation between prolonged use of cannabis and the 
onset of psychotic symptoms.  Further to this, those diagnosed with cannabis-induced 
psychosis responded more quickly to anti-psychotic treatment.  In contrast to this, other 
researchers have found no such associations between people with cannabis-induced psychosis 
and those with schizophrenia (Imade & Ebie, 1991).  Rottanburg et al. (1982) compared 20 
patients diagnosed with schizophrenia with cannabinoids in their urine with 20 schizophrenia 
patients without cannabinoids in their urine.  Patients with more cannabinoids in their urine 
had higher rates of hypomania and agitation symptoms, but less auditory hallucinations, 
flattened affect, poor speech, and hysteria relative to the non-cannabis using patients.  
Improvements in symptoms in the cannabis group were more marked through the week when 
they stopped using the drug relative to those that did not consume cannabis.  This is an 
interesting finding as it indicates that it may have been a specific induced psychosis, with 
symptoms gradually lessening with cessation from the drug; whereas those with other causes 
behind their illness showed no changes.  Conversely, using a similar research Thornicroft et 
al (1992) found very few demographic or clinical differences using a similar research sample 
and McGuire et al. (1995) also reported that the groups did not differ on their symptoms but 
the cannabis group had a higher family rate of schizophrenia (7.1%) than controls (0.7%).   
 
The average age for experimenting with cannabis for the first time usually takes place during 
early adolescence (e.g. from the age of 14) and from a neurodevelopmental view, use of 
cannabis in itself during this brain maturation stage may lead to mental health problems 
17 
 
(Bossong & Niesink, 2010).  It has been suggested that during late maturation roughly from 
the age of 10-12 years and finishing between the ages of 16-20 years (Spear, 2000), dramatic 
changes are seen in brain growth during these critical periods for changes in frontocortical 
regions (Slotkin, 2002; Chambers et al, 2003; Nelson, 2004; Cannon et al, 2005).  During 
this phase of neuronal plasticity, there is sprouting and pruning of synapses, myelination, 
changes with neurotransmission and receptor levels which are likely to impact on behavioral 
and cognitive functions (Katz & Shatz, 1996; Luna, 2009; Rice et al, 2002).  Endogenous 
cannabinoid transmitters are central to many aspects of neurodevelopment (see Sundram, 
2006; Malone et al, 2010) and therefore, exposure to THC during such critical periods in 
adolescence may disrupt natural maturation, with evidence that this drug has effects on the 
indirect release of the neurotransmitters dopamine (Beres, 2010), glutamate (Brown et al, 
2003) and GABA (Schlicker & Kaffman, 2001), as well as on numerous neurodevelopmental 
processes (see Malone et al, 2010).  Early exposure to cannabis and higher risk of 
schizophrenia has been demonstrated in animal (O’Shea et al, 2004; Cha et al, 2006; 
Schneider et al, 2008) and human epidemiological studies (Andreasson et al, 1987; Arsenault 
et al, 2002; Zammit et al, 2002; Caspi et al, 2005; De Forti et al, 2015).   
 
Exploring the link between the use of cannabis and mental health problems is useful in 
identifying potential risks factors which lead onto more severe psychopathologies, such as 
schizophrenia (Verdoux, 2004).  There are converging findings obtained from prospective 
based population studies, which suggest that cannabis use might represent an independent 
risk factor in the onset of psychosis (Andreasson et al., 1987; Arsenault et al., 2002; van Os 
et al., 2002).   
 
1.4.2 Cross sectional studies 
There have been a limited number of cross-sectional studies exploring the link between the 
use of cannabis and risk for developing psychosis (Verdoux, 2003).  Williams et al. (1996) 
was the first to explore cannabis use in relation to positive symptoms (e.g. delusions, magical 
ideation) using the Schizotypy-A scale (STA; Claridge and Bride, 1995) in two hundred and 
eleven participants.  They found that those people that had ‘ever used’ cannabis scored higher 
on this measure relative to those who had never used cannabis, even after controlling for 
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other drug use.  Kwapil (1996) assessed a group of 36 college students at baseline on drug 
use and schizotypal positive and negative symptoms and then followed up ten years later.  
Those people with higher positive symptoms had higher rates of substance misuse (including 
cannabis use); however, substance use at baseline did not predict later psychotic symptoms.  
Skosnik et al. (2001) explored dimensions of psychotic symptoms using the Schizotypal 
Personality Questionnaire (SPQ; Raine, 1991), which assesses nine subscales (ideas of 
reference; excessive socials anxiety; odd beliefs and magical thinking; unusual perceptual 
experiences; odd or eccentric behaviour; no close friends; odd speech; constricted affect) 
amongst 15 cannabis users (who used at least once per week), 10 ex-cannabis users (with no 
use in at least forty five days as one criteria) and 15 controls (with no reported lifetime use of 
cannabis as one criteria).  Cannabis users scored significantly higher on all subscales of the 
SPQ relative to ex users and controls. Nunn et al. (2001) also explored dimensions of 
psychosis using the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE, 
Mason et al., 1995) in 196 students; those who used cannabis only, alcohol only, alcohol and 
cannabis and no alcohol or cannabis.  The O-LIFE measures four subscales of psychotic 
symptoms; positive, negative, cognitive disorganisation and impulsivity non-conformity.  An 
additional measure was used to assess for delusion ideation called the Peters et al.’s Delusion 
Inventory (PDI; by Peters et al., 1999).  Those participants using cannabis only had higher 
rates of positive symptoms in the O-LIFE and higher scores on the PDI relative to non-
cannabis users, whereas, those using cannabis and alcohol scored lower on the negative 
measures for introverted anhedonia than any other group.  It may be that the cannabis using 
only group represent a distinct/unusual group where this cohort has a distinct personality 
type.  For example, people may use cannabis (as opposed to any other drugs) specifically for 
religious or creative purposes; a high level of trait creativity is linked to the positive 
symptoms in schizophrenia (Shafer et al, 2012). 
 
Dumas et al. (2002) assessed a group of 232 students who were categorised into past never 
used, past use, occasional use, or regular use of cannabis (at least twice per week) using the 
SPQ and four of the Psychosis-Proneness scales by Chapman et al.  (1994).  Those who had 
never used cannabis reported significantly fewer psychotic-like traits on the psychosis-
proneness measures, relative to the ex-cannabis and current cannabis users.  Verdoux et al. 
(2003) explored the link between cannabis use and psychosis in a group of 571 females, 
assessing lifetime and current use of cannabis and other substances.  Psychosis proneness was 
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assessed using Community Assessment of Psychic Experiences (CAPE; Stefanis et al., 2002) 
which has 42 items of positive, negative and depressive symptoms.  Cannabis use was 
categorised into frequency of use, no use in last month, once a month to once a week, more 
than one time per week.  Increased levels of cannabis use were associated with higher 
frequency of positive and negative psychotic-like symptoms.  There were no significant 
associations found for frequency of cannabis use and depressive scores, nor for alcohol use 
variables and dimensions of psychosis proneness.  
 
Overall, cross sectional studies converge to indicate that cannabis use (whether current or ex 
use) is associated with psychotic traits compared to those who report no use.  The association 
does not seem to exist for cannabis and depressive symptoms, nor for alcohol use and 
dimension of psychosis proneness.  Cross-sectional studies are often limited to relatively 
small sample sizes, and by their nature are a snap shot revealing little about the development 
of problems, baseline data, and thus causation.  Such issues are to some degree addressed by 
looking at larger populations, or by following samples over longer time periods.   
 
1.4.3 Longitudinal studies 
Like cross-sectional, a longitudinal study is observational, but researchers conduct several 
observations of the same participants over a longer period of time.  This gives the benefit of 
being able to detect developments in the characteristics of the target population (i.e. cannabis 
users) at both the group and the individual level.  The benefit of longitudinal studies is that 
they extend beyond a single moment in time, and can help to assess some causal effects as 
opposed to using correlational designs. Please refer to Table 1 as a summary of the most 
influential longitudinal studies to date assessing the link between cannabis use and risk for 
schizophrenia.   
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Table 1: Population-based and birth cohort studies on the association between cannabis misuse 
and psychosis. 
Name Country Method  Odds ratio (95% 
confidence 
interval) 
Swedish Conscripts (Andrѐasson et 
al., 1987). 
SWE 45,570 participants: follow-up 
15 years.   
6.0 (4.0-8.9) 
Swedish Conscripts (Zammit et al., 
2002). 
SWE 50,087 participants: follow-up 
27 years. 
3.1 (1.7-5.5) 
The Dunedin Multidisciplinary 
Health and Developmental Team 
(Arsenault et al., 2002). 
NZ 1.037 participants: follow-up 15 
years. 
3.1 (0.7-13.3) 
The Netherlands Mental Health 
Incidence (NEMESIS; van Os et al., 
2002). 
NED 4, 045 participants: follow-up 3 
years.   
2.8 (1.2-6.5) 
Christchurch Health and 
Developmental Study (CHDS; 
Fergusson et al., 2005). 
NZ 1,265 participants: follow-up 
after 3 years. 
1.8 (1.2-2.6 
The Early Developmental Stages of 
Psychopathology (EDSP; Henquet et 
al, 2005). 
GER 2,437 participants: follow-up 5 
years. 
1.7 (1.1-2.5) 
 
The National Psychiatric Morbidity 
Study (NPMS; Wiles et al., 2006). 
UK 8,580 participants: follow-up 
1.5 years. 
1.07 (1.04-1.09) 
EDSP (Kueper et al., 2011) GER 1,423: follow-up 8.4 years. 1.9 (1.1-3.1) 
Swedish Conscripts (Manrique-
Garcia et al., 2012). 
SWE 50,087 participants: follow-up 
35 years.  
3.7 (2.3-5.8) 
 
Andrѐasson et al. (1987) conducted one of the first studies on 45,570 Swedish Conscripts 
during a fifteen year follow up study assessing the association between those reporting drug 
use at 18 and later psychotic diagnosis.  Those that tried cannabis prior to 18 had a 2.4 risk to 
develop schizophrenia relative to those that did not use the drug.  Heavy cannabis use was 
categorised as using the drug for more than 50 times and there was a dose-response effect in 
that heavier use was associated with a greater risk.  Van Os et al. (2002) followed 4, 045 
participants without any baseline psychotic symptoms as assessed by the Brief Psychiatric 
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Rating Scale (BPRS, Overall & Gorham, 1962) over 3 years, with data re-collection at two 
time-points, 1 year and 3 years. Baseline cannabis use was a stronger predictor of psychotic 
symptoms, rather than at the 1-year and 3-year follow-up.  More than 50% of the psychosis 
diagnoses attributed to cannabis use were found if the participants reported using the drug at 
an earlier age.  There were a number of confounding factors in the Swedish Conscript study 
(e.g. other drug use and personality traits likely to predispose someone to develop a psychotic 
disorder). Zammit et al. (2002; 2004) followed the same cohort up to 27 years and concluded 
that baseline cannabis use was associated with a greater risk for developing a psychotic 
disorder and the dose-response relationship remained even after controlling for confounding 
factors.  Similarly, in the NEMESIS study by van Os et al. (2001) of 4,045 people without 
baseline psychotic symptoms, a dose-response effect was found in those using cannabis at 
baseline had developed a psychotic disorder at the 2-year follow-up period.  
 
In the one birth cohort study, Arsenault et al (2002) assessed 1,037 individuals born in 
Dunedin in 1972-3, with 96% of the sample followed up to age 26.  The researchers obtained 
information on psychotic symptoms at age 11 and drug use was noted at ages 15 and 18.  A 
standard interview was conducted using the DSM-IV.  The groups were divided into three 
based on cannabis consumption at age 15 (just under 30% whom reported three or more times 
using cannabis and continued up until 18), 18 (just under 32% using three or more times) and 
controls (65% of the sample whom had reported no use, or once or twice).  Psychiatric 
outcomes by the age of 26 were assessed based on symptoms of schizophrenia and depression 
and diagnoses of schizophreniform (a form of schizophrenia with a shorter duration of 1-6 
months) and depression.  Logistic regression revealed that people who reported having used 
cannabis by age 15 or 18 had higher rates of schizophrenia symptoms (10.3%) than controls 
(3%).  These effects remained even after controlling for baseline psychotic symptoms at 11; 
the effect was stronger for earlier use of cannabis and developing schizophreniform disorder 
(e.g. before the age of 15).  Cannabis use did not predict any depressive outcomes, but it was 
the strongest predictor of schizophrenia symptoms from drugs used during adolescence.   
 
Using data from the Early Developmental Stages of Psychopathology (EDSP) 5-year 
prospective study, of 2,437 participants, Henquet et al. (2005) reported that those scoring 
high on schizotypy reported more psychotic symptoms after cannabis use compared with 
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individuals with lower schizotypy scores.  Kuepper et al. (2011) followed up 1,423 from the 
EDSP studies who were aged 14-24 at baseline.  They assessed them at two different time 
points, which averaged at 3.5 years from the first test, then the last testing session 8.4 years 
later.  The researchers wanted to assess whether continued use of cannabis would affect 
incidence and persistent psychotic symptoms in the general population.  Individuals who 
reported no cannabis use and psychotic symptoms at baseline, then reported cannabis use 3.5 
years later, also experienced an increase in psychotic symptoms over a period of 3.5 to 8.4 
years (adjusted odds ratio of 1.9).  The incidence rate of psychotic symptoms in individuals 
exposed to cannabis from baseline to 8.4 years was 31%, compared to 20% in non-exposed 
individuals; from 3.5 years to 8.4 years, these rates were 14% in users and 8% in non-
cannabis users.  Interestingly, rates of psychotic symptoms declined upon abstention from 
cannabis use, but continued to increase with persistent use of the drug.    
 
Fergusson et al (2005) conducted a 25-year longitudinal study assessing a birth cohort of 
1,265 in a general community sample at age 18, 21, 25 on psychotic symptoms and drug use.  
A regression model revealed that those reporting daily use of cannabis had between 1.6 and 
1.8 higher rates of psychotic symptoms than non-cannabis users.  Structural Equation 
Modelling revealed that the effect of cannabis was stronger for predicting these psychotic 
symptoms rather than the effect of symptoms on cannabis use.  Wiles et al. (2006) assessed 
8,580 participants aged 16-74 using the revised version of the Clinical Interview Schedule 
(CIS-R; Lewis et al., 1992; Lewis 1994) and Psychosis Briefing Questionnaire (Bebbington 
& Nayani, 1995); those with psychotic disorder were excluded at baseline and 2,413 
completed the follow up interview.  Those dependent on cannabis had a higher risk for 
incidence of psychotic symptoms, and also those engaging in risky drinking behaviours.  
Other factors involved included life events, such as inhabiting a rural area, and tobacco 
smoking.  Grech et al. (1998), in a 4-year follow-up of 119 people diagnosed with 
schizophrenia, also found that continued use of cannabis was associated with severity of 
symptoms and longer course of the illness with positive symptoms, than those who did not 
misuse cannabis.  Further to this, Zammit et al. (2008) carried out a systematic review on the 
effects of cannabis on psychotic outcomes, and reviewed 13 studies for rehospitalisation, 
readmissions, measures for symptoms, measures for treatment, adherence to treatment.  
Continued cannabis use was associated with poorer treatment outcomes and increased 
relapse/readmissions.  Moore et al. (2007) also carried out a systematic review, in this case to 
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specifically see if cannabis use is associated with psychotic symptoms that persist beyond 
transient intoxication.  This review reported an increased risk of developing psychosis in any 
individual that reported cannabis use (adjusted odds ratio (Adj OR): 1.41), with a consistent 
dose response effect (Adj OR 2.09).  However, these data from Moore et al’s research could 
be due to alternative explanations (e.g. other drug use or pre-existing personality traits), but 
Moore et al  concluded that cannabis use increased risk for developing psychotic disorders 
and individuals should be advised about this risk.  It is somewhat surprising that few studies 
have controlled for confounds such as alcohol use at baseline, and several other 
sociodemographic factors.  Foti et al. (2010) assessed a group of 229 people diagnosed with 
schizophrenia over a 10-year period, with assessments at five time points (0, 6months, 2, 4 
and 10 years), on a range of psychiatric symptoms; psychotic, depressive, negative and 
disorganised, and controlling for numerous other possible confounds.  Lifetime use of 
cannabis was 66.2% in the sample and a greater total lifetime use was associated with earlier 
onset of psychosis.  Cannabis use in those diagnosed with schizophrenia was associated with 
worsening of psychotic symptoms and these symptoms were associated with an increase in 
cannabis use.  Importantly, this effect remained even after controlling for gender, age, 
socioeconomic status, other drug use and medication. 
 
There are several ways to explain the link between cannabis use and psychosis because a 
causal link has yet to be clearly established.  The prominent view is that cannabis use exerts 
itself as a component cause, in that it is neither a necessary (as some people develop 
schizophrenia without having used cannabis) nor a sufficient cause (as most people do not 
develop a psychotic disorder from using cannabis).  For example, Rothman and Greenland 
(1998) use a causal model, to explain the schizophrenia risk model divided into key sections 
representing a constellation of causes that inevitably lead to disease occurrence, and with 
each element having a causative influence.  The causal model contains component causes 
(e.g. environmental, genetic, cannabis) and a component is necessary for the disorder to 
occur.  A disorder may need a collection of sufficient causes, which are made up of a range of 
component causes which lead to the disorder along with range of another component cause.  
Cannabis could therefore be seen as a component in this predictive model for developing 
schizophrenia; interacting with other components such as genetics (candidate genes), or 
environmental influences (high stressors).  The model put forward for this thesis is an 
adaptation from the diathesis stress model (Gottesman, 1991) and a new multi-component 
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model which elaborates more on the known risks of cannabis in this model - please refer to 
Figure 1.  Outcomes for psychological disturbance are inextricably linked to an interaction 
between early life/neurodevelopmental, vulnerability/genetic, environmental factors and 
psychosocial stressors; as described in the diathesis stress model.  Whereas for the specific 
link between cannabis use, the component model and the diathesis stress model are missing a 
number of additional factors which are known to contribute to this risk in developing sub 
clinical symptoms and behaviours.  The prominent view is that early onset of the drug (before 
the age of 15) is linked to greater risk, as well as the type of cannabis use (primarily skunk 
and high THC potency cannabis) as well as duration of use.  It is clear that not all of those 
who smoke cannabis will go onto develop subclinical or full blown schizophrenia, but it may 
that those who smoke cannabis with more of these risk factors in the model would be 
categorised as having a higher risk, and this wold be demonstrated in the model for the output 
in that they would be pushed higher up the spectrum in subclinical schizophrenia changes.  
This therefore would be demonstrated in them showing more symptoms and having greater 
cognitive disruption as is seen in patients with full blown schizophrenia.    
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Figure 1: A multi-component model (an adaption of the diathesis stress model) for the 
link between cannabis use and risk for schizophrenia. 
 
1.5 Rationale 
There is strong evidence to support the claim that cannabis use is a risk factor for the 
development of psychotic symptoms and schizophrenia (see section 1.3 and 1.4).  
Nonetheless it is also clear that the majority of cannabis users do not go on to develop this 
disorder.  It is argued that the use of cannabis is causing some of the sub-schizophrenia 
symptoms in some users, and that prolonged use and/or heavy use of stronger versions of 
cannabis is linked to the onset of induced symptoms in people that may not have developed 
these symptoms otherwise.  The material covered in this chapter does also highlight the 
extant literature demonstrating some degree of cognitive change, and possibly elevated 
schizotypy, in recreational cannabis users.  Whilst other types of association and other 
discrete factors may very well be of significance, exploration of cannabis as at least partly 
causal in these effects is clearly warranted.  If cannabis in some individuals may contribute to 
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or even trigger episodes of schizophrenia, it may very well be the case that this potent 
psychoactive contributes to changes and/or symptoms which are part of or relate to the 
constellation of features we see in the full blown disorder.  The view of cannabis contributing 
to psychological change in the direction of schizophrenia (or sub-schizophrenic change) is 
illustrated in Figure 1, and the evidence presented in earlier sections of this chapter fit with 
the model, in which cannabis is an added component in the development of pathology.  The 
majority of cannabis users’ will have a low risk for developing full blown schizophrenia, but 
risk of some changes in that direction may be elevated (as demonstrated by having some 
subclinical symptoms and behaviours.  This might be further the case in those with additional 
underlying genetic or other vulnerability, and those with more of the risk cannabis use 
variables.  This thesis will partially test the model for cannabis use, vulnerability/genetics and 
explore this in relation to cognitive disruption and psychotic-like symptoms.  Whereas, other 
parts of the model remain untested, such as early life/neurodevelopment, environmental and 
psychosocial events. 
 
Much of the published research on the cannabis-psychosis link has focussed on schizotypal 
traits, as opposed to looking at traits combined with cognitive performance and genetic 
susceptibility.  Further to this, research has focussed mainly on clinical samples (e.g. people 
diagnosed with schizophrenia).  These studies are not without their problems as there is 
heterogeneity in symptoms and behaviours in terms of schizophrenia or psychosis.  Findings 
drawn from clinical studies are difficult to fully explain in terms of causality as a 
confounding factor is linked to clinical status, which is difficult to control.  Therefore, 
research using non clinical samples may provide a better way of attempting to elucidate the 
link between cannabis use and psychosis (e.g. Verdoux et al., 1998; van Os et al., 2000; 
2001; Verdoux and Van Os, 2002). 
 
The general aim of the current research thesis is to explore a range of cognitive functions 
affected by schizophrenia, psychotic-like personality traits, candidate genes for 
schizophrenia, in a group of recreational cannabis users (free from existing 
psychopathological disturbance) versus a control sample of non-cannabis users.  A key 
difference in this research thesis is that schizotypy has been measured alongside cognitive 
performance, in order to see if there is an interaction here and how this then relates to 
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cannabis use.  Study 1 has LI, KB and schizotypy and Study 2 adds greater personality 
analysis alongside other cognitive tasks known to be sensitive to cannabis use and to 
schizophrenia. 
 
This research aims to use cognitive tests that appear to especially affected in schizophrenia 
and link to the neuropsychological underpinning of the disorder (there may be more global 
deficits in schizophrenics, so tasks that map on to the key theorised changes that take place in 
schizophrenia are used), and schizotypy, because it exists as a general population personality 
trait as well as being strongly linked to schizophrenia itself.  Under the ideas being explored 
here is that cannabis use pushes people further along the schizotypy continuum, as part of this 
sub-schizophrenic change.  Furthermore, some risk marker genes will be assessed  that have 
emerged from the extant genetics literature, to see if (as illustrated in Figure 1) cannabis use 
alongside some degree of genetic vulnerability may be even more likely to produce some 
level of sub-schizophrenic change. 
 
Study 1 aims to assess selective attention in cannabis users relative to non-cannabis users, 
through the use of two associative learning tasks.  The LI and KB paradigms are utilised to 
assess the ability to inhibit the processing of irrelevant stimuli which have been previous 
deemed to be irrelevant.  Chapter 2 provides a detailed background to research using the LI 
and KB tests, as well as the theoretical basis for choosing such tests.  Section 1.2 above 
briefly described some data and evidence to highlight disruption in inhibitory processing and 
selective attention in cannabis users similar to people diagnosed with schizophrenia.  
Therefore, due to the mounting evidence, it is expected that the cannabis users should show 
disruption on these associative learning tasks compared to non-cannabis users. 
 
Study 2 aims to assess attention, executive control and decision-making in cannabis users 
relative to non-cannabis users.  Section 1.2 above highlights some of the key effects cannabis 
has on these cognitive processes.  Chapter 3 provides a detailed theoretical background on 
these cognitive processes with arguments as to why such tests have been chosen to 
demonstrate these functions.  In brief, executive control will be assessed through the use of 
the Anti-Saccade Task and an eye-tracking device.  Decision-making will be assessed using 
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the Iowa Gambling Task.  Selective/sustained attention and inhibitory control will be 
assessed through the use of the Continuous Performance Test.  Based on earlier research on 
cognitive dysfunction in cannabis users, it is expected that cannabis users will highlight 
higher level cognitive processing deficits compared to non-users, thus resembling sub 
schizophrenia like symptoms  (please refer to Chapter 3 for further detail).   
 
Individual differences in psychotic-like personality traits will also be assessed.  Study 1 will 
assess the three factors linked to the structure of schizophrenia symptoms, such as positive, 
negative and disorganised domains.  Study 2 will go further to explore a range of other 
psychotic-like traits which have been overlooked in the research but are gaining more 
prominence in the current literature.  For example, one would be emotional processing, where 
there is less clarity in thinking, and also ambivalence as a trait, in that people alternate quite 
rapidly between emotions (e.g. love and hate for the same thing).  Based on earlier research 
findings it is expected that cannabis users will report experiencing more of these psychotic-
like traits and there will be a correlation between earlier onset of cannabis use, frequency and 
duration of use. 
 
Chapter 4 covers the selection and measurement of a number of genetic markers which have 
previously been associated with elevated risk for schizophrenia.  The aim of this work was to 
speculatively search for some of these markers amongst the cohorts tested in the behavioural 
studies, and initially provide a focused genetic picture of the participants across and between 
groups.  This work also provided the possibility to assess the relative contribution that certain 
genetic risk markers linked to schizophrenia may have on predicting outcomes of 
performance on the battery of cognitive tasks and personality measures used in Study 1 & 2.  
It was expected that people with more of these risk marker genes (e.g. variants in the DAOA, 
COMT, NRG1) and will display more of a personality and behavioural profile similar to that 
of someone with schizophrenic symptoms.   
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In particular, it was predicted, in line with the extant literature (explored in more detail in 
Chapter 4), that people with higher prevalence of the COMT risk haplotype genes, who also 
use cannabis, may have more sub schizophrenia-like symptoms and behaviours.  Due to the 
lack of evidence looking at cannabis and gene correlates for the neuregulin gene (NRG1) and 
the cannabinoid genes (CNR1 and FAAH), it is difficult to make clear predictions, so these 
data were exploratory (please refer Chapter 4 for more detail regarding these genes). 
 
Chapter 5 provides a summary of key results across all of the work.  The contributions of the 
thesis findings to the literature are explored and methodological limitations of this research 
discussed, alongside suggestions for future work in this area.   
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Chapter 2: Latent inhibition, Kamin blocking and psychotic-like traits in regular 
cannabis users 
 
2.1  Introduction 
Selective attention is the processing of incoming information, in a quick and rapid way, to 
selectively filter relevant from irrelevant
 
information (Broadbent, 1958). Selective attention 
deficits are seen as one of the fundamental dysfunctions in the disorder of schizophrenia; and 
these are numerously reported in the literature, both from the patient and clinician (MacDonald, 
1960; McGhie and Chapman, 1961; Evans et al, 2007).  As a result of this, there have been 
many paradigms developed to test selective attention dysfunction, with Latent inhibition (LI) 
and Kamin Blocking (KB) being two of the most prominent models utilised both in human and 
animal studies (e.g. Lubow, 2005).  Animal studies have shown that LI and KB are disrupted 
by increased dopaminergic activity, and restored by dopaminergic blockade (Joseph & Jones, 
1991).  LI and KB tests are measures of associative learning when a certain stimulus comes to 
be associated with another stimulus or behavior, as through classical or operant conditioning 
(Pearce & Boulton, 2001).  The working memory system plays a key role along with the 
executive system to form new associations (Tanji & Hoshi, 2001).   
 
2.1.1 Latent inhibition (LI)  
LI is defined as occurring when: “A stimulus that is casually familiar enters into new 
associations more slowly than a novel stimulus” (Lubow & Gerwirtz, 1995, pg 87).  It was a 
term first introduced by Lubow and Moore (1959) to describe the observation that exposure to 
an irrelevant stimulus impairs the ability to form subsequent conditioned associations with that 
stimulus.  Without LI, ordinary learning would be a cumbersome process.  LI promotes the 
stimulus selectivity required for rapid, efficient learning.  LI creates a bias in favour of 
potentially important stimuli by degrading those stimuli that have been registered as 
inconsequential in the past (Lubow, 1989).  
 
Lubow (1989) postulates that there would be an overload of information processing, if the brain 
was required to process all of the incoming input of information, as being similar and of equal 
importance; but it seems the natural adaptive response evolved for human/animal learning and 
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attention requires an automatic selection of information that is deemed to be the most 
important, with inconsequential information being filtered out as unimportant.  An everyday 
application of LI would be the ability to block out irrelevant information on a train journey 
whilst reading a book; this is generally done in an unconscious manner.  People deemed to be 
high in latent inhibition would easily block out any irrelevant information (i.e. the overload of 
advertising, high volume of people, other people’s distracting behaviours etc.) whereas, those 
with low latent inhibition would find it difficult to read because they would be easily distracted 
by the external stimuli within this type of setting.   
 
The majority of LI experiments to date have used the instrumental learning-to-criterion method, 
with the number of trials to criterion used as dependent variable (Lubow & Gewirtz, 1995).  A 
typical LI experiment for this paradigm would have two separate groups: one pre-exposed (PE) 
and the other non-pre exposed (NPE).  The PE group engage in a masking task which involves 
listening to a series of nonsense syllables and are asked to select one syllable and count how 
many times it is repeated.  During the PE condition, alongside the nonsense syllables, the 
participants are presented with a number of trials where the to-be-conditioned stimulus (e.g. a 
burst of white noise) appears.  The NPE group are presented with a similar task for the 
nonsense syllables, but with the to-be-conditioned stimulus being absent (no white noise).  The 
test phase for all participants involves the to-be-conditioned stimulus (e.g. the white noise) 
becoming the target for which all participants should respond to (e.g. by pressing a button when 
a counter incrementally increases); the white-noise always precedes the counter incrementing.  
The measure is the number of trials-to-criterion (with at least five correct consecutive responses 
of the paired association between the white noise and counter incrementing).  Participants in 
the PE condition with the white noise take a significantly longer time to learn the association 
than those who have not been previously exposed to the white noise; this is what is referred to 
as the latent inhibition effect.  The LI effect in healthy individuals has been replicated in 
numerous studies (e.g. Baruch, Hemesley & Gray, 1988; Gray, Hemsley, & Gray, 1992; 
Escobar et al, 2002; Lubow, 2005; Kaplan & Lubow, 2010).   
 
2.1.2 Latent inhibition and schizophrenia 
Support for the model of LI being disrupted in schizophrenia comes from research showing that 
LI can be attenuated or abolished in rats treated with a dopamine (DA) agonist, such as 
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amphetamine (Soloman et al. 1981; Weiner, Lubow & Felton, 1981, 1984).  This effect can be 
reversed through the administration of a dopamine antagonist (e.g. haloperidol; demonstrated 
by Christison, Atwater, Dunn, & Kilts, (1988); Solomon et al. (1981); Weiner & Feldon, 
(1987); Weiner and Feldon, & Katz, (1987)).  Additionally, Dunn et al’s (1993) research 
indicated that what might be termed the LI ‘super’ effect (e.g. increased latent inhibition) seems 
to be specific to antipsychotic drugs.  These drug effects on LI fit into the model of 
schizophrenia being related to deficits in attentional processing (Anscombe, 1987; Mirsky & 
Duncan, 1986; Nuechterlein & Dawson, 1984) and that the dopamine system has been 
implicated in playing a role in this attentional dysfunction (Matthysse, 1978; Swerdlow & 
Koob, 1987).  
 
 
High levels of dopamine in the ventral tegmental area are associated with a decrease in LI 
(Swerdlow et al, 2003).  Other neurotransmitters may also be involved, including glutamate, 
GABA (gamma aminobutyric acid) and acetylcholine (for reviews refer to Kleinman, 
Casanova, & Jaskiw, 1988; Owen & Crow, 1987; Reynolds, 1988; Weinberger, 1987).  Baruch 
et al’s (1988a) research has demonstrated a loss of LI (i.e. a lack of filtering out of a previously 
conditioned stimulus that is normally ignored or deemed to be irrelevant) in acute but not 
chronic schizophrenic patients.  However, this effect was not found after the patient was in 
drug treatment for 6-7 weeks, and there was a positive correlation between lower amount of 
clinical symptoms and higher LI.  Interestingly, patients with acute schizophrenia (at least two 
weeks into medication treatment) when pre-exposed to the to-be-conditioned stimulus learnt 
the relationship much faster than healthy controls.  This therefore rules out any effects that may 
have been due to a lack of motivation and/or interference from their clinical symptoms and 
medication, when considering that schizophrenic patients generally show poorer performance 
on most cognitive tests (e.g. Heinrichs & Zakzaris, 1998). 
 
 
2.1.3 Latent inhibition, schizophrenic-like traits and other individual differences 
Baruch et al. (1988b) used the LI paradigm as a way to assess the general population for 
individual differences in psychotic-proneness.  Prior to this work, psychotic-like traits were 
assessed utilising measures such as Launey and Slade’s (1981) Hallucination scale, Claridge 
and Brokes (1984) Schizotypal Scale (STA) and Eysenck and Eysenck’s (1975) Psychoticism 
questionnaire.  Baruch et al found that higher levels of psychotic-like traits were directly 
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related to lower levels of LI.  These psychosis-proneness effects have been replicated by 
numerous researchers, including Lubow et al (1992), De la Casa (1993) and Serra et al. (2001).  
Serra et al (2001) investigated learning in chronic schizophrenics and their first-degree relatives 
versus a healthy control sample.  The first-degree relatives were divided into two groups, those 
who were high/low in schizotypy.  The controls showed latent inhibition (i.e. reduction in 
learning when pre-exposed to the to-be-conditioned stimulus).  People diagnosed with 
schizophrenia and both their schizotypal and non-schizotypal relatives performed much worse 
overall on basic associative learning, and also showed a loss of LI.  Serra et al’s findings run 
counter to previous models in that disruption of LI was due to slower learning in the two 
conditions, and the controls were faster to learn in the NPE condition.  They also found a lack 
of difference between the schizotypal relatives and non-schizotypal relatives.  Taken together, 
it was argued by Serra et al that these differences or lack of findings between the groups may 
highlight genetic markers of risk for schizophrenia.   
 
2.1.4  Kamin Blocking 
Broadbent (1971) describes information processing as a function which limits capacity to avoid 
overload, and represents parts that are made up of response biases, based on prior experiences 
and this in turn leads to the inhibition of redundant or irrelevant information.  Other models 
provide support for the inhibition of irrelevant information and this is thought to bias 
information in an automatic rather than a controlled response (see Schneider and Shiffrin, 1977; 
Posner, 1982).  Kamin Blocking, similar to LI, has been developed to test this model of 
attentional processing.  However LI has been more extensively researched as a paradigm 
relative to the KB effect.  
 
The Kamin Blocking Effect (KBE) procedure consists of four stages with two experimental 
conditions: blocking (BL) and non-blocking (NBL); participants are placed in to one of two 
conditions.  During stage one, participants initially complete some keyboard skills by pressing 
the space bar when they see a yellow cross.  In stage two, participants are presented with some 
coloured shapes on the screen, and in the NBL condition there is no association between any of 
the stimuli, whereas in the BL condition they see a coloured shape (CS1 – blue square) that is 
always followed by a second one (the UCS – yellow square).  Stage two is entirely 
observational.  During stage three, both groups are asked to predict when the yellow square 
 
 
34 
 
should appear and are exposed to the same sequence in which the UCS (yellow square) always 
follows the same pattern made up of CS1 (blue square) and an additional stimulus (CS2 - a 
small light ‘flanker’ stimulus presented both to the left/right of the computer screen). In the 
final stage, the blue square (CS1) is dropped from the sequence; this time the task is to predict 
when the yellow square will appear, which is now preceded only by the light flankers when 
they appear on the screen alongside any coloured square. The KBE is demonstrated as slower 
learning of this CS2 plus or minus the UCS association, in the BL compared to the NBL 
condition (e.g. Serra et al, 2001).   Please refer to section 2.2 below for full details of the 
method and stimuli.  
 
 
2.1.5 Kamin Blocking and Schizophrenia 
Previous research to test information processing biases in schizophrenia has shown the KBE is 
affected by the administration of amphetamine (a DA agonist), and like LI this is reversed by 
the dopamine antagonist haloperidol (Crider et al, 1982, 1987; Ohad et al, 2003; O’Tuathaigh 
et al, 2003); this finding ties in to the dopaminergic hypothesis of schizophrenia.   A Kamin 
Blocking Effect (KBE) was found between the BL and NBL in healthy participants (e.g. Jones 
et al, 1990).  The same KB task was administered to a group of 29 people diagnosed with 
schizophrenia (14 acute and 15 chronic), and it was found that blocking was not present in 
acute patients tested within two weeks of admission as opposed to chronic patients stabilised on 
medication, suggesting that these inhibitory distortions can be found at the earlier stages of the 
disorders and can thus be treated with anti-psychotic medication.  Further research by Serra et 
al (2001) found that KBE is absent in people diagnosed with chronic schizophrenia, schizotypal 
personality disorder and non-schizotypal relatives.  
 
Moran et al. (2003) investigated the KB paradigm in 27 healthy volunteers and 21 people 
diagnosed with schizophrenia, and also explored schizotypal personality traits.  They found a 
negative relationship between the two subscales of the O-life questionnaire (unusual 
experiences and cognitive disorganisation) and KB performance.  Those people who reported 
feeling more unusual experiences and cognitive disorganisations were less likely to be affected 
by the blocking on the KB task which resulted in obtaining a lower score (i.e. they found the 
association more quickly).  They also found that KBE was attenuated in non-paranoid patients - 
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so those patients not experiencing paranoid symptoms were affected less by the blocking 
conditions. 
2.1.6 Summary and Rationale 
Associative learning and the selective attentional processing crucial to this process, appear to 
be impaired in individuals with schizophrenia and in those scoring high for schizotypy, and can 
be modulated by drugs affecting dopamine in humans and animals.  These findings are 
consistent with the dimensional view of psychosis, and neurobiological theories relating to 
aetiology of the disorder.  In the LI task, high scorers on schizotypy resemble the performance 
of people in the acute stages of schizophrenia, in that they are quicker to learn the association in 
the PE groups.  The clearest evidence comes from research looking at differences between 
high/low schizotypy with high scorers overall on psychosis-proneness measures predicting a 
reduced LI performance.  Findings with the KB task are more variable, but largely support 
those found for LI.  To date no known published research has looked at LI and KB performance 
in regular cannabis users, apart from my research conducted at undergraduate level (Lynch & 
Turner, 2006), which found subtle associative learning differences between cannabis users and 
non-cannabis users.  It was found that cannabis users took less time overall on both tasks but 
mainly for the LI task they were less affected by the pre-exposure conditioning, as is seen in 
patients in the acute stages of  schizophrenia.  However, this aforementioned study was limited 
for a number of reasons.  
1. It relied heavily on subjective reporting of abstinence from cannabis and this was not            
objectively verified through drug screening methods.  Subjective reporting is open to bias in 
terms of the drug group not being honest.  Therefore, the differences found arguably could 
be due to the sub-acute effects of smoking cannabis or other recent drug use 
2. There is a lack of a full drug history, to look for use of other substances which might 
chronically affect cognitive processing, such as use of high doses of cannabis over long 
periods, dependency on cannabis and use and co-use of other psychoactives – some of this 
was explored, but only relatively superficially in the earlier work.  
3. Participants were not screened for mental health history, both personal and familial to 
account for a biological predisposition towards schizophrenia.    
4. It lacked external validity as most of the participants were undergraduate psychology 
students who were not offered any remuneration so may not have been that motivated to 
take part. 
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The current study aimed to address these issues and further explore the link between smoking 
cannabis and schizophrenic-like behaviours, by testing a group of cannabis users versus non-
cannabis users, on LI and KB performance, to see if there are subtle differences between both 
groups.   Based on the literature reviewed in Chapter 1, it is clear that cannabis use in some 
people may contribute to schizophrenia.  Cannabis use is also frequently associated with acute 
and sub-acute psychotic-like experiences; in normal, non-pathologised individuals as well as in 
clinical populations.  Such effects may be underpinned by alterations in dopamine produced by 
THC; acutely, sub-acutely and chronically.  If cannabis use is producing such effects at a stable 
level, elevating schizotypy in many, leading to more serious disturbance in others, then we 
should also see noticeable differences amongst cannabis users, in other behaviours and 
cognitive processes affected by psychosis.  As such, the filtering out of irrelevant information 
typically seen in normal healthy adults, but which has been shown to be disrupted in people 
diagnosed with schizophrenia, those administered with dopamine agonists and high schizotypy 
scorers may also be significantly affected by regular/frequent cannabis use.  The hypothesis 
therefore is that cannabis users will show moderate impairments on the associative learning 
tasks for selective attention, namely LI and KB.  In addition, both cannabis users and control 
participants will be classified as either having high or low psychotic-like traits from using their 
scores on the SPQ-B measure (Raine & Benishay, 1995), and this will be explored to look at 
differences between these groups on their LI and KB performance.  Previous research has 
demonstrated that individual differences in psychotic-like personality traits results is linked to 
disrupted associative learning, namely for the LI and KB tests.   Therefore it is predicted that 
those scoring higher for psychotic-like traits will also showed reduced LI and KB performance. 
 
The regular use of cannabis has been associated with experiencing more psychotic-like traits, 
and this research was presented in the review Chapter one (section 1.4).  Therefore it is 
predicted that cannabis users in this study will report a greater number of SPQ-B traits when 
compared to non-cannabis users.   The review chapter also explored early onset of cannabis use 
and frequency of use of cannabis as key predictors in schizophrenic-like behaviours.  Therefore 
deficits in LI and KB performance will be mostly marked in those with earlier onset of 
cannabis use; notably those who first used before age 15.  Problems are also more likely to be 
seen and to be more significant in individuals who use cannabis heavily and/or very regularly 
(e.g. daily use). 
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2.2 Method 
2.2.1 Participants 
Twenty cannabis users and twenty non-cannabis users took part in this study and had an age 
range of 18-45, with a mean age of 30 (refer to Table 2 for a full list of demographic details).  
Five additional participants were tested and included in the non-cannabis using group for the 
secondary analysis, with the age range for all participants from 18-42 and a mean age of 29.  
Refer to Table 8 for a list of participants’ demographic details used in the secondary analysis.  
Participants contacted the researcher by telephone or via e-mail, in response to adverts (see 
below), and were screened for eligibility for inclusion.  Exclusion criteria were based on those 
that were currently taking any psychoactive medication, had a diagnosis of epilepsy, had any 
brain trauma or those cannabis users that did not abstain for two days prior to testing (as 
verified by a drugs screening kit using an oral salivary assay).   
 
Recruitment 
Recruitment was varied to attract a wide range of participants, through advertising in local 
London newspapers (Camden New Journal), online social networking sites (such as setting up a 
group on Facebook) and by placing numerous ‘wanted’ advertisements in Gumtree. Student 
participants at UEL were contacted via the internal e-mail system and by posters placed on 
walls throughout the UEL Stratford campus; this also created a snowball effect, with students 
contacting their friends and family outside of the university.  There was a remuneration 
payment of a £10 love-to-shop gift voucher for participation.  
 
Ethical clearance 
Ethical clearance was obtained through the UEL Graduate School; reference = ETH/08/56 (see 
appendix xvi).  All codes and regulations for compliance with the BPS (1978, 2009) Ethical 
Codes of Conduct for conducting research using human participants were upheld throughout.  
Example forms can be found in the appendices: information sheet (appendix i), consent form 
(appendix ii) and de-briefing sheet (appendix iii). 
 
Research setting 
Testing took place at 11 am or at 2pm in the recreational drugs lab at UEL or in small teaching 
rooms when the drugs lab was not available.  
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2.2.2 Materials 
 
Drugs Test 
Salivary drug testing was carried out in all participants using the Multiline Wondfo 6 in 1 
Saliva Drug Testing Kit DSW-765 from: http://www.drug-testing-kit.co.uk.  These single use 
tests allowed for the qualitative screening of the following drugs: Amphetamine, Cocaine, 
Cannabis, Methamphetamine, Opiate, and Phencyclidine. 
 
 
Cognitive Testing 
Latent Inhibition Task 
The LI procedure here is a replication of that used in Serra et al’s (2001) study. This method 
consists of two experimental conditions and two stages, with participants from the control and 
drug groups counterbalanced in a between participants design to allocate them to either the pre-
exposed (PE) or the non-pre exposed (NPE) conditions.  During the first stage those placed in 
the PE condition were asked to listen to a tape recording of nonsense syllables (NS; e.g. gid, 
gad, yik & yak) and, via written and verbal instructions, were asked to count the number of 
times one of them recurs.  The use of NS serves as a distracter, which diverts attention from the 
true purpose of the task; which has been deemed necessary to demonstrate LI with human 
participants (Lubow, 1989; Serra et al, 2001).  Alongside the NS syllables those in the PE 
condition also hear bursts of low-intensity white noise, the conditioned stimulus (CS), which 
are randomly superimposed on the recording and are played at different levels of intensity and 
are played for a total of five minutes along with the nonsense syllables.  Those placed in the 
NPE condition hear the exact same recording of NS without the CS (white noise recording).  
 
In stage two participants are all played the same recording as was in the PE condition above. In 
other words they are all (in both PE and NPE groups) hear the NS played with the white noise, 
but this time they are instructed to predict when a counter display will be incremented by 
pressing the tab located underneath the counter display; increments, which represents the 
unconditioned stimulus  (UCS) are always preceded by the white noise CS.  In other words, 
each time there is a burst of white noise the counter on the screen always increases by 1. The 
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trials stop after learning has been achieved as a result of getting five correct consecutive trials 
of the CS (white noise) and counter increasing (UCS).  Otherwise testing ends after 25 
associations between the CS and UCS. LI is demonstrated as slower learning in the PE than 
NPE condition, as in the PE condition participants have been previously introduced to the CS 
without any other consequence and hence should take longer to find this paired association 
between the CS and UCS.  The masking task consisted of a series of 40 nonsense syllables 
recorded at different intensity levels (70±78 dB) on the same recording for the PE condition 
and for testing in Stage 2; the recording used a female voice.  The LI task involved two stages 
(one observational and one for the real test phase; please refer to Figure 2 for a visual 
representation of this tasks design). 
 
Stage One  
Pre-exposed condition: A series of NS was presented for about 5 min through headphones 
(TDK HP100); these were repeated five times in a fixed order, with participants being unaware 
of when any one series starts and ends.  Under both the PE and NPE conditions all participants 
listened to the masking material with instructions (on-screen) to `choose one syllable and count 
how many times it is repeated'. In the PE condition 25 bursts of white noise (the to-be-CS) 
were superimposed on the left-ear of the audiotrack, in conjunction with the nonsense syllables. 
These white noise burst varied randomly between five intensity levels (range: 64±76 dB) and 
five durations (range: 1±3 s) throughout the recording and were presented at randomly varied 
inter-stimulus intervals over the range of 2 ± 22 s.   
Non pre-exposed condition: The nonsense syllables were played as in the PE condition minus 
the superimposed white noise bursts. 
 
 
Stage Two 
Testing session: Participants were told that they had to move on to the next task; and the aim 
of this task was to predict when they think the counter (on-screen starting at 0 and then 
increasing to 1, then 2 and so forth) would change, by pressing the left mouse button, on the tab 
which would be directly underneath the counter.  All participants now listened to the recording 
with superimposed white-noise bursts, as used previously in stage one of the PE condition. 
Counter increments (the UCS) took place after each burst of white noise (the CS).  The learning 
criterion was based on the completion of five consecutive correct responses (i.e. a button press 
within the duration of a CS presentation response) of the white noise and counter incrementing. 
 
 
40 
 
The test phase was completed either when the learning criterion was achieved or after a total of 
25 UCS presentations (i.e. unsuccessful learning).  The overall score is the number of trials 
before they get five consecutive correct presentations of the CS/UCS pairings.  Those who did 
not reach the learning criterion were assigned a final score of 21. 
 
 
 
 
 
 
 
 
 
                                Figure 2: Figurative representation of the LI task 
 
 
 
Kamin Blocking Effect  
The KBE procedure is based on Serra et al’s (2001) study.  The KB task involved four stages 
altogether.  The School’s programmer designed the task and each stimulus was presented at the 
centre of the screen for 1.5 seconds on a 9 x 7 inch Dell laptop screen at inter-stimulus intervals 
of: 2.5 s: 2 x 2 cm crosses and 2x2 squares (seven in total) of different colours (yellow, brown, 
navy blue, pink, green, purple and red); a pair of light grey 1 x 1 cm triangle vertical flankers  
were timely placed to display at the centre of the upper and lower margins of the screen, a pair 
of white 1 x 1 cm square horizontal flankers were timely placed to display at the centre of the 
left and right side margins of the screen. In addition to this, computer-generated white noises 
was randomly placed and displayed at different intensity and frequency levels (ranging from 
70±80 dB), the white noise were normally presented along with each of the squares and for the 
same length of time, although there was an exception of this during the pre-exposure phase (see 
below non blocking condition). The KB task involved four stages altogether.   
  
Stage 1 
PE 
 
 
NPE 
CS + NS NS 
Stage 2 
PE 
 
NPE 
 
 
CS – UCS pairing + WN 
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Stage One: Participants started with some basic keyboard skills to familiarise participants with 
the materials used, with some of the coloured crosses appearing with the noise.  At this stage, 
participants were asked to press the space bar when they see a cross symbol on the screen. 
   
Stage Two: The participants in the blocking (BL) but not the non-blocking (NBL) condition 
were introduced to the association between conditioned stimulus 1 (CS1; blue square) and the 
unconditioned stimulus (UCS; yellow square), as they had to predict when the yellow square 
would appear (on the computer screen) by pressing the space bar.    
  
Stage Three (Conditioning):  All participants in both conditions were then introduced to a new 
association which predicts the occurrence of the yellow square appearing (i.e. the UCS).  When 
combined CS1 (blue square) and conditioned stimulus 2 (CS2; the horizontally placed light 
grey square flankers) predicted that the UCS will appear.  Altogether there were 70 
presentations of the coloured squares; included in both the BL and NBL conditions along with 
20 trials of the CS1 & 2 preceded the UCS.  Participants were instructed to press the space bar 
when they think the yellow square will appear.  This stage ended either after the learning 
criterion was achieved, which was five consecutive correct responses (i.e. the correct pressing 
of the space bar preceding five presentations of CS1 and CS2 and the UCS); or the tested ended 
after 20 presentations of the yellow square, in total.  
 
Stage Four (Test): All participants in the BL and NBL condition received the exact same 
stimuli.  This time the blue square (CS1) was eliminated for predicting the occurrence of the 
UCS. Altogether there were 160 presentations of the coloured squares which were set to play in 
a randomised order.  The presentation was set-up to include 40 squares (random colours) set to 
be displayed along with the horizontally placed light grey square flankers (CS2).  After each 
presentation of the CS2 combined with any coloured square would now predict the occurrence 
of the yellow square appearing next.  Participants were instructed to press the space bar when 
they thought the yellow square will appear.  The overall score is the number of trials before 
they get five consecutive correct presentations of the CS2/UCS pairings.  Those who did not 
reach the learning criterion were assigned a final score of 36; please refer to Figure 3 for a 
visual representation of this tasks design. 
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Stage 1 
 
 
Basic keyboard skills 
 
Stage 2 
BL 
 
 
NBL 
 
 
 
CS1 – UCS pairing No association – UCS 
 
 
Stage 3 
BL 
 
NBL 
 
 
CS1 + CS2 + UCS pairing 
 
 
Stage 4 
BL 
 
NBL 
 
CS2 + UCS pairing 
                                
                                Figure 3: Figurative representation of the KB task 
 
 
Questionnaires 
The Severity of Dependency Scale (SDS; Gossop et al, 1995 – see appendix iv) 
The SDS was used to assess possible dependency in the cannabis group.  It measures 
compulsive use of a drug along with five questions which relate to the individual’s perceived 
anxieties about their own drug use and feelings of impaired control of the over the use of the 
drug. 
 One example question is:  
 
1. Did the prospect of missing a smoke make you anxious or worried? 
 
Responses to each question is on a 4 point likert scale (e.g. question 1, 2 & 4 (0 = Never or 
almost never; 1 sometimes; 2 often; 3 always or nearly always).  All items are added to give a 
total SDS score ranging from 0 – 15.  The SDS has been previously used to reliably screen for 
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dependency and its severity in adults for a number of substances of abuse.  Martin et al. (2006) 
verified the validity and reliability of this scale in participants (n = 100) for cannabis use and 
found good internal consistency (Chronbach’s alpha of 0.83) and good test-retest reliability 
(intraclass correlation coefficient of 0.88).   
 
Schizotypal Personality Questionnaire (SPQ-B; Raine & Benishay, 1995 – see appendix v) 
The SPQ-B is an easy to administer questionnaire with 22 items and is based on the most 
reliable items from the original SPQ-B.  The SPQ-B yields a total score along with three main 
sub-factors: cognitive-perceptual (example question: Do you often pick up hidden threats or 
put-downs from what people say or do), interpersonal (e.g. People sometimes find me aloof and 
distant) and disorganised thinking (e.g. I find it hard to communicate clearly what I want to say 
to people).  There is good internal reliability of these sub-scales (ranging from .72 to .80, with a 
mean of .76 and test-retest reliability (.86 to .95, mean = .90).  According to Raine and 
Benishay (1995) research indicates that the criterion validity was good for correlations between 
SPQ-B subscales and clinical interview measures of Schizotypal Personality Disorder: the total 
scale (.66) cognitive-perceptual (.73) and interpersonal (.63), but are lower for disorganised 
thinking (.36).  Participants are required to respond to each question Yes or No; with each Yes 
response scoring a point.  Total scores range from 0-22, cognitive-perceptual 0-8, interpersonal 
0-8 and disorganised thinking 0-6. 
 
UEL Drug Use Questionnaire and other participant information (Parrott et al., 2000) – see 
appendix vi. 
All participants were required to give personal details of both their history and familial history 
of mental illness and whether they or their immediate family members has a current or had a 
past diagnosis of anxiety, depression, obsessive compulsive disorder, schizophrenia or 
paranoia, eating disorders, alcohol or drug dependency.  This questionnaire also asked whether 
they have been hospitalised with brain trauma, or were taking any current medications.  They 
were asked to answer further questions about current and past drug use for Ecstasy, 
Amphetamine, Cocaine, LSD, Magic Mushrooms, Poppers, Ketamine, GHB, Prozac, Crack, 
Opiates, Benzodiazepines, Anabolic Steroids, Solvents and other drugs.  For each drug a yes/no 
response was required to indicate whether it had ever been taken; age of first use, how many 
times they had taken this drug, and how long ago they last consumed the drug.  Questions about 
alcohol, tobacco and cannabis were more extensive to assess for weekly consumption.  For 
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cannabis specifically, questions included which types of cannabis are consumed most often, 
why they choose to smoke their most consumed type, how many joints smoked per day/week, 
age of onset, who introduced them to the drug, duration of use, the last time they smoked 
cannabis and whether they had perceived any acute psychological/health problems from using 
higher doses of cannabis.   
 
2.2.3 The Experimental Procedure:   
Informed consent was obtained and the participants signed the consent form; thereafter the 
study consisted of three phases: 
Phase 1:  All participants providing a saliva sample and for drug testing using the Multi-drug 
One Step:  Multi-line 6 Drug Screen Test Device (Oral Fluid) (from drugtesting.co.uk) which 
includes a test device, collectors (sponge applicator), tubes for collecting sample.  Oral fluid 
specimens were collected using the sponge end of the collector was placed inside the mouth 
and rubbed around in the inside of their mouth and tongue for a total of three minutes until the 
sponge becomes saturated.  The sponge collector was then removed and fully strained the oral 
liquid into the collector tube.  The oral fluid was transferred by adding three drops of the 
sample (approximately 100 microlitres) into each well of the test device.  Participants are 
informed not to place anything in their mouth prior to testing (including: gum, food, drink, 
tobacco products) for at least ten minutes prior to testing.  The device was read after ten 
minutes and a digital picture was taken and stored as a record of the test.  All samples were 
then disposed of through UEL hazardous waste procedures. 
 
Phase 2: Buccal swabs were used in each participant to extract some cheek cells, for 
subsequent DNA extraction and screening.  This procedure and the data obtained are detailed 
and explored in Chapter 4. 
 
Phase 3:  Testing:  Administration of the cognitive tests (LI and KB).  The participants were 
counterbalanced for each test: 1) PE condition for LI task and NBL condition of the KB test, or 
2) NPE condition for the LI task and BL condition of the KB test.  On completion, the 
participants were asked to complete the SPQ-B, SDS and UEL Drug Use questionnaires. 
 
The study lasted up to 1.5 hours for each participant. 
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2.3 Results  
A primary dataset for the LI task and the KB tasks were analysed and Table 2 highlights the 
demographics for these groups.  However, the primary dataset was changed and revised with 
five non-cannabis using participants added for a secondary analysis.  Three participants were 
removed based on previous lifetime history of cannabis use in the past 20, 105 and at least 250 
times respectively.  Further to this, two participants were also excluded who failed to meet the 
learning requirements for the task (i.e. learn the association between the white noise and 
counter incrementing and were assigned a final score of 21).  Four of the new non-cannabis 
using participants were allocated to the NPE condition and one to the PE condition.  The 
following results therefore include information from the primary data set for the LI, KB, and 
drug use variables, in addition to this revised data set, a secondary analysis was performed on 
the LI and drug use data only; the KB task was not repeated due to complete ceiling effects 
found in both groups (cannabis users and non-cannabis users). 
 
Data Screening 
Normality of variables for the SPQ-B measure and LI, KB data 
According to Tabachnick and Fidell (2007) convention alpha levels at 0.01 or 0.001 are used to 
evaluate the level of skewness and kurtosis with small to moderate samples.  All of the SPQ-B 
scales were positively skewed; the KB and LI were bi-modal.  These data were then 
transformed using logarithms and square roots functions.  No substantive difference was found 
between the transformed and untransformed data, therefore only results using the 
untransformed data are reported both for the primary and secondary analysis. 
 
2.3.1 Primary analysis for demographic/health details and patterns of drug use   
Possible demographic differences between the groups (cannabis and non-cannabis users) were 
assessed using a t-test analysis for age and Chi² analyses for all other measures.  From Table 2 
it can be seen that no significant differences were found between the cannabis group and non-
cannabis using group for demographic descriptors (all p>0.05), except nationality; with 
significantly more British than non-British people in the non-cannabis group (p=0.028).      
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Table 2: Primary results for participants’ demographics and personal and familial health 
information  
 Non-
cannabis 
group 
(20 
Participants) 
Cannabis 
group 
(20 
Participants) 
 
Test 
T  X² 
 
p 
Age Range, Mean (SD) 19-45, 28 
(7.8) 
 18-42, 31.85 
(7.4) 
1.479 Ns 
Gender (n=Males/Females) 
  
9/11 14/6 2.55 Ns 
Nationality (British/Non British) 
(n = )   
15/5 9/11 3.656 0.028 
Ethnicities (White European/Black/Asian) 
(n = )   
16/3/1 19/1/0 2.25 Ns 
Occupation 
(Employed/Unemployed/Student) 
(n = )   
11/1/8 9/2/9 0.592 Ns 
Health Rating (Poor/Moderate/Fine /Good)  
(n = )   
0/3/7/10 0/3/8/9 0.119 Ns 
Personal Mental Health History (diagnosis) 
(n = )   
3 5 0.625 Ns 
Familial Mental Health History (diagnosis) 
(n = )   
11 8 0.902 Ns 
Brain Injury (yes) 
(n = )   
0 0 - - 
Medication (yes) 
(n = )   
1 0 - - 
Ns = not statistically significant (p>0.05). 
Table 3(i) and 3(ii) below shows reported lifetime drug use.  Differences between groups for 
reporting use, amount of use and age of first use/onset were assessed using Mann Whitney U 
tests (a non-parametric test).  Cannabis users reported significantly more lifetime polydrug use 
(includes having taken two drugs together over a period of time such as MDMA, amphetamine 
and/ or cocaine: p=0.01).  Compared to the non-cannabis users, the cannabis group reported 
greater use of tobacco, cocaine and MDMA, earlier onset and had higher lifetime use of these 
aforementioned drugs.  There was a trend in the same direction for amphetamine use.  Cannabis 
users were also more likely to have used LSD (p=0.019), Poppers (p= 0.005), ketamine 
(p=0.09) and Crack cocaine (p=0.04), but no difference for alcohol use, in terms of age of 
onset, frequency and duration of use (p>0.05).    
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Table 3(i): Primary results for participants’ information about lifetime and current drug use 
(part A) 
Variables Non-cannabis 
group (n=20) 
Cannabis 
group (n=20) 
      U   p (2-
tailed) 
Cigarettes (n= Yes) 4 13 110.00 0.004 
Cigarettes/day 
Mean(SD) 
9.50 (7.93) 10.38 (4.77) 105.00 0.004 
Cigarettes - age of 
onset Mean(SD) 
15.2 (1.70) 16.1 (3.26) 106.00 0.005 
Cigarettes -  * last time 
used (days) 
1(1); 2(1); 10(1) 1(9); 2(2); 7(1); 
30 (1) 
115.00 0.01 
Alcohol  (n= Yes) 17 19 180.00 0.01 
Alcohol (units per day) 
Mean(SD) 
9.36 (6.61) 21.5 ( 39.4) 170.5 Ns 
Alcohol – age of onset 
Mean(SD) 
17.31 (3.59) 16.8 ( 3.72) 175.50 Ns 
Alcohol – last time 
(days) 
1(4); 2(1); 5(2); 
7(2); 12(2); 
14(2); 31(1); 
62(1) 
1(8); 2(2); 3(3); 
4(1); 7(2); 
14(2); 120(1) 
174.00 Ns 
MDMA (n= Yes) 4 14 100.00 0.002 
MDMA – age of onset  
Mean(SD) 
24 (5.5)  20.1 (4.62) 113.5 0.01 
MDMA – number of 
times used 
Mean(SD) 
7.37 (8.51)  144.5 ( 269.56) 89.0 0.001 
MDMA – last time 
used days (SD) 
12.7 (3.4) 10.9 (4.58) 105.5 .005 
Poppers  (n= Yes) 5 10 150.0 Ns 
Poppers times 
Mean(SD) 
4.6 ( 4.15) 24.5 (34.4) 138.0 0.054 
Ketamine  (n= Yes) 0 6 140.0 0.009 
Ketamine times 
Mean(SD) 
- 22.6 (38.4) - - 
GHB  (n= Yes) 0 2 180.0 Ns 
GHB times Mean(SD) _ 1.5(.70)  - 
Prozac  (n= Yes) 1 0 190 Ns 
Prozac times 
Mean(SD) 
0 0 - - 
Poly Drug Use  (n= 
Yes) 
3 15 90.0 0.01 
Current  Poly Drug 
Use  (n= Yes) 
0 6 - - 
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Table 3(ii): Primary results for participants’ information about lifetime and current drug use 
(part B)   
 
Variables Non-cannabis 
group (n=20) 
Cannabis 
group (n=20)  
    U     P 
Amphetamine   (n= Yes) 3 8 150.0 .082 
Amphetamine – age of 
onset Mean(SD) 
18.3 (0.57) 18.6 (3.7) 149.5 .082 
Amphetamine –times 
Mean(SD) 
13.6 (10.96) 100 (158.49) 146.5 0.066 
Amphetamine – last time   - 13.6 ( 3.54) - - 
Cocaine   (n= Yes) 6 15 110.0 0.005 
Cocaine– age of onset  
Mean(SD) 
 22.2 (4.79) 21.2 (3.8) 115.5 0.015 
Cocaine – times 
Mean(SD) 
6.1(7.5) 108.4 ( 172) 130.0 0.001 
Cocaine – last time used 
Mean(SD) 
1-6 months (2); 
3years+(4) 
1-2 weeks (2); 
1-6months(7); 
18-24months(2); 
3 years (4) 
27 Ns 
LSD  (n= Yes) 1 7 140.0 0.019 
LSD- times Mean(SD) - 8.1 (6.46) 138.8 0.016 
Benzo  (n= Yes) 1 5 160.0 0.08 
Benzo- times Mean(SD) - 5.20 (5.63) 161.0 0.08 
Mushrooms  (n= Yes) 5 8 170.0 Ns 
Mushroom times 
Mean(SD) 
1.6 (0.54) 8.25(6.56) 153.0 0.001 
Crack  (n= Yes) 0 4 160.0 0.037 
Crack- times Mean(SD) - 7.25 (6.39) - - 
Opiates  (n= Yes) 1 2 190.0 Ns 
Opiate times   Mean(SD) - 4.75 (3.88) - - 
Steroids  (n= Yes) 0 0 - - 
Steroid times Mean(SD) - - - - 
Solvents  (n= Yes) 0 2 189.5 Ns 
Solvent times Mean(SD) - 1.5(.70) - - 
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Table 4 reports cannabis use data for both groups.  As can be seen the non-cannabis group did 
report some lifetime use of the drug (n = 6), onset was between the ages of 14-18 years, and 
last use of the drug was 12 or more years ago.  Three of the non- cannabis users were removed 
in the secondary analysis for long duration and heavy cannabis use in the past (from section 
2.3.2). 
 
Table 4: Primary results for participants’ information about current and lifetime cannabis use 
Variables Non-cannabis group Cannabis group 
Cannabis use 
(current/past/never) 
(n=) 
0/6/14 20 
Amount of joints  per day  
Range, Mean (SD) 
1-7, 0.45 (1.57)  1-5.50, 2.52 (3.18) 
Frequency of use 
(n=) 
 
2-3 times per month (1); 
once a month (1) less than 
once a month (4) 
Everyday (3); Almost everyday (7); 3-4 
times per week (5); 1-2 per week (2); 2-
3 times per month (2); once a month (1) 
Cannabis age of onset 
range & mean (SD) 
14-18, 15.16 (1.6) 12-30, 17.4 (4.19) 
Cannabis introduction 
(n=) 
Friends = 4; Family = 2 Friends = 16; Family = 4 
Cannabis last time  
(n=) 
12 years plus = 6 2 days =  (9); 3-7 days =  (5); 14 days 
plus=  (3) 
Cannabis acute problems  
(n=) 
Yes = 2; No = 4 Yes = 9; No = 11 
Types used most often 
(n=) 
Skunk = 4; Grass = 2 Skunk = 9; Grass = 5; Resin = 6  
Cannabis duration 
(n=) 
5 years = 1; 7 years = 1 1-3 years (3); 4- 7 years (5); 9-14 years 
(6); 15 years plus (6) 
Cannabis Dependency 
Score 
(range & mean (SD) 
- 0-12; 3.35 (3.18) 
 
2.3.2 Primary analysis for cognitive outcomes 
Latent inhibition  
Overall latent inhibition performance, and the number of participants actually learning the 
association, was compared between Groups using a Chi² analysis.  The cannabis users were far 
more likely to have learnt the association (i.e. found the association between the white noise 
and counter incrementing) than the non-cannabis group (p=0.014).  
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A 2x2 ANOVA was used to look at main effects and possible interactions between Group and 
Condition (Pre-exposed versus Non Pre-Exposed).  The ANOVA on the primary data set 
revealed a statistically significant main effect of group (cannabis versus non-cannabis) on LI, 
(F (1, 36) = 10.3, p = 0.003).  In sum, LI was abolished in the cannabis group with no 
significant difference found between the PE and NPE conditions, whereas this was not the case 
for the non-cannabis group.  This was confirmed by post-hoc follow-up t-tests which revealed a 
trend towards significance in non-cannabis users with lower scores in the PE condition (t (18) = 
1.35, p=0.08), but no differences in the cannabis group in PE and NPE trials (t (18) =.072, p = 
0.47).  It seems that cannabis users performed better overall on the task and were not affected 
by the PE condition of the task relative to the NPE condition and relative to the non-cannabis 
group (see Figure 4 below).  No main effect of task was found for condition (PE versus NPE) 
(F (1, 36) =1.834, p > 0.05) and no interaction was found (F (1, 36) = 1.55, p > 0.05).  A 
follow-up t-test revealed that there was a significant difference between the cannabis users and 
non-cannabis users in the NPE condition (t (19) = 3.39, p = 0.01), but not in the PE condition (t 
(17) = 1.32, p > 0.05), with cannabis users performing better under this condition.  Please refer 
to Figure 4 below for a graph illustration of LI performance between cannabis users and non-
cannabis users under the PE and NPE conditions. 
 
Figure 4: Primary results for Latent inhibition: mean LI scores for cannabis and non-cannabis 
group in the PE and NPE conditions. LI score represents the mean trials to criterion for finding 
the association between the white noise and the counter incrementing. 
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Kamin Blocking 
The Kamin Blocking data were analysed using the same methods as for the Latent Inhibition 
data.  There was no difference in learning the association between the groups for the KB task 
(p>0.05).  A 2x2 ANOVA test was carried out to look at the main effects of group (cannabis 
versus non-cannabis) on condition (BL versus NBL) - refer to Figure 5 below.  The preliminary 
ANOVA revealed no main effect of group (cannabis versus non-cannabis) on KB performance 
(p > 0.05) and no main effect of condition, BL versus NBL (p > 0.05).  There was a trend 
towards an interaction (F (1, 36) = 3.53, p = 0.06), with the non-cannabis using group being 
less affected by the BL condition on their KB performance and this group performed better 
under the BL condition as opposed to the NBL condition (indicating an abolished KB effect), 
whereas the regular cannabis users took more time to find the paired association in the BL 
condition relative to the NBL condition (indicating a normal KB effect).  However, on closer 
inspection it can be seen that the mean scores appeared to be ceiling effects in each of the 
conditions; the highest possible score is pre-set at 36, with the range of scores for this study 
falling between 22-36; 45% of the sample obtained the highest score of 36.  A Chi² analysis 
revealed that there was no significant difference between cannabis users and non-users for 
learning the association overall.  Therefore, interpretation of these data should consider the 
high overall means and that there was no significant difference between the groups (cannabis 
user versus non-cannabis user) for correctly learning the association on the KB task.   
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Figure 5: Primary results for Kamin blocking: mean KB scores in cannabis and non-cannabis 
groups in the BL and NBL conditions. 
 
2.3.3 Primary Analysis for SPQ-B data analyses 
 
The Schizotypal Personality Questionnaire data was assessed using t-tests.  There were no 
significant differences between the cannabis users and non-cannabis users on the SPQ-B total 
and sub-factor scores (all p > 0.05; see Table 5).  However, some exploratory analysis revealed 
differences between the conditions of tasks PE (and NBL) and NPE (and BL) conditions, with 
those in the PE (and NBL) condition reporting a significantly higher total SPQ-B score 
(p=0.018). 
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Table 5: Primary results for a breakdown of participants’ SPQ-B variables. 
Variables Non-cannabis 
group (n=20) 
Cannabis group  
(n=20) 
  
 Mean (SD) Mean (SD)   T      p 
SPQ-IP 1.65 (1.77) 1.8 (0.4) 1.05 Ns 
SPQ-CP 1.8 (0.41) 1.75 (0.4) 3.70 Ns 
SPQ-DT 1.8 (0.41) 1.85(0.36 4.06 Ns 
SPQ-total 6.8 (5.09) 6.3 (0.36) 3.43 Ns 
SPQ-total 
PE (and 
NBL)/NPE 
(and BL) 
conditions 
8.31(4.85)/ 
4.95(3.69) 
8.6(4.15)/ 
4.36(2.90) 
6.152 0.018 
 
2.3.4 Primary analysis for high/low SPQ-B and associative learning task performance 
Although there were no clear differences between the cannabis users and non-users for the 
SPQ-B scores, this variable was subsequently utilised to explore possible effects of schizotypy 
on associative learning.  The group were assessed for high versus low SPQ-B and division of 
groups was based on the same method used by Laws et al (2008).  Participants were divided 
into high/low scorers on the SPQ-B total, for two non-overlapping groups.  The SPQ-B mean 
was 6.5, and the scores ranged from 0-18, thus 5 people were removed who had a score 
between 6-8; this left 20 people with scores from 0-5 and 14 people with scores from 9-18.   
 
A 2x2 ANOVA assessed possible differences between the groups for SPQ-B total scores under 
both LI Conditions.  The groups were broken down initially into groups (cannabis versus non-
cannabis) for high/low SPQ-total score, but these were too small and imbalanced to make 
viable statistical comparisons across the conditions (PE versus NPE).  Therefore the entire 
group overall (pooling together cannabis and non-cannabis users) was divided into high/low 
SPQ-B groups for LI performance (refer to Table 6).  A 2 X 2 ANOVA found no main effect 
LI performance (F (1, 30) =1.511, p > 0.05), but did show a main effect for SPQ-total group 
(high versus low scorers) (F (1, 30) = 4.634, p = 0.04) and no significant interaction between LI 
(PE versus NPE) and SPQ-total group (high versus low scorers; F (1, 30) = 2.577, p > 0.05).  
Follow-up t-tests were conducted and revealed no significant differences between low versus 
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high SPQ-B scorers in the PE condition (t (15) = 0.692, p > 0.05), but a significant difference 
was found between low and high SPQ-B scorers in the NPE condition, with low SPQ-B scorers 
taking fewer trials overall to find the paired association t (15) = 4.567, p < 0.001).  No 
significant difference was found between conditions (PE versus NPE) for low SPQ-B (t (18) = 
0.283, p > 0.05), whereas there was a significant difference between the conditions (PE versus 
NPE) for high SPQ-B scorers (t (10) = 3.198, p = 0.005) who took less time overall to find the 
paired association under the PE condition.   
 
Table 6: Primary results showing mean LI performance in groups scoring high and low on the SPQ-B 
 
 
 
 
 
The same analysis was run for KB outcomes on high/low SPQ-B scores – refer to Table 7.  No 
main effects were found for KB (BL versus NBL) on KB performance (F (1, 30) = 0.348, p > 
0.05), no main effect was found for SPQ-total group (high versus low scorers) (F (1, 30) = 
0.013, p > 0.05); no interaction found between KB (BL versus NBL) and SPQ-total group (high 
versus low scorers) F (1, 30) 0.054, p > 0.05.  No follow-up tests were done due to lack of 
differences found between the group and conditions. 
 
Table 7: Primary results for high versus low SPQ-B scores on KB outcomes.                                         
 
 
 
 
 
 
SPQ-total High Low High Low   
                    PE                 NPE        F P 
LI scores  
mean (SD) 
11.3(8.5) 9.57(8.8) 20.2(1.5) 8.38(8.96) 4.634 
0.04 
 (N =  ) 10 7 4 13  
SPQ-total High Low High Low   
                    BL 
 
                NBL    F p 
Kamin Blocking 
Scores 
29(8.4) 28.5(10.3) 25.8(11.5) 27.14(9.2) 0.013 Ns 
 (N =  ) 4 13 10 7  
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2.3.5 Secondary analysis for demographic/health details and patterns of drug use 
A number of interesting findings were found with the LI data, but there were issues around 
overlap in cannabis use between the groups and the non-cannabis group appeared to be 
performing quite poorly compared to the cannabis group.  Therefore the primary dataset was 
revised to remove 5 non-cannabis users.  It was 3 of the non-cannabis users who reported 
previous lifetime use of cannabis, and in addition to this, 2 participants were also removed who 
had failed to meet the learning requirements for the task (correctly learning the paired 
association) in the NPE condition.  Therefore, 4 new participants were allocated to the NPE 
condition and one participant to the PE condition.  Statistical analyses were the same as those 
conducted in the primary analyses.  Please see Table 8 for demographics of the cannabis and 
non-cannabis users.  The secondary analysis did not include re-examination of the KB task data 
due to overall poor performance as 50% of the sample reached a ceiling effect of a score of 33, 
34, 35 & 36.  With the KB data there were no marked differences between groups and so 
further analyses would be unlikely to reveal any additional findings.   
 
From Table 8, with the removal of the non-cannabis users based on past drug use, this reduced 
the amount of people in the non-cannabis group reporting a Personal Mental Health History 
(PMHH) from 3 (in the primary analysis) to 0 (in the new secondary analysis) and this left a 
significant group difference (p = 0.04) between non-cannabis users and the cannabis group.  
There was also a gender difference between both groups, with significantly more males in the 
cannabis using group (p = 0.05).  Compared to the primary analysis there was now no 
difference between the number of British/non British participants between the cannabis users 
and non-cannabis users. 
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Table 8:  Represent the secondary results for demographic and drug use details for controls 
versus the cannabis group 
 
Variable Non-cannabis 
group 
(20 
Participants) 
 
Cannabis group 
(20 Participants) 
 
T   X ²    P 
Age 
Range, Mean (SD) 
  
19-42, 30 (6.8) 
 
 18-42, 29 (7.7) -.801 Ns 
Gender (Males/Females) 
(n=) 
7/13 14/6 4.91 0.05 
Nationality (British/Non British) 
(n=) 
11/9 9/11 0.400 Ns 
Ethnicities (White 
European/Black/Asian/Mixed 
Race) 
(n=) 
14/3/2/1 19/1/0/0 1.495 Ns 
Occupation 
(Employed/Unemployed/Student) 
(n=) 
11/2/7 (9/2/9) 0.450 Ns 
Health Rating 
(Poor/Moderate/Fine /Good)  
(n=) 
0/1/7/12 (0/3/8/9) 1.495 Ns 
Personal Mental Health History 
(diagnosis) 
(n=) 
0 5 5.174 0.04 
Familial History (diagnosis) 
(n=) 
9 8 .102 Ns 
Brain Injury (yes) 
(n=) 
0 0 - - 
Medication (yes) 
(n=) 
0 0 - - 
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Tables 9(i) and 9(ii) below show that the cannabis group frequently reported use of other drugs 
such as MDMA, ketamine, crack, solvents and LSD; they had significantly more tobacco 
smokers (p = 0.001) with earlier onset of tobacco smoking (p = 0.002) and smoked tobacco 
more often (p = 0.001), which is in line with the primary analysis.  Whereas the secondary 
analysis now revealed a difference between alcohol use, with the cannabis group reporting 
higher use of alcohol per week (p = 0.02). 
 
From Table 10, it can be seen that the majority of the cannabis group (n = 12) last used 
cannabis at the specified 2 days abstinence period, with the rest of the sample (n = 8) from 3 -
14 days prior to the testing session.  Nearly half of the cannabis sample reported acute 
problems with higher doses of cannabis and the sample mainly used the skunk variety (n = 9).  
Cannabis dependency scores were on average 3.35 (out of 12); and a score of over 4 is seen as 
indicative of dependency to the drug. 
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Table 9(i): Secondary results for participants’ information about lifetime and current drug (part A) 
Variables Non-cannabis 
group 
Cannabis 
group 
    U   P   Variables Non-
cannabis 
group 
Cannabis group     U   P   
Cigarette (Yes) 
(n=) 
3 13 100.0 0.001 MDMA (Yes) 
(n=) 
3 14 90.0 0.01 
Cigarette/day 
Mean (SD) 
6(4.58) 10.38 (4.77) 89.0 0.001 MDMA – age of onset 
Mean (SD) 
19.6(5.5) 20.14(4.62)  89.0 0.001 
Cigarettes - age of 
onset 
Mean (SD) 
16(1) 16(3.26) 101.0 0.002 MDMA – number of 
times used 
Mean (SD) 
7.66 (10.69) 144.5 (269) 77.5 <0.001 
Cigarettes -  last 
time used 
1 day (1); 2 days 
(1); 10 days (1) 
1 day (9); 2 
days (2); 7 days 
(1); 30 days (1) 
107.0 0.004 MDMA – last time used 
 
1-6 
months(1); 
18-
24months(1); 
3years+(1) 
1-2 weeks(1); 1-
6months(5); 18-
24months(1); 
3years+(7) 
20.5 Ns 
Alcohol (Yes) 
(n=) 
13 19 140 0.019 Amphetamine (Yes) 
(n=) 
1 8 130 0.009 
Alcohol (units per 
week) 
Mean (SD) 
7.46 (6.89) 
 
 20.55 (38.6) 140 0.021 Amphetamine – age of 
onset 
Mean (SD) 
- 18.6(3.7) 130.5 0.01 
Alcohol – age of 
onset 
Mean (SD) 
16.5 (15.9) 16.8 (3.72) 170 Ns Amphetamine – number 
of times used 
Mean (SD) 
-  100 (158) 126.5 0.007 
Alcohol – last time 
Mean (SD) 
1(3); 2(1); 5(2); 
7(1); 12(1); 14(1); 
31(1); 62(1) 
1(8); 2(2); 3(3); 
4(1); 7(2); 
14(2); 120(1) 
149.5 Ns Amphetamine – last 
time used 
 
_ 1-6months(1); 6-
18months(1); 
3years+(5) 
- - 
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Table 9(ii): Secondary results for participants’ information about lifetime and current drug (part B) 
Variables Non-
cannabis 
group 
Cannabis 
group 
     U   P  (2-
tailed)  
Variables Non-
cannabis 
group 
Cannabis 
group 
    U    P  (2-
tailed) 
Cocaine (Yes) (n=) 3 15 80.0 <0.001 Ketamine (Yes) (n=) 0 6 140 0.009 
Cocaine– age of onset 
Mean (SD) 
23.6 
(10.96) 
 
21.2(3.8) 
 
86.5 0.001 Ketamine times Mean (SD) - 22.6(38.4) 140 0.009 
Cocaine – number of times 
used Mean (SD) 
 7.3 (10.96)  108.4(172) 
 
-66.5 <0.001 GHB (Yes) (n=) 0 2 180 Ns 
Cocaine – last time used   1-
6months(1); 
3years+(2) 
 1-2 weeks(1); 
1-6months(8); 
6-18months 
(2); 3years+(4) 
14 Ns GHB times 
Mean (SD) 
- 1.5(0.70) 180 Ns 
LSD (Yes) (n=) 0 7 130.0 0.04 Prozac (Yes) (n=) 1 0 190 Ns 
LSD times Mean (SD) - 8.1(6.46)  130.0 0.04 Prozac times  Mean (SD) - - 190 Ns 
Benzo (Yes) (n=) 0 5 150.0 0.018 Crack (Yes) (n=) 0 4 160.0 0.037 
Benzo times  Mean (SD) - 5.20 (5.63) 
 
150.0 0.019 Crack times  Mean (SD) - 7.25 (6.39) 160 0.038 
Mushrooms (Yes) 
(n=) 
3 8 150.0 Ns Opiates (Yes) 
(n=) 
0 2 180 Ns 
Mushroom times Mean 
(SD) 
1.33 (0.55) 8.25 (6.56) 
 
139.0 0.036 Opiate times  Mean (SD) - 4.75 (3.88)  180 Ns 
Poppers(Yes) (n=) 2 10 120.0 0.006 Steroids (Yes) (n=) 0 0 - - 
Poppers times Mean (SD) 4.5(4.94)  24.5(34.4) 
 
114.5 0.004 Steroid times  Mean (SD) - - - - 
Solvents (Yes) 
(n=) 
0 2 180.0 Ns Past poly drug use (Yes) 
(n=) 
2 13 90.0 <0.001 
Solvent times Mean (SD) -  1.50(0.707) 
 
180.0 Ns Current poly drug use (Yes) 
(n=) 
0 8 120.0 0.002 
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Table 10: Secondary results for current and lifetime cannabis use 
Variables Non-cannabis group 
(n=20) 
Cannabis group 
(n=20) 
Cannabis use 
(current/past/never)(N=) 
(0/3/17) 20 
Amount of joints  per day 
Mean (SD) 
-   2.52 (3.18) 
Frequency of use - Everyday (3); Almost everyday 
(7); 3-4 times per week (5); 1-2 
per week (2); 2-3 times per 
month (2); once a month (1) 
Cannabis age of onset 15-16 17.4 (4.19) 
Cannabis introduction friends (3) Friends (16); Family ( 4) 
Cannabis last time  
(N=) 
12 years plus ( 3) 2 days =  (12); 3-7 days =  (5); 
14 days plus=  (3) 
Cannabis acute problems 
(with higher doses of 
cannabis)(N=) 
No (3) Yes (9); No (11) 
Types used most often - Skunk  (9); Grass (5); Resin( 6)  
Cannabis duration 
(N=) 
- 1-3 years (3); 4- 7 years (5); 9-
14 years (6); 15 years plus (6) 
Cannabis Dependency 
Score Mean(SD) 
- 3.35 (3.18) 
 
2.3.6  Secondary analysis for LI performance 
In contrast to the primary analysis there was no significant difference found between the 
cannabis and non-cannabis users for the number of people finding the association between the 
white-noise and the counter incrementing on the LI task.  In contrast to the primary analysis, a 
normal LI effect was now found in the non-cannabis group, with faster learning in the NPE 
compared to the PE condition.  These data in Figure 6 show that overall the non-cannabis users, 
in both conditions, took longer to reach the learning criterion compared to the cannabis users.  
An ANOVA was carried out to see if there was an interaction between group (cannabis versus 
non-cannabis) and condition (pre-exposed versus pre-exposed), no interaction was found (p = 
0.33).  There was no main effect of LI for condition (F (1, 36) = 7.81, p>0.05), a main effect 
was found for group (F (1, 36) = 5.83, p = 0.02), with cannabis users taking significantly less 
time overall to find the association versus those in the non-cannabis group.  Follow up t-tests 
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revealed a significant difference between non-cannabis users in the PE versus NPE conditions 
(t (18) = 1.36, p = 0.009).  Whereas there was no difference between the cannabis group in the 
PE and NPE conditions (t (18) = 0.72, p > 0.05).  A second follow up t-test revealed that there 
was a significant difference between cannabis users and non-cannabis users on the PE 
condition (t (17) = 2.58, p = 0.01), with cannabis users taking less time to find the paired 
association.  There was no significant difference found between the Group in the NPE 
condition (t (19) = 0.970, p > 0.05). 
 
 
Figure 6: Compared to figure 4, this figure is the secondary result of mean learning scores across 
group (cannabis versus non-cannabis) and conditions PE (pre-exposed) versus the NPE (non pre-
exposed).   
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2.3.7  Secondary analysis for SPQ-B data analyses    
From Table 11, it can be seen that the results were the same for the primary and secondary 
analysis for SPQ-B outcomes.  There were no statistically significant differences between the 
group (cannabis versus non-cannabis user) for individual differences in psychotic-like traits 
assessed via the SPQ-B total score and three subscales (all p > 0.05).  Table 12 shows the 2 X 2 
ANOVA for main effect of condition for SPQ-B total for cannabis users versus non-cannabis 
user under the PE condition versus those in the NPE condition.  It seems that there was an 
effect of condition, in that those in the pre-exposed condition (and counterbalanced NBL for 
the KB task) scored higher on the SPQ-B measure compared to those in the NPE (BL) and this 
was statistically significant (p < 0.05).  There was no main effect of cannabis on SPQ-B scores 
or interaction between both Condition and Group (p > 0.05). 
 
Table 11: Represents the secondary data set for SPQ-B scores between cannabis users and non-
cannabis user, and for SPQ-B subscales under each condition of the LI task 
Variables 
SPQ-B scores 
Non-cannabis 
group 
Cannabis 
group 
F P 
SPQ–IP 
Mean (SD) 
2.5 (1.7) 2.0(1.7) 0.865 Ns 
SPQ-CP 
Mean (SD) 
2.5(1.7) 2.5(1.9) 0.007 Ns 
SPQ-DT 
Mean (SD) 
2.0(2.2) 1.7( 1.7) 0.161 Ns 
SPQ-total 
Mean (SD) 
7.05(5.36) 6.3( 4.06) 0.248 Ns 
SPQ-total 
PE and NBL/NPE and BL  
Mean (SD) 
9.2(5.94)/ 
4.9(3.9) 
8.6(4.15)/ 
4.36(2.90) 
9.79 0.003 
 
2.3.8 Secondary analysis for high/low SPQ-B and associative learning task performance 
Similar to the primary analysis the group was broken down into high/low SPQ-B scores based 
on the same method as Laws et al (2008).  The mean score was 6.67 and the scores ranged 
from 0-18, 4 people were removed who scored between 6-8, with 22 participants in the low 
SPQ-B group who scores ranged from 0-5, and 14 in the high SPQ-B group who scores ranged 
from 9-18.  A 2X2 ANOVA was therefore carried out to see if there was any effect of high/low 
SPQ-B on LI performance.  It was found that there was no main effect of LI condition (PE 
versus NPE) (F (1, 32) = 0.264, p > 0.05), a main effect was found for SPQ-total into high/low 
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for LI performance (F (1, 32) = 6.32, p = 0.017), and an interaction was found between SPQ-
total high/low for LI (PE versus NPE) on LI performance (F (1,32) = 4.28, p = 0.05) – refer to 
Table 12.   
 
A follow-up t-test revealed that there was no significant difference between low and high SPQ-
B scorers in the PE condition (t (15) = 0.77, p > 0.05), whereas a significant difference was 
found between low and high SPQ-B scorers in the NPE condition, with low SPQ-B scorers 
taking less time to find the paired association relative to the high scorers (t (17) = 3.573, p = 
0.001).  There was no significant difference found for low SPQ-B scores between the LI 
conditions (PE versus NPE), (t (20) =1.358, p > 0.05).  Whereas the high SPQ-B scorers took 
less time in the PE condition rather than the NPE condition (t (12) = 2.81, p = 0.008), thus 
those scoring high on the SPQ-B measure seem to represent an abolishment of LI in this group.    
However, it should be noted that large means were found for the high SPQ-B scorers in the 
NPE condition which may represent a ceiling effect.  Lack of differences found under the PE 
condition between high/low scorers might give an indication that the differences found with the 
cannabis group on LI performance may be a specific effect of the drug as opposed to 
higher/lower SPQ-B traits.  
 
Table 12: Secondary results for participants’ LI performance and SPQ-B (high/Low) 
 
2.3.9 Correlations for cognitive, trait and cannabis use variables in the primary and 
secondary analyses 
Finally, a series of correlations were carried out to explore the SPQ-B traits on LI scores and 
KB scores in primary data analysis (see Table 13) and then for SPQ-B traits and LI scores in 
the secondary analysis (see Table 14).  From Tables 13 and 14, it can be seen that all SPQ-B 
measures correlated with one another (p < 0.001).  In the primary data set it can be seen from 
SPQ-total High Low High Low   
                    PE 
 
                NPE F P 
LI  scores  
mean (SD) 12.2(8.6) 10.8(9.02) 20(1.7) 6.12(6.54) 6.32 0.017 
 (N =  ) 11 6 3 16  
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Table 13 that none of the SPQ-B traits was related to KB performance (all p > 0.05).  None of 
the SPQ-B variables in the primary analysis was linked to LI performance (all p > 0.05), 
whereas in the secondary analysis the SPQ-B total, and subscales of Interpersonal and 
Cognitive Perceptual was linked to LI performance (all p < 0.05), in that those with higher 
scores on the SPQ-B measure overall, and for the two subscale IP and CP also was linked to 
higher scores in the LI task.  Higher scores on the LI task represent that it took people longer to 
find the paired association, so performed less well on the task.  Cannabis use variables, in terms 
of dependency, frequency and duration of use were explored in relation to SPQ-B variables and 
LI/KB performance (see Table 15).  The measure for cannabis dependency was associated with 
the SPQ-B - IP subscale which is related to interpersonal traits.  People who scored more 
highly on the measure for problems with their cannabis use also reported higher schizotypal 
traits related to negative symptoms associated with schizophrenia.  Higher numbers of joints 
smoked per week was related to higher SDS and increase in schizotypal traits, which includes 
the subscales of SPQ-IP, SPQ-CP and SPQ-DT.  Age of onset of cannabis use was negatively 
associated with scores on the SPQ-DT subscale, with earlier onset of the drug related to higher 
scores on this third subscale of disorganised thinking.  Also earlier onset of the drug was 
associated with lower scores on the KB task.  Seven out of twenty of the cannabis cohort 
reported a Cannabis SDS of four and above and this is seen to be indicative of being dependent 
on cannabis use, however these regular drug users were able to adhere to the abstinence period 
for a minimum of two days without using cannabis.  The SPQ-B traits were not associated with 
the LI performance in the cannabis group (all p>0.05).  Therefore a final correlation analysis 
(not shown in the tables below) was run for the non-cannabis group only and it was found that 
LI performance was linked to all of the SPQ-B measures.  LI performance was positively 
associated with SPQ-B total, (r (20) = 0.422, p = 0.03), interpersonal (r (20) = 0.40, p = 0.04), 
disorganised thinking (r (20) = 0.393, p = 0.04) and a trend for a positive association between 
cognitive perpetual scores and LI performance (r (20) = 0.349, p=0.006).  Interestingly, this 
was not the same for the cannabis group for traits linked to LI performance. 
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Table 13: Correlational data in primary analysis for SPQ-B traits, LI and KB outcomes. 
  
 
 
 
 
 
 
 
 
**. Correlation is significant at the 0.01 level (1-tailed).  
 
 
Table 14: Correlational data exploring the secondary analysis for SPQ-B traits and LI outcomes.  
 
 
 
 
 
 
 
**. Correlation is significant at the 0.01 level (1-tailed) 
*. Correlation is significant at the 0.05 level (1-tailed). 
 
 
Table 15: Correlation between drug use characteristics, SPQ-B traits and LI performance in the 
cannabis group. 
 
 
 
 
 
 
 
 
 
 
 
**. Correlation is significant at the 0.01 level (1-tailed) 
*. Correlation is significant at the 0.05 level (1-tailed). 
 
Variable SPQ-
total 
SPQ-
CP 
SPQ-
IP 
SPQ-
DT 
LI score KB 
score 
SPQ-total 
N =  
1 0.795
** 
40 
0.764
** 
40 
0.817
** 
40 
0.174 
40 
0.020 
40 
SPQ- CP 
N = 
 1 0.378
** 
40 
0.528
** 
40 
0.241 
40 
0.134 
40 
SPQ-IP 
N = 
  1 0.418
** 
40 
0.149 
40 
0.107 
40 
SPQ-DT 
N = 
   1 0.026 
40 
-0.195 
40 
Variable SPQ- 
total 
SPQ-CP SPQ-IP SPQ-DT LI score 
SPQ-total 
N =  
1 0.828**
 
40 
0.814** 
40 
0.863** 
40 
0.336* 
40 
SPQ-CP 
N = 
 1 0.491** 
40 
0.595** 
40 
0.322* 
40 
SPQ-IP 
N = 
  1 0.552** 
40 
0.312* 
40 
SPQ-DT 
N = 
   1 0.213 
40 
Variable SDS Age of 
onset 
Joints per 
week 
LI Score
 
KB score 
SPQ-total 
N =  
.288 
20 
-0.242 
20 
.434* 
20 
0.217 
20 
0.045 
20 
SPQ-CP 
N = 
.095 
20 
-0.93 
20 
0.28* 
20 
0.354 
20 
0.014 
20 
SPQ-IP 
N = 
0.409 * 
20 
0.00 
20 
0.561** 
20 
0.147 
20 
0.060 
20 
SPQ-DT 
N = 
0.152 
20 
-0.468* 
20 
0.416* 
20 
-0.037 
20 
0.0327 
20 
SDS 
N = 
1 0.095 
20 
0.370* 
20 
-0.07 
20 
0.123 
20 
Age of onset 
N = 
 1 -0.132 
20 
0.109  
20 
0.427* 
20 
Joints per week 
N = 
  1 -0.234 
20 
0.189 
20 
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2.4  Discussion 
The purpose of this first study was to look at the performance of a group of regular cannabis 
users in associative learning tasks which have previously been shown to be disrupted in 
schizophrenic populations, first degree relatives of people with schizophrenia and by drugs 
which affect dopamine.  The predictions here, derived from the literature linking cannabis use 
to psychosis, were that cannabis users would show disruption in the LI and KB tasks because of 
the chronic effects of this potent psychoactive on dopaminergic and other systems underpinning 
the attention and associative learning based systems crucial to performance.  This study also 
looked at the personality trait of schizotypy as measured using the SPQ-B. 
 
2.4.1 Latent inhibition and cannabis 
Cannabis users seem to be showing a schizophrenic-like profile on the LI task. LI was 
abolished in the PE condition, with no significant difference found in LI scores between the 
task conditions (PE versus NPE) for the cannabis users.  In the primary analysis, the cannabis 
users took less time overall to find the paired association between the white noise and the 
counter incrementing in the PE condition relative to the cannabis group in the NPE condition.  
Further to this, there was a LI effect in the non-cannabis users but opposite to the expected 
direction (i.e. faster learning in the PE condition).  On closer inspection of the data, 7 out of 20 
in the non- cannabis group successfully learnt the paired association overall compared to 
sixteen out of twenty in the cannabis group.  There was no intelligence test administered to see 
if differences in intelligence was a reason why the non-cannabis group performed badly overall 
on the LI task.  The only clear differences is that more males and non-British participants were 
in the cannabis using group overall, and there were 5 internal participants (i.e. students/workers 
at the UEL) compared to the non-cannabis group who used 12 internal candidates. 
 
The study removed 5 people in the non-cannabis group who did not reach the learning criterion 
(e.g. did not successfully learn the paired association), and those in particular who reported 
cannabis use in the past.  To eliminate the possible influence of these non-users, who did not 
reach the criterion and those who had previously used cannabis, these data points were 
excluded and a secondary set of analyses carried out, which also included 5 new participants. 
Looking at this revised secondary data set, there was now a significant difference between the 
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PE versus NPE conditions for the non-cannabis group; thus indicating a normal LI effect (i.e. 
slower learning in the PE condition).  Furthermore, in the secondary analysis there was a 
significant difference between cannabis users and non-cannabis users in the PE condition but 
not under the NPE condition, indicating that cannabis users overall were less affected by the 
pre-exposure to the white noise during the masking task (of the PE condition), thus indicating a 
trend for abolition of normal LI.  These LI findings do fit the idea that use of cannabis may be 
disrupting associative learning in the fashion seen in psychotic populations, first degree 
relatives and following amphetamine use.  Cannabis has been independently associated with 
deficits in the PFC (e.g. Block et al, 2002; Lundquist et al, 2001; Solowij et al, 2002) and these 
are linked to attentional dysfunction (e.g. Weinberger et al, 2001).  Cannabis use is also 
associated with increased mesolimbic dopamine transmission in the brain (e.g. Tanda et al, 
1997; Voruganti et al, 2001); dopamine is critical for LI performance (Soloman et al, 1981; 
Weiner et al, 1981; 1984) and appears to be central in some forms of attentional dysfunction 
(e.g. Matthysse, 1978; Swerdlow & Koob, 1987; Swerdlow et al, 2003), thus it could be argued 
that cannabis use is accounting for the disruption of normal LI in this current study. 
 
Further to this, CB₁ receptors have a known role in associative learning in animals (e.g. Gruart 
et al, 2012) and disrupted associative learning has been found in humans using cannabis (e.g. 
Jager et al, 2007; Skosnik et al, 2007).  Disrupted associative learning (as demonstrated by the 
Latent inhibition task) is argued to be due to the failure of inhibiting attention to the irrelevant 
stimuli during the pre-exposure stage, which may be a result of cannabis increasing DA 
transmission.  This DA mechanism may also be involved in producing positive symptoms of 
schizophrenia when cannabis users are reporting higher rates of paranoia, hallucinations and 
delusional thoughts (e.g. Crippa et al, 2009).  Recent research by Granger et al (2012) looked at 
LI performance in healthy controls and assessed them using the O-Life measure and found that 
the main subscale of ‘unusual experiences’ linked to paranoia and the positive symptomology 
was the best predictor of LI disruption.  In the current study, the numbers were too small across 
the groups to make robust statistical comparisons across the SPQ-B subscales for LI 
performance, but there were differences in LI performance between high and low SPQ-B 
outcomes (see SPQ-B section 2.4.3 below).  What is not clear, if this is a transitory or long term 
effect of using the drug and/or an underlying vulnerability of executive dysfunction, or an 
interaction between both cannabis use and executive dysfunction.  Realistically longitudinal 
birth cohort studies are best for providing a clearer picture into the ‘cause and effect’ specific 
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drugs may have on the developing brain.  There have been many published studies looking at 
the long-term effects of cannabis on cognition (for a review see Solowij, 2000; 2002).  The 
only published study looking at current cannabis use and former cannabis use (in ex users) on 
associative learning was conducted by Skosnik et al (2012).  This study found that ex users 
performed better than current cannabis users on associative learning, but ex-cannabis users still 
had problems with the acquisition of conditioned responses and timing on the Eye blink 
Conditioning (EBC) task compared to healthy controls. 
 
In the primary analysis, low SPQ-B scorers took significantly less time than high SPQ-B 
scorers under the NPE condition.  In the secondary analysis low SPQ-B scorers took 
significantly longer to find the paired association in the PE condition versus the NPE condition 
and thus showed a normal LI effect.  This was contrasted by high SPQ-B scorer’s performing 
significantly better at finding the paired association in the PE condition relative to the NPE 
condition, thus indicating abolishment of normal LI in these high SPQ-B scorers.  The 
participant numbers are relatively low when comparing the LI effect between PE and NPE 
conditions in high and low SPQ-B scores but these findings support previous research in the 
area (e.g. Baruch et al, 1998a; Wuthrich & Bates, 2001; Granger et al, 2012).  Interestingly, the 
differences between those with high versus low SPQ-B scores are more apparent under the 
NPE conditions, with high scorers performing worse which represents poorer basic associative 
learning skills.  The correlation data also highlighted that the non-cannabis group in the 
secondary analysis scoring higher on the SPQ-B measure and its three subscales was positively 
associated with higher scores on the LI task, but this was not the case for the cannabis group.   
Therefore it could be argued that the LI abolition effects in this current study, under the PE 
condition, are drug specific, as opposed to being linked to the schizotypal personality traits.    
  
2.4.2 Kamin Blocking and cannabis 
In the current study cannabis users were slower to learn the association in NBL condition of the 
KB task relative to the non-cannabis using group.  A normal KB effect was found in the 
cannabis group (e.g. slower learning in the BL relative to the NBL condition), but this was not 
replicated in the non-cannabis using group.  Serra et al (2001) found that schizophrenic patients 
were slower to learn the association in both conditions; and the controls were faster to learn the 
paired association in both conditions.  In Serra et al’s study people diagnosed with 
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schizophrenia who were allocated to the BL condition had a mean score of 19.91 of trials to 
criterion for KB performance, compared to their schizotypal relatives who had a mean score of 
21.70.  In the current study the cannabis group had a mean score of 31.2 in the BL condition 
relative to 26.4 for the non-cannabis using group, which together indicate that both groups had 
poorer associative learning overall for this task when compared with Serra et al’s findings for 
the KB task.  In the non-cannabis group 45% of the sample did not meet the learning criterion 
versus 60% in the cannabis group, therefore due to lack of differences found in the primary 
analysis, the KB task was not used in the secondary analysis as performance was poor in both 
groups.  In previous studies, 50% of the clinical sample did not reach the learning criterion of 
the KB tasks compared to the control sample of 10-20% who do not reach the learning criterion 
(Oades et al, 1996; Moran et al, 2003; Moran et al, 2008).  In some instances participants 
would be excluded or not put forward for further assessments for behavioural measures (i.e. 
fMRI assessment: Bott et al, 2007).  Serra et al (2001) excluded those who did not detect the 
learning association in stage three of the KB task (the same test used in this study), but retained 
all participants who reached the final testing stage regardless of meeting the learning criterion.  
This rule of excluding participants who failed at stage three was not applied to the current 
study. 
 
The lack of effect found in the KB data may also reflect the inconsistencies in findings using 
this paradigm by other researchers (Jones et al, 1990; Jones et al, 1991). Jones et al (1990) 
found no difference between schizotypy scorers and the KB task, whereas a later study found 
significant differences between those with greater positive symptomology of SPQ scores, for 
those in the acute phase of schizophrenia versus chronic stage of schizophrenia on the KB task 
(Jones et al, 1991).  The evidence for both studies was re-examined by Jones et al by breaking 
the participants down into distinct schizotypy groups, on the STA measure and the findings 
were still less clear (Jones et al, 1992).  A trend existed for participants scoring high on magical 
thinking, unusual experiences; these people tended to show less effects from the blocking, 
which links into the acute positive symptoms (e.g. hallucinations etc.) in the earlier stages of 
schizophrenic symptoms.  However, the authors concluded that the inconsistencies in the 
evidence for the KB task may be due to the insensitive nature of the between participants 
design.  Jones et al (1997) re-looked at the KB using a between and within participants design 
and found a similar result from before, in that KB was abolished in schizophrenic participants 
mainly with positive psychotic symptoms; they did not find any difference between relatives of 
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these patients who were assessed and labelled as a schizotypal and non-schizotypal relative.  
Further to this, Oades et al (1997) found that KBE was attenuated in young non paranoid 
patients, but this was not the case for those with significant paranoid symptoms.  Interestingly, 
in participants overall (controls and patients) attenuated blocking was linked to higher levels of 
dopamine activity as measured in 24 hour urine samples  Higher levels of dopamine and 
attenuated blocking ties into the argument of KB performance being linked to genetic 
differences as certain genes (e.g. COMT) are involved in the breakdown of dopamine 
(Eisenhofer et al., 2001).   
 
In the current study there were no significant differences found for KB performance between 
high and low SPQ-B scorers under the conditions BL versus NBL.  There have been quite a 
few inconsistencies using the KB task in Jones’ study, (the same task and procedure as used in 
the present investigation).  However, it does seem that some consistent findings have come 
about using the Oades paradigm, in that KB deficits are found in non-paranoid schizophrenic 
patients and these results were replicated by Moran et al (2003).  Moran et al. also 
distinguished aspects of schizotypy which reduce blocking and found a negative relationship 
between KB performance and positive symptoms (e.g. unusual experiences) and 
disorganisation (i.e. cognitive disorganisation).   
 
2.4.3 SPQ-B, cannabis use and dependency 
There were no significant differences found between the cannabis and non-cannabis users on 
the SPQ-B measure.  This does not support previous research (e.g. Skosnik et al, 2001; Barkus 
et al. 2008; Friedberg et al. 2010).  Lack of findings could be due to the low participant 
numbers with the current study and/or a lack of sensitivity in the SPQ-B as a measure.  The 
SPQ-B requires a simple Yes/No response and many anecdotal responses from the participants 
related to how they sometimes “felt like that and at other times did not”, therefore the 
participants often marked the response as a straight ‘no’ and did not allow for any recognition 
for levels of this trait.  A study published by Cohen (2010) adjusted the SPQ measure using a 
likert-scale and found that it was much more sensitive than the original version for uncovering 
a psychosis-proneness personality profile.    
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The amount of cannabis used was explored and heavier use of cannabis was associated with 
higher number of reported traits on the SPQ-B measure both for positive, negative symptoms 
and disorganised thinking.  This supports previous research by Compton et al. (2009) who 
found that heavier cannabis use in early adulthood is associated with higher rates of schizotypy.  
Age of onset of cannabis use was negatively associated with scores on SPQ-DT, with earlier 
onset of use of the drug related to higher scores on this third subscale of disorganised thinking. 
This differs from Compton et al’s (2009) study as early age of onset of cannabis was associated 
with interpersonal schizotypy.  Compton’s research, however, used two distinct testing groups 
(e.g. first-degree relatives of patients versus non-psychiatric controls) and this therefore makes 
it difficult to generalise these findings against a sample of cannabis users versus non-cannabis 
users on these SPQ-B traits, especially as the current sample did not report any family histories 
of psychosis.  What is clear is that earlier use of cannabis and higher frequency of use is linked 
to experiencing more of these psychotic-like traits which arguably may account for the reason 
why some people at are a higher risk for the development of schizophrenia (e.g. Bossong & 
Niesink, 2010).   
 
Cannabis dependency was assessed using the Severity of Dependency Scale (Gossop, 1995).  It 
is debatable about the cut-off mark for dependency as there is no single cut-off mark for all 
drugs of dependence (Trosi et al, 1998), however, optimal marks for cut-off points for 
amphetamine, cannabis and cocaine are reported as 5, 3 and 3 respectively.   Martin et al 
(2006) were the first to reliably use the SDS as a screening tool for cannabis dependency in a 
non-clinical sample of adolescent cannabis users and concluded that the optimal score was four 
for cannabis dependence.  Seven out of twenty of the cannabis group in this current 
investigation reported a cannabis SDS of four and above, thus indicative of cannabis 
dependency.  A significant association was found between cannabis dependency scores and 
negative symptomology from the SPQ-IP subscale which relates to interpersonal traits that link 
to paranoid ideation, social anxiety, no close friends and constricted affect.  An important point 
to make is that SDS scores are not appearing to predict other relationships, as there was nothing 
clearly linked with this measure to LI scores or other SPQ-B variables.  Whereas joints per 
week (actual use whether dependent or not) correlates to all the SPQ-B variables.    
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Research on severity of drug dependency (namely cannabis use) and psychotic-like symptoms 
is very limited but this finding is backed up by one previous study (Hides et al, 1997).  Hides et 
al used a sample of 153 in-patients diagnosed with schizophrenia spectrum disorder and used 
the CIDI measure with criteria from the DSM-IV (American Psychiatric Association, 1992) to 
assess the sample for cannabis dependency, of which 54% met the criteria for cannabis 
dependence.  Individuals with a score greater than or equal to 2 on the Severity of Dependence 
Scale were nearly 30 times more likely to have a DSM-IV diagnosis of cannabis dependency.  
In their study, cannabis dependency was linked to having more positive symptoms (odds ratio 
of 1.09) and negative symptoms (odds ratio of 0.90) associated with schizophrenia (as assessed 
by the Positive and Negative Syndrome Scale; Kay et al, 1987).   
 
Dumas et al. (2002) attempts to explain the relationship between cannabis use and schizotypal 
symptoms in terms of  the ‘self-medication’ hypothesis, with high schizotypal individuals 
attempting to reduce their negative symptoms using a psychostimulant drug, which in turn may 
bring about or intensify the positive symptoms.  Some researchers now postulate that the 
endocannabinoid system may underpin vulnerability to schizophrenic-like symptoms and also a 
vulnerability to cannabis consumption (Schnieder et al, 1998; Leweke et al, 1999; Bossong & 
Niesink, 2010).  This genetic vulnerability will be assessed by comparing the SPQ-B data 
across all three studies in Chapter 4 for candidate genes in psychosis-proneness.   
 
2.4.4 Evaluation of research 
In the primary analysis the non- cannabis group did not demonstrate a normal LI effect as they 
achieved fewer trials to criterion in the pre-exposed condition versus the non pre-exposed 
condition.  The cannabis group also demonstrated better associative learning skills under the 
NPE condition compared to the non-cannabis group.  Overall only 35% of the non-cannabis 
users achieved the learning criterion compared to 80% of the cannabis users.  The non-cannabis 
group overall performed less well, but there was no intelligence test administered to check if 
there were apparent differences between the group.  The non-cannabis group had 3 participants 
reported heavy lifetime use.  Therefore, a new group of 5 non-cannabis users were tested (1 in 
the PE and 4 in the NPE conditions) and this revealed a true LI effect as they were faster under 
the NPE condition compared to the PE condition, with 60% of the sample achieving the 
learning criterion. In the primary analysis most of the participants for non-cannabis users were 
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internal candidates from the UEL, so it could be argued that there motivation to take part may 
not have been as high as those willing to travel to the university to take part in the research.  
However, in the secondary analysis the five new participants were internal candidates and this 
actually increased performance for the non-cannabis group, as opposed to decrease 
performance.  There were more males in the cannabis using group in both the primary and 
secondary analysis.  This gender difference may have impacted on the findings, as recent 
research by Kaplan & Lubow (2010) indicated that low schizotypal healthy males, but not 
females, exhibited LI.  Further to this, cannabis users experiment with other drugs and in this 
current study they reported a greater degree of past and current polydrug use and this must be 
noted before any firm conclusion can be drawn regarding the impact of cannabis on cognitive 
functioning; polydrug use may be a key reason for cognitive disruption, as opposed to cannabis 
use alone (e.g. Croft et al, 2001).  Cannabis users frequently reported use of other party drugs 
such as cocaine, amphetamine and high use of MDMA, all which are neurotoxic and affect 
cognition in their own right (and especially in combination) (e.g. Rogers & Robbins, 2001; 
Gouzoulis-Mayfrank & Daumann, 2001).  Therefore, it is difficult to draw conclusions about 
the sole impact of cannabis, especially as elevated psychopathology is associated with polydrug 
use in general (e.g. Parrott et al, 2001).  Moreover, having just two-group comparisons 
(between the cannabis users and non- cannabis users) makes it difficult to assess the true 
impact of cannabis use, especially as cannabis use is varied within this drug group as well high 
polydrug use.  A way to overcome this for future research would be to use a three-group 
comparator 1) cannabis use and high polydrug use, 2) cannabis use with low polydrug use, and 
3)  a non-drug using sample (with little party drug history).  
 
The KB task has not been as extensively researched as a paradigm in human participants as the 
LI paradigm, and may need much more refining and developing to reduce the inconsistencies 
found between existing studies.  Also, by excluding participants based on not achieving basic 
associative learning skills in testing stage three would have helped to  eliminate ceiling effects.  
The cannabis group were asked to abstain for at least two days prior to testing and this was 
assessed objectively though saliva based drug tests, so these LI effects cannot be directly 
accounted for as acute effects of smoking cannabis.  It could be argued that these LI effects are 
due to withdrawal from the drug (e.g. Pope et al, 1995), but these current drug users were able 
to abstain for two days without any difficulty and those unwilling (or unable) to abstain made 
this known to the researcher and were not included in the study.  
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2.4.5 Summary of key findings  
Cannabis users seem to have abolished LI and as predicted were showing a more 
schizophrenic-like impairment on the LI task; they were less affected by the pre-exposure to the 
white noise under the PE condition.  There were no significant differences found in SPQ-B 
scores between the Groups (cannabis versus non-cannabis) and this measure was limited to a 
simple Yes/No response, which made it difficult to assess more subtle levels of the traits.  
Therefore, in studies two and three additional personality measures will be added which assess 
psychosis-proneness by adopting a likert-scale to explore levels of schizophrenia-like 
personality traits.  The key outcome for the SPQ-B data is that those that reported earlier onset 
of cannabis use and higher frequency of use (regardless of being dependent or not dependent) 
reported experiencing more psychotic-like personality traits.   
 
Due to the small numbers in each group (cannabis versus non-cannabis) for the PE/NPE 
conditions, it was difficult to break these down into low and high SPQ-B scores.  The entire 
group was therefore collapsed into one sample and were allocated to the high or low SPQ-B 
group based on the criteria set by Laws et al (2008).  A normal LI effect was found in low 
SPQ-B scorers, but was abolished in high SPQ-B scorers between the PE and NPE conditions, 
with high SPQ-B scorers being more distracted by the pre-exposed white noise and learnt to 
find the association more quickly.  There was a lack of differences found under the PE 
condition between high/low scorers might give an indication that the differences found with the 
cannabis group on LI performance may be a specific effect of the drug as opposed to 
higher/lower SPQ-B traits.  
 
Overall the cannabis users do seem to be showing subtle differences in brain inhibitory function 
akin to previous research with schizophrenic patients, their first degree relatives and high 
schizotypy scorers.  Cannabis users also highlighted individual differences in psychosis-
proneness personality traits when they had earlier onset of cannabis, higher frequency of use, 
and higher levels of dependency to this drug.  These findings could be argued to fit with 
suggestions that regular cannabis use and its association with DA transmission in the PFC is 
involved in the breakdown of normal information processing and may account for selective 
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attention dysfunction and the experiencing of more psychotic-like personality traits.  These 
findings also fit in with ideas that cannabis use at earlier ages may disrupt normal 
neurodevelopment regulated by endocannabinoids; such that the differences observed may be 
evidence of neuro-difference in users and non-users. 
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Chapter 3: Decision-making, selective and sustained attention, inhibitory control and 
psychotic-like traits in regular cannabis users 
 
The growing evidence for a relationship between cannabis use and potential risk for 
developing schizophrenia was discussed in Chapter one.  Chapter two explored the link 
between cannabis use and schizophrenia-like behaviours, by assessing the performance of a 
group of cannabis users versus non users on two associative learning tests, namely Latent 
Inhibition and the Kamin Blocking effect; these tests have been shown to be disrupted in 
people diagnosed with schizophrenia.  The rationale to investigate cognitive disturbances in 
cannabis users which parallel those found in schizophrenic patients was presented in Chapter 
1.  In brief, pharmacological evidence suggests that the endocannabinoid (eCB) system has a 
known role in learning, memory and higher cognitive processing (Herkenham et al, 1990).  
Evidence exists that chronic exposure to cannabinoids can alter the functioning of cognitively 
relevant neuromodulater systems; e.g. dopaminergic, cholinergic, serotonergic, GABAergic 
and glutamatergic (Sundram et al, 2004).  Furthermore, research on administering THC to 
schizophrenic patients reveal enhanced sensitivity to this psychoactive drug for cognitive 
dysfunction (e.g. D’Souza et al, 2005), and administering THC to normal controls also 
mimics schizophrenic-like symptoms (e.g. Morrison and Murray, 2009).   
 
   
Moving on from the findings in the first study, the current chapter aims to further explore 
whether regular cannabis users show a profile of personality traits and cognitive dysfunctions 
characteristic of schizophrenia.  Secondly, it aims to explore the inter-relationships between 
personality traits, cognitive performance and cannabis use. 
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3.1 Decision-making – the Iowa Gambling Task 
People diagnosed with schizophrenia have decision making problems (see Alves et al, 2006 
for a review), which are a result of poor executive functioning (Goldman-Rakic  et al, 1997, 
1999; Rüsch et al, 2007).  People diagnosed with schizophrenia also demonstrate deficits on 
cognitive tasks which assess emotion (Kring and Neale, 1996; and see Kring, 1999 for a 
review).  More specifically, those displaying more negative symptoms of schizophrenia 
(related to the emotional element of affective or motivational symptoms) also show greater 
deficits on frontal lobe functioning tasks (Wolkin et al, 1992).  One way that this has been 
assessed is to look at performance on the Iowa gambling task (IGT), an emotional based 
neurocognitive learning task specifically designed to tap into ‘real-life’ decision-making 
abilities, which requires the individual to simultaneously weigh up the costs and benefits of 
their decisions.  The participants are required to choose cards from one of four available decks 
of cards, typically labelled as decks A, B, C and D. On selection of these cards a win or lose 
outcome is displayed on the screen.  The difference between the decks of cards are that the first 
two packs (A and B) provide immediate higher wins (e.g. £100) but can also result in higher 
losses (e.g. £1125), whereas the other two packs (C and D) provide moderate wins (e.g. £25) or 
minor losses (e.g. £75).  Typically, ‘normal’, healthy, control participants learn to avoid decks 
A and B and adopt the more beneficial strategy of opting for packs C and D.  Over time there is 
a net loss of £25 per card from packs A and B, whereas there is a net profit of £25 per card 
from C and D.  The task ends after 100 card selections and the total net score is calculated as a 
loss or gain from the monetary funds (e.g. £2000) that participants were awarded at the start of 
the game.  Please refer to Table 16 for a summary of the research detailed below on IGT and/or 
similar tasks to the IGT. 
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Table 16: A summary of research using the Iowa Gambling Task in cannabis users, 
schizophrenia, and brain damaged patients. 
 
Study  Participants  Cognitive 
Task 
Main results  
Damasio et al (1991) Clinical – brain 
damaged patients 
IGT Patients lacked anticipatory response (via SCRs) for 
riskier decks. 
Bechara et al (2000) Clinical – brain 
damaged patients 
IGT Poorer decision-making in the patient group. 
Verdejo et al ( 2004) Substance use 
disorder 
IGT Poorer decision-making in the patient group. 
Bark et al, 2005; Beniger 
et al 2003; Shurman et 
al, 2004;  
Schizophrenia IGT Poorer decision-making in the patient group. 
Whitney et al (2004) Schizophrenia and 
OCD 
IGT Patients with schizophrenia performed worse than 
patients with OCD. 
Ritter et al (2004) Schizophrenia and 
Schizoaffective 
disorder 
IGT Patient groups performed worse when compared to 
controls. 
Mata et al (2008) Acute 
schizophrenia – 
cannabis use 
versus no 
cannabis use 
IGT Patients who used cannabis prior to schizophrenia 
diagnosis performed worse compared to 
schizophrenia group who did not use cannabis. 
Evans et al, 2005; 
Premkumar et al, 2008; 
Turnball et al, 2003 
Schizophrenia IGT Normal decision making in schizophrenia when 
compared to a control sample. 
Hermann et al, 2009 Cannabis use IGT Poorer decision making in cannabis users compared 
to controls.  Dose response effect with higher levels 
of THC and poorer IGT performance. 
Whitlow, 2004 Cannabis use IGT Poorer decision making associated with long-term 
use of cannabis. 
Grant et al (2012) Cannabis use Cambridge  
Gambling 
Task 
Poorer decision making in cannabis users compared 
to controls. 
Bolla et al (2005 Cannabis use  IGT & 
brain 
imaging  
Cannabis users performed worse than controls on the 
IGT and showed greater activation in cerebellum and 
less activation in OFC and right DLPFC.  Heavy use 
was associated with greater activation in brain 
regions with greater CB1 density. 
Wesley et al (2011) Cannabis use  IGT & 
brain 
imaging  
Cannabis users performed worse than controls on the 
IGT and showed under-responsiveness in brain areas 
such as: anterior cingulate, medial prefrontal, and 
superior parietal cortices, dorsal cerebellum and 
occipital lobes. 
 
Cannabis users had insensitivity to loss from the 
earlier stages of the IGT. 
Yarkomi et al, 2005 Schizophrenia IGT & 
brain 
imaging 
Greater attention to reward is associated with greater 
activation of grey matter volume in PFC in controls. 
Shenton et al (2001) Chronic 
schizophrenia 
IGT & 
brain 
imaging 
Reduced activation of gray matter volume in PFC for 
chronic patients. 
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The IGT was initially developed to assess patients with lesions of the orbito-/ventromedial 
prefrontal cortex (OFC/VMPFC) which affects learning and decision-making (e.g. Bechara et 
al, 1994).  Damage to these brain regions has been linked to impaired emotional 
expression/feelings, with patients showing impairments in psychophysiological responses to 
emotional (in relation to neutral stimuli) (Damasio et al, 1990).  In work exploring his Somatic 
Marker Hypothesis (SMH) for emotion based decision making, Damasio et al (1991) reported 
that damage to the VMPFC was linked to decision making deficits, particularly for emotion 
based biasing signals (or somatic markers) when making value led decision.  According to 
Damasio and colleagues, decision making can be viewed as a cost benefit analysis and 
‘markers’ for how punishing or rewarding an action is will be used when a detailed logical 
analysis cannot be performed in complex situations (Damasio et al, 1991; 1994; 2004).  Key 
support for the SMH comes from correlational data on performance on the IGT and Skin 
Conductance Responses (SCRs) in patients with VMPFC damage and healthy controls.  Both 
groups showed normal SCRs on punishment and rewards at the beginning of the IGT, but soon 
into the task the controls developed anticipatory SCRs, which were higher for the riskiest card 
deck.  This anticipatory response was absent in the patient group and this correlated with poor 
performance on the IGT.  Bechara et al (1996) argued that failure to identify good/bad 
outcomes in a situation of uncertainty was a result of a failure to activate the somatic marker for 
learning previous punishments in bad decks, which ultimately results in a lack of sensitivity to 
the possibility of future punishments on that deck.  Thus, based on the SMH, performance on 
the IGT was seen as people developing ‘hunches’ for outcomes on the good/bad decks.  
Opposing theories on IGT performance have been put forward to argue that performance on the 
test is not due to somatic biases but to cognitive outcome expectancies where people are 
consciously aware of the outcomes on the task from learning the deck advantage/disadvantage 
outcomes earlier in the task, and thus they take less risk overall (see Turnball et al, 2003).  
Irrespective of opposing theories on IGT performance it is seen as a robust measure of decision 
making and findings have been consistent even after changes to its testing parameters (e.g. 
giving a real financial reward; Bowman and Turnball, 2003) and time delays (Bowman et al, 
2005).   
 
Relatively consistent findings have been shown in people with damage to frontal brain regions 
(Bechara et al 2000), those diagnosed with substance disorders (Verdejo et al, 2004; Bechara et 
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al, 2001) and psychiatric disorders; groups which generally perform much worse compared to 
healthy controls.  For example, Bark et al (2005) tested a group of 8 people diagnosed as 
catatonic schizophrenic and 19 paranoid schizophrenics versus a group of 26 healthy controls 
and found that the disadvantaged decks were selected more often by the schizophrenia groups.  
Whitney et al (2004) tested a group of 26 people diagnosed as schizophrenic with obsessive 
symptoms and 26 schizophrenics without obsessive symptoms, and 11 people diagnosed with 
obsessive compulsive disorder (OCD).  There was a trend for both schizophrenia groups to 
select the disadvantaged decks more often than the OCD group.  It could be that the patients 
with OCD have higher anxiety sensitivities and thus take less risk.   
 
Research which excluded those with a history of substance abuse, indicated that people 
diagnosed with schizophrenia choose the disadvantaged packs more often (i.e. those with 
immediate higher reward but greater losses overall) than the advantage packs (i.e. moderate 
wins but with less loss overall) when compared to a group of healthy controls (Beniger et al, 
2003; Ritter et al, 2004; Shurman et al, 2004).  Beniger and colleagues compared a group of 36 
people with schizophrenia with 18 controls and found that those with schizophrenia using 
atypical antipsychotic medication performed worse on the IGT.  Shurman and colleagues 
compared a group of 39 people with schizophrenia and 10 controls and found that people 
diagnosed with schizophrenia had poorer decision making.  Similarly, Ritter and colleagues 
compared 20 people with schizophrenia or schizoaffective disorder with 15 controls and found 
that controls chose the advantageous packs (e.g. C and D) and this resulted in better decision 
making overall compared to people with schizophrenia or schizoaffective disorder. 
 
Mata et al (2008) assessed 132 people in the acute stages of schizophrenia and tested them on 
the IGT, and separated the group into those currently using cannabis versus no cannabis use.  
It was found that patients who had abused cannabis prior to the onset of psychotic symptoms 
showed poorer performance on the decision-making task.   Nevertheless, some studies, which 
did not account for substance abuse, demonstrated a pattern of normal decision-making on the 
IGT in schizophrenia (Evans et al, 2005; Premkumar et al, 2008; Turnball et al, 2003).   
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3.1.1 Cannabis, schizophrenia, neuroimaging and decision-making 
Cannabis users have shown to be less risk averse and choose the disadvantaged packs more 
often relative to non-cannabis users, which resulted in less monetary returns on IGT (e.g. 
Hermann et al, 2009).  Hermann et al also assessed hair samples of cannabis users, along with 
their subjective ratings on the trait tridimensional personality questionnaire, in 13 users and 
13 controls and this was correlated with performance on the IGT.  THC correlated negatively 
with the last subtrial (cards 80-100 which given an indication of whether the participants 
learnt the more advantageous strategy) of the IGT (r=-0.67), thus higher levels of THC found 
in the participant’s hair was also indicative of poorer decision-making (e.g. higher loss). 
Greater use of cannabis was also associated with greater loss overall on the IGT.  On the trait 
measure, the dimension of harm avoidance correlated negatively with IGT (r=-0.43).  The last 
subtrial correlated with adventure seeking, (0.43), negatively with harm avoidance (-0.39), 
and with reward dependence (r=0.44).  More importantly, a regression model indicated that 
heavy THC consumption rather than personality traits was the strongest predictor of IGT 
performance.  Poorer decision making on the IGT has also been associated with duration of 
cannabis use, more specifically those with a profile of long-term heavy use chose the riskier 
card decks with immediate higher gain but higher losses overall (Whitlow, 2004).  These 
studies suggest that cannabis use, particularly heavy use, might lead to poor decision-making.  
Cannabis use has also been linked to risky decision-making on the Cambridge Gamble Task, 
an analogue of the IGT (Grant et al, 2012).    
 
Brain regions which are rich in CB₁ receptors are linked to decision-making and emotional 
processing (Herkenham et al, 1990; Whitlow et al, 2004; Wesley et al, 2011).  Poor decision-
making in cannabis users have also been objectively verified with supporting evidence from 
brain imaging data.  Bolla et al (2005) reported differences between cannabis users and non-
cannabis users, with cannabis users showing greater activation in the cerebellum and less 
activation in the right lateral Orbito-prefrontal cortex (OFC) and right Dorso-lateral Pref 
frontal cortex (DLPFC), areas linked to decision-making (e.g. Bechara et al, 1994).  Heavy 
cannabis use showed greater activation in brain regions dense with cannabinoid receptors, 
such as the cerebellum and hippocampus, and less activation in the medial OFC.  Wesley et 
al (2011) reported that cannabis users performed significantly worse than non-cannabis users 
on the IGT and also demonstrated under-responsiveness in brain areas such as anterior 
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cingulate, medial prefrontal, and superior parietal cortices; with under-responsiveness in 
these brain areas as well as portions of the dorsal cerebellum and occipital lobes being 
associated with monetary losses in the cannabis group.  A correlation was also found between 
early loss evaluations in the non-cannabis group, with early loss evaluation associated with 
better decision making during the rest of the task, whereas this was not the same for the 
cannabis group, and the researchers argued that cannabis users had some insensitivity to 
losses even at the earlier stages of the task.  These findings by Wesley et al (2011) are 
supported by growing evidence for abnormalities in affective responding in cannabis users 
and long terms users (e.g. Degenhardt et al, 2003; Skosnik et al, 2008).  Wesley and 
colleagues argued that long term users of cannabis and functional insensitivity to monetary 
losses may be the result of a disrupted cannabinoid system due to long term use of the drug.   
 
Brain activation and functioning in people diagnosed with schizophrenia has also been assessed 
during the IGT, and it was found that greater attention to reward is associated with greater 
activation of grey matter volume in PFC in healthy controls (Yarkomi et al, 2005), but marked 
by reduced activation in chronic schizophrenic patients (Shenton et al, 2001).  These brain 
scanning data run parallel to the under responsiveness found in the cannabis group by Wesley 
et al (2011), but rather than an under-responsiveness to punishment, people in the chronic 
stages of schizophrenia differentially respond to rewards when compared to a healthy control 
sample. 
 
Overall, it seems that emotional decision-making (as measured by the IGT) is disrupted in 
people with prefrontal brain damage, psychiatric conditions and mainly those diagnosed with 
schizophrenia.  Those people with schizophrenia that use cannabis prior to the onset of 
symptoms also seem to have poorer decision making abilities (e.g. Mata et al, 2008).  Further 
to this, cannabis users seem to perform in a similar way to people diagnosed with 
schizophrenia, even though performance is correlated with differential responding in brain 
activation.  There are differences observed in drug users’ performance depending on the 
amount of cannabis they consume and the length of period cannabis had been consumed for 
(e.g. Hermann et al, 2009; Whitlow et al, 2004). 
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3.2 Selective attention, sustained attention and inhibitory control 
Sustained attention (i.e. maintaining a consistent focus) and selective attention (i.e. focusing 
on relevant as opposed to irrelevant information) and inhibitory control (i.e. being able to 
inhibit a response by not selecting irrelevant stimuli) have also been proposed as 
endophenotypes of schizophrenia.  A common measure of attention is the Continuous 
Performance Test (CPT; Rosvald et al., 1956), which exists in a number of versions: for 
example, the identical pair version where participants are asked to perform a computer task 
and press the keypad when the same digits are repeated (e.g. 43578 is followed by 43578).  
Some of these digits are trick digits (e.g. 62897 is followed by 62895) and some are correct 
(e.g. same digits are repeated) and others are novel digits (e.g. new arrangements of digits 
follow the preceded trial).  Throughout the task distracter digits ‘12345’ are randomly 
presented (e.g. Cornblatt et al, 1989).  Earlier studies which used the CPT as a measure of 
selective and sustained attention analysed measures of perceptual sensitivity (e.g. 
discriminating targets from non-targets), omission error counts (or sometimes known as 
motor errors) which represent impulsive responses to filler stimuli (e.g. Dawkins et al,  2007) 
and commission errors (or false alarm) which are incorrect responses to the target. Many 
recent researchers also focus on reaction times, which reflect the speed for all correct 
responses as a measure of selective attention (e.g. Chen et al., 2004).  Please see Table 17 
below for a summary of the research using the CPT and/or similar tasks.  
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Table 17: A summary of research using the Continuous Performance Test in schizophrenia 
patients, cannabis users and high schizotypy. 
 
Study  Participants  Cognitive 
Task 
Main results  
Strauss et al (1993) Schizophrenia and 
schizoaffective disorder 
CPT Selective attention deficits 
associated with higher symptom 
scores on the BPRS. 
Vollema and Postma 
(2002) 
Unaffected first-degree 
relatives of people 
diagnosed with 
schizophrenia. 
CPT Clinical interview SPQ dimensions 
were associated with deficits in 
motor and commission errors on 
CPT, whereas the SPQ binary 
question was only associated with 
deficits on the false alarm variable.  
Rodríguez-Sánchez et al 
(2010a) 
Schizophrenia and 
cannabis 
CPT Schizophrenia patients who used 
cannabis performed worse overall 
on the CPT. 
Rodríguez-Sánchez et al 
(2010b) 
Schizophrenia and 
cannabis 
CPT No differences were found between 
people with schizophrenia who used 
substances and those who did not 
Jockers-Scherübl et al 
(2007) 
Schizophrenia and 
cannabis 
CPT Cannabis use before the age of 17 
was associated with better 
performance on CPT for people 
diagnosed with schizophrenia, and 
the opposite was found for controls.   
Pope et al (2001) Cannabis users CPT Current cannabis users asked to 
abstain for 28-days and were 
assessed on days 0, 1, 7 and 28.  
There were no differences found 
between controls and current users 
on CPT at any of the four testing 
stages. 
Bedwell et al (2009) Non-clinical CPT –AX 
version 
Higher scores on the structured 
clinical interview for Schizotypal 
Personality Disorder associated with 
poorer performance on the CPT.  In 
contrast, scores from the 
psychometric abbreviated SPQ in 
the same sample did not correlate 
with accuracy scores on the CPT.   
 
Chen et al (1997) Non-clinical CPT AX 
version. 
Adults scoring high on the subscale 
SPQ-IP for poor interpersonal 
relationships had lower scores on the 
CPT. 
Bedwell et al (2006)  Non-clinical CPT Participants with higher scores on 
the SPQ-B made more omission 
errors than controls. 
Bergida and 
Lenzenweger (2006)  
Non-clinical 
 
 
CPT-IP 
version. 
There was a negative correlation 
between CPT accuracy and the 
reality distortion subscale scores 
from the SPQ. 
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3.2.1 Schizophrenia, cannabis and selective attention 
Selective attention deficits have been found in people diagnosed with schizophrenia as well 
as those in remission (e.g. Amamow and MacCimmon, 1978).  Strauss et al (1993) assessed 
CPT performance in a group of schizophrenic patients and also in those with schizoaffective 
disorder and measured symptoms using the Brief Psychiatric Rating Scale (BPRS; Overall 
and Gorham, 1980).  They found that selective attention was moderately correlated with 
measures of thought disorder using the BPRS, in that higher symptom scores were associated 
with greater deficits on the CPT. 
 
Vollema and Postma (2002) used a sample of unaffected first-degree relatives of individuals 
with schizophrenia to examine schizotypal personality features and CPT.  In addition, they 
used a self-scoring SPQ and also a structured interview for SPQ dimension scores for 
different factors of schizotypal personality.  It was found that the clinical interview 
dimensions scores for disorganised symptomology was positively associated with false 
alarms (or motor errors) and commission errors, whereas the SPQ total was only associated 
with the false alarm variable.  As alluded to in the previous chapter, this latter limited finding 
may in part be because the binary-nature of the SPQ measure may not allow this scale to fully 
capture all of the schizophrenia-like symptoms which affect cognition.     
 
Rodríguez-Sánchez et al (2010a) examined the use of cannabis and its impact on cognition in 
people in their first episode of schizophrenia symptoms, with 104 people with schizophrenia 
(with non-affective psychosis) and 37 controls.  Patients were classified into cannabis use 
before the onset of the illness (n=47) and non-cannabis users (n=57).  This was a cross-
sectional and longitudinal study with assessments at baseline and then at a 1-year follow-up 
period.  It was found that the people with schizophrenia who were using cannabis performed 
well on tasks for attention.  The controls only outperformed the non-cannabis using people 
with schizophrenia at two different time points on the CPT for selective attention, but there 
was no difference found between cannabis users and non-cannabis using groups of people 
with schizophrenia.  In a later study, no differences were found between people with 
schizophrenia who used substances and those who did not (Rodriguez-Jimenez et al, 2010b). 
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Jockers-Scherübl et al (2007) investigated cannabis use and cognitive changes in people with 
schizophrenia and healthy controls.  The researchers assessed cognitive effects after a 28-day 
abstinent period, using two groups of participants:  39 schizophrenics (19 cannabis users and 
20 non-cannabis users) and 39 controls (18 cannabis users and 21 non-cannabis users).  In 
contrast to what is expected, cannabis use before the age of 17 was associated with better 
performance on CPT for people diagnosed with schizophrenia, and the opposite was found 
for controls.   
 
3.2.2 Cannabis and selective attention 
There have been few studies looking at CPT performance and cannabis use in non-clinical 
samples.  Pope et al (2001) assessed current and former cannabis users who had smoked at 
least 5000 joints, versus controls.  Current cannabis users were asked to abstain for 28-days 
and were assessed on days 0, 1, 7 and 28.  There were no differences found between controls 
and current users on CPT at any of the four testing stages (for total correct responses and total 
errors).  The CPT may not have been sensitive enough to assess for selective attention deficits 
in Pope at al’s study compared to Solowij’s (1995) study looking at Event Related Potentials 
(ERPs) in response to processing of irrelevant information (see Chapter 1). 
 
3.2.3 Selective attention and individual differences 
Bedwell et al (2009) explored the relationship between schizotypal personality dimensions 
(SPD) and performance on the CPT.  The researchers used the AX test where participants had 
to press the space bar after the letter X was presented on screen, but only if it was preceded 
by the letter A.  Interestingly their research examined CPT performance alongside continuous 
dimension scores created from a structured clinical interview for schizotypal personality 
disorder, which looked at the severity and breadth of each symptom.  The study found 
positive associations between interpersonal symptoms and omission errors (r = .47) and 
disorganised symptoms and false alarms (r = .40).  Higher scores for SPD were associated 
with poorer performance on the CPT.  In contrast, scores from the psychometric abbreviated 
SPQ in the same sample did not correlate with accuracy scores on the CPT.   
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Chen et al (1997) found that adults scoring high on the subscale SPQ-IP for poor 
interpersonal relationships had lower scores on the CPT AX.  Bedwell et al (2006) found that 
individuals scoring higher on the abbreviated scale for of the SPQ (the SPQ-B) made more 
omission errors than controls, but this was related to cognitive-perceptual (CP) subscale 
scores, which is related to more of the positive symptomology.  Bergida and Lenzenweger 
(2006) used the CPT-IP which places more demand on working memory, and found a 
negative correlation between CPT accuracy and the reality distortion subscale scores from the 
SPQ.  This subscale is similar to the CP subscale in that it represents positive symptomology 
such as delusions and hallucinations and as such parallels the finding by Bedwell et al (2006) 
for the CPT AX version and CP.  Overall, from these studies it seems that selective attention 
as measured by the CPT can be linked to some schizophrenia-like personality traits. 
 
3.2.4 Brief Summary: Selective attention, CPT and Cannabis 
It seems that schizophrenic patients, their first degree relative and people scoring high on 
positive symptomology and disorganised thinking make more omission errors on the CPT for 
selective attention.  There appears to be a strong genetic loading, as these CPT deficits are 
also found in first-degree relatives of patients, including their parents, siblings and offspring.   
The results are contradictory for cannabis use, with one study finding an improvement in 
CPT performance in patients that used cannabis prior to 17, and in another no difference 
found between patients that use cannabis versus those that do not.  Interestingly, healthy 
controls seem to perform better than schizophrenics that do not use cannabis, but not people 
with schizophrenia who use cannabis recreationally.  Further to this, no differences were 
found between cannabis users who underwent a 28-day abstinence period, under four 
separate testing sessions on the CPT.  Inconsistencies within the literature assessing CPT 
performance may be the result of researchers using different versions of the CPT (see Khan et 
al, 2012).   
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3.3 Executive control - Anti-saccade task  
Executive control is a term used to describe a range of cognitive processes (such as working 
memory, inhibition, cognitive flexibility) which are  involved in the regulation of goal 
directed behaviour (Rogers and Bennetto, 2000).  There are many research paradigms used to 
assess executive control such as the Stroop Paradigm (Stroop, 1935; Homack, 2004), Trail 
Making Test paradigm (AITB, 1944; Aruthnott and Frank, 2000), and the Wisconsin Card 
Sorting Test (Golman-Rakic, 1987; Berman et al, 1995) and these demonstrate key functions 
linked to frontal brain regions (Hallet, 1978).  One paradigm which has been widely used is 
the Anti-Saccade Task (AST; Hallet et al, 1978; Everling and Fisher, 1998; Munoz and 
Everling, 2004).  The anti-saccade task is a measure of volitional control of behaviour (eye-
movement), whereby participants are asked to focus their gaze centrally and inhibit a normal 
saccadic response by looking in the opposite direction of a small moving target.  The eye 
movements are measured via eye-tracking equipment.  Following the moving object would 
result in a pro-saccade response, whereas, inhibiting this natural urge to follow the moving 
target and looking in the opposite direction is referred to as an anti-saccade (Godijin and 
Kramer, 2007).  Anti-saccade responses are seen to be slower than pro-saccades due this 
condition requiring people to inhibit the prepotent prosaccade response as well generating a 
correct anti-saccade response (e.g. Masson, 2004).  Godijin and Kramer (2007; 2008) argue 
that outcomes of the task are influenced by inhibition as well as attentional and working 
memory capacities.  Patients with attentional problems and lesions to the DLPFC make more 
errors on the AST, than on the pro-saccades stage of the task when compared to healthy 
controls (Guitton et al, 1985) and patients with damage to their frontal eye field have slower 
response times on the AST than healthy controls (e.g. Gaymard et al, 1998).  A number of 
variables can be assessed such as error rate, latency and gain.  Error rate reflects the number 
of incorrect anti-saccade or prosaccade responses, latency is recorded as the speed of 
responding, and gain is a measure of how closely the eye gaze meets the designated target (in 
the AST the eye gaze should be in the exact opposite location to where the dot has moved to 
on the screen).  Please refer to Table 18 below for a summary of the research using AST 
and/or similar tasks. 
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Table 18: A summary of research using the anti-saccade task in schizophrenia patients, brain 
damaged patients, and cannabis users. 
 
Study  Participants  Cognitive 
Task 
Main results  
Masson (2004) Non-clinical AST Anti-saccade responses are slower than pro-
saccade responses. 
Guitton et al (1985) Clinical – 
brain damage 
AST When compared to controls the patients with 
attentional problems and lesions to the DLPFC 
make more errors on the AST, than on the pro-
saccades. 
Gaymard et al (1998) Clinical – 
brain damage 
AST When compared to controls the patients with 
damage to their frontal eye field have slower 
response times on the AST. 
Curtis et al, 2001;Karoumi 
et al, 2001; Katsanis et al, 
1997; Calkins et al, 2001; 
Reuter and Kathmann, 2004 
Schizophrenia AST When compared to controls the patients with 
schizophrenia had poorer executive control. 
Bremner et al (2001) Schizotypal 
Personality 
Disorder 
AST Greater deficits were found in patients on the 
anti-saccade task relative to controls. 
Katsanis et al (1997); 
Ettinger et al (2004) 
Schizophrenia 
and first-
degree 
relatives 
AST Schizophrenic patients performed the worst on 
the AST. 
Browstein et al, 2003; 
Crawford et al, 1998. 
Schizophrenia 
and first-
degree 
relatives 
AST No difference in AST performance. 
Ettinger et al (2006) Schizophrenia 
and Non 
schizophrenia 
MZ twins 
AST Schizophrenic twins had poorer executive 
control compared to the non-schizophrenic 
twins. 
Larrison et al (2000) Non-clinical AST Those displaying more psychotic like traits 
also had poorer executive control. 
Graber and Yurgelun-Todd, 
2005; Streeter et al, 2008 
Cannabis Stroop Test Cannabis users had higher commission errors 
compared to the controls. 
Ding et al (2014) Cannabis Go/No Go 
and brain 
imaging. 
Differences were found between cannabis users 
and controls in brain areas associated with 
inhibition such as, the inferior parietal lobe, 
precuneus, right thalamus, premotor cortex, 
and middle frontal gyrus.    
Ploner et al (2002) Non-clinical 
samples and 
acute THC 
AST Healthy volunteers who were administered 
with 10 mg of oral THC made more anti-
saccade errors.   
Huestegge et al (2009) Cannabis AST  Chronic cannabis users had prolonged latencies 
for the memory guided AST, in that they could 
not correctly identify the right location 
compared to the controls.   
Chung et al (2010) Cannabis use 
disorder 
AST and 
brain 
imaging 
Increased activation in the PFC and 
oculomotor control in the frontal eye fields in 
those with cannabis use disorder compared to 
controls.  Cannabis users’ performance was 
facilitated by punishments rather than rewards. 
Abdullaev et al (2010) Cannabis AST and 
brain 
imaging 
Cannabis users had longer reaction times and 
more errors for processing incongruent stimuli 
compared to controls.  The cannabis group also 
had greater activation of the PFC during the 
AST. 
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3.3.1 Saccadic eye movement and schizophrenia 
Abnormalities in saccadic eye movement are now proposed as an endophenotype (e.g. 
psychobiological marker) associated with schizophrenia; and this is captured using the AST 
(Curtis et al, 2001; Karoumi et al, 2001; Katsanis et al, 1997; Calkins et al, 2001; Reuter and 
Kathmann, 2004).  The existence of abnormalities in eye movement for those diagnosed with 
a psychiatric condition was first described by Diefendendorf and Dodge (1902).  Since then 
there has been 50 plus peer reviewed articles consistently reporting anti-saccade deficits 
amongst schizophrenic patients; specifically that such individuals find it more difficult 
controlling this natural urge to follow the moving target, as opposed to looking to the 
opposite side (see Turetsky et al, 2009).   
 
Similar findings have emerged in high-risk populations (e.g. those diagnosed with 
schizotypal personality disorder) and greater deficits were found in these groups on the anti-
saccade task relative to controls (Bremner et al, 2001).  Variable results have been found in 
first-degree relative of those people with schizophrenia (Levy et al, 2004; Katsanis et al, 
1997; Ettinger et al, 2004; 2006; Karoumi et al, 2001).  Katsanis and colleagues assessed a 
group of 51 people with psychotic symptoms as assessed by the DSM-IV (APA, 1994), 51 of 
their first degree relatives (e.g. sister, brother, mother) and 38 unaffected healthy controls.  It 
was found that people with schizophrenia made more errors on the AST than their relatives 
with some psychotic symptoms, whereas those with some psychotic symptoms performed 
much worse relative to the controls. This reflects some underlying genetic loading for AST 
performance.  However, other studies have found no significant differences between people 
with schizophrenia and their relatives without schizophrenia (e.g. Browstein et al, 2003; 
Crawford et al, 1998).  
 
Ettinger et al (2004) examined 24 people with schizophrenia, 24 healthy siblings and 24 
controls.  People with schizophrenia made more errors on the AST and have reduced gain 
(ratio of eye over the target velocity) compared to controls.  The siblings performed in between 
the control sample and their relatives with schizophrenia, with deficits mostly marked on the 
reduced gain of the AST.  These data also support the endophenotypic/heritable significance 
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of AST, further explored by Ettinger et al (2006) in a study which used the AST to assess for 
executive control performance in 10 monozygotic twin pairs discordant for schizophrenia and 
10 monozygotic twin pairs without schizophrenia as controls.  It was found that the 
schizophrenic twins made more errors compared to the non-schizophrenic twins healthy 
control twins.  The healthy control twins did not differ from each other, whereas the non-
schizophrenic twins performed worse than the comparison healthy control twins on the gain 
(how close it spatially meets the target) and latency (speed of responding) but did not differ 
from their own twin on these measures on the AST.  AST errors were correlated with 
negative symptoms in the patients, which contrasted with Ettinger’s initial two findings.  It 
can be inferred from these studies that people diagnosed with schizophrenia and those with a 
great number of schizotypy traits have poorer executive control.  Twin studies also highlight 
a genetic link with executive control problems in people diagnosed or at-risk for 
schizophrenia. 
 
Deficits on the anti-saccade task seem to be sensitive to the positive symptoms of 
schizophrenia (O’Driscoll et al, 1998; Holahan and O’Driscoll, 2005).  The role of 
schizotypy has also been examined in saccadic eye movements, with higher positive 
schizotypal traits predicting greater error on the anti-saccade task, rather than negative 
symptomology (e.g. Ettinger et al, 2005).  Those displaying more psychotic like traits also 
had poorer executive control in that they made more errors on the AST (Ettinger et al, 
unpublished research; Larrison et al, 2000).   
 
3.3.2 Executive control, cannabis use and brain scan data 
Animal models of AST performance indicate that cortical and subcortical structures are 
involved in the suppression of a saccadic eye-movement, including the DLPFC, the lateral 
intraparietal area, the frontal eye-field (FEF) and superior colluculus (Munoz and Everling, 
2004).  Human studies support these animal models and have shown that Structural Eye 
Field, which controls the FEF and DLPFC and basal ganglia might be involved in the 
executive control of voluntary eye-movements (Munoz and Everling, 2004).  In addition, the 
DLPFC and the basal ganglia are areas rich in cannabinoid receptors and affected by direct 
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THC administration Volkow et al (1991; 1996).  Therefore, it is likely that cannabis use may 
cause disruption in these areas and affect performance for normal executive control.   
 
There is little published research looking at the effects of cannabis on executive control. 
Some studies report that cannabis users had higher commission errors using the Stroop task 
(Graber and Yurgelun-Todd, 2005; Streeter et al, 2008).  Ding et al (2014) reported no 
differences in the go/no go task in adolescent cannabis users, but in the same study 
differences were found in fMRI performance between cannabis users and non-cannabis users 
for differential activation in the brain areas associated with the response inhibition pathways 
(e.g. inferior parietal lobe, precuneus, right thalamus, premotor cortex, and middle frontal 
gyrus).  Very few studies have been published looking at non clinical samples of cannabis 
users on the AST.  Some studies have looked at the effects of acutely administered THC in 
healthy controls and chronic users, as well as eye movement control and visual scanning in 
cannabis users for clinical and non-clinical samples.  For example, Baloh et al (1979) 
research was the first to look at the acute effects of THC on controls and observed no effects 
in saccade control for latencies, peak velocities and visually guided saccades on a memory 
saccade task (where a target is presented on the sides of the screen and then disappear and 
participants need to look in the opposite direction but to the exact location of the target; this 
therefore involves an inhibitory and memory component).  Ploner et al (2002) replicated 
these findings but also examined the acute effects of THC on executive control of eye 
movements and found that from baseline testing 12 healthy volunteers who were 
administered with 10 mg of oral THC made more anti-saccade errors.  Huestegge et al (2009) 
examined the long-term effects of chronic cannabis use using a memory guided AST and they 
found that chronic cannabis users had prolonged latencies for the memory guided AST, in 
that they could not correctly identify the right location compared to the control group.   
 
Chung et al (2010) assessed responses to rewards presented during the anti-saccade task and 
brain activation in 12 adolescents (with cannabis use disorder) and 12 controls.  The 
researchers found that brain activation in those diagnosed with cannabis use disorder under 
the functional magnetic resonance imaging (fMRI) scans found increased activation in the 
PFC and oculomotor control in the frontal eye fields, which are associated with response 
inhibition.  Monetary incentives facilitated inhibitory control in both groups, however there 
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was no difference in error rate for neutral and reward conditions, whereas cannabis users 
performance was facilitated by punishments rather than rewards.  Abdullaev et al (2010) 
assessed executive control and fMRI functioning in a group of 14 chronic cannabis users 
versus 14 non-cannabis users.  The chronic cannabis users had longer reaction times and 
more errors for processing incongruent stimuli compared to the orienting or alerting 
components of the task, which was reflective of the executive control network.  The fMRI 
data indicated that the cannabis group had greater activation of the PFC during the AST and 
the researchers argued that the cannabis group had less efficient executive control for 
attention in tasks which reflect some conflict resolution, and more demands were put on the 
PFC to deal with this conflict. 
 
3.3.3 Brief summary of AST findings 
Neuroimaging data have led to the hypothesis that deficits found with schizophrenic patients 
on the AST may be a product of pre-frontal cortical dysfunction (Reuter and Kathmann, 
2004).  The AST assesses for executive control and may provide some indication of those 
who are liable to be pre-disposed to schizophrenia.  The key findings thus far in the research 
on executive control in people with schizophrenia, their first degree relatives and in those 
scoring high for schizotypy, is that they make more errors on the anti-saccade task and take 
longer to respond.  Healthy controls that are administered with THC seem to mimic the 
problems found in the schizophrenia spectrum for AST performance, whereas no problems 
are found with basic smooth pursuit eye movements.  People with cannabis use disorder also 
demonstrate similar problems on the AST.  There has been limited research looking at non-
clinical samples of cannabis users versus non users on performance on the AST.   
 
3.4 Individual differences, cannabis use, and cognitive functioning 
The review in Chapter 1 indicated that cannabis users score higher on key personality traits 
which reflect a risk for developing psychosis (Bailey and Swallow, 2004), and furthermore 
having a greater number of these traits can predict performance on tests with known 
sensitivity to schizophrenia, such as the IGT (e.g. Hermann et al, 2009), AST (e.g. Holahan 
and O’Driscoll) and CPT (e.g. Bedwell et al, 2009).  Whilst the first study only included a 
measure of schizotypy (the SPQ-B, see chapter 2) the current study sought to include several 
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other measures of potential significance: so in addition to schizotypy, ambivalence, mood and 
paranoia and impulsivity were included. 
 
3.4.1 Ambivalence and Mood 
Ambivalence is seen as a core trait in schizophrenia, where people fluctuate easily between 
conflicting emotions.  For example, people with schizophrenia might have intense feelings of 
love for someone followed by intense feelings of hatred.  Bleuler (1950) believed that 
ambivalence was one of the four fundamental symptoms that were constant among patients.  
Meehl (1980; 1999) proposed that ambivalence played a secondary role and that more people 
are schizotypes, in that they are genetically predisposed to develop schizophrenia, but few do; 
these people tend to share characteristics similar to schizophrenia patients and also have 
intense ambivalence.  Ambivalence as a psychological construct has been poorly understood 
(Rawlin, 1986).  Rawlin (1986) developed an intense ambivalence 65-item scale and then 
revised this to a 19-item scale to assess for schizotypal ambivalence.  Kerns (2006) used the 
shortened schizotypal ambivalence scale (SAS) and found that disorganised schizotypy was 
associated with increased ambivalence, and moreover, ambivalence was strongly associated 
with decreased emotional clarity (as measured by the subscale ‘clarity’ on the trait-meta 
mood scale: TMMS; Salovey et al, 1993).  Emotional processing is also under investigated in 
cannabis users.   In a recent study, Platt et al (2010) identified that heavy cannabis users’ ability 
to understand emotional expressions (e.g. sadness, anger or happiness) was reduced when 
compared to healthy controls.  This possible reduction in ability to identify emotional 
expressions could also be a sign that cannabis users have difficulty with expressing emotion 
and thus would be likely to have more ambivalence traits.  Therefore in this current study, the 
cannabis users will also be assessed for emotional processing using the subscale of clarity of 
thoughts on the TMMS and ambivalence as assessed by the SAS.   
 
3.4.2 Paranoia 
Persecutory delusions and paranoia are the second most common symptom of psychosis 
(Johnson et al, 1991), and such experiences/states also appear to be commonplace in cannabis 
users and following use of cannabis.  In non-clinical samples, D’Souza et al (2004) conducted a 
double-blind placebo controlled study and found that participants who were injected with 
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intravenous THC exhibited a  greater display of positive symptoms (including paranoid 
thinking) compared to those administered placebo.  Verdoux et al (2003) also found that those 
who reported experiencing more delusions or hallucinations also showed increases in 
perceptual experiences after smoking cannabis.  Freeman et al (2008) assessed levels of 
delusional thoughts and paranoid thinking and suggested that paranoid symptoms and 
delusional thoughts are strongly linked with negative affect.  Paranoid thinking was assessed 
for levels of delusional thoughts and persecutory ideas, using the Green et al Paranoid 
Thoughts Scale (GPTS, 1995), which is a 19-item measure with two parts: part A assesses 
social reference to paranoia (e.g. suspicious of other people), whereas Part B represents ideas of 
persecution (e.g. people are out to intentionally harm you).  Previous research indicates that 
people who score highly on this measure were three times more likely to infer that neutral 
stimuli was more threatening in a virtual reality experiment of an underground tube ride, 
compared to those low on paranoia.   
 
3.4.3 Impulsivity 
Impulsivity (or impulsiveness) is defined as multifactorial construct that involves a tendency 
to act hastily (i.e. acting on a whim) or displaying behaviours characterised by little forward 
thinking, or consideration of the consequences (Dick et al, 2010).  Impulsivity has been 
implicated in numerous psychiatric disorders which includes schizophrenia and substance 
abuse (Moeller et al, 2001; Ouzir, 2013).  A person may impulsively use drugs to alleviate 
self-medicate, or because they are unable to foresee negative consequences associated with 
this risky behaviour.  The schizophrenia-sensitive cognitive assessments discussed above: 
IGT, CPT and AST are linked together by trait impulsivity, in that performance deficits (in 
decision-making and inhibitory control) are correlated with higher trait scores of impulsivity 
(Morgan et al, 2006, Jacob et al, 2010, Wrege et al, 2014).  Studies have shown the non-
clinical samples of recreational cannabis users showed increased impulsivity personality traits 
(Verdejo-Garcia et al, 2008).  It could be argued that cognitive performance may be the result 
of underlying increased impulsivity in the drug group, as a result of the links between 
cannabis and impulsive behaviour (e.g. Dalley et al, 2011; Robbins et al, 2012) and also 
because the cognitive assessments used in this study are measures of behavioural impulsivity.  
Therefore, the Barratts Impulsivity Scale (BIS-II, Patton et al, 1995) measure will be 
 96 
 
included to assess the relative impact of trait impulsivity on cognitive performance in 
cannabis users.   
 
3.4.4 Rationale 
In line with the general hypothesis in this thesis, that cannabis use may shift aspects of 
behaviour further along a schizophrenic-schizotypic spectrum, and in line with extant data 
(see above), it is predicted that the sample of cannabis users in this study will show cognitive 
performance and personality differences from controls, in this direction.  In the cognitive 
assessments, the cannabis users are predicted to show worse performance on the AST, IGT 
and CPT tests, and on the personality measures to score higher on the traits of schizotypy, 
paranoia, ambivalence, impulsivity and lower in clarity of thinking.  
 
What is unique about this research work is the combination of cognitive tests and personality 
measures in one study, and this should allow for some light to be shed on how/if cannabis is 
affected each variable/measure, and whether it is the cannabis use per se that best explains the 
differences (especially variables like level of use, age of onset of cannabis), or if a more 
complex set of interactions best accounts for the data.  It is acknowledged that some of these 
measures may naturally interact, and that, for example, some personality traits may predict 
cognitive performance, regardless of drug use.  Such interactions will be explored using 
multiple regressions to attempt to statistically account for the relative contribution of 
cannabis use to cognitive performance outcomes, against that of factors such as schizotypy.   
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3.5 Method 
3.5.1 Participants 
Thirty regular cannabis users and thirty non-cannabis users took part in this study, with 16 
males and 44 females with an age range of 18-47, and a mean age of 25.  The exclusion 
criteria were use of psychoactive medication, a diagnosis of epilepsy; brain trauma or a 
positive drug screening result.  
 
Recruitment 
The same recruitment methods as previously used in Study 1 (see section 2.2) was applied 
with the exception of placing an advertisement in the Evening Standard newspaper as 
opposed to the Camden New Journal.  Further, general ‘wanted participants to take part in 
psychological research’ posters were placed on the community advertisement boards in the 
local supermarkets, such as Sainsbury’s and Morrsions.  
 
Ethical clearance 
Ethical clearance was obtained through the UEL Graduate School (reference = ETH/11/24 – 
see appendix xvii). All codes and regulations for compliance with the BPS (1996) Ethical 
Codes of Conduct for conducting research using human participants were upheld throughout. 
 
Research setting 
All testing was conducted at the UEL recreational drugs lab, School of Psychology, Stratford 
campus.  A separate lab in the same research suite was used for eye tracking.  Testing mainly 
took place at 11 am or at 2pm.  
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3.5.2 Materials 
Cognitive tests 
The anti-saccade task (AST) 
The AST was administered using a Tobii eye tracking system (Tobii Studio 1.3; Tobii, 2011).  
The AST was similar the one used by Ettinger et al (2004).  A white target of circular shape 
(approximately 0.3° of visual angle) was presented on a black background using a 17-inch 
computer monitor.  Participants sat in a comfortable chair at a distance of 60 cm from the 
monitor.  A standard (no-gap, non-overlap) anti-saccade task was used.  Four practice trials 
each began with the target in the central location (0°) for a duration of 100ms.  Participants 
were instructed to look in the opposite direction of a moving target on the screen and, 
secondly, when the target moved to the right the participants were to look in the same 
distance to the left where the target rests (and vice versa).  The experimenter observed the eye 
tracking in a different screen to validate that participants understood the task. 
 
The real test began by relaying the same instructions to the participants and the trials (video 
files) were randomised to be presented for a duration of 1000–2000 ms: specifically at 1000, 
1250, 1500, 1750 and 2000ms.  The target was then stepped to one of two peripheral target 
locations (±6°) where it remained for 1000 ms, before moving back to the centre for the next 
trial. Each peripheral location was used 15 times, resulting in a total of 30 trials.  Our test had 
a variation of the AS-T test by adding a new target location of (±12°) repeated the same way 
25 times, resulting in an additional 30 trials; so 60 trials overall.  Participants were instructed 
to look at the target while it was positioned in the centre of the screen and to redirect their 
gaze to the exact opposite location of the target as soon as it moved to its target location.  The 
main emphasis was to assess the inhibition of a reflexive saccade towards the target.  Two 
dependent variables are AST error and latency.  IGT error represents an incorrect trial (i.e. 
following the moving target as opposed to looking in the opposite direction) and latency 
which is the speed of responding.  The preparation and testing took between 20-30 minutes. 
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The Iowa Gambling Task (IGT) 
The IGT is the same version as the original used by Bechara, Damásio, Tranel and Anderson 
(1994).  The computerised task was run using a laptop computer and mouse.  Participants had 
to choose from a deck of four cards which appeared on the screen named A, B, C or D.  The 
cards are set in a pre-determined order for payoffs and losses.  Decks A and B are considered 
disadvantageous, with high immediate gains but also expensive losses, producing a net loss 
of 250€ every 10 cards. Decks C and D are considered advantageous ones, with smaller 
immediate gain and smaller losses, causing a net gain of 250€ every 10 cards.  The 
participants are instructed to ‘win as much money as they can’ by picking one card at a time 
from each of the four decks (A-D).  The participants could do this in any order until the 
computer instructs them to stop at the 100th choice.  Participants are initially given a budget 
of €2000 and can see their wins/losses at the top of the screen, which is updated after each 
card choice.  IGT dependent variables are IGT total score and IGT learning score.  The total 
score is calculated by subtracting the total number of cards selected from the disadvantageous 
pack (A and B) from the total number of cards selected from the advantageous pack (C and 
D).  The learning score is calculated over the 5 blocks of 20 cards assessing the difference 
between the number of cards picked from advantageous decks (C and D) minus those picked 
from disadvantageous ones (A and B).  No financial incentive was given for the IGT and the 
task took up to 15 minutes to complete.   
 
 
Continuous Performance Test (CPT) 
The CPT was similar to that used by Connors (2000) and it was administrated to all 
participants on a Laptop computer.  The practice test involved the presentation of 20 number 
sequence with digits presented at 1000 millisecond intervals, with participants asked to press 
the mouse button when they have seen the presentation of a specific pattern of numbers.  The 
test involved the presentation of 75 separate 5-digit numbers (e.g. 43578) (at 500 millisecond 
intervals) played in a random order.  Participants are instructed to press the keypad when the 
same digits are repeated (e.g. 43578 is followed by 43578).  Some of these digits are trick 
digits (e.g. 62897 is followed by 62895) and some are correct (e.g. same digits are repeated) 
and others are novel digits (e.g. new arrangements of digits).  Throughout the task the digits 
‘12345’ are presented 3 times in between each of the 5-digit number presentations and these 
are known to the participants as ‘distracters’ - the participants are initially told to ignore these 
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stimuli.  CPT dependent variables are: Hit rate (reacting correctly to the target stimuli), Hit 
reaction time (index of the speed for the correct response) and commission error (or 
sometimes known as false alarm) equals an incorrect response to the target, omission errors 
represents the number of incorrect motor responses (index of the amount of incorrect 
responses to trick, novel or distracter stimuli).  The time taken to complete the task was up to 
20 minutes. 
 
All of the tests were counterbalanced: 1) IGT, CPT and AST; 2) CPT, IGT, and AST, 3) 
AST, IGT and CPT, 4) IGT, AST, and CPT; 5) CPT, AST and IGT; 6) AST, CPT and IGT. 
 
 
Questionnaires                                                             
Severity of Dependence Scale (SDS) (Gossop et al., 1995 - see appendix iv) and 
Schizotypal Personality Questionnaire (SPQ–B) (Raine and Benishay, 1995 - see 
appendix v) – both questionnaires are described under section 2.2.2 
 
UEL drug use questionnaire (Parrott et al, 2001) (see appendix vi) 
Please refer to Chapter two (section 2.3) for a full description of the Personal History 
Questionnaire and Lifetime drug use questionnaire, the SPQ-B and the SDS.  
 
The Paranoid Thoughts Scale (GPTS; Green et al, 2008 - see appendix vii)  
The GPTS is a trait measure of paranoia with two 16-item scales assessing ideas of social 
reference and ideas of persecution.  Participants were asked to rate their agreement with 
statements referring to experiences, thoughts or feelings over the last month, scoring from 1 
to 5, where 1 = “Not at all” and 5 = “Totally”.  They were asked to complete both Part A and 
Part B and instructed not to “rate items according to any experiences you may have had under 
the influence of drugs”.  A total score is for each scale is obtained by summing Part A or Part 
B, respectively and higher scores indicate greater levels of paranoid thinking. The internal 
consistency of the scale and test–retest reliability are good and convergent validity has been 
demonstrated with the Paranoia Scale (Fenigstein & Vanable, 1992). 
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Part A is a self-report measure of social reference of paranoid thinking in the past month and 
consists of a list of sixteen items. Two example questions were:  
9. I was convinced that people were singling me out 
16. It was hard to stop thinking about people talking about me behind my back 
Part B is a self-report measure of the occurrence of persecutory ideation in the past month. It 
contains a list of sixteen items and two example questions were: 
3. People have intended me harm 
13. The thought that people were persecuting me played on my mind 
 
Trait meta-mood scale (TMMS; Salovey et al., 1995 - see appendix viii) 
The TMMS is a measure of emotional intelligence with 30-items and has three subscales: 
attention to feeling, clarity and repair.  Similar to Kern et al’s (2005) study only the Clarity 
subscale of the TMMS was used in this study to assess how much someone understands their 
own emotional states.  The Clarity subscale, consists of 11-items (5 reversed scored); an 
example question would be “sometime I can’t tell my feeling are”.  Participants were asked to 
read each statement and indicate the degree to which they agreed or disagreed with each 
using a tick box likert-scale ranging from Strongly Disagree (1) to Strongly Agree (5).  The 
subscale of Clarity has adequate internal consistency (0.87) and good convergent and 
discriminant validity (Solovey et al, 1995)   
   
Schizotypal Ambivalence Scale (Rauling, 1986 - see appendix ix) 
The schizotypal ambivalence scale (SAS) is a 19-item true/false questionnaire which is 
designed to assess the trait of ambivalence, which is seen as one of the core characteristics of 
schizotypy and schizophrenia.  Participants were asked to answer each item by circling T 
(True) or F (False) and were required to respond to all items even if they were unsure of the 
answer.  A total SAS score is obtained by summing all of the (True) responses (i.e. score 
range 0-19).  The SAS has good internal consistency reliability (.84) and correlates 
moderately with other psychometric measures of schizotypy.  Example questions were: 
1)         T          F          Often I feel like I hate even my favorite activities.                           
8)         T          F          I always seem to have difficulty deciding what I would like to do. 
10)       T          F          Love and hate tend to go together.      
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Barratt Impulsiveness Scale version 11 (BIS-11: Patton et al., 1995 - see appendix x) 
The BIS-11 is a 30-item questionnaire designed to assess general impulsiveness which is 
broken down into six BIS-1
st
 order factors (attention, motor, self-control, cognitive 
complexity, perseverance, cognitive instability) and three BIS-2
nd
 order factors (attentional 
impulsiveness (attention and cognitive instability), motor impulsiveness (motor and 
perseverance), non-planning impulsiveness (self-control and cognitive complexity).  The 
items are scored on a four point scale from 1 (Rarely/Never), 2 (Occasionally), 3 (Often) to 4 
(Almost Always/Always).  Example questions are:  “I do things without thinking”; “I act on 
impulse”; “I often have extraneous thoughts when thinking”.  A total BIS score is obtained by 
summing the first and second-order factors.  The reported internal consistency coefficients 
for the BIS-11 total score range from 0.79 to 0.83 for different populations groups: under-
graduates, substance-abuse patients, general psychiatric patients, and prison inmates (Barratt 
et al, 1995).  In a review by Stanford et al, 2009 internal consistency for the First order 
subscales were: Attention (0.72), Cognitive Instability (0.55), Motor (0.64); Perseverance 
(0.27), Cognitive Complexity (0.48), SC = Self-Control (0.72) and in the Second order: 
Attention (0.74), Motor (0.59), Non-Planning (0.72). 
 
3.5.3 Procedure 
 
The procedure was similar to that of study one for informed consent (see appendix xii), drugs 
screening and DNA screening (see section 2.2.3 for further details). The participants then 
completed the cognitive assessments and questionnaires.  All participants’ were de-briefed 
accordingly (see appendix xiii) and if any questions arose about the true nature of the study, 
these were effectively addressed at this particular time.  Participants were provided with an 
information sheet (see appendix xi) that contains the relevant contact details of professional 
bodies, who directly deal with questions relating to mental health issues and drug use advice.  
Participants were awarded between £15-£20 remuneration for participation. 
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3.6 Results  
 
Data Screening 
Normality of variables for the SPQ measure  
Data were explored using boxplots to look for outliers defined as one and a half times the 
length of the box from either end of the box.  The SPQ-B measure and its subscale of 
‘interpersonal’ had 2 outliers removed: 1 from the cannabis group and 1 from the non-
cannabis group.  Part A of the GPTS had 6 outliers removed: two from the cannabis group 
and 4 outliers for the non-cannabis group.  Part B of the GPTS had five outliers removed, 
three from the cannabis group and two from the non-cannabis group.  The BIS-2
nd
 order had 
one outlier removed from the cannabis group data.  Data from all the cognitive tests were 
generally normally distributed, although some minor changes were required as follows: 
  2 anti-saccade error scores were removed from the cannabis user group data 
 2 outlier scores were removed from the IGT dataset in the non-cannabis group 
 Several outliers were removed from the CPT data: 1 for hit rate in the cannabis group; 
2 for commission errors in the cannabis group; 3 for motor errors (1 in the non-
cannabis group and 2 from the cannabis group) were removed which resulted in better 
distribution.   
 
Skewness and kurtosis of each data set after exclusion of outliers were all below 0.2 or 0.1 
respectively.  In the cannabis group, there was missing data for profit/loss made after every 
10 card selections in one participant due to technical issues and having to use a different 
version of the IGT, however, the overall total IGT score was obtained for all participants.  
Due to some technical problems with the Tobii eye tracking equipment, 4 participants’ in the 
cannabis group and 8 participants’ data in the non-cannabis group was not obtained on the 
AST.  There was 1 missing data point in the non-cannabis group for the CPT. 
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3.6.1 Demographic/health details and patterns of drug use   
Possible differences in the mean ages of the participant groups (cannabis and non-cannabis) 
were analysed using the t-test statistic, whilst gender and other demographics were explored 
using Chi² tests.  It can be seen from Table 19 that there were significantly more males and 
white Europeans in the cannabis group, as well as lower health ratings (measured on a 4-point 
likert scale), and more personal and familial mental health diagnosis histories in this group 
(such as depression and anxiety).  The cannabis sample in the Study 2 had slightly older 
participants in this cohort compared to Study 1.  
 
Table 19:  Demographic and health details for cannabis users and non-cannabis users 
 Non-cannabis 
group 
(30 Participants) 
 
Cannabis 
group 
(30 
Participants) 
 
Test  
      
X² 
 
p 
Age Range, mean (SD) 18-37, 24 (5.5) 18-47, 26 (8.6) 0.938 ns 
Gender (Males/Females) 4/26 12/18 5.45 0.02 
Nationality (British/Non British) 20/10 22/8 0.31 Ns 
Ethnicities (White 
European/Black/Asian/Mixed Race) 
15/4/7/7 21/7/1/1 8.11 0.04 
Occupation 
(Employed/Unemployed/Student) 
10/2/18 11/3/16 0.365 Ns 
Highest Qualification (GCSE/ A level 
or further/ Degree/ Post grad/ PhD) 
0/22/3/4/1 2/25/2/1/0 3.191 Ns 
Health Rating (Poor/Moderate/Fine 
/Good)  
0/7/6/17 1/11/12/6 9.13 0.02 
Personal Mental Health History 
(diagnosis) 
2 10 6.66 0.02 
Familial History (diagnosis) 8 17 5.55 0.03 
Brain Injury (yes)  0 0 - - 
Medication (yes)  1 0 - - 
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Table 20 below summarises other drug use in the cannabis and non-cannabis users.  Group 
comparisons, just including the data for each drug from those participants in each group 
admitting to have used that drug, was assessed as follows: polydrug use was assessed using a 
Chi² analysis amount of use, age of onset was assessed using Mann Whitney U tests.  
Cannabis users reported more drug use than non-cannabis users for alcohol, MDMA, 
poppers, ketamine, GHB, Prozac, amphetamine, cocaine, LSD, Benzodiazepine, Mushrooms, 
and Opiates as well as other drugs not listed (e.g. legal highs) and reported more unusual 
experiences from these drugs.  Only 2 participants reported current polydrug use (2 or more 
drugs as well as current cannabis use).  Higher drug use was reported in the cannabis group in 
Study 2 (see Table 20) with 15 out of 20 cannabis users reporting polydrug use.  Further, the 
sample in this study was also different to the previous study sample (in Study 1) due to the 
history of opiates and crack cocaine.
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Variable Cannabis group  Non-cannabis group  U   x² p or ns Variable Cannabis group  Non-cannabis 
group 
U x² p or ns 
 
Cigarettes (n= Yes) (26) (4) 32.269 <0.001 Amphetamine –times 
Mean(SD) 
 121(243) 1-2, 1.5(0.7) -1.537 ns 
 
Cigarette/day Range,  
Mean(SD) 
1-30, 7.5(6.5) 2-30, 14.25(11.7) -1.133 Ns Amphetamine – last time  1-2 weeks (2); 6-12 months 
2); 3+years (3) 
3+ years (1) 1.5 ns 
 
Cigarettes - age of onset 
Mean(SD) 
16.4(3.64) 14.75(2.9) -0.676 Ns Cocaine   (n= Yes) (20) (2) 23.25 <0.001 
 
Cigarettes -  last time used 
(n=  ) 
That day (21) one day (5) That day (2) one year 
(1) one year plus (1) 
-1.735 Ns Cocaine– age of onset  
Mean(SD) 
14-30, 20(4.4) 19-23, 21(2.82) -0.288 ns 
 
Alcohol  (n= Yes) (28) (22) 4.320 0.04 Cocaine – times Mean(SD) 91(249) 27 (32.5) -0.344 ns 
 
Alcohol (units per week) 
Mean(SD) 
12.7(6.5) 4.43(6.98) -3.081 0.002 Cocaine – last time used 
Mean(SD) 
1-2 weeks (6); 1-6 months 
(4); 6+-18 months (4); 18+-
24 months (2); 3+years (4) 
6+-18 months (1); 
3+years (1) 
10.5 ns 
 
Alcohol – age of onset 
Mean(SD) 
16.5(3.17) 17.37(2.51) -1.058 Ns LSD   (n= Yes) (6) (0) - - 
 
Alcohol – last time  (n=) 1 day (7); 1 week (19); 1 
month (3); 1 year+ (1) 
1 day (1); 1 week (12); 
1 month (6); 1 year (2) 
-2.257 0.024 LSD- times Mean(SD) 87(140) - - - 
 
MDMA (n= Yes) (16) (2) 15.56 <0.001 Benzo  (n= Yes) (4) (0) - - 
 
MDMA – age of onset  
Mean(SD) 
20(4.68) 16.5(2.1) -1.273 Ns Benzo- times Mean(SD) 127(162.8) - - - 
 
MDMA – number of times 
used   Mean(SD) 
121(243) 1.5(0.7) -1.993 0.03 Mushrooms  (n= Yes) (13) (0) - - 
 
MDMA – last time used 
(n=) 
1-2 weeks (4); 1-6 months 
(5); 6+-18 months (2); 
18+-24 months 2); 3+years 
(3) 
3+ years (2) 3.0 0.03 Mushroom times Mean(SD) 1-365, 35(99) - - - 
 
Poppers  (n= Yes) (12) (1) 11.88 0.001 Crack  (n= Yes) (6) (1) 4.05 0.05 
Poppers times Mean(SD) 105(246) - -1.617 Ns Crack- times Mean(SD) 45.5(78) 50 - 
 
- 
Ketamine  (n= Yes) (9) (0)  - Opiates  (n= Yes) (4) (0) - - 
Ketamine times Mean(SD) 27.5(25.5) - - - Opiate times   Mean(SD) 95(179) - - - 
GHB  (n= Yes) (4) (0) - - Steroids  (n= Yes) (0) (0) - - 
GHB times Mean(SD) 135(265) - - - Steroid times Mean(SD) - - - - 
Prozac  (n= Yes) (2) (0) - - Other Drugs 1 (2) (0) - - 
Prozac times Mean(SD) 7(4.24) - - - Other Drugs 2 (2) (0) - - 
Solvents  (n= Yes) (2) (0) - - Poly Drug Use  (n= Yes) (2) (1) 20.26 - 
Solvent times Mean(SD) 1.5(.70) - - - Current  Poly Drug Use  (n= 
Yes) 
(2) (0) - 0.006 
Amphetamine   (n= Yes) (7) (1) 5.192 0.026 Unusual Experiences (n= Yes) (5) (0) - - 
Amphetamine – age of 
onset Mean(SD) 
19 (4.26) 16.5(2.1) -1.098 Ns   
Table 20: Other drug use in cannabis and non-cannabis user groups. 
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Table 21 below indicates that the amount of use per day was quite varied between one joint to 
twenty joints per week.  Most of the participants were introduced to cannabis via friends, the 
mean duration since last use was 3.6 days (note a 2 day abstinence period was requested); the 
main type used was of the skunk variety, the participants varied in terms of how long they 
used cannabis for ranging between 1-35 years, with mean years at 10.53.  The cannabis 
dependency scores ranged from 0-12, with a mean score of 4.9.  Twenty people scored a 
dependency score of 4 and above which indicates dependency of cannabis within this sample.  
 
Table 21: Patterns of cannabis use in the cannabis group. 
Variables Range or n Mean (SD) 
Number of joints  per day  
(range and mean (SD) 
 1-5.50 2.52 (3.18) 
Frequency of use -Joints 
per week (range, mean 
(SD)  
1-20 3.6(3.9) 
Cannabis age of onset 
(range and mean (SD) 
12-23,  15.56 (2.84) 
Cannabis introduction 
(n=) 
Friends = 26; Family = 4  
Cannabis last time (days)  
range and mean (SD) 
2-14 3.6(2.4) 
Cannabis acute problems  
(n=) 
Yes = 12; No = 18     - 
Types used most often 
(n=) 
Skunk = 16; Grass = 11; Resin = 3      - 
Cannabis duration 
range and mean (SD) 
1-35 10.53 (9.29) 
Cannabis Dependency 
Score 
range and mean (SD) 
0-12 4.9(3.37) 
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3.6.2 Trait measures 
Table 22 shows the means and SDs for the trait measures.   One-way ANOVAs were carried 
out to see if there were any significant differences between cannabis users and non-cannabis 
users on the trait measures. It was found that cannabis users scored significantly higher on the 
Schizotypal Personality Questionnaire (SPQ) for total scores (F (1, 56) = 11.88, p = 0.0004) 
and the two subscales of cognitive perceptual (F (1, 56) = 8.945, p = 0.004) and disorganised 
thinking (F (1, 58) = 13.8, p < 0.001); but not on the subscale for interpersonal of SPQ-IP.  
Cannabis users also reported experiencing more paranoid thinking, with significant 
differences found between scores on part A and part B of the Paranoid Thoughts Scale in 
relation to social reference to paranoia (F (1, 52) = 4.994, p = 0.03) and ideas of persecution 
(F (1, 53) = 7.36, p = 0.009).  Cannabis users scored significantly lower than non-cannabis 
users on emotional processing as measured by the clarity subscale on the trait meta-mood 
scale (F (1,58) = 7.666, p = 0.008) and statistically higher on the Ambivalence measure as 
assessed by the Schizotypal Ambivalence Scale SAS (F (1, 58) = 4.339, p = 0.04).  Cannabis 
users also scored significantly higher than non-cannabis users on impulsivity for the Barratt 
Impulsivity Scale-first order (F (1, 58) = 11.266, p = 0.001) and second order factors (F (1, 
57) = 10.095, p = 0.002). 
 
Table 22:  Schizotypy, paranoia, emotional clarity, ambivalence and impulsivity scores in 
cannabis and non-cannabis user groups. 
 
Trait measures Cannabis user Non-cannabis user   
Mean SD Mean  SD      F      P 
SPQ-CP 2.8 1.9 1.73 1.74 8.945 0.004 
SPQ-IP 2.7 1.87 2.03 1.77 1.91 ns 
SPQ-DT 1.96 1.30 0.97 0.97 13.8 <0.001 
SPQ-total 7.30 3.57 4.28 3.04 11.88 0.004 
GPTS Part A 25.7 8.2 20.88 4.98 4.994 0.03 
GPTS Part B 20.3 4.50 17.64 2.65 7.36 0.009 
TMMS Clarity 35.2 6.04 39.2 5.21 7.666 0.004 
SAS 7.83 4.79 5.23 4.87 4.339 0.04 
BIS-first 68.37 9.11 60.6 8.8 11.266 0.001 
BIS-Second 67.34 7.01 60.6 9.11 10.095 0.002 
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3.6.3 Cognitive outcomes 
Table 23 presents the data from the AST, IGT and CPT in cannabis and non-cannabis users. 
In the gambling task, there was a trend for cannabis users to select more for the risk decks 
A&B more often (t (56) = 1.55, p = 0.06) which resulted in the cannabis users winning more 
money on the IGT (F (1, 56) = 3.791, p = 0.05) than non-users (see Figure 7).  Further to this, 
higher use of cannabis (number of joints smoked per week) was correlated with an increase in 
riskier decision making (r = -0.326, p = 0.03).  There were no significant differences found in 
the other neurocognitive tests 
 
Table 23:  Anti-saccade (AST), IOWA gambling (IGT) and Continuous performance task 
(CPT) scores in cannabis and non-cannabis user groups 
 
Cognitive  
measure 
Cannabis user Non-cannabis user   
Mean SD Mean  SD F       p         
AST-error 26.4 20.63 21.7 26.8 0.682 ns 
AST-latency 
(ms) 
306.27 89 316.78 56.97 0.194 ns 
IGT-total 1258 933 1687 723 3.791 0.05 
IGT_net score -16 4.428 -6.85 20.30 1.55 0.06 
CPT-Accuracy 20.31 4.26 19.90 3.93 0.07 ns 
CPT-
Commission 
errors (CE) 
6.35 7.06 8.57 5.69 1.292 ns 
CPT-Response 
Time (RT) 
579.79 139.8 577.50 90.6 1.465 ns 
CPT-Motor 
errors (ME) 
1.22 1.25 1.62 1.67 0.02 ns 
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Figure 7: Represents the difference between cannabis users and non users on risky 
decision-making as assessed via the IGT. 
 
3.6.4 High/Low SPQ-B and Cognitive Variables 
The participants were divided into two non-overlapping groups based on the mean SPQ-B 
scores (M = 6.2, SD = 4.06) and the data from 5 participants at the mid-point were removed 
(Laws et al, 2008).  33 participants were in the low SPQ-B group and scores ranged from 0-6 
and 22 participants in the high SPQ-B group with scores ranging from 8-17.  The mean 
scores on the cognitive tests in these high and low SPQ-B scorers are summarised below in 
Table 24.  A third analysis was run to check for performance between these groups for 
high/low SPQ-B in terms of their cognitive performances.  A one-way ANOVA revealed 
there was a significant difference between high and low SPQ-B groups on the AST error 
measure (F (1, 41) = 9.143, p = 0.004), with high SPQ scorers making more errors on the 
AST, but there was no difference found in latency.  No significant differences were found 
between high and low SPQ groups on IGT performance.    
 
No significant differences were found between high and low SPQ-B scorers for CPT 
accuracy, motor errors or commission errors, but high SPQ scorers had faster reaction times 
on this task (CPT-RT; (F (1, 56) = 4.689, p = 0.035).    
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Table 24:  Cognitive test results between high and low SPQ-B scores. 
Cognitive Tests High SPQ-B Low SPQ-B   
Mean SD Mean  SD    F     p 
AST-error 35.07 27.22 14.29 14.03 9.143 0.004 
AST-latency (ms) 305.55 92.40 351.80 53.8 0.552 ns 
IGT-total 1379.5 822 1547 930 1.019 ns 
CPT-accuracy 20.24 3.47 20 4.52 0.049 ns 
CPT-RT 558 125.71 603 103.15 0.049 ns 
CPT-ME 1.27 1.49 1.57 1.70 1.965 0.035 
CPT –CE 6.73 4.68 7.969 7.47 0.488 ns 
 
 
3.6.5 Correlations for Cognitive and Trait Variables 
A series of Pearson correlations were conducted to look at associations between the 
personality trait measures and the cognitive task outcomes (see Table 25).  A second 
correlation analysis was performed on the cannabis group only, to explore the relationship 
between cannabis use variables (e.g. age of onset, dependency, duration and joints per week) 
on cognitive outcomes (see table 3h).  There was a medium negative relationship between 
CPT accuracy and CPT motor errors, with greater accuracy linked to fewer motor errors.  
There was a negative medium relationship between CPT mean RT with SPQ-IP, with those 
reporting more traits linked to the interpersonal dimension of schizotypy being slower to 
respond on the CPT.  There was a medium positive relationship between AST error and SPQ 
total, with higher error linked to experiencing a higher amount of psychotic like traits.   
SPQIP was also linked with AST latency, with a negative medium relationship between 
greater levels of interpersonal schizotypy and taking longer to respond on the AST task. A 
similar finding was found for SPQIP and AST error as well as BIS-2
nd
 and AST error, with 
greater levels of interpersonal schizotypy and impulsivity linked to greater AST error.    
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Table 25: Correlations between personality trait measures and the cognitive test outcomes 
 
 
 
 
 
 
 
 
 
 
 
**. Correlation is significant at the <0.001 level (1-tailed) 
*. Correlation is significant at the 0.01 – 0.05 level (1-tailed). 
 
 
Table 26 below highlights a statistically significant medium positive association between the 
first order impulsivity scale and joints per week (JPW) with higher use linked to experiencing 
more impulsive thinking.  A medium negative correlation was found between JPW and IGT, 
with an increase in joints smoked per week being linked to less monetary return on the 
gambling task.  There was a strong positive correlation between JPW and impulsivity for the 
first order factor, with an increase in joints per week linked to cannabis users having higher 
trait impulsivity.  There was a negative medium association between clarity of thoughts and 
duration of cannabis use, with longer use linked to feeling less clear in thinking.  Duration of 
use was also negatively associated with GPTS partA and the SPQ-B subscale of interpersonal 
thinking, with shorter duration of cannabis use associated with higher schizotypal 
interpersonal deficits and higher social reference to paranoia.    
Variable CPT-
RT 
CPT CE CPT ME AST-Err AST-
latency 
(ms) 
IGT-
total 
CPT-
accuracy 
*0.356  **-0.552    
CPT_CE +-0.259      
AST-latency 
(ms) 
   *-0.34   
IGT-total     *-0.31  
SPQ-total    **0.44   
SPQ-IP **-0.39 *0.211  **0.48 *-0.37  
SPQ-CP      *-0.26 
GPTS-part A  *0.211     
BIS-2
nd
    **0.46   
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Table 26:  Correlation data for cannabis use variables and trait/cognitive outcomes 
 
 
 
 
 
 
*. Correlation is significant at the 0.01-0.05 level (1-tailed). 
 
 
3.6.6 Regression analysis for cognitive and trait outcomes 
A number of regression analyses were performed to look at individual differences in 
personality and cannabis use, to see which best predicts outcomes on each of the cognitive 
measures.  The main predictor variables (PVs) were cannabis use, all of the personality trait 
measures (i.e. SPQ-B total, SAS, GPTS A and B, BIS-1
st
/2
nd
, TMMS-clarity) and the model 
was adjusted for sex due to a significantly greater number of males in the cannabis group.  
Sex was not a significant predictor/covariate.   
 
1. For the CPT data, none of the regression models were significant. 
2. The IGT was entered into the regression model as the criterion variable and the model 
was not significant and none of the PVs significantly predicted IGT outcomes.   
3. AST latency was entered as the CV but the model was not statistically and no PVs 
significantly predicted outcomes on this measure.  Anti-saccade task error as a CV was 
statistically significant (F (9, 36) = 2.390, p=0.031; R² 43%, Adj R² 28%).  Performance 
on the AST was predicted by psychotic-like personality traits and impulsivity as shown 
below in Table 27.  In that higher impulsivity and increased psychotic-like personality 
traits was linked to poorer performance, resulting in more error on the AST.    
 
A separate regression analysis removed the non-cannabis users from the model to assess the 
individual differences in the cannabis users on the SPQ-B total, SAS, GPTS A and B, BIS-
1st/2nd; TMMS-clarity; and the model was adjusted for sex.  There were no significant 
predictors of these criterion variables on cognitive performance on IGT, AST and CPT, and 
none of the models were significant (p>0.05).  There was a trend for the SPQ-B total to 
Variable JPW Duration 
AST- latency  *0.363 
IGT- total *-0.326  
CPT- RT   
TMMS- clarity  *-0.389 
GPTS-partA  *-0.334 
GPTS-partB   
SPQ- IP  *-0.342 
BIS-Ist *0.435  
BIS-2
nd
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predict outcomes on the AST for error (F (5, 25) = 2.003, p = 0.056, in that higher psychotic-
like traits were associated with more error on the AST.  
   
Table 27: Trait predictors of anti-saccade task performance 
Predictor variable     Beta p 
SPQ total 0.584 0.002 
BIS-1
st
 0.745 0.008 
BIS-2
nd
 0.726 0.007 
(sex, GTPS parts A and B, SAS, TMMS-Clarity were not significant PVs) 
 
 
3.6.7 Regression analysis for cognitive and trait outcomes and cannabis  
To further explore outcomes on these tasks, the cannabis use variables were entered into 
separate regression models as PVs to determine whether level of dependence, length of use 
and/or age of onset impacted on cognitive task performance.  The SPQ-B total was added to 
these regression analyses to check if individual differences in this personality measure are 
predictive of cognitive performance more so than cannabis use per se.    
1. The IGT model was not statistically significant but the main predictor variable for IGT 
performance was joints per week (t (23) = 2.127, p = 0.04) indicating that outcomes on 
the IGT (i.e. risky decision making) were linked to heavy cannabis use.  
2. CPT accuracy as the CV was not significantly predicted by the PVs and there were no 
significant findings for CPT RT, CPT motor errors and CPT commission errors.  
3. AST error as a CV was significantly predicted by SPQ-total (t (19) = 2.728, p = 0.01.  
Adj R² 0.127) but the model was not significant.   AST latency as a CV was not 
significant. 
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3.7 Discussion 
The main aim of this study was to compare cannabis users and non-cannabis users on 
cognitive tests with known sensitivity to schizophrenia and also to assess individual 
differences in schizotypal traits.  The cognitive assessments measured decision-making using 
the IGT, attention using the CPT and executive control using the AST.  Additionally, this 
study looked at personality variables as possible predictors of cognitive task performance in 
both the whole group and in cannabis users.  In line with the model that cannabis use may act 
to modulate cognitive function, in a direction more akin to that seen in schizophrenic and 
high schizotypy individuals, it was predicted that we would see riskier decision making, 
disruption attention and impaired executive control in the cannabis group.    
 
3.7.1 Decision-making 
In line with the general model/theme of the thesis it was predicted that cannabis users would 
show worse performance on the IGT.  The current study revealed impairments in decision-
making for IGT performance in cannabis users who selected the decks which had immediate 
higher gains but also higher losses overall (see Figure 7), and therefore made a significant 
loss in comparison to the non-cannabis users.  This is in line with previous research (e.g. 
Hermann et al, 2009; Bolla et al, 2003; Wesley et al, 2011).   
 
Heavy cannabis use was also correlated with poorer decision-making on the IGT, which 
suggests riskier decision making, and may help to explain why people continue to use the 
drug despite its potentially negative effects.  Previous research by Whitlow et al, (2004) and 
Hermann et al (2009) support this finding as they found poorer outcomes on the IGT in those 
that had used cannabis heavily relative to those with only partial use.  Further studies have 
found that cannabis intoxication was associated with poorer IGT performance compared to 
controls (Lamers et al, 2006).  Lamers et al (2006) also showed that cannabis users 
performed significantly worse on the IGT even after 15 days of abstinence.  Similarly, 
Verdejo- Garcia et al (2007) found deficits in IGT performance in cannabis users even after 
25 days of abstinence.  
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Other factors may have been involved in these decision-making strategies, for example, 
emotional and motivational processes may have played a part.  It may be that the cannabis 
users have an increased sensitivity to rewards and insensitivity to losses or risk aversion, in 
that they have specifically chosen to use an illegal substance for personal gratification and 
discount the risks associated with this psychoactive drug.  Previous research has found 
evidence to suggest that drug users reduce the value of a reward when the there is a delay in 
receiving this (e.g. Coffey et al, 2003).  Further to this, Bolla et al (2002) showed that 
cocaine users show hyperactivation in the OFC and ventral striatum, areas known to be 
involved in the evaluation of a reward (e.g. O’Doherty, 2004).  Whereas, in contrast to this, 
cannabis users in Bolla et al’s study showed decreased activation in the OFC and heavier 
cannabis users showed greater activation in the posterior cingulate and parahippocampal 
regions, which are known to be involved in working memory.  The most robust finding in the 
acute effects of cannabis use is that it is known to disrupt short-term memory, whereas it is 
argued that long-term use may result in disrupting higher level cognitive processing (e.g. 
Solowij et al, 1995; Pope at el, 1995; 2003).  Therefore, cannabis users may perform less well 
on the gambling task due to the impaired ability to track task contingencies (e.g. learning that 
packs A and B yield higher rewards but overall higher losses) and this may be related to 
impaired short-term memory updating rather than an enhanced sensitivity to the rewarding 
effects.  However, a standard measure of memory performance was not applied in the current 
investigation so the results of the current study cannot discriminate between these alternative 
explanations.   
 
Wesley et al (2011) used Magnetic Resonance Imaging (MRI) and reported that cannabis 
users performed similarly to the controls at the beginning of the task, but performed less well 
towards the end of the IGT, a pattern of findings that is echoed in the present study.  Wesley 
and colleagues reported that controls displayed greater activity to losses in the anterior 
cingulate cortex, medial frontal cortex, precuneus superior parietal lobe, occipital lobe and 
cerebellum relative to cannabis users.  Further to this, the activation in controls was positively 
correlated with losses over time, which suggests that cannabis users may be less responsive to 
the punishments of the task.  Being less responsive to emotional component of the task also 
links into the arguments of the density of CB₁ receptors in the amygdala, which is linked to 
emotional responding and fear responding (Lin, Mao and Gean, 2006).  Therefore, heavy and 
prolonged cannabis use may disrupt normal emotional processing, with participants showing 
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less responsiveness to the negative effects, which could be a reason of why they continue to 
misuse cannabis as they respond less to its negative impact. 
 
Sevy et al (2007) compared a group of people with schizophrenia with concurrent cannabis 
use disorder with schizophrenics without concurrent cannabis use, and to a healthy control 
group.  It was found that both schizophrenia groups were impaired and did worse of the IGT.  
However, there was no difference found on the IGT for patients with and without concurrent 
cannabis use.  Problems on the IGT may be more likely related to factors predisposing the 
person to schizophrenia and/or linked traits.  In this study, participants were divided into high 
and low SPQ-B total scores but that this did not impact on the IGT total score.  Those with 
high scores on the personality measure made less money than those with low SPQ scores, but 
this finding was not statically significant.  Therefore, IGT performance in this study was not 
directly affected by personality profile and was more closely linked with cannabis use per se.   
 
3.7.2 Executive control 
In line with the general model/theme of the thesis it was predicted that cannabis users would 
show worse performance on the AST.  Although the raw data showed a possible trend with 
cannabis users making more errors on the anti-saccade task and being faster to respond 
relative to the non-cannabis group, these differences were not statistically significant.  This is 
similar to the finding by Chung et al (2010) who looked at adolescents with and without 
cannabis use disorder and found no difference in performance on the AST.  In the current 
study people that use cannabis recreationally and abstained for two days did not show any 
disruption in AST performance, although some trends existed for deficits to be more 
pronounced in the heavier users of the drug.  For example, there was an association between 
increased amount of cannabis used per week and length of use was positively correlated with 
reaction time on the AST, thus the more cannabis smoked and a longer duration of use were 
both associated with faster responding on the AST.  Cannabis use varied across the group, so 
it may be that if heavier cannabis users were assessed as a single group, then deficits would 
be more prominent for this drug group.   
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In order to explore the possible influence of schizotypal personality traits on task 
performance the group was then divided into high and low SPQ scorers.  Those scoring high 
on this measure made twice as many errors on the AST.  This finding is supported by 
previous research (Holahan and O’Driscoll, 2005; Ettinger et al, 2005; Ettinger et al, 2006).   
Ettinger et al (in press) assessed for low and medium schizotypy and found that those people 
displaying more psychotic like traits had greater deficits on the AST.  Larrison et al (2000) 
found more errors on the AST in a group of people scoring high on the full version of the 
SPQ.  This aforementioned research is similar to that of the current study, thus it seems that 
the shorter version of the SPQ-B was sensitive in finding differences in AST performance.   
 
3.7.3 Selective attention 
No clear differences were found between cannabis users and non-cannabis users on the CPT 
for accuracy, speed and number of motor and commission errors.  Research in the area of 
performance on the CPT in schizophrenic patients tend to show that schizophrenic patients 
perform less well for selective and sustained attention, whereas the research on cannabis use 
in clinical samples and in non-clinical samples has been less clear.  This may help to explain 
why no difference was found between the cannabis users and non-cannabis users.  For 
example, Rodríguez-Sánchez et al (2010) found no difference between schizophrenics who 
used cannabis versus those schizophrenics that did not use cannabis.  Jockers-Scherübl et al 
(2007) found differential effects on CPT performance in schizophrenics who use cannabis 
versus controls who use cannabis after a 28-day abstinent period.  Performance was impaired 
in healthy controls if they used cannabis before the age of 17, but performance was improved 
in patients that started cannabis before the age of 17.  In the current study, the mean age of 
onset/first use of cannabis was 15.5, but this variable was not correlated with CPT outcomes.  
The current sample was compared to non-cannabis users, as opposed to a patient group, and 
further to this the abstinence level was set at 2-days, which may have yielded different 
findings on CPT outcomes.  Even after the abstinence period of 28-days it seems that Pope et 
al (2001) could not detect any differences on the CPT in cannabis users versus controls.  The 
researchers argued that the test battery for selective attention was not as sensitive as ERP 
study by Solowij et al (2002), nor was the CPT as sensitive at the selective attention LI task 
used in Study 1 (see Chapter 2).   
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CPT performance was not correlated with the SPQ-B subscales for positive symptomology 
and disorganised thinking.  Interestingly, Bedwell, Kamath and Compton (2009) found an 
association between CPT performance and disorganised and positive schizotypy when 
participants were assessed using a structured interview for severity of symptoms, as opposed 
to the psychometric assessment schizotypal personality dimensions.  When the group were 
divided into high and low SPQ-B scorers, no differences were found between the groups for 
accuracy, motor or commission errors.  However, there was a difference found for reaction 
times, with high SPQ-B scorers responding more quickly on the CPT compared to the low 
SPQ-B scorers.  
 
3.7.4 Individual differences, cannabis use and cognitive performance 
Individual differences in personality were explored between the cannabis users and non-
cannabis users for those traits commonly found to be elevated in those diagnosed with 
schizophrenia (namely schizotypy, paranoia etc.).  Cannabis users scored significantly higher 
on all of the trait measures of schizotypal personality (from the SPQ-B), paranoia (part A and 
B of the GPTS), ambivalence (SAS) and impulsivity (first and second order factors of the 
BIS).  Findings were less clear for emotions as assessed by the TMMS subscale for clarity.  
These data are therefore broadly in line with previous research that has demonstrated that 
cannabis users experience more psychotic-like traits (Arsenault et al, 2004; Henquet et al, 
2003; van Os et al, 2002; Stefanis et al, 2004; Skosnik et al, 2008; Dumas et al, 2004 
Kuepper et al, 2011) and higher and impulsivity (Schmid et al, 2004; Barkus et al, 2008). 
 
Clarity of thoughts on the TMMS was negatively correlated with duration of cannabis use, 
and the first order factor of the BIS was positively correlated with joints per week (JPW).  
Thus longer use of cannabis was linked to more emotional confusion and increased use of 
cannabis was linked to multiple aspects of impulsivity (across the spectrum of motor, 
attention, cognitive complexity, perseverance, and cognitive instability impulsivity 
constructs).  In addition, there were also weaker trends (less than 0.05 but greater than 0.01) 
linking level of cannabis use (JPW) to riskier decisions on the IGT and increased impulsive 
traits.  Thus heavy use of cannabis was more closely linked with greater deficits in decision 
making, as well as being associated with higher impulsivity. 
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3.7.5 Regression analysis 
Regression analyses were performed to assess the relative contribution of possible predictor 
variables (e.g. cannabis use and SPQ-B, paranoia measures - social reference part A and ideas 
of persecution part B; ambivalence, clarity of thoughts and impulsiveness) on cognitive 
performance.  Some of the predictor variables did predict cognitive performance.  The IGT in 
the cannabis group alone was linked to the amount of cannabis used per week.  Thus risky 
decision making seems to be affected by heavier use of cannabis.  In the first regression 
analysis, anti-saccade task error was significantly predicted by SPQ total and the first and 
second order of the BIS and was the only significant regression model with adjusted R² at 
28% shared variance.  Thus it seems that psychotic personality traits and impulsivity were the 
best predictors of outcomes on the AST, as opposed to cannabis use.  Therefore, it could be 
argued that schizotypal traits and impulsivity are seen as a deficiency of inhibitory control, as 
having higher levels of these traits was associated with poor performance on the AST. 
 
3.7.6 General Limitations 
There are several limitations to this study.  There may be residual effects of cannabis may 
have impacted on the study, as neurobehavioural effects linked to heavy use of cannabis 
include deficits in memory and executive functioning (Bolla et al, 2002; Pope et al, 2006; 
Solowij et al, 2006).  Most studies have an abstinence period of 12-72h and therefore it is 
difficult to elucidate these findings in terms of it being residuals or withdrawal effects.  The 
cannabis users in this current study abstained for two days, and 20 out of 30 participants 
scored in the range for cannabis dependency, but interestingly dependency was not linked to 
any of cognitive outcomes.  Participants in this current study were asked to abstain for two 
days (at least 48h), so any effects could be residual rather than acute effects of the drug.  
Residual means the lingering effect the drug could still have and produce two different 
mechanisms which are difficult to independently assess (Whitlow et al, 2004).  For example, 
Pope et al (1995) argue that the residual effects may be due to the presence of the drug 
residue, either a dopamine agonist, or metabolites, which continue to have an intoxication 
effect after the peak acute effects of the drug has gone, for several hours (Grotenhermen, 
2003) and up to 6 hours (e.g. Crean et al, 2012).  Further to this, a residual effect can also 
indicate that even after complete elimination of the dopamine agonist there is still changes 
that can persist, which indicate that there may be neuroadaptions (e.g. persistent changes that 
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remain and are caused by the continued drug use).  Or alternatively differences found could 
be due to withdrawal effects, such as irritability, negative affect, aggressiveness (Kouri et al, 
1999).  Withdrawal symptoms are seen to first appear after 24h upon abstinence of the 
cannabis (Budney et al, 2003).  Further, the drugs testing kit used in this study were for 
screening purposes only and did not assess for drugs within the system.  Given that cannabis 
has a half-life it can last up to one month in the body (Agurell et al, 1986).  There was an 
imbalance of some demographic and personal health information in both groups, for example, 
there were a significantly greater number of males in the cannabis group.  However the 
regression models were adjusted for sex and this factor did not predict performance on any of 
the cognitive assessments.  The participants were selected using a range of recruitment 
methods, so as to avoid using a convenience sample (i.e. the student cohort only).  A wider 
range of external participants were also recruited via social networking methods, newspapers, 
and general ‘research participants wanted’ posters were displayed on large supermarkets 
which attract a wide range of members from the general public.  However, 50% of the sample 
was made up from the UEL student cohort which limits the generalizability of the findings.  
In this current study the cannabis users reported a greater degree of past and current polydrug 
use. Therefore, it is possible that other drug use or polydrug use per se may be a key reason 
for cognitive disruption, as opposed to cannabis use alone (e.g. Croft et al, 2001). 
 
3.7.7 Final summary 
Overall, this chapter has provided experimental evidence to suggest that cannabis users made 
riskier decisions on the gambling task when compared to a group of non-cannabis users.  An 
increase in joints per week was associated with performance on the task, in that those who 
smoked more joints also took more risks overall.  Both of these findings fit in with the main 
theme in that the cannabis use and heavier use of the drug show disrupted cognition akin to 
those with schizophrenia and high schizotypy.  Cannabis users make riskier decisions which 
may be the result of responding less to punishments (e.g. losses) on the Iowa Gambling Task, 
as has been previously shown in brain scans of cannabis users when completing this task (e.g. 
Bolla et al, 2002) combined with the pharmacological effects cannabis has on the brain 
associated with fear in the amygdala (e.g. Phan et al, 2008).   
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There was a lack of findings for the anti-saccade task and CPT between the cannabis users 
and non-cannabis users.  As previously discussed, conflicting CPT outcomes in clinical and 
non-clinical samples may be due to the number of variations of the task used.  However, 
faster reaction times on the CPT were linked to negative symptomology as assessed using the 
SPQ-B and it may be that outcomes are more pronounced in people with greater negative 
symptoms, as these are more closely linked to the genetic component of schizophrenia (e.g. 
Bassett et al, 1993).  Also, those with more negative symptoms are harder to treat with anti-
psychotic medications so it may be that CPT performance deficits are more closely associated 
with those in the chronic stages of schizophrenia; rather than the milder changes, predicted in 
this work, that may be associated with regular cannabis use in non-pathologised individuals. 
 
The AST has been less widely assessed in cannabis users and it seems that cannabis users 
display more psychotic-like traits, particularly those who use cannabis more heavily.  The 
anti-saccade task performance was also moderately accounted for by personality factors 
which could be argued to constitute a profile resembling schizophrenic-like symptoms mainly 
in the cannabis using group.  The data could be taken to suggest that these traits resemble a 
liability for schizophrenia, a finding backed up by previous research (e.g. Ettinger et al, 2000; 
Larrison et al, 2002).   
 
Taken together, these data do somewhat suggest that the cannabis users in this sample present 
with a personality and behavioural profile similar to people diagnosed with schizophrenia.  
These data, along with that from Chapter 2, will be further explored in Chapter 4 to look at 
cannabis use, candidate genes for schizophrenia, psychotic-like personality traits and 
cognitive performance. 
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Chapter 4: Exploration of schizophrenia-linked candidate gene markers in the cannabis 
and non-cannabis using study cohorts and possible links to cognitive and trait data 
 
Chapters 2 and 3 have summarised the findings from a range of cognitive assessments and 
personality measures administered to regular cannabis users and non-user controls.  The core 
rationale of this work is that cannabis use, which appears to contribute to schizophrenia in a 
minority of users, may produce trends towards schizophrenia-like traits in a much larger 
number of regular users; and that this may then be observable in schizophrenia-sensitive 
assessments.  In the first study, for example, LI was abolished in cannabis users, paralleling 
the effects seen in schizophrenics and first degree relatives.  The second study revealed 
impairments in decision-making for IGT performance in cannabis users; and an increase in 
joints per week was associated with performance on the task, in that those who smoked more 
joints also took more risks overall.  Faster reaction times on the CPT were linked to negative 
symptomology as assessed using the SPQ-B.  The anti-saccade task performance was 
moderately accounted for by personality factors which could be argued to constitute a profile 
resembling schizophrenic-like symptoms mainly in the cannabis using group.  Taken 
together, these data do somewhat suggest that the cannabis users in this sample present with a 
personality and behavioural profile similar to people diagnosed with schizophrenia.   
 
An important consideration however is the role of genetic risk factors, linked to 
schizophrenia and psychosis, which may underlie a possible exacerbation of certain traits 
when the factor of cannabis use is added (see Chapter 1).  This chapter therefore looks at the 
DNA data from participants (section 2.2.1 (primary analysis) and 3.51) and then explores 
possible interactions between a subset of these schizophrenia-linked markers and the data 
from the previous chapters (sections: 2.3.2; 2.3.3; 3.6). 
 
4.1 Genetics of schizophrenia 
Schizophrenia is associated with multiple genes, each suggested to have a relatively small 
risk effect (for a review see Saha et al, 2005; Plomin et al, 1994).  Schizophrenia is likely to 
result from interactions between such risk genes (epistasis) as well as between genes and 
environmental factors (van Os et al, 2008).  There is growing evidence that novel 
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chromosomal mutations may be involved in the aetiology of schizophrenia (Bassett et al, 
2010).  Multiple family studies have shown that rates of schizophrenia are higher in relatives 
of people diagnosed with schizophrenia, than in the general population (van Os et al, 2008).  
First degree relatives are at a 3-15% risk of developing schizophrenia and healthy controls are 
at 0.5-1% risk (Shih et al, 2004).  The relative contribution of genetic and environmental 
factors has been investigated in twin and adoption studies and the concordance rate for 
schizophrenia is 45%-75% among monozygotic twin pairs but only 4%-15% among 
dizygotic pairs (Lictermann et al, 2000; Cannon et al, 1998; Sullivan et al, 2003).  These 
studies show the impact of genes as well as non-genetic effects.  A meta-analysis of 12 
schizophrenia twin studies found that estimates of heritability in liability to schizophrenia to 
be 81% (e.g. Sullivan et al, 2003).  Studies have shown that schizophrenia is 10 times higher 
among individuals who are adopted away from a parent diagnosed with schizophrenia, than 
those who are adopted away from an unaffected mother (Kety et al, 1994; Gottesman and 
Shields, 1982).  One major study by Tiernari et al (2004) followed children up from birth 
longitudinally to 21 years to assess for rearing patterns and risk for developing schizophrenia 
spectrum disorder (SSD).  They found that only those children already at risk for developing 
schizophrenia were affected by disordered rearing patterns, but the discordance rate for 
identical twins developing schizophrenia was less than 50% so this does not discount the 
effects of the environment.  Most researchers now look at the interplay between genetics and 
environments, to further understand the risk of developing schizophrenia (Harrison and 
Weinberger, 2005).  It would not be one single gene that accounts for schizophrenia; it is 
likely to be multiple genes that have an additive effect of acting in a combined fashion.   
 
4.1.1 Molecular genetics  
Molecular genetics started in the 1980’s with the introduction of modern technologies such as 
Polymerase Chain Reaction (PCR) methods, which allowed researchers to amplify the 
regions of DNA of interest for further investigation (e.g. Strachan and Read, 1999).  There 
are two main approaches for identify candidate genes: linkage analysis and association 
studies (e.g. Badner et al, 2002; Hamshere et al, 2004).  Linkage studies are conducted on 
two or more affected individuals and are studies to assess for genomic regions which could 
indicate the transmission of the disease.  Statistical analyses are performed to see is two 
segments of DNA are transmitted to the offspring higher than what would be expected by 
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chance.  Researchers scan the genome for several markers for possible disease genes and this 
approach has been successful for some disorders such as neurofibromatosis and hereditary 
non-polyposis colon cancer (e.g. Saha et al 2005; Frogatt et al, 1995).  However, some 
linkage analysis can be limited as it can only identify a region on the genome, which may 
contain a large number of genes, so it does not link the disease with a specific gene(s).  Early 
linkage studies of schizophrenia had a few genomal regions that reached statistical 
significance but failed to be positively replicated (e.g. Jurewicz et al, 2001).  Thus there are 
issues with lack of statistical power, small effects of individual genes and the use of a large 
number of markers in each of the studies (e.g. Alaerts et al, 2009).  There has been over 20 
genome-wide linkage studies of schizophrenia and several have shown the same linkage in 
two or more samples.  For example Badner et al (2002); Lewis et al, (2003); Ng et al, (2009) 
conducted meta-analyses of schizophrenia linkage and identified chromosomal regions, 1q, 
2q, 3p, 4q, 6p, 8p, 11q, 13q, 14p, 20q, and 22q, but 8p was confirmed by all three meta-
analyses.  Thus, the risk for schizophrenia might be explained by multiple genetic markers, 
but Haraldsson et al (2011) argue that this does not rule out the existence of single marker 
which confers the highest risk.  Association studies compare the frequency of alleles in 
previously identified candidate genes and then compare these to an unrelated sample of affect 
individuals with a healthy control sample from the same population.  An allele is one part of a 
pair of genetic markers that are positioned on a specific part of the chromosome.  In contrast 
to linkage studies, association studies can identify specific genes, which came about due to 
the technological advancement of DNA methods, such as PCR.  However, the lack of 
knowledge of how certain genes functions, lack of replication and how certain genes are 
involved in the aetiology of schizophrenia from linkage studies proved to be limiting for 
association studies.  One key problem was false positive findings due to a large number of 
markers being analysed which resulted in multiple testing (Haraldsson et al, 2011).   
 
Researchers can now identify candidate genes within the linkage region and apply linkage 
disequilibrium (LD), which assesses for the non-random association of alleles at two or more 
loci or on the same or different chromosomes (Saha et al 2005; Frogatt et al, 1995).  LD 
allows for the testing of specific variant within the gene such as single nucleotide 
polymorphisms (SNPs).  Each individual has many SNPs but each SNP occurs in about 1% 
of the population and the tiny changes in the DNA sequence may reflect a liability for the 
development of schizophrenia, where there is the transformation of one DNA molecule to 
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another (e.g. a C (cytosine) to a T (thymine) and these are linked across generations.  Those 
variants within alleles that are said to be in LD do not travel randomly but are transferred 
together across generations.  Therefore when researchers find a disease variant more 
frequently in patients compared to healthy controls, then this finding is not caused by 
multiple testing, and can constitute as a disease marker.  Several sets of these SNPs are 
referred to as a haplotype and analysis of a haplotype is useful in detecting true effects from a 
SNP from it LD with another SNP.  Haplotypes are elaborated below under the discussion of 
each candidate gene for schizophrenia, but in short the statistical power of haplotype analysis 
is increased as fewer SNPs are needed to identify genetic traits involving multiple SNPs by 
detecting a few SNPs from a haplotype.  Further advancements in the 21
st
 century has 
allowed research to conduct genetic wide association studies on thousands of participants, 
where researchers use microarrays or chips to rapidly scan 300,00-1,000,000 SNPs to find 
markers associated with that disease; analyses can be done to control for multiple testing (e.g. 
Harrison and Owen, 2003; Haraldsson et al, 2011). 
 
4.1.2 Genetics of sub clinical schizophrenia  
Family (e.g. Pogue-Geile, 2003; Kendler et al, 1985), twin and adoption studies (e.g. 
Torgersen et al, 2000) agree that schizotypal personality traits are genetically continuous with 
schizophrenia, in that domains of personality pathology aggregate in relatives of people 
diagnosed with schizophrenia.  As with family studies there are issues of resolving the 
relative contribution of genetics from the environmental influences in risk for schizophrenia.  
Since 2002, positional cloning methods have been successful in identifying candidate gene 
for schizophrenia which has been replicated in many studies (e.g. Fanous et al, 2007; Lien et 
al, 2009; Picchioni et al, 2010).  A meta-analysis by Sullivan et al (2003) suggests that the 
presence of allelic or locus heterogeneity in schizophrenia may compromise the statistical 
power to detect, identify or replicate candidate genes for schizophrenia.  Fanous et al (1997) 
suggest that studying subclinical traits (i.e. schizotypy) in the unaffected relatives of people 
diagnosed with schizophrenia should help to increase the statistical power and resolve some 
inconsistencies.  Fanous and colleagues were the first researchers to do this and performance 
a genome scan correlation, which used genetic linkage data to test for a genetic correlation 
between a disease and an aetiological relevant trait, in unaffected relative of PDS in the Irish 
study of high density schizophrenia families (ISHDSF).  Using 3 independent samples of 90 
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Irish Multiplex families the results were compared to those from a genome scan of narrowly 
defined schizophrenia in the same sample.  The researchers observed a significant 
relationship between schizotypy scores for these two phenotypes genome wide and 
chromosome 5q, 6p, 6q, 8p, 9q and 10p detected links for schizophrenia but were not as 
powerful for schizotypy. 
 
Several scans of the genomes have been conducted and produced significant scores for 
chromosomal locations, but the discovery of predisposition genes has remained elusive (e.g. 
Lewis et al, 2003).  There are a number of issues which hinder genetic research.  One would 
be the diagnostic and symptomatic complexity of schizophrenia, and a diagnosis of the 
disorder is made at a clinical level, rather than from a clear aetiological viewpoint.  Further to 
this, schizophrenia is a common disorder which may represent a common genetic liability 
with high frequency in the general population.  There is a general overlap of psychiatric 
disorders, so highlighting specific genes for schizophrenia is difficult due to the co-morbidity 
with other disorders.  Lastly, the genetic and environmental variables may only provide a 
small effect, which act together in an additive fashion, and results in someone having 
vulnerability for developing schizophrenia (e.g. Gottesman and Erlerimeyer-Kimling, 2001).  
As a result of these issues the research into candidate genes for schizophrenia has not been 
ground-breaking, but progress has been made due to the invention of new efficient tools for 
analysing DNA (e.g. O’Donovan et al, 2003; Harrison and Weinberger, 2005).   
 
A number of candidate genes have been implicated in the disorder which has been 
successfully replicated: DAOA or known as DAOA/G72, COMT, and neuregulin 1 (NRG1), 
(e.g. O’Donovan et al, 2003; Owen et al, 2004; Plomin et al, 2001).   Research on these 
candidate genes, as well as the cannabinoid receptor gene 1 (CNR1) and the FAAH gene will 
be addressed below.  Further to this, research presented here focuses on how these genes are 
linked to cognition disruption and subclinical personality traits in relation to schizophrenia.  
Lastly, a rationale is provided to account for why these are candidate genes are being 
explored in relation to cannabis use and risk for schizophrenia. 
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4.2 D-amino acid oxidase activator (DAOA) 
D-amino acid oxidase activator (DAOA), located on chromosome region 13q33.2, codes for a 
mitochondrial protein which plays a role in cellular energy, cell death, and cell growth (Kvajo 
et al, 2008).  Post-mortem studies of schizophrenic brains show an overexpression of the 
subtype DAOA/G72 (Korostishevsky et al, 2004).  DAOA is understood to interact with the 
enzyme D-amino acid oxidase (DAO) which then activates DAO (Chumakov et al, 2002). 
DAO is important as it oxidises D-serine, which can powerfully activate the NMDA-type 
glutamate receptor (e.g. Harrison and Owen, 2003); a receptor highly implicated in the 
aetiology of schizophrenia as well as other psychiatric illnesses such as bipolar disorder 
(Chumakov et al, 2002; Jamra et al, 2006; Jansen et al, 2009; Ma et al, 2006).  D-serine was 
found to be higher in serum of people diagnosed with schizophrenia (e.g. Hashimoto et al, 
2003) and it was higher in the cerebral spine fluid (CSF) of drug naïve schizophrenic patients 
(e.g. Hashimoto et al, 2005) and therapeutic benefits have been reported in treatments with 
D-serine (e.g. Tuominen et al, 2006).  Schizophrenia susceptibility has been mapped to 
chromosome 13q by many research teams using genetic wide studies (e.g. Blouin et al, 1998; 
Bruzstowicz et al, 1998; Shaw et al, 1998; Camp et al, 2001; Lin et al, 1997).  Jamra et al 
(2006) argued that even though inconsistencies exist in data from genome-wide studies, the 
linkage data for chromosome 13 is the most convincing across the genome.   
 
DAOA has been studied for interactions with other candidate genes for schizophrenia, for 
example, Nicodermus et al (2006) assessed for 6 SNPs in the DAOA gene and found some 
interactions with the G/G version of the COMT gene (see section 4.3).  Variation in the 
DAOA gene has also been linked to differential treatment outcomes in relation to anti-
psychotic medication (Pae et al, 2010).  DAOA has also been linked to neurocognitive 
functioning in schizophrenic groups, particularly in tasks which place demands on the medial 
temporal lobe (MTL); an area thought to play a significant role in the aetiology of 
schizophrenia (Harrison, 2004; Heckers, 2001).  Evidence exists for DAOA playing a 
modulatory role on brain activity in the MTL mainly for hippocampal and parahippocampal 
function.  For example, Goldberg et al (2006) investigated the relationship between cognitive 
performance and variants of the DAOA gene and found that variant M24 T/T was associated 
with impairment in 1-back task performance (which assesses working memory), less 
activation in the hippocampal and parahippocampal regions and weaker BOLD activity 
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during the working memory task.  Hall et al. (2008) demonstrated similar effects in 
participants at high risk for schizophrenia, with weaker scores on the Hayling Sentence 
completion task, differential activation in the left hippocampus and parahippocampus and in 
the PFC area in relation to increased task difficulty, in the T/T genotypes.  Therefore this 
research additionally provides some support that variation of the DAOA gene impacts on 
PFC functioning, an area that is vitally important for cognitive dysfunction in schizophrenia.  
Effectively the role of DAOA gene variants has also been explored in animal research, and 
the evidence of the distribution of DAOA, the effects of variants on behaviour, knock-out 
manipulations and pharmacological challenge all provide some support for the role of DAOA 
with regards to schizophrenia (see review Drews et al, 2012). 
 
4.3 Catechol-O-methyl transferase (COMT) 
The Catechol-O-methyl transferase (COMT) gene is located on chromosome 22q11.2 and is a 
major catalysing enzyme for dopamine (DA) and noradrenalin (NA).  A single nucleotide 
substitution (G→A) at 472 bp of exon 4 produces the Val/Met variant also referred to as SNP 
rs4680 Val158Met, which causes a functional difference in the breakdown of DA and NA, as 
the homozygotic Valine allele (i.e. Val/Val) has a three-to-four fold higher activity than the 
homozygotic Methionine allele (i.e. Met/Met); the heterozygotes (i.e. Val/Met) have an 
intermediate level of activity (Lotta et al, 1995; Lachman et al, 1996).   The COMT has links 
to the disorder of velocardiofacial syndrome (VCFS; Thomas and Graham, 1997; Bassett and 
Chow, 1998) and people with this disorder have significantly higher rates of schizophrenia 
(10-31%) than the general population (1%) (Shprintzen et al, 1992; Murphy et al, 1999; 
Murphy and Owen, 2001).  Around 1-3Mb of DNA deletion including the COMT gene in 
this chromosomal region is linked to the clinical features of VCFS (e.g. Murphy et al, 1997).   
 
The COMT gene has been widely reported to be implicated in the aetiology of schizophrenia, 
but its role remains controversial and results are ambiguous (see Hosak et al, 2007 for a full 
review).  SNP rs4680 G/A also known as the Val/Met variant has been widely researched 
with positive (e.g. Egan et al, 2001; Li et al, 1997; Kunugi et al, 1997a; 1997b) and negative 
findings (e.g. Chen et al, 1999; Daniels et al, 1996; Fan et al, 2005) reported in relation to  
risk for developing schizophrenia. Other studies link those carrying the A/A or Met/Met 
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allele with schizophrenia (e.g Ohmori et al, 1998) and increasingly more links have been 
made with the G/G or Val/Val allele and schizophrenia (e.g. Wanodi et al, 2003).  Handoko 
et al (2005) reported a strong association with COMT haplotype rs737865/rs4680/rs165599 
(G/G/G) and schizophrenia.  COMT plays a significant role in the metabolism of dopamine 
with the A/A allele associated with low activity of dopamine metabolism; and vice versa for 
the G/G alleles (Bilder et al, 2002).  The A/A SNP genotypes has been linked to better 
cognitive performance (Gallinats et al, 2003; Bilder et al, 2002; Bruder et al, 2005) and G/G 
carriers were linked to worse cognitive performance (Goldberg et al, 2003; Bruder et al, 
2005).   Those with A/A SNP genotypes have been linked to superior cognitive performance 
(Sheldrick et al, 2008).  Those homogenous for the G allele were linked to higher schizotypy 
scores and G/A carriers appear to show a weak association with disorganised thinking for 
schizotypy in males but not females (Avramoupoulos et al, 2002).  However, other 
researchers (e.g. Strous et al, 2006) have found no differences between rs4680 genotypes for 
clinical symptomology.  There has been a significant association found between rs4680 G/A 
carriers and higher scores on blunted affect in schizotypy (Wang et al, 2010).  Carriers of the 
G/G genotype had higher schizotypy state psychopathology scores and higher negative and 
disorganised thinking scores (Smyrnis et al, 2007).  Whereas Sheldrick et al (2008) reported 
that A/A carriers reported experiencing higher SPQ scores for disorganised thinking.   
 
The COMT SNP rs4680 has been widely studied in relation to cannabis use.  Caspi et al’s 
(2005) longitudinal reearch was one of the first studies to report that males (who used 
cannabis before the age of 15) with the G allele had higher risk for psychotic symptoms.  
Whereas Zammit et al (2011) failed to replicate these findings.  Henquet et al (2006) found a 
3-way association between THC administered to people diagnosed with schizophrenia, 
carriers of the G/G allele and higher rates of psychotic symptoms.  Animal studies support the 
links between cannabis and the COMT gene, as COMT knock-out mice demonstrate 
sensitivity to chronic THC exposure on behaviours related to psychosis and memory 
(O’Tuathaigh et al, 2010).  Pelayo-Teran et al (2010) reported that age of first use of 
cannabis was later in carriers of the A/A genotype.  Van Wickel et al (2008) reported that a 
haplotype (rs46333; rs4680) of the COMT gene and earlier onset of cannabis (less than 16 
years) was associated with greater scores on the BPRS. Costas et al (2011) reported that 
rs4680 G/A doubled the probability of lifetime cannabis use compared to G/G carriers.   
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In sum rs4680 has been extensively studied, and despite some inconsistencies in the data is 
widely considered to be a possible risk marker for schizophrenia; and will be hypothesised as 
such in this current study.  In addition to this, SNP rs165599 and SNP rs737865 will be added 
as together with rs4680 these three SNPs have been consistently reported as a risk COMT 
haplotype, with C-G-G positively associated with schizophrenia (De Rosse et al, 2006; 
Schifman et al, 2002; Handoko et al, 2004).  In addition, the T-A-A haplotype has also been 
linked to schizophrenia and the T-G-G has been characterised as a protective haplotype 
(Kotrotsou et al, 2012). 
 
4.4 Neuregulin1 (NRG1) 
The NRG1 gene is located at chromosome 8p 13 and it plays an important function in many 
organs including the heart, breast and nervous system.  In the nervous system the NRG1 is 
involved in many important functions such as neuronal specification, synapse formation, 
myelination, regulation of NMDA, GABA and nicotinic receptors to name a few.  NRG1 
expression has been found in the nervous system in the prefrontal cortex, hippocampus, 
cerebellum, and substantia nigra, in animals (Kerber et al, 2003) and humans (Harrison and 
Law, 2006).   NRG1 plays a central role in cognition (Harrison and Law, 2006) and it has 
been widely linked to genetic susceptibility to schizophrenia (Steffansson et al, 2003; Zhao et 
al, 2004; Zou et al, 2005).  Steffansson and colleagues found that SNP rs221553 (C allele) 
was over-represented in people diagnosed with schizophrenia and a 5 marker haplotype 
(known widely as the Icelandic haplotype - including SNPs rs221553, rs241930, rs243177 
and microsatellites 433E1006) doubled the risk for schizophrenia.  These findings have been 
replicated with positive (Williams et al, 2003; Zhau et al, 2004; Bakker et al, 2004) and 
negative findings (Kampman et al, 2004; Duan et al, 2005; Thistleton et al, 2004).  Whereas, 
Georgieva et al (2008) reported that it was the T allele that was over-transmitted in people 
diagnosed with schizophrenia.  One meta-analysis of 13 population studies confirmed the 
association between the NRG1 gene and schizophrenia with positive findings for rs241930, 
rs23177, rs221132 and rs221553, and two microsatellites 478B14-848 and 420 M9-1395 (Li 
et al, 2006).  The most robust SNP to be consistently associated with schizophrenia was 
rs221553 and all of the published research up to 2006 was included in a meta-analysis but 
this SNP was not significant; and the Icelandic haplotype was the only marker to reach 
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significance levels.  Few brain scan studies have been conducted in relation to SNP rs221533 
to explore its links with schizophrenia.  For example, Winterer et al (2008) found that white 
matter was reduced in medial frontal cortex for those carrying the risk ‘C’ allele.  Further, 
Suarez-Pinilla et al. (2015) in a 3-year follow-up study of people in their first episode 
psychosis and healthy controls found that the risk C allele was significantly associated with 
increased lateral ventricle volume across time. After the follow-up period it was found that 
the C allele carriers had significantly less white matter compared with participants who were 
homozygous for the T allele. 
 
In animal research, NRG1 knockout gene mice display more attentional problems (Rimmer et 
al, 2005) and social behaviour problems but their memory was intact (O’Tuathaigh et al, 
2007).  Interestingly, these mice had less cognitive impairment when exposed to THC, but 
had higher levels of anxiety (Karl et al, 2010) and male rats with this manipulation were 
more sensitive to the psychotropic effects of THC (Long et al, 2010).  Since SNP rs221533 
has been widely studied and has produced the most consistent findings, it was included as a 
risk marker in this current study. 
 
4.5 Cannabinoid receptor gene and the Fatty Amide Hydrolase (CNR1 and FAAH) 
The endogenous cannabinoid system and its links to schizophrenia were outlined in Chapter 
1.  The cannabinoid receptor (CNR1) and the fatty acid amide hydrolase (FAAH) genes are 
located on chromosomes 6 and 1 in the 6q15 and 1p33, respectively (Mastuda et al, 1990); 
this region is considered to be a susceptibility locus for risk of schizophrenia (Cao et al, 
1997).   The CNR1 and FAAH genes have been implicated in the risk for schizophrenia, with 
the CNR1 gene receiving more support (Dawson et al, 1995) compared to the FAAH gene 
(e.g. Martinez-Gras et al, 2007; Costas et al, 2012).  One SNP in particular on the CNR1 
gene (the rs1049353 G/G genotype) has been associated with schizophrenia (e.g. Leroy et al, 
2001), although some researchers have not replicated this finding (Ujike et al, 2002).   An 
AAT triplet repeat on the CNR1 gene has also been associated with schizophrenia (Zhang et 
al, 2004), though again this is not an unequivocal finding (Tsai et al, 2000; 2001).  There 
have been differences found in sensitivity to THC and P300 responses with this AAT triplet 
under the THC condition (Stadelmann et al, 2011).   
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The FAAH gene is strongly linked to cannabis dependence (Sipe et al, 2002; Morita et al, 
2005).  In SNP rs324420, the A/A variant has been more commonly found in those diagnosed 
with schizophrenia with co-morbid substance dependence. Schact et al (2009) reported that 
A/A or C/A genotypes were linked to having more cannabis withdrawal and Sipe et al (2002) 
reported that individuals with the A/A genotype reported more dependence on cannabis.  
Cannabis users with the A allele also displayed more negative psychotic like symptoms (as 
assessed with the disorganised thinking measure of the SPQ (Arias et al, 2010).  MRI scan 
data in people with the A allele showed lower threat related activity in the amygdala and 
higher reactivity to reward, and this cohort reported lower anxiety and impulsivity scores; 
whereas the C allele was associated with higher anxiety and higher threat related  brain 
activity (Hariri et al, 2009).  Given that SNP rs1049353 on the CNR1 gene and SNP 
rs324420 on the FAAH gene has been widely studied, both SNPs were included as risk 
markers in this current study. 
 
4.6. Summary and Rationale 
Overall, this is a relatively new area examining schizophrenia-linked genotypes in relation to 
performance on neuropsychological/cognitive tests which are sensitive to schizophrenia.  
Other genes have been implicated in the aetiology of schizophrenia (e.g.  DISC1 (Disrupted 
in Schizophrenia), and DTNBP1 (Dysbindin; Stefansson, 2008,2009; Harrison and Owen 
2003; O'Donovan et al 2003, 2008; Owen et al 2004), but the DAOA, COMT and NRG1 
markers were chosen as these genes have been most widely researched with relatively more 
consistent findings in relation to schizophrenia. Whilst it is acknowledged that this work is 
speculative, the following predictions were made with regards to each marker:   
 
DAOA 
The T/A genotype for SNP rs142129 has been linked with schizophrenia and the T/T 
genotype within the literature which is linked to poorer cognitive performance, particularly in 
those diagnosed with schizophrenia (e.g. Goldberg et al, 2006).    
 Given the consistent findings with SNP M24 rs1421292, this will be put forward as a 
risk marker in this current study.     
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COMT 
There has been conflicting findings for the COMT gene in relation to SNPrs4680 (G/G, G/A 
and A/A) genotypes and schizophrenia.  However, most of the current research converges to 
report that the G/G allele is the strongest predictor of being associated with schizophrenia.   
 Therefore, it is likely that those carrying the G/G allele will be more like to have 
higher SPQ scores.   
 Having the A/A allele has been linked with increased cognitive performance and the 
G/G allele has been linked to worse cognitive performance, so it is predicted that the 
A/A carriers will have better cognitive performance on each of the cognitive tests.   
 Further to this, it is predicted that those people who use cannabis with the risk G allele 
will be more likely to have higher subclinical schizophrenia symptoms, as well as 
higher cognitive disruption.  
 A secondary analysis will explore variation in the at-risk COMT haplotype.  This at-
risk haplotype has not been investigated in cannabis users, but it is likely that 
cannabis users with this at-risk haplotype will highlight subtle differences in 
performance in cognitive functioning and individual differences in psychotic-like trait 
compared to non-cannabis users.   
 
NRG1 
 For the NRG1 gene, given the consistent findings with SNPrs221533, it is likely that 
those carrying the C allele will have more schizophrenia-like traits and behaviours.  
This combined with cannabis use may be predictive with the highest trait scores and 
performance patterns more closely aligned to schizophrenic type behaviour in the 
tasks. 
 
CNR1 and FAAH 
These two genes are less researched in schizophrenia, but given the nature of this study 
looking at the possible links between the cannabinoid system and schizophrenia, these 
markers may prove highly pertinent.    
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 For CNR1, it is likely that those individuals with the rs1049353 G/G genotype will 
show responding biases in the direction of schizophrenic traits and behaviours, which 
may be even more likely, or increased, in the presence of concurrent cannabis use. 
 
 The FAAH SNP rs324420 A/A genotype may be linked to higher psychotic-like traits 
and cognitive dysfunction, most notably when combined with cannabis use.   
 
 Combined effects 
 It is predicted that those with a profile of multiple risk alleles from the candidate 
schizophrenia genes (i.e. the presence of two or more from the DAOA, COMT, 
CNR1, FAAH and, NRG1 markers) may show greater biases on cognitive tests and 
schizophrenia-like personality symptoms, in the direction of schizophrenia-like 
deficits and differences. 
 
 In line with the general hypothesis that cannabis use and gene markers serve as 
distinct and possible component causes of schizophrenia, it is predicted that cannabis 
users with multiple risk alleles will show the strongest bias towards a schizophrenia 
like behavioural profile in the measures employed. 
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4.7 Method 
4.7.1 Participants 
The samples from 50 cannabis users and 50 non-cannabis users were made up of a 
combination of the 40 participants from Study 1 and 60 participants from Study 2.  In total, 
there were 67 females and 33 males, with an age range from 18-47 (mean of 27; SD 7.7). The 
participants were from a variety of different ethnicities and nationalities. 
 
4.7.2 Materials 
Please refer to Chapter 2 (section 2.2.2) and Chapter 3 (section 3.5.2) for information on 
ethics documentation and drugs screening.  The SPQ-B, latent Inhibition task is outlined in 
section 2.5.2.  The Iowa Gambling, Continuous Performance and Anti-Saccade tasks are 
outlined in section 3.5.2.   
 
4.7.3 Genotyping 
DNA was collected using buccal swabs (Copan Diagnostics) to extract some cheek cells, by 
rubbing the swab vigorously on the inside cheek at least 6-10 times.  Intensive and extensive 
preparatory work and validation testing was completed from 2009-2012 (see appendix xiv).  
Initially the samples were found using the Primer Blast website: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/   Each primer was 20bp in length, and one 
forward and one reverse primer for each SNP was ordered from and synthesised by MWG-
Biotech, UK.  Table A (in Appendix xiv) highlights 20 SNPs that were used in the initial 
investigation and these were then used for PCR primer testing.  Testing was conducted on 
three SNPs with different amounts of DNA, primer, magnesium chloride, PCR master mix 
and water to achieve the optimal outcomes.  The washed and prepared PCR products for each 
of the SNPs were confirmed that DNA is present in each of the samples from electrophoresis 
(via the gel capture by appearance of the florescent rings); the product was stored in the 96 
well plates, at -20 degrees.  The SNP extension primer was carried out using the Beckman 
Coulter Primer Extension Kit for the Genome Lab ™ and AB gene ready mix.  The SNP 
primers were created using the Primer 3 blast function and successful primers should be in 
the range of 60 degrees – 75 degrees and a Poly (T) tail was added to the 5’ (please refer to in 
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Appendix xiv Table C3, for a list of SNP primers and Table D4 for the primers with their 
Poly (T) tails.  The SNP analysis was run according the Beckmann and Coulter manual for 
the CEO 8000 software.  10 separate multiplexing analyses were conducted and some of 
these worked and others did not (see Figure D4 and E5, in Appendix xiv).  The in-house 
method used resulted in relatively weak and inconsistent genotyping despite repeated 
attempts and alterations in method: 
1. changes in DNA concentration during each of the PCR runs  
2. changes in concentrations of the SNP  PCR primers 
3. rewashing the DNA for more purified DNA concentrations 
 
All of the intensive lab work was conducted over a period of 36 months (at a minimum of 10 
hours of lab work per week). At this point, to facilitate the process and spend no further time 
on this aspect of the work, samples were sent to K-biosciences (LGC Genomics, 
Hertfordshire).  Therefore all of the PCR samples (n=100) were washed using the Qiagen kit  
and then run through the PCR, using the same protocol as Table B2 (in Appendix xiv), but 
for only 7 out of the 20 SNPs were selected to be sent externally to K-Biosciences (see table 
F6, in Appendix xiv).  The first batch of analysis (which included the SNP primer PCR 
products) had a poor success rate at K-Biosciences (under 60%).  Therefore a secondary 
batch was sent which including all of the original DNA samples and were cleaned to increase 
the % of purified DNA.  All DNA samples (n=100) were eluted in 10mM Tris buffer and re-
sent to K-Biosciences for a final attempt to genotype the DNA without any PCR or SNP 
primers, and it was much more successful with a hit rate of (89%-99%).  The SNP markers 
were genotyped using the KASP™ method, a competitive allele-specific polymerase chain 
reaction incorporating a fluorescent resonance energy transfer quencher cassette, for further 
details see: http://www.kbioscience.co.uk/reagents/KASP.html 
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4.8 Results  
4.8.1 Data screening  
Data were screened and cleaned in the second and third chapters, but owing to the small 
number of participants outliers were not removed in the combined psychological measures 
and DNA data analyses. However, a check for the standard deviations (SDs) was run to make 
sure that outliers did not affect the results.  Due to the high SDs one participant (from the 
non-cannabis group) was removed from the CPT motor error data.  Additionally, two 
participants were removed from the final analysis assessing cannabis use variables as co-
variates, as both reported excessive amounts of cannabis per week (e.g. 120 joints per week).  
There were missing genetic data for some participants for the following SNPs: SNP rs142129 
(n=2); SNP rs737865 (n=3); SNP rs4680 (n=10); rs165599 (n =11); rs1049353 (n =1); 
rs324420 (n =5); SNPrs221533 (n=3).  For the COMT haplotype those with missing data in 
any of the three SNPs were excluded, so there were 18 missing data for the COMT haplotype.   
The findings are reported as either significant (p<0.05) or leaning towards significance (p 
0.15) are discussed below. 
   
4.8.2 Hardy Weinberger Equilibrium (HWE) 
The Hardy Weinberger Equilibrium (HWE) theory states that the percentage of each 
genotype should remain constant in a population (Nature, 2013).  To test that HWE was met 
the HWE Calculator was used from Court (2005-2008).  This calculation is based on a similar 
principle to Chi ² analyses, and were run for the entire group to look for differences (in 
observed and expected frequencies) in genotype for each SNP (see Table 28).  In addition, 
Chi² analyses were run between groups (e.g. cannabis user and non-cannabis user) for 
frequencies of genotype and alleles (see Table 29).  If the p-value was < 0.05 then the result 
is not consistent with the HWE.  Also for those data with cells < 5 then an F statistic was run 
using SPSS version 18.   
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4.8.3 HWE Result of Genotyping data    
Table 28 below summarises, for each gene SNP, the frequency distribution of corresponding 
genotypes across all participants (cannabis and non-cannabis users, from studies 1 and 2).  
Chi² analyses were run to look at differences and it was found that there were significant 
differences for the frequency of occurring alleles under each genotype, with the homogenous 
recessive allele (referred to a q in Table 28) occurring less than the homogenous dominant 
alleles (referred to as p in table 28).   SNP 9 p (or allele T) occurs more frequently in the 
sample at 57%, as opposed to q (or the A allele) at 43%.  Two SNPs are not consistent with 
the HWE due to p<0.05 for COMT rs737865 and CNR1 SNP rs1049353 having zero 
participants carrying the A/A allele.  Having larger sample sizes would be ideal for making 
the data becoming more consistent for frequency of alleles. 
 
Table 28:  Distribution of SNP dominant and recessive genotypes in the whole group and chi-
square analyses. 
 
Gene SNP Genotype frequencies X² p         1Allele 
DAOA rs142129 T/T T/A A/A   p  q  
30 51 17 0.35 0.56 0.57 0.43 
COMT 2rs737865 T/T T/C C/C     
57 27 13 8.68 0.003 0.73 0.27 
COMT rs4680 G/G G/A A/A     
39 36 15 1.73 0.188 0.63 0.37 
COMT rs165599 G/G G/A A/A     
15 43 31 0.001 0.99 0.46 0.54 
CNRI  rs1049353  G/G G/A A/A     
93 6 0 0.10 0.75 0.97 0.03 
FAAH rs324420 C/C C/A A/A     
57 29 9 3.08 0.08 0.75 0.25 
NRG1 rs221533 T/T T/C C/C     
75 19 3 1.58 0.21 0.87 0.13 
 
 
                                                          
1
 In each table the allele is listed a ‘p or q’; a standard procedure in the genetics literature to denote the 
dominant and recessive alleles.   
2
 In the literature the rs737865 is also referred to as G/G, G/A or A/A genotypes.  The C allele of the rs737865 
corresponds to the G allele in the literature. 
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Table 29 below highlights the occurrence of each SNP and their corresponding genotype in 
the cannabis users and non users.  Distributions of the CNR1 SNP rs1049353 A/A, and 
NRG1 SNP rs221533 (C/C) were not consistent with the HWE; each having less than five in 
one cell for both cannabis and non-cannabis users.  The FAAH gene is not consistent with the 
HWE in the cannabis users as there were less than five participants having the A/A genotype.  
The SNPs that remained consistent with the HWE in both groups was COMT rs4680 and 
rs165599 and COMT rs737865 for the non-cannabis users; the FAAH gene for the non-
cannabis users all p-values are greater than 0.05.  When the cannabis group was compared to 
the non-cannabis group for frequency of alleles there was a trend for significance for 
variation in the DAOA gene X² (2) = 7.231, p = 0.055.  The T/A genotype occurred much 
more frequently in the cannabis users. 
 
Table 29:  Distribution of SNP dominant and recessive genotypes in cannabis and non-
cannabis users, and chi square analyses. 
 
  
SNP Genotype X² (HWE) 
within 
each group 
P            Allele 
p                          q 
X² - between 
the cannabis 
users and 
non users 
P (2-
tailed) 
 T/T T/A A/A       
DAOA 
rs142129 
Cannabis user 9 31 9 3.44 0.06 0.86 0.14 7.231 0.055 
Non-cannabis user 21 20 8 0.727 0.39 0.89 0.11   
 T/T T/C C/C       
COMT 
rs737865 
Cannabis user 29 12 7 6.46 0.01 0.73 0.17 0.418 0.949 
Non-cannabis user 28 15 6 2.66 0.10 0.73 0.17   
  G/G G/A A/A       
COMT 
rs4680 
Cannabis user 19 14 9 3.61 0.06 0.60 0.40 2.012 0.729 
Non-cannabis user 20 22 6 0.00 0.989 0.65 0.35   
  G/G G/A A/A       
COMT 
rs165599 
Cannabis user 7 20 15 0.006 0.94 0.40 0.60 0.016 0.910 
Non-cannabis user 8 23 17 0.002 0.96 0.40 0.60   
 G/G G/A A/A       
CNR1 
rs1049353 
  
Cannabis user 48 2 0 0.02 0.88 0.98 0.02 0.753 0.329 
Non-cannabis user 45 4 0 0.089 0.76 0.95 0.05   
 C/C C/A A/A       
FAAH 
rs324420 
Cannabis user 27 15 4 0.78 0.37 0.75 0.25 0.209 0.941 
Non-cannabis user 30 14 5 2.53 0.11 0.75 0.25   
  T/T T/C C/C       
NRG1 
rs221533 
Cannabis user 37 11 1 0.03 0.86 0.87 0.13 0.810 0.882 
Non-cannabis user 38 8 2 2.72 0.10 0.88 0.12   
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4.9  Genotyping data by measure and groups 
 
4.9.1 SPQ data: studies 1 and 2 (whole sample) 
Table 30 presents the SPQ data for all participants from studies 1 and 2, broken down by SNP 
genotypes across the 5 key gene markers.  An ANOVA revealed a significant difference 
between participants with variation in the NRG1 rs221533 on scores in the SPQ-CP subscale 
(F(2, 94) =3.183, p=0.046), with the post-hoc Tukey test revealing that this finding was 
attributable to the significance between the T/C and T/T genotypes (p=0.05). There were also 
trends represented by low marginally non significant differences for the SPQ-DT subscale for 
the COMT rs165599 G/G genotype (F (2, 24) = 2.623, p = 0.078) in that these carriers 
reporting experiencing more disorganised thinking (e.g. problems with communication).  
Whereas, the opposite was found for the NRG1 rs2215533 T/T (F (2, 94) = 2.468, p = 0.09), 
in that they reported less disorganised traits relative to the T/C and C/C genotypes. 
 
4.9.2 SPQ data: studies 1 and 2 (cannabis users and non-cannabis users) 
Data was taken from studies one and two from the SPQ-B personality measure.  Table 31 
provides the mean scores along with the respective schizophrenia candidate genes in both the 
cannabis users and non-cannabis users for the SPQ-B total scores along with three of its 
subscales for disorganised thinking, interpersonal and cognitive perceptual.  A one-way 
ANOVA revealed that there were no significant differences found between variation in each 
of the genes and their respective genotypes.  A trend was found for variation in the NRG1 
gene for SNPrs221533 for cognitive perceptual with the T/C genotype scoring higher on 
SPQCP than T/T and C/C (F (2, 91) = 2.43, p = 0.09).  A trend found for variation in the 
COMT gene for SNP rs165599 and outcomes on the SPQDT (F (2, 83) = 2.509, p = 0.08).  
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       Table 30:  SPQ total,  cognitive perceptual (CP), interpersonal (IP) and disorganised thinking (DT) scores   
                         explored across SNP genotypes in all participants. 
 
  SPQ 
total 
  SPQ CP   SPQIP   SPQDT   
Gene SNP Mean 
(SD) 
F p Mean 
(SD) 
F p Mean 
(SD) 
F p Mean  
(SD) 
F p 
DAOA rs142129 T/T 
(22) 
5.53 
(5.0) 
1.05 0.355 2.18 (2.3) 0.405 0.668 2.22 
(2.34) 
1.99 0.141 1.64 
(1.73) 
0.368 0.693 
 T/A 
(37) 
6.92 
(3.99) 
 2.4 (1.62)  3.00 
(2.00) 
 1.57 
(1.625) 
 
A/A 
(14) 
6.11 
(3.37) 
2.0 (2.0) 1.92 
(1.59) 
1.357 
(1.736) 
COMT 
 
 
 
 
 
 
 
rs737865 T/T 
(42) 
6.23 
(5.59) 
0.84 0.436 2.59 
(2.03) 
0.520 0.596 2.33 
(2.21) 
1.913 0.153 1.66 
(1.88) 
1.283 0.282 
 T/C  
(23) 
6.0 
(3.84) 
 1.896 
(1.65) 
 2.739 
(1.86) 
 1.08 
(1.08) 
 
C/C  
(8)  
7.77 
(3.37) 
1.625 
(1.59) 
3.25 
(1.83) 
2.25 
(1.58) 
COMT 
 
rs4680 G/G  
(31)  
6.64 
(4.66) 
1.66 0.196 2.45 
(2.01) 
0.631 0.534 2.806 
(2.22) 
1.643 0.199 1.677 
(1.93) 
0.984 0.378 
 G/A 
(28) 
5.14 
(4.02) 
 2.035 
(1.83) 
 1.96 
(1.77) 
 1.250 
(1.32) 
 
A/A 
(14) 
7.13 
(5.74) 
2.28 
(1.85) 
3.214 
(2.08) 
1.857 
(1.61) 
COMT 
 
rs165599 G/G 
(13) 
8.06 
(4.68) 
1.45 0.241 2.384 
(2.18) 
1.995 0.142 2.84 
(2.07) 
0.655 0.522 2.23 
(1.48) 
2.623 0.078 
 G/A 
(36) 
6.09 
(4.41) 
 2.53 
(2.05) 
 2.50 
(1.99) 
 1.22 
(1.64) 
 
 A/A 
(24) 
5.87 
(4.02) 
1.79 
(1.44) 
2.50 
(2.24) 
1.66 
(1.71) 
CNR1 
 
rs104935
3  
G/G 
(68) 
6.4 
(4.28) 
0.76 0.385 2.26 
(1.87) 
0.188 0.666 2.58 
(2.08) 
0.02 0.889 1.602 
(1.685) 
2.137 0.147 
 G/A 
(5) 
4.8 
(3.76) 
 2.20 
(2.49) 
 2.2  
(1.92) 
 0.80 
(1.095) 
 
A/A - - - - 
FAAH rs324420 C/C 
(45) 
6.47 
(4.19) 
0.09 0.918 2.33 
(1.78) 
1.101 0.337 2.48 
(2.12) 
0.421 0.658 1.511 
(1.604) 
0.194 0.824 
 C/A 
(21) 
6.55 
(4.68) 
 2.33 
(2.24) 
 2.57 
(2.11) 
 1.76 
(1.81) 
 
 A/A 
(7) 
5.88 
(3.48) 
1.57 
(1.61) 
3.00 
(1.82) 
1.142 
(1.67) 
NRG1 rs221533 T/T 
(56) 
5.83 
(4.31) 
2.25 0.111 2.08 
(1.95) 
3.183 0.046 2.571 
(2.147) 
0.353 0.702 1.375 
(1.59) 
2.468 0.09 
 T/C 
(15) 
8.05 
(2.91) 
 3.066 
(1.53) 
 2.6(1.8)  2.133 
(1.88) 
 
 C/C  
(2) 
6.00 
(4.26) 
1.00 
(1.41) 
2.00 
(2.82) 
2.0  
(1.41) 
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Table 31:  SPQ total,  cognitive perceptual (CP), interpersonal (IP) and disorganised thinking (DT) scores explored across SNP genotypes in cannabis users and non-cannabis users 
 
  (n = ) Cannabis 
user 
Non-
cannabis 
user 
F or p Cannabis 
user 
Non-
cannabis 
user 
F or p Cannabis 
user 
Non-
cannabis 
user 
F or p Cannabis 
user 
Non-
cannabis 
user 
F or p 
Gene SNP genotype 
(cu: ncu 
 
SPQ total 
Mean (SD)  
SPQ total 
Mean (SD)  
  SPQ IP 
Mean 
(SD) 
SPQ IP 
Mean (SD) 
  SPQ CP 
Mean (SD) 
SPQ CP 
Mean (SD) 
  SPQ DT 
Mean (SD) 
SPQ DT 
Mean (SD) 
  
DAOA rs142129 T/T (9; 21) 8 (4.21) 4.47 (5.0) 0.361 0.698 8.0 (2.0) 1.61 (2.18) 1.44 0.24 2.88 (2.36) 1.76 (1.94) 0.05 0.95 2.11 (1.45) 1.095 (1.60) 0.02 0.98 
  T/A (31; 20) 6.9 (3.6) 6.95 (4.81)  2.61 
(1.83) 
3.20 (2.19)  2.64 (1.64) 2.25 (1.55)  1.83 (1.44) 1.50(1.79)  
  A/A (8; 8) 6.4 (3.7) 5.75 (3.0) 1.4 (1.50) 2.75 (1.28) 3.0 (2.29) 1.62 (2.06) 2.0 (1.66) 1.37 (1.99) 
COMT rs737865 T/T (29; 28) 6.41 (4.07) 6.03 (5.15) 0.705 0.497 2.0 (1.85) 2.39 (2.26) 1.99 0.14 2.75 (2.01) 2.25 (1.99) 0.40 0.672 1.72 (1.6) 1.39 (1.93) 1.07 0.35 
  T/C (12; 15) 6.91 (3.26) 5.27 (4.21)  3.08 
(1.78) 
2.40 (1.91)  2.75 (1.66) 1.53 (1.55)  1.41 (1.08) 1.33 (1.49)  
  C/C (7; 6) 8.71 (3.15) 3.87 (4.63) 3.00 
(1.53) 
3.66 (2.25) 2.57 (1.98) 1.83 (1.32) 3.14 (0.89) 1.16 (1.33) 
COMT rs4680 G/G  (19; 20) 6.21 (3.95) 7.05 (5.32) 1.203 0.305 2.16 
(1.38) 
3.05 (2.58) 1.37 0.26 2.47 (1.86) 2.55 (2.09) 0.42 0.614 1.74 (1.63) 1.45 (1.95) 0.79 0.456 
  G/A (14; 22) 5.57 (8.13) 4.86 (4.54)  2.07 (1.9) 1.90 (1.97)  2.64 (1.94) 1.64 (1.62)  1.07 (0.92) 1.32 (1.67)   
  A/A (9; 6) 8.66 (3.94) 4.83 (1.94) 3.22 
(2.68) 
2.66 (1.21) 3.00 (1.94) 1.17 (0.75) 2.44 (1.51) 1.0 (1.2) 
COMT rs165599 G/G (7; 8) 7.85 (3.71) 8.25 (5.65) 1.339 0.268 2.57 
(1.62) 
3.37 (2.32) 0.579 0.56 3.0 (2.3) 2.37 (2.13) 2.00 0.141 2.43 (1.40) 2.5 (1.77) 2.50 0.09 
  G/A (20; 23) 6.95 (3.99) 5.34 (4.69)  2.40 
(1.57) 
2.22 (2.2)  3.0 (2.13) 2.13 (1.94)  1.75 (1.58) 1.0 (1.68)  
  A/A (14; 17) 6.35 (3.85) 5.47 (4.19) 2.29 (2.4) 2.59 (2.09) 2.0 (1.36) 1.53 (1.46) 2.07 (1.59) 1.35 (1.62) 
CNR1 rs1049353  G/G (48; 45) 6.91 (3.78) 5.84 (4.73) 0.356 0.552 2.39 
(1.84) 
2.51 (2.21) 0.037 0.85 2.7 (1.93) 1.95 (1.72) 0.06 0.804 1.92 (1.47) 1.38 (1.76) 1.59 0.211 
  G/A (2; 4) 6.50 (4.94) 4.00 (3.5)  3.5 (2.12) 1.75 (1.5)  2.5 (0.70) 1.75 (2.87)  1.0 (1.41) 0.50 (1.0)  
  A/A (0; 0) - - - - - - - - 
FAAH rs324420 C/C (27; 30) 6.37 (3.95) 6.56 (4.46) 0.019 0.981 2.11 
(1.78) 
2.76 (2.14) 0.569 0.57 2.7 (2.2) 2.16 (1.58) 0.98 0.378 1.63 (1.44) 1.63 (1.73) 0.062 0.940 
  C/A (15; 14) 7.73 (3.55) 5.28 (5.49)  2.86 
(1.73) 
2.14 (2.44)  2.93 (1.53) 1.93 (2.4)  2.20 (1.52) 1.21 (1.80)  
  A/A (4; 5) 9.0 (2.16) 3.4 (1.81) 4.0 (1.41) 2.40 (1.52) 2.0 (2.0) 1.0 (0.70) 3.0 (1.41) 0 
NRG1 rs221533 T/T (37; 38) 6.18 (3.95) 5.47 (4.67) 1.899 0.156 2.24 
(1.86) 
2.47 (2.22) 0.329 0.72 2.33 (1.99) 1.89 (1.82) 2.43 0.09 1.67 (1.35) 1.11 (1.66) 2.319 0.104 
  T/C (11; 8) 8.81 (2.35) 7.0 (3.42)  2.81 
(1.78) 
2.75 (1.91)  3.82 (1.17) 2.37 (1.40)  2.45 (1.80) 1.87 (1.64)  
  C/C 
 (1; 2) 
8.0 (-) 5.0 (5.65) 3.0 (-) 2.0 (2.83) 2.0 (-) 1.0 (1.41) 3.0 (- 2.00 (1.41) 
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4.9.3 LI data: study one (whole sample) 
ANOVAs were performed for the entire group to assess for possible differences between 
SNP types and cognition: with associative learning assessed by LI test (see Table 32).  For 
the LI data, There was a non-significant difference between carriers of SNP rs737865 on the 
COMT gene and LI outcomes (F (1, 33) = 2.526, p = 0.09).   
Table 32:  
3
LI  performance data explored across SNP genotypes in all participants 
Gene SNP genotype 
 (n= ) 
                                                       
Cognitive data 
mean (SD) 
 
LI  Mean (SD) F P 
DAOA rs142129 T/T (11) 16.27 (7.68) 2.414 0.103 
 T/A (22) 9.40 (8.67)  
A/A (7) 11.42 (8.92) 
COMT 
 
 
 
rs737865 T/T (23) 13.69 (8.82) 2.526 0.09 
 T/C (11) 12.0 (8.57)  
C/C (3) 2.0 (-) 
COMT 
 
 
rs4680 G/G  (13) 8.38 (8.8) 1.846 0.174 
 G/A (19) 13.57 (8.31)  
A/A (4) 7.25 (9.18)  
COMT rs165599 G/G (2) 10 (1.41) 0.182 0.834 
 G/A (18) 11.5 (9.67)  
 A/A (16) 13.06 (8.70) 
CNR1 
  
 
rs1049353  G/G (39) 11.89 (8.73) 1.125 0.270 
 G/A (1) 2 (-)  
A/A  
FAAH rs324420 C/C (22) 12.64 (8.81) 0.028 0.868 
 C/A (13) 13.15 (8.93)  
 A/A (0) 0 
NRG1 rs221533 T/T (29) 11.96 (9.22) 0.160 0.853 
 T/C (6) 9.66 (8.75)  
 C/C (2) 11.0 (-) 
 
 
 
 
 
                                                          
3 Due to relatively small numbers, in the context of genotyping work, the LI data was grouped together for the PE and the NPE conditions 
and put together as one score for LI associative learning, rather than as a LI score which looks specifically at the conditioning phase. 
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4.9.4 LI data: study (cannabis users and non-cannabis users) 
The cannabis and non-cannabis user groups SNP profiles were assessed on cognitive 
outcomes including LI.  The cognitive performance data are presented by SNPs and group in 
Table 33 below. ANOVAs conducted on the dataset revealed a significant main effect for 
COMT gene SNP rs737865 and LI outcomes (F (2, 31) = 3.89, p = 0.03), cannabis users with 
T/T and T/C genotypes took significantly less time to find the paired association compared to 
carriers of these alleles in the non-cannabis group.  There were no other clearly significant 
effects in the cognitive data. 
 
4.9.5 IGT, CPT and AST: study 2 (whole group) 
Selective/sustained attention/executive control assessed by the CPT (see Table 34), executive 
control assessed by the AST (see Table 35), and decision-making assessed by the IGT (see 
Table 36).  After controlling for multiple testing, SNP rs1049353 on the CNR1 gene was 
significantly associated with higher commission error scores in the G/A genotype participants 
compared to those with the G/G version (F (1, 57) = 8.96, p = 0.004).  There was a weak and 
non-significant trend for those with SNP rs1049353 G/G to be significantly faster on the CPT 
than the G/A genotype (p = 0.08).  There was also a possible trend for COMT rs165599 G/A 
to be associated with higher motor errors than G/G and A/A genotypes (p = 0.085).  Variation 
in the DAOA, NRG1 genes was not linked to CPT performance. 
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Table 33:  LI performance data explored across SNP genotypes in cannabis users 
and non-cannabis users 
 
 Cannabis 
user 
Non 
cannabis 
user 
 
Gene SNP LI Score 
Mean (SD)  
LI Score 
Mean (SD)  
F P Geno-type 
(n =  ) 
DAOA rs142129 15 (8.48) 16.5 (8.05) 0.31 0.59 T/T (2; 9) 
  5.87(7.18) 18.8 (4.02)  T/A (16; 6) 
  15.0 (8.48) 10 (9.62) A/A (2; 5) 
COMT rs737865 9.84 (8.9) 18.7 (5.9) 3.89 0.03 T/T  (13; 10) 
  4 (4.38) 15.0 (7.87)  T/C (3; 8) 
  2 (-) 2 (-) C/C  (1; 1) 
COMT rs4680 3.0 (2.5) 17  (8.39) 1.25 0.30 G/G  (8; 5) 
  10.85 (8.93) 15.16 (7.8)  G/A (7; 12) 
  2.5 (0.70) 12 (12.72) A/A (2; 2) 
COMT rs165599 9.0 (-) 11.0 (-) 0.039 0.96 G/G  (1;1) 
  8.3 (9.5) 14.6 (9.26)  G/A (9; 9) 
  6.6 (7.5) 16.9 (7.17) A/A (6; 10) 
CNR1 rs1049353  8.0 (7.9) 15.6 (7.92) - - G/G (19; 20) 
  2.0 (-) -  G/A (1; 0) 
    A/A (0; 0) 
FAAH rs324420 5.77 (6.46) 17.38 (6.95) 0.351 0.59 C/C  (9; 13) 
  12.57 (9.64) 13.83 (8.86)  C/A  (7; 6) 
    A/A  (0; 0) 
NRG1 rs221533 8.66 (8.80) 15.5 (8.57) 0.39 0.56 T/T (15;14) 
  4.23 (3.20) 20.5 (0.70)  T/C  (4; 2) 
  - 11.0 (9.89) C/C  (0; 2) 
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Table 34: The Continuous Performance Test (CPT) for Accuracy (Acc), Response Time (RT), Motor Errors (ME) and 
Commission Errors (CE) data explored across SNP genotypes in all participants  
 
 
 
Gene 
 
 
SNP 
 
Geno- 
type 
 (n= ) 
Cognitive data 
CPT 
Acc 
Mean 
(SD) 
F p CPT 
RT 
Mean 
(SD) 
F p CPT 
ME 
Mean 
(SD) 
F p CPT 
CE 
Mean 
(SD)  
F P 
DAOA 
 
 
rs142129 T/T 
 (18) 
19.63 
(5.72) 
0.82 0.44 563.36 
(90.0) 
0.10 0.90 1.16 
(1.15) 
1.25
4 
0.29
4 
10.94 
(9.28) 
0.97 0.39 
 T/A 
(28) 
18.96 
(5.63) 
 542.41 
(194.04) 
 1.53 
(1.6) 
 8.37 
(9.83) 
 
A/A 
(10) 
21.4 
(2.36) 
563.87 
(239.49) 
2.2 
(2.25) 
6.2  
(5.63) 
COMT 
 
 
 
 
 
rs737865 T/T 
(34) 
20.29 
(4.87) 
0.98 0.38 574.38 
(153.38) 
0.31 0.74 1.84 
(2.18) 
0.40
8 
0.66
7 
9.29 
(8.30) 
0.18 0.83 
 T/C 
(16) 
18.18 
(5.92) 
 539.20 
(193.31) 
 1.46 
(1.47) 
 8.37 
(10.86) 
 
C/C 
(10) 
19.1 
(4.3) 
533.05 
(227.00) 
1.3 
(1.15) 
7.4  
(8.85) 
COMT 
 
 
 
 
rs4680 G/G 
(26)   
20.34 
(4.98) 
1.02 0.37 552.19 
(197.05) 
0.12 0.89 1.48 
(1.47) 
0.42
3 
0.65
7 
9.96 
(9.45) 
0.29 0.75 
 G/A 
(17) 
19.03 
(5.66) 
 554.14 
(206.98) 
 1.87 
(1.87) 
 8.11 
(11.06) 
 
A/A 
(11) 
18.00 
(5.17) 
583.59 
(119.60) 
2.09 
(2.2) 
7.81 
(6.67) 
COMT rs165599 G/G 
(13) 
19.69 
(4.03) 
1.38 0.26 544.78 
(212.99) 
0.23 0.80 1.00 
(0.91) 
2.59 0.08 9.46 
(10.24) 
0.24 0.79 
 G/A 
(25) 
19.28 
(3.49) 
 575.97 
(178.81) 
 2.4 
(2.25) 
 9.08 
(9.94) 
 
 A/A 
(13) 
17.0 
(6.63) 
538.40 
(181.10) 
1.5 
(1.82) 
7.40 
(4.05) 
CNR1 rs104935
3  
G/G 
(54) 
19.43 
(5.33) 
0.43 0.52 570.34 
(161.71) 
0.32 0.08 1.69 
(1.98) 
0.10
4 
0.75 7.68 
 (7.7) 
8.96 0.004 
 G/A 
 (5) 
21 
(1.58) 
 424.49 
(291.3) 
 1.4 
(1.14) 
 19.6 
(15.56) 
 
A/A  
(0) 
    
FAAH rs324420 C/C 
(35) 
19.29 
(6.09) 
0.15 0.86 523.45 
(178.41) 
1.59 0.21 1.36 
(1.94) 
0.95
8 
0.39
0 
8.6 
(10.02) 
0.83 0.44 
 C/A 
(16) 
20.12 
(3.36) 
 606.43 
(184.97) 
 1.94 
(1.77) 
 7.19 
(5.23) 
 
 A/A  
(9) 
19.44 
(3.36) 
603.59 
(130.66) 
2.22 
(1.98) 
12.0 
(10.17) 
NRG1 rs221533 T/T 
 (46) 
20.09 
(4.61) 
1.67 0.20 554.22 
(170.60) 
0.23 0.80 1.69 
(1.94) 
0.37
6 
0.68
8 
9.22 
(9.93) 
0.50 0.61 
 T/C 
 (13) 
18.08 
(6.37) 
 578.84 
(204.53) 
 1.66 
(1.87) 
 6.69 
(4.73) 
 
 C/C  
(1) 
13 – 
 
467.69 - - 13.0 - 
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There was no evidence of any significant influence of the SNP genotypes for DAOA, COMT, 
CNR1, FAAH and NRG1 in relation to anti-saccade task (AST) outcomes (See Table 35; all 
comparisons p>0.05).   
 
Table 35: Anti Saccade Task (AST) outcomes explored across SNP genotypes in all participants 
Gene SNP geno- type 
 (n= ) 
AST error 
Mean (SD) 
F p AST latency 
Mean (SD) 
F p 
DAOA rs142129 T/T (15) 24.29 (24.23) 1.01 0.37 335.34 (62.68) 0.94 0.40 
 T/A (25) 32.27 (31.10)  299.28 (81.51)  
A/A (8) 17.68 (11.76) 307.65 (84.93) 
COMT rs737865 T/T (27) 20.64 (19.45) 1.87 0.16 318.09 (67.80) 0.29 0.75 
 T/C (13) 36.92 (31.40)  305.34 (106.38)  
C/C (8) 31.85 (35.98) 296.78 (37.49) 
COMT rs4680 G/G  (19) 30.33 (26.39) 0.40 0.68 316.75 (75.75) 1.32 0.28 
 G/A (15) 22.66 (23.22)  322.63 (74.50)  
A/A (9) 25.88 (28.76) 274.88 (62.27) 
COMT rs165599 G/G (9) 33.37 (25.79) 1.40 0.26 301.97 (72.6) 0.02 0.98 
 G/A (22) 33.65 (30.35)  303.34 (82.12)  
 A/A (10) 16.95 (19.20) 298.30 (55.16) 
CNR1 rs104935
3  
G/G (43) 27.44 (25.59) 0.00 0.99 314.96 (74.83) 1.21 0.28 
 G/A (4) 27.25 (41.63)  271.13 (93.71)  
A/A (0)   
FAAH rs324420 C/C  (31) 25.75 (25.47) 0.25 0.78 312 (70) 0.03 0.97 
 C/A (11) 31.90 (28.86)  312 (89)  
 A/A (6) 23.83 (32.02) 303.37 (90) 
NRG1 rs221533 T/T (34) 
 
26.78 (28.0) 0.277 0.601 301.70 (65.73) 1.04 0.36 
 T/C (13) 22.42 (16.29)  336.88 (97.51)  
 C/C (1) 90(-)  
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There was no evidence of any significant influence of the SNP genotypes for DAOA, COMT, 
CNR1, FAAH and NRG1 in relation to IGT performance (see Table 36; all comparisons p > 
0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 36: Iowa Gambling Task (IGT) outcomes explored across SNP 
genotypes in all participants 
Gene SNP geno- type 
(n= ) 
IGT Mean (SD) F p 
DAOA rs142129 T/T (19) 1293.42 (1002.35) 0.764 0.471 
 T/A (29) 1522.41 (949.82)   
A/A (10) 1110.00 (1009.75) 
COMT rs737865 T/T (34) 1286.02 (1032.59) 0.656 0.523 
 T/C (16) 1400.00 (1000.74)   
C/C (10) 1682.50 (559.02) 
COMT rs4680 G/G  (26) 1473.07 (1119.48) 0.188 0.829 
 G/A (17) 1389 (797.06)   
A/A (11) 1256.81 (902.02) 
COMT rs165599 G/G (13) 1140.38 (1089.65) 0.808 0.452 
 G/A (25) 1543 (873.2)   
 A/A (15) 1270 (1084.39) 
CNR1 
 
rs1049353  G/G (54) 1347.69 (990.00) 0.935 0.338 
 G/A (5) 1785 (570.25)   
A/A (0) - 
FAAH rs324420 C/C (35) 1267.85 (1042.5) 1.11 0.337 
 C/A (16) 1398.44 (908.86)   
 A/A (9) 1800.00 (199.52) 
NRG1 rs221533 T/T (34) 1408.70 (943.7) 0.012 0.912 
 T/C (13) 1375 (1037.2)   
 C/C (0) - 
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4.9.6 IGT, CPT and AST: study 2 (cannabis users and non-cannabis users) 
Selective/sustained attention/executive control assessed by the CPT (see Table 39), executive 
control assessed by the AST (see Table 38), and decision-making assessed by the IGT (see 
Table 36) were explored across SNP genotypes in the cannabis users and non-cannabis users.  
No significant differences were for outcomes on the IGT in relation to variation in each of the 
genes –see Table 37.  Table 38 below indicates no main effect was found between cannabis 
users but a trend for an interaction was found between cannabis users and SNP 4680            
(F (2, 37) =2.865, p = 0.07).  Cannabis users with the SNPrs4680 A/A had higher AST errors 
than non-cannabis group with the A/A genotypes, whereas cannabis users with G/A 
genotypes had higher AST error relative to G/A carriers in non-cannabis users.  There was a 
significant finding between variation in the CNR1 gene and AST error.  A trend was found 
between AST latency and CNR1 rs1049353 for the SNP (F (1, 43) = 3.017, p = 0.09), with 
the A/A carriers responding more quickly on the task. 
 
There were two significant findings for the CNR1 genotypes on CPT outcomes.  Firstly, 
those with the CNR1 rs1049353 G/G genotypes were faster to respond on the CPT                  
(F (1, 58) = 5.4, p = 0.045) compared to the G/A genotypes.  Secondly, those with the G/A 
genotypes had higher commission errors on the CPT (F (1, 58) = 25.63, p < 0.001).  
Although these effects may both skewed by the inclusion of the single cannabis user with the 
G/A allele.  A trend existed for significance of SNP rs165599 in the COMT gene for CPT 
ME (F (2, 46) = 2.511, p= 0.09) with G/G carriers having more motor errors on the task than 
G/A and A/A.   
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Table 37: Iowa Gambling Task (IGT) outcomes explored across SNP genotypes in 
cannabis users and non-cannabis users 
 
  (n = CU; 
NCU) 
Non-
cannabis 
users  
Cannabis 
users 
  
Gene SNP genotype IGT Score 
Mean (SD) 
IGT Score 
Mean (SD) 
F p 
DAOA rs142129 T/T (7; 12) 1071.43 
(874.93) 
1422 
(1084.84) 
0.300 0.610 
  T/A (15; 14) 1495 
(877.25) 
1531.79 
(1034.77) 
 
  A/A (7; 3) 850 
(1099.9) 
1716.66 
(412.56) 
COMT rs737865 G/G (16; 18) 937.5 
(873.26) 
1595.8 
(1086.7) 
0.756 0.474 
  G/A (9; 7) 1408.3 
(1042.6) 
1389.29 
(1026.7) 
 
  A/A (5; 5) 2015 
(320.4) 
1350 (569.26) 
COMT rs4680 G/G  (11; 15) 1436.36 
(1072.46) 
1500 
(1189.33) 
0.157 0.885 
  G/A (7; 10) 1210.71 
(667) 
1515 (889)  
  A/A (7; 4) 1232.14 
(1144.98) 
1300 (293.68) 
COMT rs165599 G/G (6; 7) 1883.33 
(464) 
503.57 
(1081.7) 
0.568 0.571 
  G/A (11; 14) 1111.36 
(791.78) 
1882.14 
(802.4) 
 
  A/A (8; 7) 837.50 
(1284.94) 
1764.28 (532) 
CNR1 rs1049353  G/G (29; 25) 1240.3 
(944.5) 
1472.7 
(1047.7) 
0.570 0.453 
  G/A (1; 4) 1775 (-) 1787 (658.4)  
  A/A (-) - - 
FAAH rs324420 C/C (18; 17) 1158.3 
(982.49) 
1383 
(1120.79) 
1.33 0.273 
  C/A (8; 8) 984.37 
(752.36) 
1812.50 
(901.19) 
 
  A/A (4; 5) 2256.25 
(201.45) 
1435 (558.06) 
NRG1 rs221533 T/T (22; 24) 1380.68 
(889.32) 
1434.38 
(1009.35) 
0.442 0.645 
  T/C (7; 6) 1014.28 
(1075.2) 
1795.83 
(894.48) 
 
  C/C (1; -)    
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Table 38:  AST outcomes explored across SNP genotypes in cannabis users and non-cannabis users. 
   Cannab
is user 
Non-
cannabis 
user 
F or p  Cannab
is user 
Non-
cannabis 
user 
F or p 
Gene SNP geno-
type 
(n = 
cu; 
ncu)  
AST 
error 
Mean 
(SD)  
AST 
error 
Mean 
(SD)  
  geno-
type 
(n = cu; 
ncu)  
AST 
latency  
Mean 
(SD) 
AST 
latency 
Mean 
(SD) 
  
DAOA rs142129 T/T  
(6; 7) 
33.63 
(25.6) 
16.28 
(21.6) 
0.885 0.42 T/T  
(6;7) 
344.61 
(55.3) 
327.36 
(71.71) 
0.854 0.433 
  T/A 
(14; 
11) 
35.31 
(31) 
28.4  
(32) 
 T/A  
(14; 11) 
285.86 
(97) 
316.36 
(55.77) 
 
  A/A 
 (3; 3) 
18.7 
(7.57) 
16 
 (19.05) 
A/A  
(5; 3) 
313.65 
(107) 
297.66 
(45.65) 
COMT rs737865 T/T 
(14; 
13) 
22.45 
(16.7) 
18.96 
(22.56) 
0.854 0.43 T/T 
(14;13) 
309.28 
(68.56) 
327.57 
(68.3) 
0.174 0.841 
  T/C  
 (9; 4) 
44.94 
(31.73) 
14.37 
(16.69)  
 T/C   
(9; 4) 
298.74 
(127.56) 
319.75 
(38.43) 
 
  C/C   
(3; 3) 
25.93 
(31.90) 
35.4 
(41.39) 
C/C  
 (3; 5) 
314.25 
(58.53) 
286.30 
(19.51) 
COMT rs4680 G/G  
(10; 9) 
25.51 
(18.03) 
36.11 
(33.68) 
0.475 0.63 G/G  
(10; 9) 
311.52 
(89.21) 
322.55 
(62.34) 
1.259 0.296 
  G/A 
 (7; 8) 
30.21 
(27.28) 
16.06 
(18.28) 
 G/A 
 (7; 8) 
319.36 
(98.6) 
325.50 
(52.42) 
 
  A/A  
(5; 4) 
41.8 
(30.39) 
6.0 
 (4.90) 
A/A 
 (5; 4) 
281.20 
(93.1) 
267 
(18.67) 
COMT rs165599 G/G 
 (5; 4) 
21.06 
(16.45) 
48.75 
(29.00) 
1.696 0.20 G/G  
(5; 4) 
270.35 
(61) 
341.50 
(73.30) 
0.026 0.974 
  G/A  
(11; 
11) 
44.40 
(31.27) 
22.90 
(26.98) 
 G/A 
(11;11) 
291.90 
(102.97) 
314.77 
(57.20) 
 
  A/A 
 (5; 5) 
28.26 
(21.63) 
5.7  
(6.57) 
A/A 
 (5; 5) 
307.30 
(70.2) 
289.30 
(41.26) 
CNR1 rs1049353  G/G 
(25; 
18) 
29.02 
(23.8) 
25.25 
(28.3) 
1.876 0.18 G/G 
(25;18) 
311.79 
(86.45) 
319 
(56.98) 
3.017 0.09 
  G/A 
(1; 3) 
89.0 
 (-) 
6.66 
(7.63) 
 G/A 
 (1; 3) 
168 
 (-) 
305.33 
(78.4) 
 
  A/A  
(0; 0) 
- - A/A  
(0; 0) 
- - 
FAAH rs324420 C/C 
(17; 
14) 
25.33 
(21.97) 
26.25 
(30.04) 
1.711 0.19 C/C 
(17;14) 
319.91 
(79.8) 
302.39 
(57.8) 
0.510 0.604 
  C/A   
(7; 4) 
41.28 
(29.0) 
15.5 
(23.04) 
 C/A 
  (7; 4) 
302.43 
(107.5) 
330.75 
(51.37) 
 
  A/A 
 (2; 4) 
47.5 
(50.20) 
12.0 
(17.57) 
A/A 
 (2; 4) 
203.57 
(60.6) 
353.12 
(51.16) 
NRG1 rs221533 T/T 
(18; 
16) 
29.63 
(27.6) 
23.56 
(28.91) 
2.810 0.07 T/T 
(18;16) 
293.95 
(73.2) 
310.40 
(57.14) 
0.958 0.392 
  T/C   
(7; 6) 
27.28 
(9.1) 
16.75 
(21.56) 
 T/C  
 (7; 6) 
339.57 
(127.27) 
333.75 
(57.96) 
 
  C/C  
 (1; 0) 
90  
(-) 
- C/C  
 (1; 0) 
295 
 (-) 
- 
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Table 39: CPT outcomes explored across SNP genotypes in cannabis users and non-cannabis users. 
 
  (n= ) CU NCU F or p (n = ) CU NCU F p (n = ) CU NCU F or p (n =  ) CU NCU F or p 
Gene SNP 
geno-
type 
(CU; 
NCU      
CPT 
accurac
y 
Mean 
(SD)  
CPT 
accurac
y 
Mean 
(SD)  
  
genotyp
e 
(CU; 
NCU  
 
CPT 
RT 
Mean 
(SD) 
CPT RT 
Mean 
(SD) 
  
genotype 
(CU: NCU  
 
CPT 
ME 
Mean 
(SD) 
CPT 
ME 
Mean 
(SD) 
  
genotype 
(CU: NCU  
 
CPT CE 
Mean 
(SD) 
CPT 
CE 
Mean 
(SD) 
  
DAOA rs142129 
T/T (7; 
12) 
18.45 
(8.46) 
20.3 
(3.62) 
0.656 0.523 
T/T (6; 
12) 
558.74 
(119.98) 
565.67 
(77.26) 
0.268 0.766 T/T (6; 12) 
1.5 
(1.22) 
1.0 
(1.12) 
1.179 0316 T/T (7; 12) 
13.86 
(13.73) 
9.25 
(5.46) 
0.930 0.401 
  
T/A (15; 
4) 
19.86 
(3.68) 
18.0 
(6.89) 
 
T/A (15; 
14) 
575.67 
(142.69) 
506.77 
(237.76) 
 
T/A (15; 
14) 
1.13 
(1.35) 
2.0 
(1.90) 
 
T/A (15; 
14) 
8.26 (11.3) 
8.5 
(8.43) 
 
  
A/A (7; 
3) 
21.57 
(2.69) 
21.0 
(1.73) 
A/A (7; 
3) 
646.78 
(153.48) 
370.41 
(327.44) 
A/A (7; 3) 2.0 (2.4) 
2.66 
(2.08) 
A/A (7; 3) 5.0 (5.6) 
9.0 
(5.57) 
COMT rs737865 
T/T (16; 
18) 
19.75 
(6.21) 
20.7 
(3.59) 
1.145 0.326 
T/T (15; 
18) 
623.05 
(137) 
533.8 
(157.5) 
0.40 0.672 
T/T (15; 
18) 
2.0 
(2.61) 
1.72 
(1.8) 
0.368 0.694 
T/T (16; 
18) 
6.87 (8.94) 
11.4 
(7.26 
0.190 0.828 
  
T/C (9; 
7) 
19.8 
(3.29) 
16 
(7.95) 
 
T/C (9; 
7) 
545.49 
(146.4) 
531.1 
(254.3) 
 
T/C (9; 7) 
1.22 
(1.56) 
1.83 
(1.94) 
 
T/C (9; 7) 
11.11 
(13.8) 
4.85 
(3.80) 
 
  
C/C/  (5; 
5) 
20.0 
(3.1) 
18.2 
(5.4) 
C/C (5; 
5) 
620.19 
(170.8) 
449.9 
(262) 
C/C (5; 5) 
1.60 
(1.51) 
1.0 
(0.70) 
C/C (5; 5) 9.20 (12.5) 
5.6 
(3.57) 
COMT rs4680 
G/G  
(11; 15) 
22.18 
(5.23) 
19.33 
(4.59) 
0.801 0.455 
G/G  
(10; 15) 
615.24 
(138.5) 
510.16 
(222.5) 
0.015 0.985 
G/G  (10; 
15) 
1.1 
(0.99) 
1.73(1.7
0) 
0.456 0.637 
G/G  (11; 
15) 
10.27 
(12.4) 
9.73 
(7.02) 
0.181 0.833 
  
G/A (7; 
10) 
20.43 
(2.99) 
18.10 
(6.99) 
 
G/A (7; 
10) 
600.5 
(209.6) 
521.7 
(209.8) 
 
G/A (7; 
10) 
2.28(3.1
4) 
1.53(1.9
4) 
 
G/A (7; 
10) 
9.57 (16.7) 
7.1 
(5.30) 
 
  
A/A (7; 
4) 
16.43 
(5.38) 
20.75 
(3.94) 
A/A (7; 
4) 
610.5 
(134.8) 
536.4 
(81.5) 
A/A (7; 4) 
2.28 
(2.16) 
1.75 
(1.25) 
A/A (7; 4) 6.14 (3.43) 
10.75 
(10.34) 
COMT rs165599 
G/G (6; 
7) 
19.83 
(4.02) 
19.57 
(4.35) 
1.272 0.290 
G/G (6; 
7) 
621.7 
(184.9) 
478.8 
(226.3) 
0.287 0.752 G/G (6; 7) 
1.16 
(1.16) 
0.857 
(0.69) 
2.511 0.092 G/G (6; 7) 8.33 (11.6) 
10.4 
(9.72) 
0.215 0.807 
  
G/A 
(11; 14) 
19.18 
(2.78) 
19.36 
(4.07) 
 
G/A 
(11; 14) 
612.16 
(172.5) 
547.5 
(184.8) 
 
G/A (11; 
14) 
2.09 
(2.77) 
2.64 
(1.82) 
 
G/A (11; 
14) 
8.0 (13.4) 
9.9 
(6.49) 
 
  
A/A (8; 
7) 
16.75 
(5.17) 
17.43 
(8.42) 
A/A (8; 
7) 
582.7 
(118.85) 
487.7 
(233.3) 
A/A (8; 7) 
2.12 
(2.16) 
0.66 
(0.81) 
A/A (8; 7) 8.25 (4.16) 
6.42 
(3.99) 
CNR1 
rs104935
3  
G/G 
(29; 25) 
19.79 
(5.01) 
19 
(5.38) 
0.284 0.596 
G/G 
(28; 25) 
610.4 
(132.6) 
525.4 
(181.35) 
4.3 0.045 
G/G (28; 
23) 
1.678 
(2.17) 
1.70 
(1.78) 
0.004 0.952 
G/G (29; 
25) 
7.2 (8.3) 
8.24 
(7.11) 
25.63 <0.001 
  
G/A (1; 
4) 
21 (-) 
21 
(1.82) 
 
G/A (1; 
4) 
264.1 (-) 
464.5 
(320) 
 
G/A (1; 4) 2.0 (-) 
1.25 
(1.25) 
 
G/A (1; 4) 47 (-) 
12.75 
(3.2) 
 
  
A/A (0; 
0) 
 
A/A 
(0;0 ) 
- - A/A (0; 0) - - A/A (0; 0) - - 
FAAH rs324420 
C/C (18; 
17) 
19.72 
(5.87) 
18.82 
(6.45) 
0.143 0.867 
C/C (17; 
17) 
558.31 
(147.6) 
488.58 
(203) 
1.66 0.199 
C/C (17; 
17) 
1.35 
(2.17) 
1.37 
(1.75) 
0.940 0.397 
C/C (18; 
17) 
9.55 
(12.43) 
7.58 
(6.85) 
0.745 0.479 
  
C/A (8; 
8) 
20.0 
(3.42) 
20.25 
(3.53) 
 
C/A (8; 
8) 
658.56 
(116.6) 
554.3 
(231.3) 
 
C/A (8; 8) 2.0 (2.2) 
1.875 
(1.35) 
 
C/A (8; 8) 5.25 (4.10) 
9.12 
(5.71) 
 
  
A/A (4; 
5) 
20.0 
(3.56) 
19.0 
(3.53) 
A/A (4; 
5) 
649.09 
(163.6) 
567.18 
(101.6) 
A/A (4; 5) 
2.5 
(2.08) 
2.0 
(2.12) 
A/A (4; 5) 
10.50 
(14.0) 
13.20 
(7.39) 
NRG1 rs221533 
T/T (22; 
24) 
19.95 
(5.24) 
20.20 
(4.05) 
2.152 0.126 
T/T (21; 
24) 
597.39 
(148.2) 
516.4 
(182.7) 
0.34 0.70 
T/T (21; 
24) 
2.0 
(2.39) 
1.42 
(1.44) 
0.657 0.421 
T/T (22; 
24) 
9.45 
(12.43) 
9.0 
(7.17) 
0.494 0.62 
  
T/C (7; 
6) 
20.42 
(3.64) 
15.3 
(8.04) 
 
T/C (7; 
6) 
620.45 
(147.7) 
530.28 
(262.6) 
 
T/C (7; 6) 1.0 (1.0) 2.6(2.5) 
 
T/C (7; 6) 5.0 (3.82) 
8.6 
(5.24) 
 
  
C/C (1; 
0) 
13.0 (-) - 
C/C (1; 
0) 
467.69 
(-) 
- C/C (1; 0) 0 (-) - C/C (1; 0) 13.0 (-) - 
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4.9.7 Cannabis use variables and genotypes 
 
A Chi² analysis was run for genotype for cannabis users only assessing cannabis use variables 
(e.g.  Joints per Week (JPW); Age of Onset (AOO) of cannabis use; and Cannabis Duration 
(CD) to see whether those with the known risk alleles would also be an indication of riskier 
drug use – see Appendix xv for Table G7 of the results.   There was a significant difference 
between duration of cannabis use in variation of the NRG1 with the T/C genotypes using the 
drug for a significantly longer time relative to the T/T genotypes (X² (2) = 76.14, p < 0.001). 
 
 
 
4.9.8 Results for the COMT Haplotype 
It was found that 6 (4 cannabis users and 2 non-cannabis users) out of 79 participants were 
carriers of the C-G-G haplotype (also known as G-G-G in the literature) and this was not 
enough to make decent statistical comparisons.  Please refer to Table H8 in appendix xv for 
the frequency of all versions of the COMT haplotype (T-G-A, T-A-A; T-G-G; T-A-G; C-G-
A; C-A-A; C-G-G and C-A-G) in the whole group and between the cannabis users and non-
users.  The T-G-G haplotype which is linked to having a protective effect from schizophrenia 
occurred in 42 out of 79 participants.  Table I9 and J10 (in appendix xv) shows that most of 
the findings reached the level of significance in the whole group for the COMT haplotype in 
relation to cognitive and trait outcomes (all p > 0.05).  Trends existed for those with the non-
protective haplotype to perform slower on the AST.  Trends existed for those in the COMT 
Haplotype and disorganised thinking – please refer to Table J10 in appendix xv.  There was 
no main effect of cannabis (F (1, 78) = 1.249, p = 0.207); no main effect of COMT haplotype 
(F (1, 78) = 0.469, p = 0.495) but an interaction was found for COMT and Cannabis on 
SPQDT outcomes (F (1, 75) = 4.281, p = 0.042).  Cannabis users with the protective 
haplotype had lower SPQDT scores (which may reduce negative symptoms), whereas those 
cannabis users without protective haplotype had higher SPQDT scores, whereas the opposite 
effect was found in the non-cannabis group.   
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4.9.9 Results for the combination of risk markers in relation to trait and cognitive 
outcomes between the cannabis users and non-users. 
The genetics data were analysed to combine the number of risk SNP markers each participant 
had and these were categorised for those having (0-5) of the known risk SNPs (i.e. T/T or 
T/A for DAOA SNP rs142129, G/G or G/A for COMT rs4680, G/G for CNR1 rs1049353, 
A/A for the FAAH SNP rs324420, and C/C for NRG1 SNP rs221533).  Please refer to Table 
K11 (in Appendix xv) for a full table of results of those which did not reach significance or 
were leaning toward significance.   
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4.10 Discussion 
The current study assessed 5 candidate schizophrenia genes (DAOA, COMT, NRG1, CNR1, 
and FAAH) in a group of cannabis users and non-cannabis users.  The aim was to assess for 
potential differences in variation of these genes (i.e. SNPs) and possible interactions with 
cannabis in relation to outcomes on the LI associative learning tests from Study 1 (Latent 
inhibition only and Study 2 (Iowa Gambling Task, a decision making task; Continuous 
Performance Test, a measure of attention and impulsivity; and the Anti-saccade task, a 
measure of attentional control).  All of these tests have known sensitivity to schizophrenia.  
One personality measure was also included from data taken from Study 1 and 2, which 
assessed for traits linked to schizotypal personality disorder (e.g. SPQ-B, Raine and 
Benishay, 1995).  Below is a discussion of some of the main outcomes as well as findings 
from the three SNP at-risk haplotypes from the COMT gene.  The findings discussed below 
were either significant with a p-value less than 0.05 or were non-significant findings but 
possibly indicated a trend towards significance (p-value greater than 0.05 but less than 0.15).  
 
4.10.1 DAOA gene 
One SNP (rs142129) was assessed in the DAOA gene.  Although none of the reported 
findings for this SNP were statistically significant (most likely due to the reasons discussed 
below - see limitations), there were some interesting differences in the frequencies of 
genotypes in relation to the cognitive and trait (SPQ-B) outcomes that are worthy of 
comment.   
 
There was a trend towards significance in that the T/A genotype occurred more frequently in 
the cannabis users.  In previous studies the T/A genotype for SNP rs142129 was positively 
associated with schizophrenia (e.g. Chumakov et al, 2002; Schumacher et al, 2004).  Though 
it was only a weak trend, the difference between cannabis users and non-users for T/A 
genotype may be contributing to differences in performance and trait scores in the cannabis 
users.  In a larger follow up study matched cannabis users with the T/A genotype could be 
compared to those without this genotype to see if there is a noticeable difference –and so 
highlight if there is any form of cannabis use and T/A interaction effect.   
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The T/T genotype was associated with the poorest associative learning on the LI task.  
Interestingly, it is the T/T genotype within the literature which is linked to poorer cognitive 
performance, particularly in those diagnosed with schizophrenia (e.g. Goldberg et al, 2006).   
Furthermore, it was this SNP T/T which has previously been reported as conferring the 
highest risk for susceptibility to methamphetamine psychosis (Kotaka et al, 2009).  Even 
though the results for this SNP on the DAOA gene were not statistically significant, the 
findings were in the predicted direction.   
 
4.10.2 COMT gene 
Three SNPs (rs737865; rs4680; rs165599) were assessed in the COMT gene individually and 
then assessed together as a protective haplotype for carriers of the T-G-G alleles.  The COMT 
gene SNP rs4680 has been widely assessed in the literature with over 250 peer-reviewed 
studies published since 1996; it is the most studied gene in psychiatry (Haraldsson et al, 
2009).  There was a significant finding in the whole sample with the T/T allele of SNP 
rs737865 occurring more frequently than the T/A and C/C genotypes.  Furthermore, there was 
a trend for the cannabis users to have the risk G/G allele SNP rs4680 occur much more 
frequently.  There was no significant variation on the risk SNP rs4680 for individual 
differences in psychosis-like personality traits, which is not in line with previous studies 
(Swart et al, 2011; Ucok et al, 2010; Smyrnis et al, 2007; Sheldrick et al, 2008).  There were 
trends found in SNP rs737865 in that those individuals with the C/C alleles reported higher 
interpersonal problems compared to the T/T genotypes in the whole group and when the 
group was broken down the trend existed for the cannabis group, not for the non-cannabis 
users.  In the whole group it was those individuals with SNP rs165599 A/A genotypes who 
had lower cognitive perceptual and interpersonal sensitivity scores on the SPQ-B.  
Furthermore, those with the G/G alleles reported higher problems with disorganised thinking 
in both the cannabis users and non-cannabis users.  Most of the literature links rs4680 A/A 
with better cognitive performance (Bilberg et al, 2002; Goldberg et al, 2003; Jorber et al, 
2002; Sheldrick et al, 2008) whilst the G allele is associated with the worst cognitive 
performance (Bruder et al, 2003; Bertolino et al, 2006; Goldberg et al, 2003).  None of the 
findings reached a level of significance or trends for significance for the most widely studied 
SNP rs4680 and CPT outcomes.  A study by Symrnis et al (2007) also assessed COMT SNP 
rs4680 carriers and reported no effect of this gene on CPT outcomes.  There has been 
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inconsistent findings with the COMT gene (SNP rs4680) and this also reflects research 
published in this area with negative findings (Chen et al, 1999; Daniels et al, 1996; Rosa et 
al, 2004) and positive findings with G/A (Egan et al, 2001; Kunugi et al, 1997a; 1997b) and 
with G/G (e.g. Wanodi et al, 2003).   
 
Cannabis use and SNP rs4680 has been widely studied but less is known regarding the other 
two SNPs (rs737865 and rs165599) on the COMT gene in relation to schizophrenia.  Trends 
for significance were found for the following results.  Individuals with SNP rs737865 C/C 
genotypes (also known as G/G in the literature) performed better on the LI task regardless of 
whether or not they used cannabis.  It was the G/A genotypes of SNP rs165599 who had 
poorer attentional control as they made more motor errors on the CPT.  In the AST, it was the 
T/T (also known as A/A) genotypes of SNP rs737865 in the whole group who had better 
attentional control as they made the least errors on the task.  Even though these trends for 
results were not statistically significant it does seem that they were in the direction predicted.  
However, these findings were taken from the whole group as opposed to these being specific 
cannabis group effects.   
 
Some of the inconsistencies in the data may be the result of multiple SNPs being involved, as 
opposed to one single marker.  Therefore, one haplotype was investigated in all three SNPs 
(rs737865, rs4680 and rs165599) on the COMT gene.  In the literature the risk haplotype C-
G-G is positively associated with schizophrenia (De Rosse et al, 2006; Schifman et al, 2002; 
Handoko et al, 2004).  The T-A-A haplotype has also been linked to schizophrenia 
(Kotrotsou et al, 2012).  However, the risk haplotypes T-A-A occurred in 6 participants and 
the C-G-G haplotypes occurred in 8 participants, so this was not enough to make for viable 
statistical comparisons. The COMT haplotype data were reviewed without completing any 
statistical analysis to check if there were any common variables amongst the cannabis group 
with this haplotype compared to the other COMT haplotypes.  Interestingly, the cannabis 
users with the risk C-G-G haplotype that had the lowest use of drugs such as MDMA, 
amphetamine, cocaine, alcohol, tobacco, and cannabis, whereas those with the T-A-A risk 
haplotype had the highest use of all of these aforementioned drugs (x4 times greater use).  
The T-A-A haplotypes also had higher schizotypal personality traits.  Another haplotype T-
G-G known to have a protective effect with regards to schizophrenia was identified in 50% of 
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the sample and was therefore compared against the rest of the sample to assess for potential 
differences in trait and cognitive outcomes.  There were trends for those individuals with the 
protective haplotype to take longer to respond on the AST.  Trends also existed for cannabis 
users with the protective haplotype to have lower SPQ-DT scores (which may reduce 
negative symptoms), whereas those cannabis users without protective haplotype had higher 
SPQ-DT scores, which could be taken to suggest that the haplotype actually is protecting the 
user from possible negative effects of cannabis on thinking.  This is the first study to date to 
assess the T-G-G haplotype in cannabis users and the SPQ-B disorganised thinking trait data 
seems to be in line with Kotrotsou et al’s (2012) research that this is haplotype has a 
protective effect. 
 
4.10.3 NRG1 
Only three participants in the entire sample had the risk SNP rs221533 C/C allele, with most 
of the group having the T/T genotype.  This, therefore, contravened the criteria for the HWE 
and also made it difficult to draw comparisons from these data against previous studies (e.g. 
Stefansson et al, 2002; 2004) which link the rs221533 (C/C) allele with schizophrenia. 
Trends existed within the whole group, with the T/C genotypes reporting higher SPQ-B 
scores and the T/T genotype reporting the lowest SPQ-B scores.  There was a trend for SNP 
rs221533 (T/C) carriers to have higher scores on the SPQ-CP and SPQ-DT subscales, 
naturally suggesting problems with cognition, perception and thinking.  The effect was there 
in the overall group data, with no effect of cannabis user/non-user status, or regardless of 
whether or not individuals were cannabis users.  Some behavioural trends also existed for 
SNP rs221533: cannabis users with the T/C allele made 50% more errors on the AST than 
non-cannabis users with the T/C genotype, whereas cannabis users and non-cannabis users 
with the T/T did not differ in AST errors.  Thus, in line with previous research, it seems that 
cannabis users with the C allele was linked to worse cognitive performance and in the whole 
group was associated with having more psychotic traits relative to the T allele.  This is the 
first known study to demonstrate variation on the NRG1 gene for SNP rs221533 in relation to 
cannabis use, cognition and trait outcomes. 
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4.10.4 CNR1 gene and the FAAH gene 
No participant had the SNP rs1049353 A/A allele for the CNR1 gene and the majority of the 
sample had the risk G/G allele (96%), so this contravened the HWE as the result of low 
participant numbers.  Therefore, interpretations of these data are limited.  Trends were found 
in the whole group for those with SNP rs1049353 G/G genotypes reporting the highest SPQ 
scores and this is supported by previous research which links this allele with schizophrenia 
(Leroy et al, 2001).  In Study 2, those with the SNP rs1049353 G/G genotype were faster to 
respond on the CPT.  One would expect that these carriers in the at-risk group G/G would 
perform worse on this measure of cognition.  However the reverse was found in this study, as 
there was a significant difference between SNP rs1049353 G/G and G/A genotypes, with G/G 
carriers making significantly fewer commission errors on the CPT.  A trend was found in the 
cannabis group for those individuals with the G/A genotypes in SNP rs1049353 to be slower 
to respond in the CPT and made significantly more commission errors on the task.  The G/A 
allele has previously been shown to be positively associated with schizophrenia (Costa et al, 
2012).  However, on further investigation only one participant had the G/A genotype in the 
cannabis group, so this person’s poor performance may have skewed these data.  
 
There was no significant variation in the FAAH gene on trait outcomes and no interactions 
with cannabis use.  A significant difference was found between variation in SNP 324420 C/C 
and C/A for Kamin Blocking outcomes, as those with the C/C genotype had better associative 
learning performance scores in both the cannabis users and non-users.  Interestingly within 
the literature it is the A allele which is linked more often to a schizophrenia profile.  This is 
the first study to report findings from variations in the CNR1 and FAAH genes in relation to 
cognitive outcomes for associative learning. 
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4.10.5 Cannabis use variables 
None of the cannabis use variables for the DAOA, FAAH and CNR1 genes showed 
significant variation on cannabis use variable outcomes for joints per week, duration of use 
and age of onset.  There was a trend for variation in the NRG1 gene; those with the SNP 
rs221533 T/C genotype reported the longest duration of cannabis use compared to users with 
the T/T genotype.  Interestingly, recent research linked variation in the NRG1 gene to 
cannabis dependence (Tan et al, 2012). 
 
4.10.6 Combined SNP risk markers 
It was predicted that those with a profile of multiple risk alleles from the candidate 
schizophrenia genes may show greater biases on cognitive tests and schizophrenia-like 
personality symptoms, in the direction of schizophrenia-like deficits and differences.  
However, none of the findings were statistically significant, which may be due to having low 
participant numbers across multiple cognitive assessments. 
 
Overall though, genetic research is a complex area and research is moving towards using 
haplotype data, as opposed to single risk markers (Clarke, 2004).  The key finding above was 
linked to the COMT protective haplotype in cannabis users associated with lower 
disorganised traits compared to cannabis users without this protective haplotype.  This 
research is useful as it looked at the combination of trait, cognitive and genetic data in the 
risk model of schizophrenia, which helps to further understand the link between cannabis use 
and schizophrenia.  In this current research, the significant findings for the genetic data were 
mainly for the whole group, as opposed to these being specific cannabis effects.    
 
4.10.7 Methodological issues 
The COMT gene SNP rs737865, CNR1 gene SNP rs1049353 and NRG1 gene SNP rs221533 
all contravened the HWE. To overcome this issue a future replication would need more 
participants to increase the power of the study.  The aim of the study was not to assess for 
gender or ethnic differences but given the link these factors have on genetic expression of 
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some of these SNPs, this cannot be ruled out of the findings.  Further to this, the cannabis 
users frequently reported lifetime or current use of other drugs, so polydrug use is a factor 
that needs to be accounted for when interpreting these findings.  Due to the already small cell 
sizes in these data (when divided by cannabis use and genotype) further breakdowns or 
covariance using other drugs use, gender and/or ethnicity would weaken the statistical 
validity of tests even further.  However, if replicated in much larger cohorts then these would 
be important additional variables to allow for inter analyses and grouping of data.  These 
limitations alongside others will be explored in more detail in the next chapter (see section 
5.5). 
 163 
 
Chapter 5: Summary and general discussion  
 
There exists a substantial body of empirical research, alongside anecdotal observations, 
indicating that cannabis use is a contributory risk factor for the development of psychotic 
symptoms and schizophrenia in some users (e.g. Smit et al. 2004; Semple et al, 2004; Moore 
et al, 2007; and see Chapter 1, sections 1.4, 1.4.1 and 1.4.2).  Cannabis use related psychosis 
has been argued to be related to effects of THC on normal endocannabinoid functioning 
during crucial stages in early and late neurodevelopment (Spear, 2000, Cannon et al, 2005), 
induced release of dopamine in frontal circuits (Szabo & Schlicker, 2005) and to 
combinations of these effects, alongside an array of psychosocial and genetic vulnerabilities 
(see section 1.4.2 and 1.5).  Implicit in such models are notions of additive or compound 
effects, and the possibility therefore that THC use may act to push individuals towards a 
‘pathological tipping point’.  If correct, it could be argued that outside of clinical populations 
of cannabis users (i.e. the larger population of non-clinical/non-pathologised recreational 
cannabis users) such effects of THC may well push individuals along psychosis-linked 
continua; perhaps never producing pathology but leading to observable changes in selective 
psychological parameters relative to non-users, for example.  
 
Nonetheless it is also clear that the majority of cannabis users do not go on to develop this 
disorder.  It is argued that the use of cannabis in some users is causing some of the sub-
schizophrenia symptoms, and that prolonged use and/or heavy use of stronger versions of 
cannabis is linked to the onset of induced symptoms in some people who may have otherwise 
not developed any of these symptoms.  Much of the published research on the cannabis-
psychosis link has focussed on schizophrenia-like symptoms, as opposed to looking at these 
symptoms combined with cognitive performance and genetic susceptibility.  Furthermore, 
research has focussed mainly on clinical samples (i.e. people diagnosed with schizophrenia).  
These studies are not without their problems as there is heterogeneity in symptoms and 
behaviours in terms of schizophrenia.  Moreover, findings drawn from clinical studies are 
difficult to fully explain in terms of causality as a confounding factor is linked to clinical 
status, which is difficult to control.  Research using a sample of recreational users may 
provide a better way of attempting to elucidate the link between cannabis use and psychosis 
(Verdoux et al., 1998; van Os et al., 2000; 2001; Verdoux and Van Os, 2002).  The first issue 
is whether cannabis use is possibly producing changes in some aspects of the user’s 
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psychology, in the direction of psychosis, which is important in its own right because most 
people who use cannabis see it as a harmless drug, and the majority of users will never be 
diagnosed with schizophrenia.  Then secondly, depending on what is found this may then 
inform our understanding of the link between cannabis use and schizophrenia (in a much 
smaller cohort of users).  Therefore, the general aim of the thesis was to explore a range of 
cognitive functions, psychotic-like personality traits, and candidate genes for schizophrenia, 
in a group of recreational cannabis users (free from existing psychopathological disturbance) 
and a control sample of non-cannabis users.  In line with the model that cannabis use may 
impact on cognitive function, in a direction seen in those diagnosed with schizophrenia and 
high schizotypal individuals, it was predicted that cannabis users would show more 
impairment on these measures when compared against a group of non-cannabis users.   
 
The cognitive tasks chosen had particular significance to the field of psychosis due to 
performance being significantly affected by schizophrenia, high schizotypy, and in relatives 
of those diagnosed with schizophrenia.  Study 1 assessed LI, KB and schizotypy (please refer 
to sections: 2.1.2, 2.1.3 for further details on LI; sections: 2.14, 2.1.5 for KB (due to lack of 
findings will not be discussed under this final discussion), and section 2.2.2 for materials, and 
study 2 added further personality analyses (see section 3.41, 3.4.2 for further details on 
Ambivalence, Mood and Paranoia) and alongside other cognitive tasks (refer to section 3.1.1, 
3.2.1, and 3.3.1 for further details on the IGT, CPT, and AST respectively) known to be 
sensitive to cannabis use and to schizophrenia.  It was predicted that cannabis users would 
show impaired associative learning in Study 1, and in Study 2 show riskier decision making, 
disrupted attention and poorer executive control.  A key difference in this research thesis 
compared to previous research looking at purely cognitive effects of cannabis, is that 
schizotypy has been measured alongside cognitive performance, in order to see if there is an 
interaction here and how this then relates to cannabis use.  It is important to measure 
schizotypy for a number of reasons.  Many studies have not done this before but an obvious 
question is whether any disruptions seen in cognitive performance are due to the use of THC 
or to underlying personality traits which might interfere in performance of cognitive tasks 
that have previously been shown to be disrupted by schizophrenia.  Another important 
consideration is the role of genetic risks which may underlie a possible exacerbation of 
certain traits when cannabis use is added.  Therefore, Chapter 4 assessed the relative 
contribution of 5 candidate genes linked to schizophrenia in relation to outcomes from the 
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battery of cognitive measures (from Chapters 1 and 2) along with one trait measure, 
schizotypy, assessed across both studies (SPQ-B, Raine & Benishay, 1995).  Tables 40 and 
41 below summarise the key findings of the research presented in this thesis: the main 
behavioural and trait outcomes (Table 40) and the genetic data and interactions with 
measures (Table 41). 
Table 40: A summary of the key behavioural and trait measure findings 
Measure  Key Significant findings    Test statistic     p 
Study 1: Primary analysis 
– LI 
LI was abolished in cannabis users F 10.3 0.003 
Study 1: Primary analysis 
– LI & SPQ-B 
In the whole group low SPQ-B scorers were better at associative learning under 
the NPE condition compared to high SPQ-B scorers. 
T  4.567 <0.001 
Study 1: Primary analysis 
– LI & SPQ-B 
In the whole group high SPQ-B scorers showed disrupted LI under the PE 
condition relative to low SPQ-B scorers 
T  3.198 0.005 
Study 1: Secondary 
analysis – LI 
LI was abolished in cannabis users under the PE condition. F  5.83 0.02 
Study 1: Secondary 
analysis – LI 
In the whole group, LI was abolished under the PE condition in high SPQ-B 
scorers. 
F  6.32 0.017 
Study 1: Secondary 
analysis – SPQ-B and LI 
In the whole group, poorer performance on LI task was correlated with higher 
SPQ-B scores.    
R  0.336 
 
 <0.05 
Study 1 – Cannabis 
Dependency and SPQ-B 
Cannabis dependency was higher scores on the SPQ-B subscale of Interpersonal 
Thinking 
R 0.409 <0.05 
Study 1- Cannabis use and 
SPQ-B 
Heavy use of cannabis was associated with higher dependency, R 0.370 <0.05 
Study 1- Cannabis use and 
SPQ-B 
Heavy cannabis use was associated with higher scores on all three SPQ-B 
subscales for interpersonal thinking, cognitive perceptual; disorganised thinking 
R 0.561; 0.28; 
0.416 
(respectively) 
0.01;  < 0.05. 
<0.05 
(respectively) 
Study 1- Cannabis use and 
SPQ-B 
Earlier onset of cannabis was associated with higher scores on the SPQ-B 
subscale for disorganised thinking. 
R 0.468 0.01 
Study 2: IGT Cannabis users demonstrated riskier based decision-making F 3.391 0.05 
Study 2: IGT and heavy 
cannabis use 
Heavier use of cannabis was association with riskier based decision making R 0.326 0.03 
Study 2: AST and SPQ-B In the whole group, high SPQ-B scorers demonstrated poorer executive control F 9.143 0.004 
Study 2: CPT and SPQ-B In the whole group, high SPQ-B scorers were faster to react during the CPT F 4.689 0.035 
Study 2: CPT and SPQ-B In the whole group, higher scores on the SPQ-B subscale of ‘interpersonal’ 
deficits were associated with slower performance on the CPT.   
R 0.39 <0.001 
Study 2: AST and SPQ-B In the whole group, higher scores on the SPQ-B subscale of ‘interpersonal’ 
deficits were associated with slower performance on the AST. 
R 0.37 <0.05 
Study 2: AST and SPQ-B In the whole group, those reporting more traits linked to the SPQ-B subscale of 
interpersonal were associated with poorer executive control. 
R 0.48 <0.001 
Study 2: AST and BIS-2nd. In the whole group, those with higher reporting more impulsive traits were 
associated with poorer executive control. 
R 0.46 <0.001 
Study 2: IGT and SPQ-B Cannabis users with higher SPQ-B scores were associated with riskier based 
decision making. 
R 0.326 <0.05 
Study 2: AST and SPQ-B Cannabis users with higher SPQ-B scores were associated with poorer executive 
control. 
R 0.325 0.01 
Study 2: Cannabis use and 
BIS-1st 
Heavy use of cannabis was associated with having more impulsive traits. R 0.435 0.01 
Study 2: Cannabis use and 
clarity 
Longer duration of cannabis use was associated with being less clear in 
thinking. 
R 0.389 <0.05 
Study 2: Trait data Cannabis users reported more schizotypal traits linked to cognitive perceptual, 
disorganised thinking, and ambivalence, as well as more social reference to 
paranoia, ideas of persecution, impulsivity, and less emotional clarity.  
F ranged from 
4.99-13.8 
 all  
≤ 0.03 
 
Key: 
AST: Anti-saccade task                BIS-2nd: Barratt Impulsivity Scale -2nd order factor                CPT: Continuous performance test                            
IGT: Iowa Gambling Task  LI: Latent inhibition                  SPQ-B: Schizotypal Personality Questionnaire-Brief                 
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Table 41: A summary of the key genetic findings in groups and across measures  
Gene and SNP Key Significant findings    Test statistic     p 
DAOA rs142129 T/A genotype occurred more frequently in cannabis users. X² 7.231 0.055 
NRG1 rs221533 
and SPQ-B 
In the whole group, T/T genotypes scored higher on the SPQ-B subscale 
of interpersonal compared to the T/C genotypes F 3.183 0.046 
COMT rs165599 
and SPQ-B 
In the whole group, the G/G genotypes experienced more disorganised 
thinking problems F 2.623 0.078 
NRG1 rs2215533 
and SPQ-B 
In the whole group, the T/T genotypes reported less disorganised 
thinking problems. F 2.468 0.09 
NRG1 rs221533 
and SPQ-B 
In the whole group, the T/C genotypes scored higher on having cognitive 
perceptual problems. F 2.509 0.08 
COMT rs737865 
and LI 
In the whole group, the C/C genotypes took less time to find the paired 
association for the LI task. F 2.526 0.09 
COMT rs737865 
and LI 
Cannabis users with the T/T and T/C alleles took less time to find the 
paired association in the LI task compared to non-users with the same 
alleles. F 3.89 0.026 
CNR1 rs1049353 
and CPT 
In the whole group, those individuals with the G/A genotypes had higher 
commission errors relative to G/G genotypes. F 8.96 0.004 
CNR1 rs1049353 
and CPT 
In the whole group, those individuals with the G/A genotypes were 
slower to perform on the CPT relative to G/G genotypes. F 0.32 0.08 
COMT rs165599 
and CPT 
In the whole group, those individuals with G/A genotypes showed 
increased motor errors relative to G/G and A/A genotypes. F 2.59 0.08 
COMT rs4680 
and AST 
An interaction was found between variation in SNP rs4680 and AST 
performance.  Cannabis users with the G/A genotypes showed impaired 
executive control relative to the non-cannabis users with the G/A 
genotypes.  Cannabis users with the A/A genotypes showed improved 
executive control relative to non-cannabis users with the A/A genotype. F 2.865 0.07 
CNR1 rs1049353 
and AST 
In the whole group, those individuals with the A/A genotypes were faster 
to respond on the AST. F 3.017 0.09 
CNR1 rs1049353 
and CPT 
In the whole group, those individuals with the G/G genotypes were faster 
to respond on the CPT compared to the G/A genotypes. F 5.4 0.045 
CNR1 rs1049353 
and CPT 
In the whole group, those individuals with the G/A genotypes made more 
commission errors on the CPT. F 25.63 <0.001 
COMT rs165599 
and CPT 
In the whole group, those individuals with the G/G genotypes made more 
motor errors on the CPT. F 2.511 0.09 
NRG1 rs221533 
and cannabis 
The T/C genotypes had used cannabis for a longer duration than the T/T 
genotypes X² 76.14 <0.001 
COMT 
haplotypes (T-G-
G) and SPQ-B 
Those cannabis users without the TGG protective haplotype had higher 
disorganised thinking traits, whereas cannabis users with the TGG 
protective haplotype had lower disorganised traits, whereas the opposite 
effect was found in the non-cannabis group. F 4.281 0.042 
 
Key: 
AST: Anti-saccade task                                       BIS-2nd: Barratt Impulsivity Scale -2nd order factor                CNR1: Cannabinoid Receptor 1                  
COMT: The Catechol-O-methyl transferase                 CPT: Continuous performance test                DAOA: D-amino Acid Oxidase Activator     
FAAH: Fatty Acid Amide Hydrolase NRG1: Neuregulin                IGT: Iowa Gambling Task                  LI: Latent inhibition            
SPQ-B: Schizotypal Personality Questionnaire-Brief            
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5.1 Neuropsychological assessments – study one 
The purpose of study one was to assess the performance of a group of cannabis users relative 
to non-cannabis users, through the use of two associative learning tasks with known 
sensitivity to schizophrenia: the latent inhibition and kamin blocking paradigms (see sections 
2.1.1 and 2.1.4).  Both tasks have also been shown to be disrupted in first degree relatives of 
people with schizophrenia, and by drugs which affect dopamine.  It was predicted that 
cannabis users would show disruption on the LI and KB tasks due to the effect of cannabis on 
the dopaminergic and other key systems underpinning attention and associative learning.  The 
first study also assessed schizotypal personality traits as measured by the SPQ-B.   
 
5.1.1 Associative Learning – Latent inhibition 
Cannabis users appeared to show performance akin to a schizophrenic-like profile on the LI 
task, as normal LI was abolished in the PE condition, with no significant difference found in 
LI scores between the task conditions (PE and NPE) for the cannabis users.  In the primary 
analysis, the cannabis users took less time overall to find the paired association between the 
white noise and the counter incrementing under the PE condition compared to the cannabis 
group in the NPE condition.  There was a LI effect in the non-cannabis users but in the 
opposite direction to what is expected (i.e. faster learning in the PE condition).  There were 
no clear explanations as to why the controls performed badly.  It was 5 participants in the 
non-cannabis group who were excluded for not reaching the learning criterion (e.g. did not 
successfully learn the paired association) and those in particular who reported cannabis use in 
the past.  A secondary set of analyses were carried out, which also included 5 new 
participants: four new participants allocated to the NPE condition and one participant to the 
PE condition.  There was a significant difference between the PE versus NPE conditions for 
the non-cannabis group; thus indicating a normal LI effect (i.e. slower learning in the PE 
condition).  Furthermore, there was a significant difference between cannabis users and non-
cannabis users in the PE condition but not under the NPE condition, indicating that cannabis 
users overall were less affected by the pre-exposure to the white noise during the masking 
task (of the PE condition), thus indicating a trend for abolition of normal LI in the secondary 
analyses.   It could be argued that these LI findings fit the idea that use of cannabis may be 
disrupting associative learning as also seen in psychotic populations, first degree relatives of 
schizophrenia sufferers (Serra et al, 2001) and following amphetamine use (Soloman et al, 
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1981).  Cannabis has been independently associated with deficits in PFC activity (Block et al, 
2002; Lundquist et al, 2001; Solowij et al, 2002) linked to attentional dysfunction 
(Weinberger et al, 2001) and increased mesolimbic dopamine transmission in the brain 
(Tanda et al, 1997; Voruganti et al, 2001).  This parallels to the finding that dopamine is 
critical for LI performance (Soloman et al, 1981; Weiner et al, 1981; 1984) and appears to be 
central in some forms of attentional dysfunction (Matthysse, 1978; Swerdlow & Koob, 1987; 
Swerdlow et al, 2003).  Further to this, CB1 receptors have a known role in associative 
learning in animals (Gruart et al, 2012) and cannabis has been shown to disrupt associative 
learning in humans (Jager et al, 2007; Skosnik et al, 2007).  Disrupted associative learning 
(as demonstrated by the LI task) is therefore argued to be due to the failure of inhibiting 
attention to the irrelevant stimuli during the pre-exposure stage of the task, which may be 
linked to cannabis increasing DA transmission.   
 
5.1.2 Individual Differences – study one 
Individual differences in psychotic-like personality traits were assessed using the SPQ-B 
(Raine & Benishay, 1995) but no significant differences were found between the cannabis 
and non-cannabis users in Study 1.  This does not support previous research (Skosnik et al, 
2001; Barkus et al. 2008; Friedberg et al. 2010).  These data may indicate that if cannabis use 
is in some way pushing users in a psychosis-linked direction, then this effect is clearly not so 
profound as to be causing significant personality change in everyday recreational users.   
Additionally in Study 1, this data indicates that the controls and users were matched 
effectively on underlying schizotypy traits –thus any cognitive differences observed cannot 
easily be attributable to existing psychosis-linked differences or as secondary effects to a 
more profound shift towards schizotypy/psychosis due to cannabis use.  Or it could be argued 
that the lack of findings could be due to the low participant numbers within study one (n=40), 
or alternatively it could be due to a lack of sensitivity in the SPQ-B as a measure.  The SPQ-
B requires a binary Yes/No response and does not allow for any recognition for levels of this 
trait.  The owner (Adrian Raine) was contacted via email in 2008 to ask if the SPQ-B 
measure can be modified to adopt a Likert-scale responding for Study 2 of this thesis, but he 
refused the request.  Then a study published by Cohen et al. (2010) adjusted the SPQ-B 
measure using a likert-scale and reported that the brief revised SPQ was much more sensitive 
than the original version for uncovering a psychosis-proneness personality profile.  This 
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adaption was not made for Study 2, but instead a range of additional psychotic-like measures 
which used likert scale responding were added (see section 3.5.2). 
 
5.1.3 Individual differences and associative learning  
In the primary analysis, when collapsing data across groups (combining cannabis users and 
controls) there were no significant differences were found in the PE condition for high and 
low SPQ scorers, whereas low SPQ scorers took significantly less time than high SPQ scorers 
under the NPE condition to make the association.  This agrees with Wuthrich and Bates 
(2001) who found that when levels of schizotypy increase, learning of the paired association 
in the LI task decreased.  Baruch et al’s (1988a) research also reported that LI is attenuated in 
people with a high-schizotypy relative to low schizotypy scorers.  In the secondary analysis, 
low SPQ scorers took longer to find the paired association in the PE condition versus the 
NPE condition, thus highlighting a normal LI effect.  This was contrasted by high SPQ 
scorer’s performing significantly better at finding the paired association in the PE condition 
relative to the NPE condition, thus indicating abolishment of normal LI in these high SPQ 
scorers.  When the data was separated for cannabis users and non users, the correlation data 
also highlighted that for the non-cannabis group in the secondary analysis, scoring higher on 
the SPQ-B measure and its three subscales was positively associated with higher scores on 
the LI task, but this was not the case for the cannabis group.  Therefore the findings strongly 
support the argument that the LI abolition effects in this current study, under the PE 
condition, are drug specific, as opposed to being linked to personality traits.    
 
5.2 Neuropsychological assessment – study two 
This study aimed to further look at this issue of cognitive disruption in cannabis users which 
seems to parallel to schizophrenia.  Thus far from Study 1 only the LI task had shown some 
effects in the predicted direction. It was important therefore, given the lack of an effect in 
KB, to explore whether this effect was limited to LI or whether other domains typically 
affected by schizophrenia were also impacted upon by cannabis use at recreational (non-
dependent) levels. It was important to again look at schizotypy as a possible driver or 
confound in any cognitive effects.  The possible limitations of the SPQ-B were also 
addressed by using additional psychosis-linked trait measures.  The cognitive tasks assessed 
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decision-making using the IGT, attention using the CPT and executive control using the AST 
(see sections 3.1, 3.2 and 3.3 for a full review of the tests and 3.7 for a full discussion of the 
key findings).  In line with the key predictions of the thesis, decision-making impairments 
were found in cannabis users for IGT performance, in that they selected the decks which had 
immediate higher gains but also higher losses overall (see Figure 7) and made a significant 
loss in comparison to the non-cannabis users.  This finding is supported by previous research 
(Hermann et al, 2009; Bolla et al, 2003; Wesley et al, 2011).  Other factors may have been 
involved in these decision-making strategies, for example, emotional and motivational 
processes may have played a part.  It may be that the cannabis users have an increased 
sensitivity to rewards and insensitivity to losses, or are generally less risk-averse individuals 
because they have specifically chosen to use an illegal substance for personal gratification 
and to discount the possible risks associated with this psychoactive drug.  Previous research 
found evidence to suggest that drug users reduce the value of a reward when there is a delay 
in receiving this (e.g. Coffey et al, 2003).   
 
Cannabis users made more errors on the AST and were faster to respond relative to the non-
cannabis group, but these differences were not statistically significant.  No clear differences 
were found between cannabis users and non-cannabis users on the CPT for accuracy, speed 
and number of motor and commission errors.  Research in the area of performance on the 
CPT and AST in schizophrenic patients tends to show that schizophrenic patients perform 
less well compared to controls, whereas the research on cannabis use in clinical samples and 
in non-clinical samples has been less clear.  This may help to explain why no differences 
were found between the cannabis users and non-cannabis users.  For example, Chung et al 
(2010) looked at adolescents with and without cannabis use disorder and found no difference 
in performance on the AST.  Rodríguez-Sánchez et al (2010) found no difference on CPT 
performance between schizophrenics who used cannabis versus those schizophrenics that did 
not use cannabis.  Jockers-Scherübl et al (2007) found that performance on the CPT was 
impaired in healthy controls if they used cannabis before the age of 17, but performance was 
improved in a group of patients that started cannabis before the age 17, after a 28-day 
abstinent period.   
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5.2.1 Individual differences – study two 
Study 2 used the SPQ-B measure and also explored a range of other psychotic-like traits such 
as ambivalence, emotional processing, and paranoid thinking, using scales which adopted 
likert responding.  Cannabis users reported experiencing more Paranoia (part A and B of the 
Green et al 2008, Paranoid Thought Scale), Ambivalence (SAS) and Impulsivity (first and 
second order factor of the Barratt Impulsivity Scale) and were less clear for their emotions 
assessed by the trait meta-mood questionnaire subscale for clarity.  These findings support 
previous research that cannabis users experience more psychotic-like traits (Arsenault et al, 
2004; Henquet et al, 2003; van Os et al, 2002; Stefanis et al, 2004; Skosnik et al, 2008; 
Dumas et al, 2004 Kuepper et al, 2011) and impulsivity (Schmid et al, 2004; Barkus et al, 
2008).  Unlike Study 1, cannabis users scored significantly higher on the SPQ-B and all sub 
factors, and this may be the result of having a higher number of participants in the total group 
(n=60).  A review of other drugs used between cannabis users in Study 1 and 2 was explored 
to see if this could explain these SPQ-B differences.   There was higher use of other drugs 
amongst cannabis users in Study 1 (see Table 3i and Table 3ii) with 15 out 20 cannabis users 
reporting polydrug use (i.e., two or more drugs as well as current cannabis use), as opposed to 
2 out of 30 in Study 2 (see Table 20).  There were no apparent differences between amount of 
cannabis use and type of use between the users in Study 1 and Study 2, whereas cannabis 
users in Study 2 had a lower mean age of cannabis first use, and a higher mean dependency 
score.  These SPQ-B differences in Study 2 may specific to cannabis as opposed to polydrug 
use. 
 
5.2.3 Individual differences and decision-making/executive control/attention 
In the entire sample when the data was collapsed across users and non users for high/low 
scores on the total SPQ-B there was no impact on IGT performance. Although, risky 
decision-making (on the IGT) was associated with positive schizotypy (as assessed by the 
SPQ-CP).  This finding links to Wout and Stanfley (2010) research who found that higher 
scores on the SPQ-CP were predictive of poorer bargaining behaviours in game theory.  
Therefore, positive symptoms could influence normal everyday decision making.  
Participants with higher total SPQ-B scores made twice as many errors on the AST, which 
supports previous research in that increased psychotic like traits are associated with greater 
deficits on this task (Holahan & O’Driscoll, 2005; Ettinger et al, 2005; Ettinger et al, 2006; 
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Ettinger et al (in press); Larrison et al’s (2000).  Interestingly, deficits in AST performance 
were linked more to psychotic traits than cannabis use per se.  CPT response time was 
affected in those with high SPQ scores as they had significantly faster reaction times.  CPT 
performance was also linked to Interpersonal Deficits on the SPQ-B, but was not correlated 
with the SPQ-B subscales for positive symptomology and disorganised thinking.  
Interestingly, Bedwell, Kamath and Compton (2009) found that CPT was associated with 
severity scores obtained from a structured interview of schizotypal symptoms, but not with 
those scores from a self-report psychometric assessment of schizotypal personality 
dimensions.  Therefore, the binary method of assessing psychotic traits may be limited in 
assessing the breadth and subtleties of psychosis-like experiences.   
 
There was a lack of findings for the AST and CPT between the cannabis users and non-
cannabis users.  As previously discussed, there are conflicting CPT outcomes in clinical 
samples and non-clinical samples, and this may be due to variations in the task used across 
studies.  Also, CPT RT was linked to the negative symptomology (for Interpersonal Deficits) 
as measured by the SPQ-B, and so it may be that outcomes are more pronounced in people 
with greater negative symptoms, as these have been more closely linked to genetic 
components of schizophrenia (Bassett et al, 1993).  The AST has been less widely assessed in 
cannabis users.  Overall, AST performance was predicted by psychosis linked personality 
scores, and particularly so in the cannabis using group.  This suggests that these traits may 
constitute a liability for some of the cognitive disruption seen in schizophrenia, a finding 
backed up by previous research (e.g. Ettinger et al, 2000; Larrison et al, 2002).   
 
5.3 Cannabis use variables – study one and study two 
Throughout the thesis, a correlation between earlier onset of cannabis use, frequency and 
duration of use was assessed in relation to neuropsychological performance.  In study one, the 
amount of cannabis used was explored and it was found that heavier users of cannabis scored 
higher on SPQ-B measures for positive (SPQ-CP), negative (SPQ-IP) and disorganised 
thinking (SPQ-DT), which supports previous research (e.g. Compton et al, 2009).  It is well 
documented that cannabis use is linked to increased positive symptoms (Negrete et al, 1996; 
Skosnik et al, 2001; Verdoux et al, 2002; Skosnik et al, 2008) and disorganised thinking in 
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schizotypy (e.g. Skosnik et al, 2001; Dumas et al, 2002; Bailey and Swallow, 2004).  
Whereas, the findings have been less clear for the negative symptoms with some significant 
(e.g. Bailey and Swallow, 2004; Compton et al, 2009) and non significant findings (Skosnik 
et al, 2001).  It is unclear whether an increase in schizotypal traits is a causal influence or 
consequence of cannabis use.  It may be that people are predisposed to use cannabis, or that 
use of cannabis results in eliciting positive (i.e., hallucinations) or negative (i.e., flat affect) 
psychotic symptoms in heavy users (Verdoux et al, 2002).  Age of onset of cannabis use was 
negatively associated with scores on SPQ-DT, with earlier onset of the drug related to higher 
scores on this third subscale of disorganised thinking.  This differs from Compton et al’s 
(2009) study as early age of first use of cannabis was associated with interpersonal 
schizotypy symptoms.  Compton’s research, however, used two distinct testing groups (first-
degree relatives of patients and non-psychiatric controls) and this therefore makes it difficult 
to generalise these findings against a sample of recreational cannabis users on these SPQ 
traits.  What is clear is that earlier use of cannabis and higher frequency of use is linked to 
experiencing more of these psychotic-like traits, which arguably may account for why some 
people at are a higher risk for the development of schizophrenia (Bossong & Niesink, 2010).   
 
In Study 2, heavy cannabis use was also correlated with poorer decision-making on the IGT, 
which suggests that heavier use of cannabis was linked to riskier decision making, and may 
help to explain why people continue to use the drug despite its potentially negative effects.  
Previous research by Whitlow et al (2004) and Hermann et al (2009) support this as they 
found significantly poorer outcomes on the IGT in those that had used cannabis heavily 
relative to those with lighter more partial use.     
 
Clarity of thoughts on the trait-meta mood scale was negatively correlated with duration of 
cannabis use, and the first order factor of the BIS was positively correlated with joints per 
week (JPW).  Thus longer use of cannabis was linked to having more emotional confusion 
and increased use of cannabis was linked to impulsivity (across the spectrum of motor, 
attention, cognitive complexity, perseverance, and cognitive instability).  Trends existed for 
heavy use of cannabis to be linked with greater deficits on the AST and IGT as well as with 
people experiencing more psychotic traits such as ambivalence, loss of clarity of thoughts, 
and impulsivity.  An increased amount of cannabis used per week and length of use was 
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positively correlated with reaction time on the AST, with heavier use of cannabis and longer 
duration of use both being associated with faster responding.  Longer duration and heavier 
use were both linked to increased cognitive disruption on the decision making and inhibition 
tasks, as well as increased scores on psychotic-like personality traits.  Taken together, this 
does support the general notion that more problems are seen in the heavier users and those 
who have taken the drug for longer periods of time (Solowij et al, 1998; Fletcher et al, 1996; 
Pope et al, 1996).  Furthermore, cognitive dysfunction associated with long term or heavy use 
of cannabis has been proposed as possible vulnerability markers for schizophrenia (Solowij & 
Michie, 2007; Pope et al, 2001).  Cannabis use and duration of use varied across the group, 
so it may be that if heavier cannabis users and those categorised as short-term versus long-
term users were assessed as separate groups, then deficits may be more prominent for this 
drug group.   
  
5.4 Summary findings of the SNP markers (DAOA, COMT, CNR1, FAAH and NRG1) 
in relation to study one and study two 
As previously stated, numerous genetic markers have been explored in the field of 
schizophrenia research and increasingly alongside other risk factors such as cannabis use. 
Genetic susceptibility to schizophrenia is widely accepted as underpinning this illness and as 
acting in combination with other causative factors in the aetiology of the pathology (e.g. Van 
Os et al, 2008).  As explored in sections 1.4 and 1.5, cannabis use has been clearly linked to 
some instances of psychotic illness and may be a possible driver of psychosis-linked changes 
in recreational user populations (as supported by some of the findings here).  Taken together 
with the genetic research in this field, therefore, it is likely that any psychosis-like changes 
linked to cannabis use in non-pathologised populations, will be more pronounced where one 
or more schizophrenia-linked (psychosis-risk) genetic markers are present.  With this model 
in mind, all participants were screened for several genetic risk markers linked to 
schizophrenia.  A final 5 candidate schizophrenia genes (DAOA, COMT, CNR1, FAAH, 
NRG1 – please refer to section 4.2 for a background to these genes) and three SNP marker 
haplotypes from the COMT gene were assessed.  The aim was to assess for potential 
differences in variation of these genes (i.e. SNPs) in relation to outcomes on cognitive tests 
from study one and two.  One personality measure was also included in these analyses which 
assessed traits linked to schizotypal personality disorder (SPQ-B, Raine & Benishay, 1995).  
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In addition to allowing some evaluation of these markers in relation to possible compound 
effects of cannabis use and genetic risk on task/measure outcomes, the genetic analyses 
(presented in Chapter 4) also explored the possible contributions of these risk-markers to 
outcomes more generally (regardless of drug use). All the key genetic findings for Chapter 4 
were discussed in detail under sections 4.8 and 4.10, and are presented above in Table 41.  A 
short summary of some of the key findings mainly for the cannabis users, which were either 
significant (p<0.05) or leaning towards significance (p 0.15) are discussed below. 
 
DAOA gene 
One SNP (rs142129) was assessed for the DAOA gene.  In the literature T/A genotypes are 
more commonly found in patients with schizophrenia (Chumakov et al, 2012, Schumacher et 
al, 2004), and T/T genotypes more closely linked to cognitive disruption in schizophrenia 
(Goldberg et al, 2006) and methamphetamine psychosis (Kotaka et al, 2009).  In the current 
study a trend for significance was found in that the T/A genotype occurred more frequently in 
the cannabis users, demonstrating a degree of overrepresentation of this genotype in the users 
which could be influencing findings across measures.  Further, in the entire group (users and 
controls together) the T/T genotype was associated with the poorest associative learning on 
the LI task.   
 
COMT  
The most widely studied COMT SNP rs4680 was assessed alongside two other COMT SNPs: 
rs737865 and rs165599.  A trend existed for the risk G/G allele in SNP rs4680 to occur much 
more frequently in cannabis users compared to the G/A and A/A alleles.  There was no 
significant effect of variation of the risk SNP rs4680 across all participants with regards to 
scores on individual differences in psychotic-like personality traits, which does not align with 
previous studies (Swart et al, 2011; Ucok et al, 2010; Smyrnis et al, 2007; Sheldrick et al, 
2008).  Most of the literature links the rs4680 A/A allele with better cognitive performance 
(Bilberg et al, 2002; Goldberg et al, 2003; Jorber et al, 2002; Sheldrick et al, 2008) and the G 
allele with the worst cognitive performance (Bruder et al, 2003; Bertolino et al, 2006; 
Goldberg et al, 2003).  SNP rs4680 has now been widely studied (see Williams et al, 2007) 
but less is known regarding the other two SNPs (rs737865 and rs165599) on the COMT gene 
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in relation to schizophrenia.  The T/T genotypes (also known as A/A in the literature) of SNP 
rs737865 occurred significantly more in the cannabis group compared to the C/C genotypes 
(also referred to the G/G in the literature).  A trend was found in the cannabis users with SNP 
rs737865 C/C genotypes to report higher interpersonal problems as measured on the SPQ-IP 
subscale compared to the T/T genotypes.  Those individuals with SNP rs165599 A/A 
genotypes had lower SPQ reported cognitive perceptual and interpersonal problems, and 
those with the G/G alleles reported more problems with disorganised thinking in both the 
cannabis users and non-cannabis users.  Cannabis users with SNP rs737865 C/C genotypes 
performed better on the LI task.  Other trends were found in the whole group with the A 
allele on the COMT gene linked more to improved cognitive performance and the G allele 
more closely linked to cognitive disruption similar to that seen in people diagnosed with 
schizophrenia.  For example, it was the G/A genotypes of SNP rs165599 who had poorer 
attentional control as they made more motor errors on the CPT.  It was the T/T genotypes of 
SNP rs737865 who demonstrated better attentional control as they made the least errors on 
the AST.  
 
Three SNPs (rs737865, rs4680, rs165599) were then assessed together as a haplotype marker.  
In the literature the risk haplotype (C-G-G) is positively associated with schizophrenia (De 
Rosse et al, 2006; Schifman et al, 2002; Handoko et al, 2004) and the T-A-A haplotype has 
also been positively associated with schizophrenia (Kotrotsou et al, 2012), so both are 
deemed to be risk markers for schizophrenia.  However, in the current study the risk 
haplotypes T-A-A occurred in 6 participants and the C-G-G haplotypes occurred in 8 
participants, so the numbers were too small to allow clearly viable statistical comparisons.  
Common variables amongst the cannabis group with this haplotype compared to the other 
COMT haplotypes were explored.  The cannabis users with the risk C-G-G haplotype had the 
lowest use of drugs such as MDMA, amphetamine, cocaine, alcohol, tobacco, and cannabis, 
whereas those with the T-A-A risk haplotype had the highest use of all of these 
aforementioned drugs (x4 times greater use).  The T-A-A risk haplotypes also had a higher 
number of schizotypal personality traits.  Another known haplotype T-G-G was identified in 
50% of the sample and compared against the rest of the sample to assess for potential 
differences in trait and cognitive outcomes.  The T-G-G appears to be a protective haplotype 
with regards to psychosis (Kotrotsou et al, 2012).  Trends existed for cannabis users with the 
protective haplotype to have lower disorganised thinking scores as measured by the SPQ-DT, 
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compared to those cannabis users without the protective haplotype.  No other study has 
assessed this T-G-G haplotype in cannabis users, but the SPQ-DT data in the current study 
seems to be in line with Kotrotsou et al’s (2012) research, further suggesting that this 
haplotype has a somewhat protective effect. 
 
NRG1 
Only 3 participants in the entire sample had the risk SNP rs221533 C/C allele, with most of 
the group having the T/T genotype.  This, therefore, contravened the criteria for the HWE and 
also made it difficult to draw comparisons from these data against previous studies.  Please 
refer to Chapter 4 (see section 4.10.3) for a speculative discussion of these findings.  
 
CNR1 gene and the FAAH gene 
The majority of the entire sample had the risk SNP rs1049353 G/G allele (96%) in the CNR1 
gene, so this contravened the HWE and interpretation of these data may be limited.  Please 
refer to Chapter 4 (section 4.10.4) for speculative discussion of these findings.  
 There was no significant variation in the FAAH gene SNP 324420 on trait outcomes.  In the 
whole sample, a significant difference was found between the C/C and C/A genotypes for 
Kamin Blocking outcomes. Those with the C/A genotype had worse associative learning 
compared to those with the C/C genotypes.  Interestingly, the ‘A’ allele is linked more to a 
schizophrenia profile (Arias et al, 2010).   
  
SNP markers and cannabis use variables 
There was a trend for variation in the COMT gene SNP rs4680, with those individuals with 
A/A genotypes reporting the highest use of cannabis.  Interestingly, this SNP has links with 
drug reward/addiction and related differences in the metabolism and breakdown of DA (Chen 
et al, 2004).  The low enzymatic A/A genotype has previously been linked to drug 
dependence (Lohoff et al, 2008), sensation seeking in females (Lang et al, 2008) and a 
greater responsiveness to reward (Lancaster et al, 2012).   
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The ‘C’ allele is known as the schizophrenia risk allele in the NRG1 gene and in the current 
study those individuals with SNP rs221533 T/C genotypes reported the longest duration of 
cannabis use compared to the T/T genotypes.   The NRG1 has recently also been put forward 
as a gene linked to cannabis dependence (Tan et al, 2012).  Taken together, these findings 
warrant further investigation of the COMT gene and NRG1 gene for possible links to drug 
dependence. 
 
Combined SNP marker effect 
It was predicted that those with a profile of multiple risk SNP markers from the candidate 
schizophrenia genes may show greater cognitive disruption and personality symptoms in the 
direction towards schizophrenia-like deficits, but none of the findings reached the level of 
statistical significance.  This lack of finding may be due to the low participant numbers when 
assessing cognitive performance with different tasks in Study 1 and Study 2, as opposed to 
using at least one similar cognitive task across both studies. 
 
5.5 General limitations 
The general limitations for this thesis were summarised in sections 2.4.5, 3.7.6 and 4.10.7 
respectively.  In Study 1, the non-cannabis group did not demonstrate a normal LI effect as 
they achieved fewer trials to criterion in the pre-exposed condition versus the non pre-
exposed condition in the primary analysis.  Further, the cannabis group also demonstrated 
better associative learning skills under the NPE condition compared to the non-cannabis 
group, with 35% of the non-cannabis users achieving the learning criterion compared to 80% 
of the cannabis users.  Thus, the non-cannabis group overall had poorer performance. There 
may be a range of reasons for this unpredicted effect,  
 No intelligence tests were administered to check for possible differences between the groups, 
and it would have been useful to use a measure such as the NART or Ravens matrices as a 
pre-test screen to match groups. 
 The non-cannabis group had 3 participants who reported heavy lifetime use.  Therefore, a 
new group of 5 non-cannabis users were tested (1 in the PE and 4 in the NPE conditions) and 
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this revealed a true LI effect, as the non-cannabis users were faster under the NPE condition 
compared to the PE condition, with 60% of the sample achieving the learning criterion.  
 Most of the non-cannabis user controls were internal candidates from the UEL in the primary 
analysis, so it could be argued that their motivation to take part may not have been as high as 
those willing to travel to the university to take part in the research.  However, counter to this 
argument is that in the secondary analysis the 5 new participants were internal candidates and 
this actually increased performance for the non-cannabis group, as opposed to decreasing or 
not affecting performance.  
 The cannabis users were self-selected and the study may have created a bias in attracting 
higher functioning and more motivated individuals; which may have helped to widen the 
performance gap between users and controls.  Those users with poorer cognitive functioning 
may have been less likely to take part for various reasons (e.g. more disorganised thought, 
poorer planning etc. would work against interest in and attention to volunteering), and other 
issues such as paranoia could be problematic for this recruitment method as well.  Future 
alternative recruitment strategies could be explored, such as online interest groups and a 
direct approach. 
 
There was a gender imbalance in study one with more males in the cannabis using group in 
both the primary and secondary analysis.  This gender difference may have impacted on the 
findings, as previous research by Kaplan & Lubow (2010) indicated that low schizotypal 
healthy males, but not females, exhibited LI.  In Study 2, there were a significantly greater 
number of males in the cannabis group.  However the regression models were adjusted for 
sex and this factor did not predict performance on any of the cognitive assessments.   
 
The COMT gene SNP rs737865, CNR1 gene SNP rs1049353 and NRG1 gene SNP rs221533 
all contravened the HWE. To overcome this issue a future replication would need more 
participants to increase the power of the study.  The aim of the genetic analysis was not to 
assess for gender or ethnic differences but given the link these factors have on genetic 
expression of some of these SNPs, this cannot be ruled out of the findings.  Due to the 
already small cell sizes in these data (when divided by cannabis use and genotype) further 
breakdowns or covariance using other variables such as gender and/or ethnicity would 
weaken the statistical validity of tests even further.  However, if the genetic research would 
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be replicated in much larger cohorts, then these would be important additional variables to 
allow for inter analyses and grouping of data. 
  
The cannabis users in this current study abstained for at least two days (at least 48h).  Those 
cannabis users scoring in the range for dependency was not linked to cognitive performance, 
both in Study 1 and 2 (see sections 2.3.9 and 3.6.5).  However, it could be argued that 
differences found between the cannabis users and non users on the trait and cognitive data 
could be residual effects from cannabis.  Residual effects are difficult to assess (Whitlow et 
al, 2004) and Pope et al (1995) argue that such effects may be due to the presence of drug 
residue, either a dopamine agonist, or metabolites, which continue to have an intoxication 
effect for several hours (Grotenhermen, 2003; Crean et al, 2012) after peak acute effects.  A 
residual effect can also indicate that even after complete elimination of the dopamine agonist-
like effect of THC there are still changes that can persist, which indicate that there may be 
ongoing neuroadaptions (e.g. persistent changes that remain and are caused by the continued 
drug use).  Or alternatively differences found could be due to withdrawal effects, such as 
irritability, negative affect and/or aggressiveness (Kouri et al, 1999).  Withdrawal symptoms 
are seen to first appear after 24h abstinence from cannabis use (Budney et al, 2003), but the 
current drug users in both studies were able to abstain for two days without any difficulty; 
and those unwilling (or unable) to abstain made this known to the researcher and were not 
included in the study.  Most studies have an abstinence period of 12-72h and therefore it is 
difficult to make firm conclusions about residual or withdrawal effects, because of this 
variability in research protocols.   
 
It is clear that many cannabis users experiment with other drugs and in this current study they 
reported a greater degree of past and current polydrug use.  Cannabis users frequently 
reported use of other party drugs such as cocaine, amphetamine and high use of MDMA, all 
which are neurotoxic and impact on cognition (e.g. Rogers & Robbins, 2001; Gouzoulis-
Mayfrank & Daumann, 2006).  Therefore, it is difficult to draw conclusions about the sole 
impact of cannabis, especially as elevated psychopathology is associated with polydrug use in 
general (e.g. Parrott et al, 2001), and as such it is possible that other drug use or polydrug use 
per se may be a key reason for cognitive disruption, as opposed to cannabis use alone (e.g. 
Croft et al, 2001). For example, Soar et al (2015) have very recently demonstrated that LI is 
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disrupted by recreational cocaine use; although cocaine use levels were higher and generally 
much more recent in this sample than the cohorts studied for this thesis.  It should also be 
stressed that in the current cohorts cannabis was the most commonly used drug, and polydrug 
use was far more varied, such that the impact on the data of any single drug other than 
cannabis was likely to be minimal.  Whilst some of the cannabis users here had used cocaine, 
all of the cocaine users in Soar et al’s study were also cannabis users.   
 
Moreover, there are limitations to having just a two-group comparisons (between the 
cannabis users and non- cannabis users), which makes it difficult to assess the true impact of 
cannabis use, especially as cannabis use is varied within this drug group as well high 
polydrug use.  A way to overcome this for future research would be to use a three-group 
comparator: 1) cannabis use and high polydrug use, 2) cannabis use with low polydrug use, 
and 3)  a non-drug using sample (with little party drug history).  
 
5.6 Interpretation of the findings  
Regular cannabis use (particularly heavier use) was linked to higher schizotypal personality 
traits and cognitive dysfunction which parallels some problems seen in people diagnosed with 
schizophrenia.  A cursory comparison with extant data was carried out to briefly examine the 
mean scores on those tasks in the current study which were affected by cannabis use (namely 
LI, the IGT and SPQ-B data).  The cannabis users’ and non-cannabis users’ mean scores for 
the SPQ-B data were lower than those from the original SPQ-B data from Raine & Benishay 
(1995) for non clinical samples.  The means scores were however similar to Compton et al’s 
(2009) large study of non clinical samples.  Studies with clinical samples do show higher 
mean scores across different psychiatric groups, namely substance use disorder and 
personality disorder (e.g. Axelrod et al, 2001) in comparison to the current cohorts.   
 
Normative data does not exist for the IGT (Evans et al, 2004) and a comparison to other 
studies proved to be difficult due to the variations in testing procedures, such as different 
instructions to participants, number of trials, analysis by gender, analysis of performance in 
terms of percentage of choosing advantageous cards versus a net score, or total winnings, 
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analysis by deck, use of real versus virtual cards, use of real versus virtual money (Fernie & 
Tunnet, 2006; Overman et al, 2013).  Studies which assessed decision making on the IGT in 
people diagnosed with schizophrenia generally indicate that decision making is poor when an 
overall average loss has been made (Sevy et al, 2007; Ritter et al, 2003).  In the current study 
cannabis users made significantly more risk based decisions on the IGT compared to non-
cannabis users, and their performance was akin to the performance of data taken from clinical 
samples, such as those with schizophrenia (e.g. Yang-Tae et al, 2012) and psychopathy (e.g. 
Morgan et al, 2011).  The cannabis users’ decision-making on the IGT was poorer than other 
research studies assessing the difference between cannabis users and controls (see Gonzalez 
et al, 2012).  It is notable that the controls also demonstrated poorer decision making on the 
IGT, and their performance did not match that of healthy controls in previous research (e.g. 
Kim et al, 2012; Penolazzi et al, 2013).   
 
Comparing the mean scores from the LI data to other research yielded some difficulty, as 
previous researchers have used different versions of the LI task, such as within-participants 
designs (e.g. Lubow et al, 2007), and others using between participants (e.g. Serra et al, 
2001); some have used the median value in the data analysis (e.g. Gal et al, 2009) as opposed 
to the mean for correct number of trials.  In the current LI study, cannabis users were less 
affected by the white noise and performed better (i.e. lower mean for correct number of trials) 
in the PE condition than clinical samples and controls when compared to Serra et al’s 2001 
research.  The controls in Serra et al’s study performed better than the cannabis users in the 
current study for basic associative learning under the NPE condition.  The cannabis users 
performance seemed to be better than most of the published research in clinical samples (e.g. 
Baruch et al, 1988; Granger et al, 2012; Gray et al, 1992), healthy controls (e.g. Kaplan & 
Lubow, 2011) and in those with schizotypal traits (e.g. Baruch et al, 1988b) for those placed 
under the PE condition where it should normally take longer to find the association between 
the white noise and counter incrementing.  One argument to explain this would be a self-
selection bias in the cannabis users, in that this cohort would be very relaxed, intelligent and 
open minded.  The cohort might be very motivated to take part in this study and analytical 
enough to be trying to figure out what the study is about whilst taking part.  Post-test 
interviews would uncover such an effect perhaps, such as self-rated motivation scales pre and 
post testing (to see if levels are maintained and how these compare to controls) or an 
intelligence baseline measure to control for this.  Cannabis was the user’s first drug of choice 
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and this would distinguish this type of drug users from other drug users (cocaine, MDMA 
etc.) in that they may have be more relaxed individuals (as they prefer to stay at home to get 
stoned as opposed to using party drugs) and/or have a distinct personality type (e.g. highly 
creative).  Interestingly, the performance in cannabis users mimic the performance seen in 
those deemed to be high in creativity, with decreased LI seen in those deemed high in 
creative achievement (Carson et al, 2003), which also ties into the previous argument about 
possible cohort characteristic differences.  There is growing evidence of a link between 
creativity and schizophrenia; a recently published study by Power et al (2015) found that 
people in a creative profession were 25% more likely to carry DNA variants linked to 
schizophrenia.  
 
The precise biological explanations as to why cannabis use might increase risk for 
schizophrenia is yet to be established.  A key argument from the review of the literature 
presented here (see Chapter 1) is that THC (a partial agonist) acts on CB₁ receptors in the 
areas of the brain which have been described as a ‘neural circuitry of psychosis’, including 
frontal regions, basal ganglia, hippocampus, anterior cingulate and cerebellum.  Cannabinoids 
modulate the release of a number of neurotransmitters implicated in psychosis, namely DA, 
glutamate and GABA.  Cannabis users may experience more schizotypal traits and cognitive 
disruption due to the effect cannabinoids have on these transmitter systems (see section 
1.1.1).  DA has been linked to positive symptoms in schizophrenia (Davis et al, 1991) and 
DA, glutamate and GABA have all been linked to normal and dysfunctional higher order 
cognitive processes (Goldman-Rakic, 1996; Robbins, 2000).  The interaction between 
cannabinoids and DA, GABA and glutamate may help to explain the acute effects cannabis 
has on acute positive, negative and cognitive symptoms of schizophrenia.  Less is clear is the 
mechanism of how exposure to cannabis may exacerbate the risk of developing schizophrenia 
(Radhakirshnan et al, 2014).  One of the key arguments is that schizophrenia is a 
neurodevelopmental disorder (Weinberger, 1996, Rapoport et al, 2005) and that exposure to 
cannabinoids during adolescence and young adulthood during critical phases for cerebral 
development (up to 25 years) increases the risk for psychotic-like behaviours, as has been 
demonstrated in animal (O’Shea et al, 2004; Cha et al, 2006; Schneider et al, 2008) and 
human epidemiological studies (Andreasson et al, 1987; Arsenault et al, 2002; Zammit et al, 
2002; Caspi et al, 2005; De Forti et al, 2015).  In the current research, the average age of 
cannabis first use (onset) was 15.  Therefore, it could be argued that the individual 
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differences in psychotic-like personality traits and cognitive disruption in cannabis users and 
non users are a result of early exposure to cannabis and the continued use of the drug, which 
results in being closer on the schizophrenia-spectrum compared to those who do not use the 
drug, or those who may have started use much later in life (though some additional work 
would be needed to explore this later notion in more detail).  Alternatively, or additionally, it 
could be argued that the cognitive decline from cannabis use may enhance the vulnerability 
for schizophrenia.   
 
It may be that smoking cannabis elevates schizotypy over time, which would then alone or in 
combination with other cognitive effects of THC, produce alterations in task performance.  It 
is clear that those areas rich in CB₁ receptors correlate to increased cognitive dysfunction 
(e.g. hippocampal regions = short/long term memory problems; frontal regions = executive 
dysfunction; Solowij & Michie, 2007), so naturally one would expect more cognitive 
problems in heavy users compared to non drug using controls. The issue of whether the 
cognitive effects observed here are linked to psychosis-like changes rather than more general 
cannabis-related cognitive changes is difficult to disentangle. Cognitive disruption in normal 
cannabis users for most of the cannabis–psychosis studies presented in Chapter 1 is under 
researched.  More research needs to be done to look at convergence in the data that might 
more clearly disambiguate cognitive impact more attributable to direct effects of cannabis on 
general cognitive functioning from effects more linked to a specific schizogenic process.  The 
most prominent effects of cannabis on cognition are those associated with acute intoxication 
(Hart et al, 2001), with chronic effects less consistently proven in all but the heaviest of users 
and polydrug cannabis users (Solowij & Battisti, 2008; Thames et al, 2014). Therefore if 
there is a convergence in the data towards long term effects of cannabis being seen more 
selectively in cognitive domains that overlap schizophrenia/psychosis spectrums or 
symptoms, then this would suggest the cognitive effects might be secondary or most closely 
aligned to some form of schizogenic process. 
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5.7 Suggestions for future research 
Clearly longitudinal data would be needed to monitor which comes first, cannabis use, 
schizotypy score changes or task changes; and thus would disentangle some of the 
complexities discussed above.  New repeat studies are needed, controlling for a range of 
additional variables (gender, IQ, personality traits and possibly motivation) and using bigger 
samples, and focussing on the most interesting gene marker outcomes (e.g. the protective 
haplotype data which, as a first finding, needs replication).  To help address the issue of 
cognitive disruption representing more schizophrenia-like responses as opposed to general 
cognitive deficits, it would be important to administer a more thorough battery of cognitive 
assessments, to see if the users are more generally impaired.  The findings in this thesis 
generally, but also this issue of cognitive confounds, also suggest a need for neuroimaging 
work to see whether cannabis use is more preferentially impacting upon the neural systems 
currently known to be affected by schizophrenia.  
 
The multicomponent model of cannabis use and schizophrenia presented in Chapter 1 (see 
Figure 1) is partially supported by the data in thesis (see summary of data Table 40 & 41).  
Particularly in support of this would be the research on cannabis use variables (e.g. early use 
and heavy use of cannabis) is linked to an increase in psychotic personality traits and greater 
cognitive disruption, which is pushing individuals higher up the spectrum of risk of 
subclinical symptoms compared to the non-cannabis users with a similar genetic make-up.  
For example, cannabis users reported more schizophrenia-like traits on measures of: 
paranoia, ambivalence, schizotypy, lacking emotion clarity.  Further to this, heavy cannabis 
use was associated with higher schizotypal traits and impulsive traits and riskier decision-
making (as measured by the IGT).  Earlier onset of cannabis use was associated with higher 
scores on the disorganised thinking subscale of the SPQ-B measure,  Cannabis users also 
demonstrated schizophrenia-like behaviours in that they showed abolished Latent Inhibition 
and riskier decision making compared to the non-cannabis users,  The COMT haplotype data 
was interesting in relation disorganised thinking traits (the symptoms which are seen as being 
more closely linked to the genetic component of schizophrenia, Bakker et al, 2004); the 
cannabis users with the protective T-G-G haplotype had lower disorganised traits compared 
to the cannabis users without this protective haplotype.  It is not clear what these protective 
factors would represent, but for the COMT haplotype, it may have an involvement in how 
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people react to their external environment.  The COMT gene is involved in the breakdown of 
dopamine, so this haplotype and the known impact dopamine has on brain functions (in 
frontal cortex) may be linked to motivation, how people react to stressful situations, positive 
negative drug reinforcement, inhibition and self-regulation (Luciana et al, 2012).  The 
multicomponent model does not address protective factors in the model, as it represents the 
negative factors in risk for developing schizophrenia, as opposed to also looking at what 
protects individuals.  The psychosocial factors were not addressed in this thesis, but future 
research could be explored (in conjunction with this protective haplotype) to see what social 
factors help to protect individuals from risk of subclinical to full blown schizophrenia.  One 
idea would be to explore additional factors such as: lifetime and current social stressors, 
positive and negative life experiences, assess coping strategies, diet and nutrition; all of this 
would be explored in relation to genetics, individual differences in personality traits (namely 
schizotypy and impulsivity), cognition and drug use history (using a 3-group comparison of:  
controls – no cannabis or club drug history, cannabis users with little polydrug use,  and 
polydrug users) to further explore the link between cannabis use and schizophrenia in relation 
to the known risks and potential new protective factors.  
 
From a clinical perspective research is progressing in this area and it is unlikely that there is a 
single cause for schizophrenia as it is made up of an array of positive, negative and 
disorganised symptoms as well as cognitive disruption.  In line with Radhakrishnan et al 
(2014), it is likely that cannabis-induced psychotic disorder may emerge as a sub-type of 
what is currently being diagnosed broadly as schizophrenia.  Within a clinical setting, those 
individuals seeking treatment for acute schizophrenia are generally assessed on improving 
symptoms, as opposed to also viewing cognitive disruption as a treatment target.  If cannabis-
induced psychotic disorder was treated as a sub-type, then more specific treatment strategies 
could be used to reduce the positive, negative and disorganised traits.  Sofuoglu et al’s (2013) 
research model is an example of emerging research looking to improve cognition as a 
treatment goal for drug addiction/problems.  Therefore, in parallel to drugs education and 
prevention for harm reduction, particularly amongst those at-risk individuals aged between 
14-25 years, future cannabis research should also assess factors which help improve 
cognition to reduce psychotic symptoms (or vice versa), as a preventative measure against 
psychosis. 
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5.8 Summary 
This current study is unique in its attempt to explore the cannabis-schizophrenia link using 
non-clinical recreational cannabis users, assessing cognitive functioning in psychosis-
sensitive tasks, exploring trait markers that have been strongly linked to psychosis and 
additionally looking at schizophrenia-linked genetic markers.  Furthermore, these genetic 
profiles were explored in relation to psychotic-like traits and behavioural outcomes for levels 
of attention, decision making, associative learning, and executive control; all of which are 
risk markers for schizophrenia.  The overall aim of the thesis was to explore sub-
schizophrenia like psychology in a group of cannabis users versus non-cannabis users.  Some 
of the key findings of the thesis were highlighted in Table 40 & 41 above.    
 
In sum, it seems that cannabis users showed abolished Latent Inhibition which resembles the 
performance of those in the acute stages of schizophrenia.  Cannabis users demonstrated 
riskier decision making strategies on the IGT.  Heavier use of cannabis was associated with 
poorer decision making and higher schizotypal traits.  Cannabis users scored significantly 
higher on a range of psychotic-like trait measures assessing three subscales of the SPQ-B 
measure for positive, negative and disorganised traits, as well as higher paranoia, 
ambivalence, and impulsivity.  Longer duration and heavier use of cannabis also exacerbated 
these traits.  Genetics research exploring the cannabis-psychosis link is a relatively new area 
but some of the findings here with SNPs deemed as risk markers were in line with previous 
research linking these with cognitive disruption and also linking to individual differences in 
psychotic-like traits (see section 5.4 above).  Of particular interest was the T-G-G protective 
haplotype in the COMT gene.  Cannabis users with the protective haplotype had lower SPQ-
DT scores (suggesting this haplotype may reduce negative symptoms) compared to non-
cannabis users.  This is the first study to demonstrate this T-G-G haplotype protective effect 
in cannabis users.  
 
Taken together the work in this thesis supports existing evidence that cannabis use, in non-
dependent and non-pathologised users, may be having a significant impact on everyday 
psychological functioning. These effects show some overlap with symptoms associated with 
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psychosis/schizophrenia and could be argued to support the growing evidence of a link 
between this drug and this disorder.  More profoundly these data lend some support to the 
central hypothesis of this thesis, that recreational cannabis use whilst unlikely to produce 
schizophrenic disorder in the vast majority of users, may nonetheless contribute to psychosis-
like changes; the impact of which, on daily living, is largely so far unexplored.  As such the 
current findings demand further research to inform the literature, clinical practitioners, 
communities, policy and most importantly recreational cannabis users themselves. 
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London                
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Tel: 020 8223 4038 Tel: 020 8223 4462                Tel: 020 8223 4421                     Tel: 020 8223 4082                 
 
s.m.lynch@uel.ac.uk j.j.d.turner@uel.ac.uk                                   K.Soar@uel.ac.uk l.e.dawkins@uel.ac.uk 
 
                                          
 
                                         Latent Inhibition, Kamin Blocking and Cannabis 
The study you have been asked to contribute to aims to assess whether drug users’ show a similar pattern of 
results to those found in people who have developed psychosis.   The study involves volunteering to provide a 
small sample of your DNA, which is done through the use of a standard cheek-swab to extract a saliva sample.  
Furthermore, you will be asked to complete two cognitive based associative-learning tasks; a number of 
different questionnaires assessing demographic details, personal and family psychiatric history; your patterns of 
recreational drug use; your general health and different aspects of psychotic personality traits.  The study aims 
to assess potential differences in those who use certain recreational drugs such as cannabis compared with those 
that don’t, therefore you do not have to have used recreational drugs to contribute to the research. 
                                                       
 
                                                              Confidentiality of the Data 
Confidentiality will be ensured, all personal information and questionnaire data will be anonymous and only 
identifiable by a unique participant code kept separately from your consent form.  Upon completion of the study 
all data and contact details will be shredded and disposed of as confidential waste. 
 
                                                                     Disclaimer 
Participants are not obliged to take part in this study and are free to withdraw at any stage.  Should they choose 
to withdraw from the programme they may do so without personal disadvantage and without any obligation to 
give a reason.  Please note that the nature of the study in no way implies that the University of East London 
condones the use of recreational drug. 
 
                                                 University Research Ethics Committee 
If you have any queries regarding the conduct of the programme in which you are being asked to participate 
please contact the Secretary of the University Research Ethics Committee: Debbie Dada, Graduate School, 
University of East London,  Docklands Campus, 4-6 University Way, London E16 2RD (telephone 0208 223 
2976, e-mail d.dada@uel.ac.uk) 
 
 
 
                                                         
                                             
              
                                      Appendix ii:  Consent Form – Study 1 
 
                                                                     
 
                                  Latent Inhibition, Kamin Blocking and Cannabis 
 
I confirm that I have read and understand the information sheet for the above study, understand the nature and 
purpose of the research and have had the opportunity to ask questions.  
Please tick box  
 
I understand that my participation is voluntary and I am free to withdraw at any time without disadvantage to 
myself and without being obliged to give any reason.  
Please tick box  
 
I understand that I will volunteer for a cheek-swab to be administered which extracts a saliva-sample of my 
DNA. 
Please tick box  
 
 I will perform two separate cognitive tests, and will be asked to answer a number of questions concerning ones 
personal history, including mental health issues, levels of drug use and questions assessing aspects of ones 
personality.   
Please tick box  
 
I understand that my involvement in this study, and particular data from this research, will remain strictly 
confidential and any data will only be identifiable by a unique participant code.   
Please tick box  
 
I understand that this consent form will not be linked with my data 
Please tick box  
 
I understand that the research team will not be able to provide feedback on my DNA information, cognitive 
assessment performance and questionnaire scores.  
Please tick box  
 
I hereby fully and freely consent to participate in this study which has been fully explained to me:  
 
Signature of Participant   Date    
_________________________  _____________       
 
Signature of researcher   Date 
_________________________  _____________       
                          Appendix iii:  Debriefing Sheet - Study One 
                                                            
                                                         
 
                   Latent Inhibition, Kamin Blocking and Cannabis 
 
Thank you for taking the time to participate in our study. Your time and effort is very much appreciated. 
If participation in the study has raised concerns for you about your drug use or about your mood you might find 
it helpful to discuss these concerns your general practitioner or you can also contact NHS Direct on 0845 4647 
or www.nhsdirect.nhs.org.uk 
There are also a number of voluntary agencies that may be able to help you, including: 
 
Addaction (www.addaction.org.uk) 
 
 
Drugscope  (www.drugscope.org.uk)  
 
Drugsline (www.Drugsline.org) 0808 1 606 606 
 
            
MIND (www.mind.org.uk) 0845 766 0163 open  Monday to Friday    9.15 am – 5.15 pm 
 
  
Sane (www.sane.org.uk) 0845 767 8000 
 
 
The Samaritans (www.samaritans.org) 08457 90 90 90  - open 24 hours 
 
           
 PsychNet-UK(www.psychnet-uk.com): 0845 122 8622 
            
 
 The National Drugs Helpline (www.talktofrank.com): 0800 776600 Free help and advice 24 hours a day, seven 
days a week.  
  
 
 
 
 
 
 
 
Appendix iv:  Severity of Dependence Scale Modified for Cannabis Use 
 
                                                                                    
SEVERITY OF DEPENDENCE SCALE FOR CANNABIS USE 
                         Please circle the answer which is most relevant to you! 
1. Did you ever think your use of cannabis was out of control? 
    Never or almost never       0         Sometimes                            1 
    Often                                  2         Always or nearly always      3 
2. Did the prospect of missing a smoke make you very anxious or worried? 
    Never or almost never       0         Sometimes                            1 
    Often                                  2         Always or nearly always      3 
3. Did you worry about your use of cannabis? 
          Not at all                        0              A little                                 1 
         Quite a lot                       2             A great deal                          3 
 
4. Did you wish you could stop? 
    Never or almost never    0          Sometimes                            1 
    Often                              2          Always or nearly always       3 
 
5. How difficult would you find it to stop or go without cannabis? 
    Not difficult      0                     Quite difficult                        1 
    Very difficult    2                      Impossible                            3 
 
 
 
 
 
 
 
 
 
 
 
                     Appendix v: Schizotypal Personality Questionnaire – B 
 
    
                        
NAME        SEX                                AGE  
Please answer each item by clicking Y (Yes) or N (No). Answer all items even if unsure of your answer. When 
you have finished, check over each one to make sure you have answered them all.  
 
1. People sometimes find me aloof and distant. Y  N  
 
2. Have you ever had the sense that some person or force is around you, even though you     
   cannot see anyone?  Y  N  
 
3. People sometimes comment on my unusual mannerisms and habits.  Y  N  
4. Are you sometimes sure that other people can tell what you are thinking? Y N  
 
5. Have you ever noticed a common event or object that seemed to be a special                    
   sign for you? Y  N  
6. Some people think that I am a very bizarre person. Y  N  
 
7. I feel I have to be on my guard even with friends. Y  N  
8. Some people find me a bit vague and elusive during a conversation.   Y  N  
 
9. Do you often pick up hidden threats or put-downs from what people say or do? Y N  
10. When shopping do you get the feeling that other people are taking notice of you? Y N  
 
11. I feel very uncomfortable in social situations involving unfamiliar people.    Y  N  
12. Have you had experiences with astrology, seeing the future, UFOs, ESP or a sixth sense?  Y  N  
SPQ-B 
13. I sometimes use words in unusual ways. Y  N  
 
14. Have you found that it is best not to let other people know too much about you? Y N  
 
15. I tend to keep in the background on social occasions. Y  N  
 
16. Do you ever suddenly feel distracted by distant sounds that you are not normally aware of? Y  N  
 
17. Do you often have to keep an eye out to stop people from taking advantage of you?  
    Y  N  
18. Do you feel that you are unable to get "close" to people? Y  N  
 
19. I am an odd, unusual person.  Y  N  
 
20. I find it hard to communicate clearly what I want to say to people.  Y  N  
 
21. I feel very uneasy talking to people I do not know well.   Y  N  
 
22. I tend to keep my feelings to myself.  Y  N  
  
 
 
 
 
 
 
 
 
 
 
     
 
 
            Appendix vi: UEL - Personal/ Familial health questionnaire and current/lifetime drug use 
 
 
                                     PERSONAL HISTORY 
 
Age____________________________ Gender_____________________ 
Age left education   ______________ 
Occupation  ____________________       
Nationality__________________ 
Ethnicity ___________________ 
 
 
 
 
Bad 
 
Moderate 
 
Fine 
 
Good 
Current rating of health 1 2 3 4 
 
 
Have you ever been clinically diagnosed (by a Doctor) with any of the following? 
 
Anxiety Yes  No  
Depression Yes  No  
OCD (Obsessive Compulsive Disorder) Yes  No  
Schizophrenia or Paranoia Yes  No  
Phobia Yes  No  
Panic attacks Yes  No  
Eating disorders Yes  No  
Alcohol or Drug dependency Yes  No  
 
Have any member of your immediate family ever been diagnosed (by a Doctor) with any of the following? 
 
Anxiety Yes  No  
Depression Yes  No  
OCD (Obsessive Compulsive disorder) Yes  No  
Schizophrenia or Paranoia Yes  No  
Phobia Yes  No  
Panic attacks Yes  No  
Eating disorders Yes  No  
Alcohol or Drug dependency Yes  No  
 
Have you ever been hospitalised for any brain injury? 
Yes  No  
Are you on any current medication? 
Yes  No  
If yes, what is this medication prescribed for? 
_________________________________________________________________________________________ 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
______________________________________________________________________________________ 
 
 
 
 
 
 
                                                     
Have you taken the following substances? 
 
 
       Ecstasy/MDMA No  
 
Yes  
 
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it?  ________ 
  
Approximately how long ago was the last time you took it? ________ 
   
       Amphetamine No  
 
Yes  
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________ 
 
       Cocaine No  
 
Yes  
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________  
 
           LSD No  
 
Yes  
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance?  
 years 
 
Approximately how many times have you taken it? ________ 
 
Approximately how long ago was the last time you took it? ________ 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Magic   
    Mushrooms 
No  
 
Yes  
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________  
 
Approximately how long ago was the last time you took it? ________ 
  
 
        Poppers 
 
 
 
 
 
 
 
 
 
 
 
 
 
No  
 
 
Yes  
 
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance?  
 years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________  
 
 
        Ketamine 
 
No  
 
 
Yes  
 
 
 
 
 
If yes,  
 
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________  
 
 
         GHB 
    (liquid ecstasy) 
 
No  
 
 
Yes  
 
 
 
 
 
If yes,  
 
 
Approximately what age where you when you first tried this substance? 
 years 
 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________ 
 
 
 
 
 
 
 
 Prozac  
  (not prescribed) 
No  
 
Yes  
 
 
 
If yes,  
 
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
 
Approximately how long ago was the last time you took it? ________  
 
 
          
 
 
          Crack 
 
 
 
 
No  
 
 
 
 
 
Yes  
 
 
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
 
Approximately how long ago was the last time you took it? ________ 
  
 
        Opiates (e.g.  
  (Heroin morphine) 
 
No  
 
 
Yes  
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
 
Approximately how long ago was the last time you took it? ________  
 
 
    Benzodiazepines      
(e.g. Valium) 
 
No  
 
 
Yes  
 
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Anabolic  
  Steroids 
 
No  
 
 
Yes  
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________  
 
 
         
Solvents 
 
 
No  
 
 
 
Yes  
 
 
 
If yes, 
 
Approximately what age where you when you first tried this substance? 
 years 
 
Approximately how many times have you taken it? ________ 
 
Approximately how long ago was the last time you took it? ________  
 
 
 
 
NOTES:  
Any unusual experiences from using the substances listed thus far. If yes, please specify: 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
______________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
OTHERS DRUGS USED. 
Please specify any other substances you may have used recreationally which are not listed above and indicate 
how many times you have taken them and how long it is since your last use of them:   
 
1.  ________________________________________ 
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance?  
 years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________  
 
 
 
 
2.  ________________________________________ 
 
 
 
If yes,  
 
Approximately what age where you when you first tried this substance? 
  years 
 
Approximately how many times have you taken it? ________ 
  
Approximately how long ago was the last time you took it? ________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cannabis 
 
Have you smoked cannabis?    No    Yes  
If no, please go to the next section.  
 
Which type(s) of cannabis do you smoke?  
Start in the order of the type you use most frequently:  
(a)_______________________ (b) _____________________________       
 
(c) _______________________ (d) _____________________________ 
 
 
HOW MANY JOINTS DO YOU SMOKE PER DAY? ___________ 
How many days in the week do you smoke cannabis?  
 
 everyday  almost everyday  3 - 4 times per week  
 
 1 - 2 times per week   2 - 3 times per month    once a month   
 
 less than once a month 
 
Age when you first smoked cannabis: years 
 
Who introduced you to using the drug? ____________________________ 
 
HOW MANY YEARS HAVE YOU SMOKED CANNABIS FOR:  YEARS  
HOW LONG IS IT SINCE YOU LAST SMOKED IT?_____________________________ 
Any acute psychological / health problems from using higher doses of cannabis? If yes, please specify: 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Tobacco 
 
Do you smoke tobacco?      No    Yes   
 
IF YES, HOW MANY CIGARETTES DO YOU SMOKE PER DAY ON AVERAGE?_________ 
What age did you first start smoking regularly:   years 
(daily smoking, or smoking regularly per week) 
 
Which brand do you smoke most often? ________________________________ 
 
Approximately when is the last time you smoked tobacco?   _______________ 
 
 
 
Alcohol 
 
 
Do you drink alcohol?     No    Yes   
 
IF YES, HOW MANY UNITS OF ALCOHOL DO YOU DRINK IN A TYPICAL WEEK?_________ 
What age did you first start drinking regularly:   years 
(typically consuming 2 or more units per week) 
 
Which type(s) of drink do you consume most often? 
(a) ______________________________________ 
(b) ______________________________________ 
(c) ______________________________________ 
(d) ______________________________________ 
 
Approximately when is the last time you consumed alcohol?   ___________ 
 
 
 
 
                                                    THANK YOU 
 
 
 
 
 
 
 
 
 
 
 
  
 
                Appendix vii:   Green et al’s Paranoid Thoughts Scale (Part A & B) 
 
Please read each of the statements carefully.  They refer to thoughts and feelings you may have had about 
others over the last month. 
Think about the last month and indicate the extent of these feelings from  
                                            1 (Not at all) to 5 (Totally). 
                             Please complete both Part A and Part B. 
 (N.B. Please do not rate items according to any experiences you may have had under the influence of drugs.) 
 
 
 
 
 
 
 
 
 
 
Part A Not at all        Somewhat Totally 
1. I spent time thinking about friends 
gossiping about me 
 1 2          3         4     5 
2. I often heard people referring to me  1 2          3         4     5 
3. I have been upset by friends and 
colleagues judging me critically 
 1 2          3         4     5 
4. People definitely laughed at me behind my 
back 
 1 2          3         4     5 
5. I have been thinking a lot about people 
avoiding me 
 1 2          3         4     5 
6. People have been dropping hints for me  1 2          3         4     5 
7. I believed that certain people were not 
what they seemed 
 1 2          3         4     5 
8. People talking about me behind my back 
upset me 
 1 2          3         4     5 
9. I was convinced that people were singling 
me out 
 1 2          3         4     5 
10. I was certain that people have followed 
me 
 1 2          3         4     5 
11. Certain people were hostile towards me 
personally 
 1 2          3         4     5 
12. People have been checking up on me  1 2          3         4     5 
13. I was stressed out by people watching me  1 2          3         4     5 
14. I was frustrated by people laughing at 
me 
 1 2          3         4     5 
15.  I was worried by people’s undue interest 
in me 
 1 2          3         4     5 
16. It was hard to stop thinking about people 
talking about me behind my back 
 1 2          3         4     5 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Part B 
 
 
Not at all        Somewhat Totally 
1. Certain individuals have had it in for me  1 2          3         4     5 
2. I have definitely been persecuted  1 2          3         4     5 
3. People have intended me harm  1 2          3         4     5 
4. People wanted me to feel threatened, so they 
stared at me 
 1 2          3         4     5 
5. I was sure certain people did things in order to 
annoy me 
 1 2          3         4     5 
6. I was convinced there was a conspiracy against 
me 
 1 2          3         4     5 
7. I was sure someone wanted to hurt me  1 2          3         4     5 
8. I was distressed by people wanting to harm me 
in some way 
 1 2          3         4     5 
9. I was preoccupied with thoughts of people 
trying to upset me deliberately 
 1 2          3         4     5 
10. I couldn’t stop thinking about people wanting 
to confuse 
 1 2          3         4     5 
11. I was distressed by being persecuted  1 2          3         4     5 
12. I was annoyed because others wanted to 
deliberately upset me 
 1 2          3         4     5 
13. The thought that people were persecuting me 
played on my mind 
 1 2          3         4     5 
14. It was difficult to stop thinking about people 
wanting to make me feel bad 
 1 2          3         4     5 
15. People have been hostile towards me on 
purpose 
 1 2          3         4     5 
16. I was angry that someone wanted to hurt me  1 2          3         4     5 
 
                                 Appendix viii: Trait Meta Mood Scale  
 
 
     Please read each statement and decide whether or not you agree with it by adding a tick () to one box 
 5 = Strongly 
agree 
4 = Somewhat 
agree 
3 = Neither 
agree nor 
disagree 
2 = 
Somewhat 
disagree 
1 = Strongly 
disagree 
 1. I try to think good thoughts now matter how 
badly I feel. 
     
2. People would be better off if they felt less 
and thought more. 
     
3. I don’t think it’s worth paying attention to 
your emotions or moods. 
     
 4. I don’t usually care much about what I’m 
feeling. 
     
 5. Sometimes I can’t tell what my feelings are.      
 6. I am rarely confused about what my feelings 
are. 
     
 7. Feelings give direction to life.      
8. Although I am sometimes sad, I have a 
mostly optimistic outlook. 
     
 9. When I am upset I realize that the “good 
things in life” are illusions. 
     
10. I believe in acting from the heart.      
11. I can never tell how I feel.      
12. The best way for me to handle my feelings 
is to experience them to the fullest. 
     
13. When I become upset I remind myself of all 
the pleasures in life. 
     
14. My belief and opinions always seem to 
change depending on how I feel. 
     
15. I am often aware of my feelings on a matter.      
16. I am usually confused about how I feel.      
17. One should never be guided by emotions.      
18. I never give into my emotions.      
 19. Although I am sometimes happy, I have a 
mostly pessimistic outlook. 
     
 20. I feel at ease about my emotions.      
 21. I pay a lot of attention to how I feel.      
22. I can’t make sense out of my feelings.       
23. I don’t pay much attention to my feelings.      
24. I often think about my feelings.      
25. I am usually very clear about my feelings.      
26. No matter how badly I feel, I try to think 
about pleasant things. 
     
27. Feelings are a weakness humans have.      
28. I usually know my feelings about a matter.      
29.  It is usually a waste of time to think about 
your emotions. 
     
30. I almost always know exactly how I am 
feeling 
     
                           Appendix ix: Schizotypal Ambivalence Scale   
Please answer each item by circling T (True) or F (False). Answer all items even if unsure of 
your answer. When you have finished, check over each one to make sure you have answered 
them all.  
 
1)         T          F          Often I feel like I hate even my favorite activities.                           
  
2)         T          F          My thoughts and feelings always seem to be contradictory.      
  
3)         T          F          My feelings about my worth as a person are constantly changing back and   
                                     forth. 
  
4)         T          F          Very often when I feel like doing something, at the same time I don’t  
                                     feel like doing it. 
  
5)         T          F          When I am trying to make a decision, it almost feels like I am  
                                      physically switching from side to side. 
  
6)         T          F          It’s impossible to know how you feel because the people around you  
                                     are constantly changing. 
  
7)         T          F          I always seem to be the most unsure of myself at the same time that I  
                                     am most confident of myself. 
  
8)         T          F          I always seem to have difficulty deciding what I would like to do. 
  
9)         T          F          Most people seem to know what they’re feeling more easily than I do. 
  
10)       T          F          Love and hate tend to go together.                                     
  
11)       T          F          Love never seems to last very long.                                   
  
12)       T          F          The closer I get to people, the more I am annoyed by their faults. 
  
13)       T          F          Everyone has a lot of hidden resentment toward his or her loved ones. 
  
14)       T          F          I have noticed that feelings of tenderness often turn into feelings of anger. 
  
15)       T          F          My experiences with love have always been mixed with great frustrations. 
  
16)       T          F          I usually find that feelings of hate will interfere when I have grown to love        
                                    someone. 
  
17)       T          F          A sense of shame has often made it difficult to accept complements from 
                                     others. 
  
18)       T          F          I usually experience doubt when I finish something that I have worked on for a              
                                     long time. 
  
19)       T          F          I doubt if I can ever be sure exactly what my true interests are. 
 
                               Appendix x:  Barratt Impulsivity Scale –II 
DIRECTIONS: People differ in the ways they act and think in different situations.   
This is a test to measure some of the ways in which you act and think.  Read each statement and put 
an X on the appropriate circle on the right side of this page.   
Do not spend too much time on any statement.  Answer quickly and honestly. 
                                                                                                                            
 Rarely/Never Occasionally  Often Almost 
always/ 
Always 
 
 
1    I plan tasks carefully.      О       О   О    О 
2    I do things without thinking.      О       О   О    О 
3    I make-up my mind quickly.      О       О   О    О 
4    I am happy-go-lucky.      О       О   О    О 
5    I don’t “pay attention.”      О       О   О    О 
6    I have “racing” thoughts.      О       О   О    О 
7    I plan trips well ahead of time.      О       О   О    О 
8    I am self controlled.      О       О   О    О 
9    I concentrate easily.      О       О   О    О 
10  I save regularly.      О       О   О    О 
11  I “squirm” at plays or lectures.      О       О   О    О 
12  I am a careful thinker.      О       О   О    О 
13  I plan for job security.      О       О   О    О 
14  I say things without thinking.      О       О   О    О 
15  I like to think about complex problems.      О       О   О    О 
16  I change jobs.      О       О   О    О 
17  I act “on impulse.”      О       О   О    О 
18  I get easily bored when solving thought 
problems. 
     О       О   О    О 
19  I act on the spur of the moment.      О       О   О    О 
20  I am a steady thinker.      О       О   О    О 
21  I change residences.      О       О   О    О 
22  I buy things on impulse.      О       О   О    О 
23  I can only think about one thing at a time.      О       О   О    О 
24  I change hobbies.      О       О   О    О 
25  I spend or charge more than I earn.      О       О   О    О 
26  I often have extraneous thoughts when thinking.      О       О   О    О 
27  I am more interested in the present than the 
future. 
     О       О   О    О 
28  I am restless at the theatre or lectures.      О       О   О    О 
29  I like puzzles.      О       О   О    О 
30  I am future oriented.      О       О   О    О 
 
 
 
 
                                    Appendix xi:  Information sheet - Study 2 
                                                                                                                             
 
Eye-tracking performance, schizotypy and emotional decision-making in regular cannabis users.  
 
The study you have been asked to contribute to aims to assess whether drug users’ show a similar pattern of 
results to those found in people who have developed psychosis.   You will be asked to complete a number of 
computer based assessments: 1) Anti-saccade task involves the tracking and recording of tiny eye movements 
while watching movable objects on a computer screen; 2) Iowa gambling task requires participants to choose 
from selected cards on a computer screen and the aim is to ‘win as much money as you can’; 3) Continuous 
Performance Test is an attention test and you will be asked to press the computer keypad once you have seen a 
consecutive patterns of numbers (e.g. 3, 5 7) from a continuous presentation of numbers on a computer screen.  
Further to this, a number of different questionnaires will be administered to assess demographic details, personal 
and family psychiatric history; your patterns of recreational drug (lifetime and current use); your general health; 
different aspects of perceived mood and psychotic personality traits.   
 
The study aims to assess potential differences in those who use certain recreational drugs such as cannabis 
compared with those that don’t; therefore you do not have to have used recreational drugs to contribute to the 
research.  A final assessment is to screen for five candidate genes which have been implicated in the 
development of schizophrenia, thus therefore taking part in this study also involves volunteering to provide a 
small sample of your DNA, which is done through the non-invasive procedure of using a sterile cotton swab to 
extract some cheek cells.   
 
Exclusion criteria: 1. Current psychopathology, head trauma, 2. Drug dependency and/or drugs for epilepsy; 3. 
Recreational cannabis users who have not abstained for at least two days. 
 
  
                                                            Confidentiality of the Data 
Confidentiality will be ensured, all personal information and questionnaire and computer-based data will be anonymous and only 
identifiable by a unique participant code kept separately from your consent form.  Upon completion of the study all raw data and contact 
details will be shredded and disposed of as confidential waste. 
 
                                                                  Disclaimer 
Participants are not obliged to take part in this study and are free to withdraw at any stage.  Should they choose to withdraw from the 
programme they may do so without personal disadvantage and without any obligation to give a reason.  Please note that the nature of the 
study in no way implies that the University of East London condones the use of recreational drug. 
 
                                   
 
                                                    University Research Ethics Committee 
If you have any queries regarding the conduct of the programme in which you are being asked to participate please contact the Secretary of 
the University Research Ethics Committee: Debbie Dada, Graduate School, University of East London,  Docklands Campus, 4-6 University 
Way, London E16 2RD (telephone 0208 223 2976, e-mail d.dada@uel.ac.uk 
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School of Psychology 
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Apendix xii: Consent form – Study 2 
Eye-tracking performance, schizotypy and emotional decision-making in regular cannabis users.  
 
I confirm that I have read and understand the information sheet for the above study, understand the 
nature and purpose of the research and have had the opportunity to ask questions.  
Please tick box  
 
I understand that my participation is voluntary and I am free to withdraw at any time without 
disadvantage to myself and without being obliged to give any reason.  
Please tick box  
 
I understand that I will volunteer for a cheek-swab to be administered which extracts a sample of my 
DNA. 
Please tick box  
 
 I will perform three computer-based tests, and will be asked to answer a number of questions 
concerning one’s personal history, including mental health issues, levels of drug use and questions 
assessing aspects of one’s personality.   
Please tick box  
 
I understand that my involvement in this study, and particular data from this research, will remain 
strictly confidential and any data will only be identifiable by a unique participant code.   
Please tick box  
 
I understand that this consent form will not be linked with my data 
Please tick box  
 
I understand that the research team will not be able to provide feedback on my DNA information, 
computer based assessment performance and questionnaire scores.  
Please tick box  
I understand that by signing this consent form I am agreeing to have my data used for publishing 
purposes. 
Please tick box  
 
 Cannabis users only:  I have abstained from cannabis use for at least two days 
Please tick box  
 
 
I hereby fully and freely consent to participate in this study which has been fully explained to me:  
 
Signature of Participant   Date    
_________________________  _____________       
 
Signature of researcher   Date 
         ______________________  _____________       
 
 
 
 
 
  
                                                              
 
Appendix xiii: Debriefing sheet – Study 2. 
 
Eye-tracking performance, schizotypy and emotional decision-making in regular cannabis 
users. 
 
                                            
Thank you for taking the time to participate in our study. Your time and effort is very much 
appreciated. 
If participation in the study has raised concerns for you about your drug use or about your mood you 
might find it helpful to discuss these concerns your general practitioner or you can also contact NHS 
Direct on 0845 4647 or www.nhsdirect.nhs.org.uk 
There are also a number of voluntary agencies that may be able to help you, including: 
 
Addaction (www.addaction.org.uk) 
 
 
Drugscope  (www.drugscope.org.uk)  
 
Drugsline (www.Drugsline.org) 0808 1 606 606 
 
            
 MIND (www.mind.org.uk) 0845 766 0163 - open Monday to Friday      
           9.15 am – 5.15 pm 
 
 Sane (www.sane.org.uk) 0845 767 8000 
 
 
The Samaritans (www.samaritans.org) 08457 90 90 90  - open 24 hours 
 
            
 PsychNet-UK (www.psychnet-uk.com): 0845 122 8622 
            
 
 The National Drugs Helpline (www.talktofrank.com): 0800 776600 
Free help and advice 24 hours a day, seven days a week.  
  
 
 
 
 
 
 
 
                 Appendix xiv: Laboratory work for DNA screening and analysis  
PCR primers design protocol 
In order to amplify the region of interest in the specific genes to look for the SNPs, different 
primer sets and PCR programmes were used.  All primers were found using the Primer Blast 
website: http://www.ncbi.nlm.nih.gov/tools/primer-blast/ Each primer was 20bp in length, 
and one forward and one reverse primer for each SNP was ordered from and synthesised by 
MWG-Biotech, UK.  
Table A1 highlights 20 SNPs that were used in the initial investigation and these were then 
used for PCR primer testing.  Testing was conducted on three SNPs with different amounts of 
DNA, primer, magnesium chloride, PCR master mix and water to achieve the optimal 
outcomes.  The protocol which worked best was: 0.5 μl of DNA, 1μl of forward and reverse 
primer combined; 2 μl of MgCl and 1 μl of water and was used for all SNP PCR primers. 
The washed and prepared PCR products for each of the SNPs were confirmed that DNA is 
present in each of the samples from electrophoresis (via the gel capture by appearance of the 
florescent rings); the product was stored in the 96 well plates, at -20 degrees.  Cyber safe was 
added to the agarose gel during early investigations but this was not strong enough to capture 
the DNA, so ethidium bromide was used in subsequent agarose gels (see PCR results below 
for Figure B2).   Figure A1 below highlights the standard KB+ ladder to refer to as a guide 
for the number of base pairs in the PCR results to check that the correct SNP has been 
captured.   
 
 
 
 
 
 
 
  
The next procedure was to prepare the PCR samples for multiplexing in the genotyping 
machine; this was done through the SNP start primer extension reaction.  Table B2 highlights 
the standard protocol for using the PCR machine to suit individual primers. 
 
 Table A1:  List of different forward and reverse primer used in the early PCR experiments  
                     along with their respective annealing temperature (TM) 
SNP Gene               Forward (F) and Reverse (R) Primer  TM 
1 DTNP1rs2619539b F GGCAAAATGATGTACTGCCA 59.55 
DTNP1rs2619539bR GCCTAGCTCTTAACCCGTCC 60.23 
2 DTNP1rs3213207cF ATTGGCCAGTTTCCTCAAAA 59.55 
DTNP1rs3213207cR ATTCAGTGCAGGAAACCTCC  59.14 
3 DTNP1rs2619538dF GGATGAGGCCAGTGAGGTAA 60.07 
DTNP1rs2619538dR AAGAGTGGGGAAGAGGTGGT 59.97 
4 DTNBP1rs1011313aF  AAGCCATCCATGAGGGTTG 52 
DTNBP1rs1011313aR  TGCATGGCTTATATGTGTCCA 51 
5 DA2rs6277F  AGGAGTCTTCAGAGGGGGAA  60.19 
DA2rs6277R  GGAATGGGACCTTTCACAGA 59.9 
6 DISC1rs1322783aF CAGGCCTCTTCAGCAGTGT 60 
DISC1rs1322783aR  ACCCCAGAAACCTTGACCTT 59.83 
7 DISC1rs3737597bF  AAAGGTGGCATATCACTGGG 59.81 
DISC1rs3737597bR  GTGAAGGAAACTCTGCAGGC 60 
8 DAOArs3918342aF  TGGGAAGCAGAATAACCAGG 60.07 
DAOArs3918342aR  TTGCCTTATGGGAACCTCAG 60.07 
9 DAOArs1421292bF  CACTCCACTCCCCCGTAGTA 59.98 
DAOArs1421292bR  TCATGGCTTCGAACAACAAA 60.23 
10 COMTrs737865aF GCCAGCTTTTTCTCATGTTG 50 
COMTrs737865aR CAGAGGGCCTTGGTGACTT 51 
11 COMTrs4680bF ACCAGGGAGGTGAAATACCC 60.05 
COMTrs4680bR CTTGGCAGTTTACCCAGAGC 59.88 
12 COMTrs165599cF GACGGACGCTAACGCTAAG 50 
COMTrs165599cR AGGGAGGCAACTACAGGGA 51 
13 CNR1rs1049353aF ATCAACTGGGACCCGATACA 60.2 
CNR1rs1049353aR AATCCTCTGCCCCTTTTCC 60.39 
14 CNR1rs324420bF TGTTGCTGGTTACCCCTCTC 60.11 
CNR1rs324420bR AGGGTCCACTCCAACAACTG 60 
15 CNR1rs2023239cF TTGAATCCAACCACAGGTCA 59.94 
CNR1rs2023239cR CCCTCTGTGCCTTTCTTCTG 59.98 
16 NRG1rs373597aF GGTGGCTTCCAAAAGAAGTG 59.71 
NRG1rs373597aR CCCATTTCACAGATTGCAGA 59.65 
17 NRG1rs221132bF CAGTCTTTTCCCATTGGAACT 50 
NRG1rs221132bR AAAATAGCGAGCGTTGGTG 51 
18 NRG1rs221533cF TAAGACCACGTGGCATTGAA 60.11 
NRG1rs221533cR GTTTGGTGCTTGGTCAACCT 60.01 
19 NRG1rs241930dFCCTGCTTTTGAAGGAGAGAAG 50 
NRG1rs241930dR AATGGGCTTTAGCATG 55 
20 NRG1rs243177eF AGAAGGCAAAGGGGGAGCA 56 
NRG1rs243177eR CAAATTCAAATGCCCACAGG 53 
 
 
 
 
 Table B2: Standard protocols for using the PCR machine with the exception of the primer annealing 
temperature to suit individual primers (n = 20) 
Step Temp (°C) Time (mins)  
1 95 5  
2 95 1 35 cycles 
3 50 1 35 cycles 
4 72 2 35 cycles 
5 72 5  
6 4 Holding temperature  
 
 
Preparing for the SNP Start Primer Extension Reaction 
The SNP extension primer was carried out using the Beckman Coulter Primer Extension Kit 
for the Genome Lab ™ and AB gene ready mix.  The SNP primers were created using the 
Primer 3 blast function and these were tested initially on my DNA (see Figure D4 for result).  
Successful primers should be in the range of 60 degrees – 75 degrees and a Poly (T) tail was 
added to the 5’ (please refer to table C3 for a list of SNP primers and table D4 for the primers 
with their Poly (T) tails.  Two multiplexes were created due to only a maximum of 10 SNPs 
can be used in one reaction (see Table E5).  The order of the SNPs were done in relation to 
the base pair (bp) length and the first multiplex SNP started with lowest bp (e.g. SNP 5)  and 
thereafter 6 bp in length were required between each SNP length.  
 
Table C3: List of different SNP primer sets used in the experiment along with their respective annealing temperature 
SNP  SNP Primer Allele TM BP 
1 TCAGCTCATTCTGTTATAACTAGTCTGACATGGTCT G or C 68.2 36 
2 TCTAAATGTATTAGGGAACTTTTCTTTGAAGACTTC  G or A 65.5 36 
3 CAGTGAGGTAAGTAGCACAAGTACAGGCCC A or T 69.3 30 
4 CCTTAATTCACAGGCTACAGAATGGATGTTGC  G or A 70.8 32 
5 CCCACCACGGTCTCCACAGCACTCC T or C 75.6 25 
6 TTACTGCTGCTAGAAATGCCAGAAAATGTAA T or C 67.3 31 
7 GCTGAGATGAAACTATTCTCAAATCCTGTGGAAGA T or C 71.3 35 
8 AAATCTGAGTTAGAAAAATTTGAGCATCAGCACCTT T or C 70.5 36 
9 CCAGTCCTTGCATTTTGACTTCATCAAGTG A or T 70.8 30 
10 ACGGTCCCTCAGGCTTGGAGGGTCACTTTAA  G or A 76.2 31 
11 GCGGATGGTGGATTTCGCTGGC G or A 73.7 22 
12 AGCCACAGTGGTGCAGAGGTCAGCCCT  G or A 76.1 27 
13 TTTNCCCTCAATGAAAAGGGCTGAGGAA G or A 71.9 28 
14 GCTGACTGTGAGACTCAGCTGTCTCAGGCC A or C 74.6 30 
15 AGCTAGGTTTGTGGATGTGCCAGGACCA T or C 73.5 28 
16 AACTTGATGACCACTTCAAAGACAAACTTCTTACT G or A 67.5 35 
17 TACTGTCCCAGGATCCAATCCAGGGTACCA G or C      80       37 
18 TCCAACACAATTAAACATTATGCAGCTATTAAAAGA T or C 67.8 36 
19 CAAGACAAGCAGGGGGAGGAGACCCAA G or A 75 27 
20 GAGGTTTCCCCATATCGTCCAGGCTGGTCTCA G or A 77.8 32 
 
Table D4: SNP Primer with tail extension for use in multiplexing     
SNP  SNP Primer with tail extension 
1 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCAGCTCATTCTGTTATAACTAGTCTGACATGGTCT 
2 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTAAATGTATTAGGGAACTTTTCTTTGAAGACTTC 
3 TTTTTTTTTTTTTTTTTTTTTTTTTTT CAGTGAGGTAAGTAGCACAAGTACAGGCCC 
4 TTTTTTTTTCCTTAATTCACAGGCTACAGAATGGATGTTGC 
5 TTCCCACCACGGTCTCCACAGCACTCC 
6 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACTGCTGCTAGAAATGCCAGAA
AATGTAA 
7 TTTTTTTTTTTTTTTTTTGCTGAGATGAAACTATTCTCAAATCCTGTGGAAGA 
8 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAATCTGAGTTAGAAAAATTTGAGCATCAGCAC
CTT 
9 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCAGTCCTTGCATTTTGACTTCATCAAGTG 
10 TTTTACGGTCCCTCAGGCTTGGAGGGTCACTTTAA 
11 TTTTTTTTTTTGCGGATGGTGGATTTCGCTGGC 
12 TTTTTTTTTTTTAGCCACAGTGGTGCAGAGGTCAGCCCT 
13 TTTTTTTTTTTTTTTTTTTTTTTTTTNCCCTCAATGAAAAGGGCTGAGGAA 
14 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCTGACTGTGAGACTCAGCTGTCTCAGGCC 
15 TAGCTAGGTTTGTGGATGTGCCAGGACCA 
16 TTTTTTTTTTTTTTTTTTTTTTTTAACTTGATGACCACTTCAAAGACAAACTTCTTACT 
17 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACTGTCCCAGGATCCAATCCAGGGTACC
A 
18 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCAACACAATTAAACATTATGCAGCT
ATTAAAAGA 
19 TTTTTTTTTTTTTTTTTTCAAGACAAGCAGGGGGAGGAGACCCAA 
20 TTTTTTTTTTTTTTTGAGGTTTCCCCATATCGTCCAGGCTGGTCTCA 
 
Table E5: Two multiplex set-ups for SNP primers 
Multiplex 1 SNP bp Multiplex 2 SNP  bp 
1 5 28 1 15 28+1=29 
2 11 22+11 = 33 2 10 31+4=35 
3 12 27+12=39 3 4 32+9=41 
4 19 27+18=45 4 20 32+15=47 
5 13 28+23=51 5 7 35+18=53 
6 3 30+27=57 6 16 35+24=59 
7 9 30+33=63 7 1 36+29=65 
8 14 30+39=69 8 2 36+35=71 
9 17 30+45=75 9 8 36+41=77 
10 6 31+50=81 10 18 36+47=84 
 
The nanodrop 2000c spectrophotometer machine was used to check for the concentration of 
DNA that is present.  The nanodrop result gave an indication for the amount of DNA to use 
for the SNP analysis.  The PCR product can be between 1-100fmoles and the Beckmann 
manual for the SNP extension primer provides set information on the exact quantities to use.   
 
 
 
 
 
 
Genotyping 
The SNP analysis was run according the Beckmann and Coulter manual for the CEO 8000 
software.  10 separate multiplexing analyses were conducted and some of these worked and 
others did not (see figure E5 and F6).  Due to timing issues, it was decided that the SNP work 
would be conducted externally to be more time and cost effective.  Therefore all of the PCR 
samples (n=100) were washed using the Qiagen kit  and then run through the PCR, using the 
same protocol as earlier, but for only 7 out of the 20 SNPs were selected to be sent externally 
to K-Biosciences (see table F6).  The first batch of analysis (which included the SNP primer 
PCR products) had a poor success rate at K-Biosciences (under 60%).  Therefore a secondary 
batch was sent which including all of the original DNA samples and were cleaned to increase 
the % of purified DNA.  All 100 samples were then re-sent to K-Biosciences for a final 
attempt to genotype the DNA without any PCR or SNP primers, and it was much more 
successful with a hit rate of (89%-99%). 
 
Table F6:  List of SNP final SNP markers used for the DNA analysis.   
  
Gene SNP ID Allele Y Allele X Sequence 
DAOA 
RS142129_SNP9 T A TGACTTCATCAAGTG[A/T]GCTTATGTAGTTAAG 
COMT 
RS737865_SNP10 G A AACAGGACACAAAAA[C/T]CCCTGGCTGGAAAAA 
COMT 
RS4680_SNP11 G A GTGGATTTCGCTGGC[A/G]TGAAGGACAAGGTGT 
COMT 
RS165599_SNP12 G A ATGGGGACGACTGCC[A/G]GCCTGGGAAACGAAG 
CNR1 
RS1049353_SNP13 G A AAAAGGGCTGAGGAA[A/G]TCCTCCAAAATGTGG 
FAAH 
RS324420_SNP14 C A CAGCTGTCTCAGGCC[A/C]CAAGGCAGGGCCTGC 
NRG1 
RS221533_SNP18 T C TAAACTTTTAAAATA[C/T]GTCAATACAGAGAAA 
 
 
PCR Results 
 
Cybersafe was initially used to act as a florescent for the gel capture but this yielded poor 
outcomes, therefore ethidium bromide was used instead and achieved positive results – see 
figure B2 below for SNP1 trialled on my own DNA.  The percentage of agarose gel for 
running the electrophoresis was changed from 3% to 1.5% which also yielded better results - 
see figure C3 below for an illustration of SNP 1 run with 1.5% agarose. 
 
 Figure A1.  KB+ ladder. 
 
                                            
                                                             SNP 1: length = 457bp                                           
 
Figure B2: Represents SNP 1 for my DNA using ethidium bromide 
 
 
Fig C3:  SNP 1 (1.5% agarose gel). 
 
KB+ ladder 100-1200bp 
 
The primers were assessed to make sure the right concentrations were present prior to 
genotyping.  PCRs were run on each primer using my DNA.  Figure D4 below highlights the 
gel capture for testing the primers on my own DNA for 8 SNPs.   
 
 
Fig D4: Gel capture from testing primers on my DNA for SNP 1, 2, 3, 4, 5, 10, 11 and 12 
 
10 separate multiplexing analyses were conducted using the genotyping machine and some of 
these worked and others did not (see figure E5 and F6).  Figure E5 highlights that the size 
standards in red were present, but not many SNPs.  Whereas in figure F6 the SNPs are 
represented by the peaks and the number corresponds to their pre-set base pair size.   
 
 
 
 
                       
Fig E5:  Unsuccessful output from multiplexing                       Fig F6:  Successful output from multiplexing 
    
snps 
Size standards 
Size standards 
Appendix xv: Chapter 4 result tables for cannabis use variables and SNP genotypes and 
the COMT Haplotype analyses. 
 
 
 
 
 
 
 
Table G7: Cannabis use variables explored across SNP genotypes in cannabis users  
 
Gene SNP Genotype 
(n =  ) 
Joints Per 
Week 
Mean (SD) 
[KW] 
X p Age of Onset 
Mean (SD) 
[KW] 
X p Duration X p 
DAOA rs142129 T/T (6) 23.4 (10.4) 66.27 0.270 16.33 (3.83) 20.34 0.562 7.5 (4.76) 32.24 0.804 
  T/A (16) 13.01 (12.33)  16.61  (4.46)  12.39 (9.86)  
  A/A (6) 10.75 (11.36) 17.0 (2.90) 11.00 (10.32) 
COMT rs737865 T/T (16) 17.28 (13.2) 54.58 0.673 16.47 (3.48) 21.54 0.487 13.11 (8.07) 39.88 0.476 
  T/C (8) 10.03 (10.65)  17.11 (5.63)  8.55 (8.08)  
  C/C (4) 14.15 (11.08) 16.25 (1.26) 8.5 (5.26) 
 rs4680 G/G  (12) 16.10 (12.74) 64.15 0.162 16.5 (4.85) 21.03 0.519 8.16 (5.85) 40.43 0.363 
  G/A (9) 8.0 (8.7)  17.5 (3.17)  12.8 (9.0)  
  A/A (7) 21.14 (12.5) 15.75 (4.9) 13.5 (12.66) 
 rs165599 G/G (6) 11.5 (10.8) 58.27 0.392 14.83 (2.2) 22.94 0.405 10.1 (7.14) 43.46 0.326 
  G/A (13) 12.75 (12.3)  17.5 (4.9)  9.0 (7.44)  
  A/A (9) 19.83 (12.7) 16.5 (3.0) 14.7 (11.7) 
CNR1 rs1049353  G/G (26) 15.6 (12.2) 32.64 0.338 16.57 (4.07) 10.32 0.502 11.75 (9.11) 9.85 0.971 
  G/A (2) 3.25 (0.35)  17.5 (2.12)  2.5 (3.0)  
  A/A (0) - - - 
FAAH rs324420 C/C (17) 12.89 (12.45) 54.94 0.515 17.0 (4.65) 20.33 0.562 9.11 (9.03) 41.67 0.398 
  C/A (8) 16.37 (13.00)  16.0 (3.16)  16.4 (8.53)  
  A/A (3) 21.0 (9.64) 16.3 (0.57) 7.33 (5.77) 
Nrg1 rs221533 T/T (21) 15.2 (11.87) 40.69 0.973 16.59 (4.06) 16.31 0.80 10.31 (9.27) 76.137 <0.001 
  T/C (7) 13.42 (14.28)  16.75 (3.91)  13.37 (8.83)  
  C/C (0) - - - 
         Table H8: Frequency of all COMT haplotypes (737865-4680-165599) in whole group and cannabis    
                           users and non cannabis users. 
 
COMT 
haplotype 
 
   Whole Group 
 
Cannabis user 
 
Non-cannabis 
user 
TGA 17 5 12 
TAA 8 6 2 
TGG 40 16 24 
TAG 6 3 3 
CGA 1 0 1 
CAA 1 0 1 
CGG 6 4 2 
CAG 0 0 0 
 
 
                Table I9: Cognitive and trait outcomes explored in carriers of the COMT protective haplotype     
                                  737865-4680-165599 (T-G-G) in all participants. 
 
   737865-4680-165599  
               (T-G-G)     
Protective 
Haplotype 
Protective 
haplotype  
(n =  ) 
Non protective 
haplotype 
Non 
protective 
haplotype 
 (n =   ) 
F p 
SPQ total   6.26 (4.7) 41 6.07 (4.1) 41 0.04 0.842 
SPQ CP 2.51 (2.03) 41 1.95 (1.65) 41 1.869 0.175 
SPQ IP 2.41 (2.07) 41 2.48 (2.16) 41 0.025 0.875 
SPQ DT 1.46 (1.72) 41 1.63 (1.64) 41 0.212 0.647 
CPT accuracy  19.03 (3.79) 27 18.5 (5.94) 22 0.101 0.752 
CPT response time 572.45 (177.6) 27 546.44 (211.35) 22 0.219 0.642 
CPT ME 2.07 (2.14) 27 1.57 (1.77) 22 0.750 0.391 
CPT CE 9.59 (9.8) 27 7.77 (7.89) 22 0.495 0.485 
AST error 31.3 (23.7) 21 26.8 (27.2) 17 0.268 0.608 
AST Latency 316.26 (78.63) 21 275.98 (61.7) 17 2.972 0.093 
Iowa Gambling Task 1387 (1040.99) 27 1384 (982) 22 0.00 0.989 
Latent inhibition 12.57 (9) 14 29.2 (9.9) 19 0.49 0.488 
 
 Table J10:  Cognitive and trait outcomes explored in carriers of the COMT protective haplotype 737865-
4680-165599 (T-G-G) in cannabis users and non-cannabis users. 
             Measurement     Participant 
Group 
Protective 
Haplotype 
Protective 
haplotype  
(n =  ) 
Non 
protective 
haplotype 
Non 
protective 
haplotype 
 (n =   ) 
F p 
SPQ total Cannabis user 
 
6.0 (3.86) 16 7.16 (3.9) 19 0.005 0.941 
 Non-cannabis 
user 
6.94 (5.26) 25 5.14 (4.12) 22   
SPQ CP Cannabis user 
 
2.68 (2.02) 16 2.57 (1.8) 19 1.798 0.154 
 Non-cannabis 
user 
2.4 (2.08) 25 1.4 (1.3) 22  
SPQ IP Cannabis user 
 
2.37 (1.54) 16 2.3 (2.5) 19 0.021 0.885 
 Non-cannabis 
user 
2.44 (2.3) 25 2.64 (2.13) 22  
SPQ DT Cannabis user 
 
1.25 (1.40) 16 2.26 (1.52) 19 0.469 0.495 
 Non-cannabis 
user 
1.60 (1.87) 25 1.09 (1.57) 22  
CPT accuracy Cannabis user 
 
19.2 (3.07) 9 18.3 (4.9) 12 0.100 0.753 
 Non-cannabis 
user 
18.9 (4.59) 18 18.9 (7.2) 10  
CPT response time Cannabis user 
 
608 (200) 9 630 (135) 12 0.630 0.432 
 Non-cannabis 
user 
553 (168) 18 446.08 (247) 10  
CPT ME Cannabis user 
 
2.11 (2.75) 9 1.91 (2.15) 12 0.880 0.353 
 Non-cannabis 
user 
2.05 (1.86) 18 1.15 (1.05) 10  
CPT CE Cannabis user 
 
8.66 (14.74) 9 7.81 (8.59) 12 0.348 0.558 
 Non-cannabis 
user 
10 (6.63) 18 7.6 (9.4) 10  
AST error Cannabis user 
 
32.6 (25) 9 38.3 (26) 9 0.399 0.522 
 Non-cannabis 
user 
30.3 (28.5) 8 13.9 (23.5) 12  
AST Latency Cannabis user 
 
290.7 (96) 9 271 (80.9) 9 1.356 0.126 
 Non-cannabis 
user 
335 (60) 8 281 (33) 12  
Iowa Gambling Task Cannabis user 
 
1261 (60) 9 1195 (1257) 18 0.136 0.714 
 Non-cannabis 
user 
1451 (1186) 12 1610 (523) 10  
Latent inhibition Cannabis user 
 
8.42 (8.97) 7 3.28 (2.56) 7 1.841 0.185 
 Non-cannabis 
user 
16.7 (7.45) 7 14.5 (8.57) 12  
 
 
 
 
Table K11: Represents the combination of total number of risk markers in the cannabis users and non 
cannabis users in relation to trait and cognitive outcomes. 
 1 Risk 
marker 
Mean (SD) 
n= 2 Risk 
markers 
Mean (SD) 
n= 3 Risk 
markers 
Mean (SD) 
n= 4 Risk 
markers 
Mean 
(SD) 
n= F p 
SPQ_total – 
cannabis user  
9.0 (4.0) 3 7.25 (3.94) 20 6.35(3.7) 26 8.0 1 0.284 0.837 
SPQ_total – non 
cannabis user  
5.5 (3.69) 4 6.0 (3.3) 8 5.84(5.08) 37 3.0 1   
SPQ_CP – 
cannabis user 
3.33(3.21) 3 2.75(1.8) 20 2.65(1.89) 26 1.0 1 0.342 0.795 
SPQ_CP – non 
cannabis user 
1.25(1.25) 4 2.0(2.07) 8 2.05(1.8) 37 1.0 1   
SPQ_IP – 
cannabis user 
2.0 (2.0) 3 2.5 (2.13) 20 2.42(1.67) 26 3.0 1 0.002 1.0 
SPQ_IP – non 
cannabis user 
3.0 (1.8) 4 2.37 (1.5) 8 2.48(2.37) 37 2.0 1   
SPQ_DT – 
cannabis user 
3.66(0.57) 3 2.0(1.45) 20 1.5 (1.36) 26 4.0 1 1.1.96 0.316 
SPQ_DT – non 
cannabis user 
1.25(1.5) 4 1.62(1.76) 8 1.29(1.76) 37 0 1   
AST error – 
cannabis user 
- - 32.9(28.68) 14 29.5(24.02) 12 - - 0.695 0.505 
AST error – non 
cannabis user 
4.0 (1.41) 2 6.66(7.63) 3 26.4(28.79) 17 - -   
IGT – cannabis 
user 
1512.5(724) 2 830(984) 15 1654.16 
(676.37) 
12 2425 1 0.672 0.573 
IGT – non 
cannabis user 
1425 
(247) 
2 1493.75 
(581.45) 
4 1536.95 
(1102) 
23 1025 1   
CPT accuracy – 
cannabis user 
18.5 (2.12) 2 18.53 (4.79) 15 21.8 (5.21) 12 18.0 1 0.310 0.818 
CPT accuracy – 
non cannabis 
user 
20  
(2.82) 
2 21.25 (2.2) 4 18.95 (5.88) 23 16.0 1   
LI – cannabis 
user 
21.0 1 8.4 (7.6) 5 6.5 (7.58) 14 - - 0.708 0.5  
LI – non 
cannabis user 
12.0  (12.72) 2 11.75(10.14) 4 17.2 (6.8) 14 - -   
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